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ABSTRACT 
 
Inflammatory bowel disease (IBD) is a series of disorders characterised by chronic 
intestinal inflammation, with the principal examples being Crohn’s Disease (CD) and 
ulcerative colitis (UC). A paradigm of these disorders is that the composition of the colon 
microbiota changes, with increases in bacterial numbers and a reduction in diversity, 
particularly within the Firmicutes. Sulfate reducing bacteria (SRB) are believed to be 
involved in the etiology of these disorders, because they produce hydrogen sulfide 
which may be a causative agent of epithelial inflammation, although little supportive 
evidence exists for this possibility. The purpose of this study was (1) to detect and 
compare the relative levels of gut bacterial populations among patients suffering from 
ulcerative colitis and healthy individuals using PCR-DGGE, sequence analysis and 
biochip technology; (2) develop a rapid detection method for SRBs and (3) determine 
the susceptibility of Desulfovibrio indonesiensis in biofilms to Manuka honey with and 
without antibiotic treatment. 
Mucosal biopsy DNA from 4 colitis patients and one healthy individual was used to 
amplify 16S rRNA fragments, which were separated either by DGGE or by molecular 
cloning prior to sequencing, and dissimilatory sulphite reductase (dsr) gene fragments, 
which were cloned and sequenced. The number of bands separated by DGGE varied 
from 3 to 12 for an individual. The profiles from the UC patients had a greater similarity 
than the one from the healthy individual. In total, 25 bands were excised for sequence 
analysis but only 4 produced usable sequences. The 16S rRNA gene library comprised 
250 clones, the sequences of which showed great changes in diversity from the healthy 
individual to the UC patients. The sequences from the healthy individual represented 
members of the Bacteroidetes, Clostridiaceae, Ruminococcaceae, Enterobacteriaceae, 
Coriobacteriaceae and Lactobacillaceae, whereas those form the UC patients comprise 
only members of the Enterobacteriaceae. The library for the dsr gene comprised 30 
clones, with sequences from the healthy individual representing members of the 
Desulfobacteraceae (45%), and the Desulfovibrionaceae (33%), with minor components 
from the Desulfohalobiaceae, Desulfomicrobiaceae and Desulfonatronaceae. Sequences 
from the UC patients were less diverse, being composed primarily of 
Desulfovibrionaceae sequences. 
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Oligonucleotide probes targeting SRB and other bacterial species found to be involved in 
UC were developed or selected from published sources. Cassettes with multiple probes 
were used to evaluate the hybridisation probes for inclusion in a biochip. Validated 
probes (23), with similar binding profiles, were then used to assess the levels of SRB and 
other bacteria associated with UC in healthy control and UC patient’s samples. The DNA 
from the healthy individual gave a strong hybridisation signal for Desulfovibrio piger, 
and weaker signals for Escherichia coli, Bacteroides fragilis, and a Clostridium species, 
whereas the signals Desulfobacter and Desulfovibrio gigas were present in all of the 
samples from the UC patients. Signals were also recorded for species of Fuscobacterium, 
which have been implicated in colitis.  
In this investigation, procedure for rapid detection and quantification of SRB was 
developed. The SRB growth was monitored in the presence and absence of Escherichia 
coli BP, the copy number of the dsrA and adenosine-5′-phosphosulfate reductase (aps) 
genes was detected in DNA and RNA purified from different ages of SRB culture using 
TaqMan qPCR. The result showed that in the presence of E.coli BP enhanced the growth 
of SRB and allowed the detection of SRB in low dilutions comparing with the growth of 
SRB only. 
 E. coli and SRB are both implicated in colonic infections. They pose several mechanisms 
for immune evasion and antibiotic resistance, one of these being their ability to grow in 
a biofilm. The present investigation has highlighted that Manuka honey and antibiotic 
treatment might have a protective role against SRBs and enteric bacteria. However, 
mixed bacterial population in biofilms exhibit greater resistance to both treatments, and 
this needs to be taken into account when devising a treatment based on ingestion of 
honey. 
The present investigation were conducted as a baseline study for determination the role 
of SRB in the pathogenesis of colitis through the use of novel methodology allowing for 
rapid detection and screening investigations into species and genera of interest present 
in colonic mucosa; that may allowed in further investigation to evaluate the bacterial 
role in UC through extensive studies in broad multinational cohort of patients suffering 
from this UC. 
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Section 1 
The Microbiota of the Human Large Intestine 
 
1.1 .1 General Overview 
 
The human body plays host to a complex community consisting of taxa from across the 
tree of life. Bacteria are the major microbial organism present in the gut, however, many 
other organisms can be found such as protozoa, fungi and viruses. The interactions of 
these microbes with each other and the host have a profound influence on physiology in 
both health and disease (Macpherson & Harris, 2004; O’Hara & Shanahan, 2006; 
Clemente et al., 2012). 
The microorganisms that coexist peacefully with their hosts are referred to as normal 
microflora. It is estimated that in humans this microflora community contains between 
1013 to 1014 bacteria, 10 times greater than the number of human cells present in the 
body (Hooper & Gordon, 2001).  
Almost the entire human body, including the respiratory and urogenital tracts and the 
skin, are colonized by microbiota, however, it is the gastrointestinal tract (GIT) which is 
most heavily colonized due to the abundance of nutrients as a food source. Within the 
GIT the colon has been found to contain more than 70% of the total number of microbes 
in human body (Whitman et al., 1998; Ley et al., 2006). This complex microbial 
community within the GIT plays a crucial role in human health with an influence on host 
metabolism, physiology, protection, nutrition and immune function (Ley et al., 2008). 
Therefore any alteration, imbalance (dysbiosis) or change in bacterial function within 
the GIT ecosystem, or changes in bacterial interactions with each other can impact on 
human health and is thought to contribute to the development of key intestinal diseases 
such as inflammatory bowel disease (IBD), including  ulcerative colitis (UC) and Crohn’s 
disease (Underwood, 2014; Carding et al., 2015). 
 
Bacteria are usually found in a dynamic environment containing numerous different 
microbial species populations in which frequent interactions occur (Shoaie et al., 2013). 
Therefore, a better understanding of the interactions between bacteria will help to 
improve our understanding of how bacterial genetic information can impact on human 
health and disease. Several studies have highlighted a link between intestinal bacteria 
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and human disease (Frank et al., 2007; Guinane & Cotter, 2013; Carding et al., 2015). 
Additionally, determining the growth conditions required for culturing single isolates 
remains challenging. Although much progress has been made using culture-based 
methods to characterize bacterial diversity within the GIT, with over 400-500 different 
microbial species fully identified and assessed (Hiergeist et al., 2015), it is thought that 
this method has only identified a small fraction of the full diversity existing within the 
GIT. 
Molecular ecological studies allow for more accurate analysis of the microbiota within 
the GIT, revealing that the intestinal bacterial ecosystem is more complex and diverse 
than previously expected with the vast majority of microbial species remaining 
uncultivated (Zoetendal et al., 2004). Most of these studies rely on analysis of the highly 
conserved ribosomal RNA (rRNA) sequences of bacteria. Molecular approaches used to 
study the microbial population colonizing the human colon can facilitate both high-
detail and high-throughput analysis of phylogenetic diversity (Rajendhran & 
Gunasekaran, 2011). Molecular techniques previously used include temperature or 
denaturing gradient gel electrophoresis (TGGE or DGGE), quantitative polymerase chain 
reaction (qPCR), and Microarray technology (Houpikian &  Raoult, 2002).  
The estimation of the structure of the bacterial population in the large intestine is 
moving closer to absolute quantification (Swidsinski et al., 2005; Casen et al., 2015). 
However, whilst absolute quantification of bacterial populations may soon be possible, 
the major future goal of colonic bacterial studies will be to investigate the interactions of 
these bacteria with each other and the host, and how these interactions can impact on 
human health and disease. To this end recent major advances have been made in colonic 
microbiota studies aiming to determine the identity of specific bacterial groups that may 
contribute to host colonic diseases (Guinane & Cotter, 2013; Ohland & Jobin, 2015). 
 
1.1.2 Development of the intestinal Microbiota 
 
As well as bacteria the gut microflora also contains archaea, fungi and viruses, 
advancement in sequencing technologies and the use of metagenomics approaches are 
helping to characterise these total populations; including identifying various factors 
involved in their sustenance (Hoffmann et al., 2013). All humans are born with an 
almost sterile colon, however both bottle and breastfed infants rapidly start 
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accumulating Gram-positive and Gram-negative intestinal bacteria (Koenig et al., 2011). 
The early colonizers are typically Enterococci and Enterobacteria, which are mainly 
facultative anaerobes (Zetterstrom et al., 1994; Dogra et al., 2015; Avershina et al., 
2016). Both these bacterial species significantly reduce oxygen pressure (pO2) within 
the GIT creating an environment suitable for the growth of other anaerobes mainly 
Bacteroides and Bifidobacteria (Roberts et al., 1992; Knol et al., 2005). It has been 
observed that bacterial populations in the colon varies among infants depending on 
region of birth and type of feeding, i.e. breastfeeding or formula milk (Gomez-Llorente et 
al., 2013; Patel et al., 2015). In adults, colonic microorganisms are mainly anaerobic in 
nature and the population is typically stable (Hoffmann et al., 2013). Differences do exist 
in the diversity of bacterial population among individuals from different geographical 
regions of the world. An evaluation of 13,355 prokaryotic ribosomal RNA genes from 
multiple colonic mucosal sites and faeces from healthy subjects demonstrated 
significant intersubjective variability as well as the differences between the stool and 
mucosal bacterial population (Eckburg et al., 2005). 
 
The composition and functionality of the human intestinal microbiota has long been of 
great interest. More than 1000 different species have been reported to colonize the 
human intestine, with the majority being of unknown species belonging to anaerobic 
strains (Bäckhed et al., 2005; Zoetendal et al., 2006; Rajilić-Stojanović et al., 2007; 
Jandhyala et al., 2015). Microbial colonization occurs throughout the length of the large 
intestinal gut with marked differences in the density and composition of colonization. 
The colonization of bacteria in the large intestine is influenced by many factors such as 
host secretions, environmental conditions, substrate availability, transit rates, and the 
organization of the gut wall. Thus, the large intestine mostly supports the establishment 
of a dense population dominated by anaerobic bacteria (Graf et al., 2015). Information 
on the composition of colonic microbiota is derived mainly from molecular 
characterisation of faecal samples, which do not usually reflect mucosa-associated 
bacteria. Consequently, relatively little is known about the composition of the microflora 
of the large intestine. 
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1.1.3 Normal intestinal microbiota a substantial factor in health 
 
Bacterial colonization of the human colon plays a crucial role in modulating the 
immunological, physiological and metabolic activities in the human body which can 
have a large impact on both health and disease. Bacteria can play a beneficial role by 
contributing to the host gut defence system and by supporting and maintaining normal 
gut function (Jandhyala et al., 2015). The metabolic processes of primary fermenters 
lead to the production of key nutrients that the human body is unable to manufacture or 
derive itself such as vitamins (vitamin K, vitamin B12 and folic acid), amino acids, short-
chain fatty acids (SCFA), and yielding some gases such as hydrogen (H2), Methane (CH4) 
and carbon dioxide (CO2) and hydrogen sulphide (H2S) (Wong et al., 2006; Fischbach & 
Sonnenburg, 2011). These products are important to the host but are also used as a 
carbon and energy source for other bacteria within in the human colon. Therefore, these 
fermenting bacteria must maintain the balance between oxidation and reduction 
process whilst at the same time producing the required energy (Macfarlane & 
Macfarlane, 2011). In addition to this, bacteria can breakdown non-digestible foods, 
such as resistant starches and dietary fibres generating energy (Parker, 1976; Bergman, 
1990; Maier et al., 2015). 
 
The disposal of the hydrogen produced by bacteria in the human colon during anaerobic 
fermentation along with the final products produced from their metabolism plays a key 
role in optimal large bowel function and has an important impact on host health (Conlon 
& Bird, 2015). The major protective role of resident bacteria is through barrier effect, 
colonizing the intestinal mucosa thus leaving no space for the pathogenic bacteria 
attachment and subsequent proliferation (Kamada et al., 2013). 
 
1.1.4 Intestinal Microbiota in Disease 
1.1.4.1 Ulcerative colitis (UC) 
 
UC is both an acute and chronic disorder of the large intestine, and one of the main 
forms of IBD. UC is marked by an inflammation affecting the mucosal layer of the colon 
and rectum (Di Sabatino et al., 2012). Patients with UC present symptoms such as 
idiopathic diarrhoea, abdominal pain, fever, rectal bleeding and weight loss; these 
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usually range from mild to severe depending on the extent and severity of the 
inflammation (Zhang et al., 2015).  
Epidemiological studies have found that the occurrence of UC is between 1.5 to 24.5 per 
100,000 cases, with wide variation depending upon geographical location. A significant 
increase in the occurrence of UC during the last 20 years has also been described 
(Cosnes et al., 2011; Burisch & Munkholm, 2013; da Silva et al., 2014), with a higher 
prevalence amongst people from the West, potentially indicating a strong influence of 
the western lifestyle on UC prevalence (Pajares & Gisbert, 2001; Suk-Kyun et al., 2001) 
(Figure 1.1.1). 
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Figure1.1. 1 The link between global diet, bacterial composition and the risk of colonic 
disease development (Simpson & Campbell, 2015; Vipperla K & O’Keefe, 2016) 
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Although the cause of UC remains uncertain, several factors are recognized to have a 
role in the development of the disease. Among these factors, the involvement of bacteria 
in the pathogenesis of UC has been strongly implicated. However, because there appears 
to be no single established cause of UC, this condition seems to have multi-factorial 
disease susceptibility (Fries & Comunale, 2011). The pathogenesis of UC and underlying 
mechanisms of the disease are an active area of investigation, with several longitudinal 
studies describing the mechanisms underlying the pathogenesis of this disease. 
However, the exact aetiological factors associated with UC are still unknown. 
 
1.1.4.2 Role of bacteria in UC  
 
The involvement of intestinal bacteria in the aetiology of UC is supported by studies that 
have shown that the inflammation occurs in regions of the intestine with the greatest 
concentration of bacteria, and the observation that germ-free animals do not develop 
the disease (Thompson-Chagoyan et al., 2005; Nell et al., 2010; Nagalingam et al., 2011; 
Jiminez et al., 2015). In humans, altered bacterial combinations combined with high 
numbers of bacteria in UC patients compared with healthy subjects have been reported 
by several studies (Cummings et al., 2003; Round & Mazmanian, 2009; Matsuoka & 
Kanai, 2015).  
Further evidence supporting the role of bacteria in UC comes from studies where the 
efficacy of using antibacterial agents as a therapy was assessed (Azad Khan et al., 1977; 
Sutherland et al., 1993; Moshkovska & Mayberry, 2007; Freeman, 2012). A meta-
analysis evaluating 40 years of available scientific literature (1966 -2006) relevant to 
the efficacy of antibacterial therapies in UC suggested significant clinical remission 
among UC patients taking antibacterial therapy (Rahimi et al., 2007). Another later 
meta-analysis described a similar benefit for antibacterial treatment in the clinical trials 
for UC (Wang et al., 2012).  
 
The key role of bacteria in the aetiology of UC was first proposed in the 1950’s (Marshall 
et al., 1950, Seneca & Henderson, 1950). In the following decades, some studies 
demonstrated that it was not just overall bacterial load, but also the types of bacteria 
associated with UC. Changes in the anaerobic environment of the colon, associated 
bacterial population and the generation of short chain fatty acids as fermentation 
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products which used as energy source for colonic epithelial cells brought the concept of 
colitis as an energy deficiency diseases to the fore (Roediger, 1980). This was confirmed 
by several studies suggesting that bacteria disturb the synthesis of short chain fatty 
acids generation from carbohydrates during the pathogenesis of UC (Kim, 1998). The 
question of whether a specific pathogen could cause UC has been increasingly 
investigated. Although several bacteria have been reported to contribute to UC 
susceptibility, to date no specific bacteria have been confirmed to be solely responsible 
for the disease. 
 
1.1.4.3 Bacterial composition and UC 
 
The human colon contains a rich microbial population, predominated by 4 divisions 
including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Most bacteria 
within the colon have been identified as belonging to the Firmicutes and Bacteroides. 
Firmicutes Represent ~64% of the microbiota community, whereas Bacteroidetes ~23% 
of the normal microbiota (Eckburg et al., 2005; Mao et al., 2015).  
 
There have been numerous attempts to discern the bacteria involved in UC. However, 
due to the invasive nature of the procedures, initial efforts were limited to evaluating 
the microbial content of faecal material. With the availability of colonoscopy, it has been 
easier to collect samples from the colon for further evaluation. A study focusing on the 
colon in UC reported that the bacterial population were mainly Bacteroides (Poxton et 
al., 1997). In this study the bacterial population present in biopsy samples of colon 
mucosa, collected during colonoscopy from the proximal colon and rectum of 12 
patients, (six with UC and six controls without inflammation) was characterized. The 
study revealed no difference in the bacterial counts from proximal colonic and rectal 
biopsy samples. Overall, the study reported 235 isolates representing 11 species of 
Bacteroides. These species were uniformly distributed along the colon and differed from 
the communities recovered from faeces (Zoetendal et al., 2002). 
 
Technological limitations also hampered the identification of bacterial species. Whilst 
initially cell culture techniques were used; the emergence of genomic techniques 
broadened the evaluation process. Subsequent to the completion of human genome 
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project several techniques like fluorescent in-situ hybridization (FISH), restriction 
fragment length polymorphism (RFLP), denaturing gradient gel electrophoresis (DGGE), 
quantitative dot blot hybridization, and large-scale 16S rDNA sequencing emerged as 
powerful techniques able to overcome issues with conventional microbiological plating 
methods (Mai & Morris, 2004).  
 
A GI Health Foundation sponsored supplement published in the American Journal of 
Gastroenterology in 2012 stated that there is a need for “additional therapeutic 
strategies as the overall potential of emerging techniques have not yet been validated by 
controlled clinical trials. These include blocking attachment of adherent bacteria, such 
as adherent/invasive E. coli; enhancing defective bacterial killing in genetically 
susceptible hosts; and faecal transplant to correct dysbiosis” further highlighting the 
role of bacteria in the pathogenesis of UC (Sartor & Mazmanian, 2012). 
 
1.1.5 Dysbiosis of the intestinal microbiota in UC 
 
Microbial diversity within the bacterial communities residing in the colon plays a 
significant role in modulating human health. A recent review concludes that “A healthy 
gut environment is regulated by the balance of its intestinal microbiota, metabolites, and 
the host's immune system. Imbalance of these factors in genetically susceptible persons 
may promote a disease state. Manipulation of the intestinal microbiota with probiotics, 
which can selectively stimulate the growth of beneficial bacteria, might help to maintain 
a healthy intestinal environment or improve diseased one” (Kataoka, 2016).  
 
It is important to note that culture-independent techniques, such as the molecular 
methodologies previously described have significantly aided our understanding of the 
composition and diversity of colonic microbial populations. The compositional diversity 
of gut can be evaluated at two levels. Firstly, diversity amongst resident bacteria of the 
gut; and secondly, the transient bacteria introduced from external environments 
through ingestion or other sources such as the regulary influx of bacteria by intake of 
food. Therefore, understanding the factors influencing the diversity of the mucosa 
associated bacteria is essiential in order to underlying the pathology and a critical next 
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step in further evaluating the contribution of bacteria to establishing and promoting the 
chronicity of colonic disease. 
 
In  2007 the number of bacterial species described to be present in the large intestine 
was approximately 400, although it was reconginsed that this did not describe the full 
extent of bacteiral species present in the gut (Rajilić-Stojanović et al., 2007). Three years 
later, a catalogue of microbial genes present in the human gut, established by 
metagenomics sequencing, suggested that more 1000 species-level phylotypes were 
present in the GI tract of humans (Qin et al., 2010). It is important to mention here that 
the metagenomics analysis used for predicting phylotypes is based on non-redundant 
genes contained by an average-sized genome, so it is possible that this number will be 
revised as more information becomes available.  
 
The linkage between bacteria and UC is well established, however, the exact species or 
strains involved in the pathogenesis of UC remain unknown limiting the potential for 
targeted therapies. An increase in overall bacterial population and reduction in 
protective bacteria like lactobacilli and bifidobacteria has been reported (Cummings et 
al., 2003). Additionally, probiotic modulation of bacterial populations identified key 
changes in the microbial ecosystem and certain bacterial species that may be involved in 
UC (Gerritsen et al., 2011). 
 
Interestingly Sasaki and Klapproth (2012) performed an elaborate study to evaluate 
imbalances in bacterial population during the pathogenesis of colitis. Based on their 
evaluation of existing literature they conclude that “quantitative and qualitative 
microbial imbalance in UC, defined as dysbiosis, has been characterized by an increase 
in Rhodococcus spp., Shigella spp., and Escherichia spp., but a decrease in 
certain Bacteroides spp. More specifically, Campylobacter spp., Enterobacteriae, and 
enterohepatic Helicobacter were more prevalent in a tissue sample from UC patients 
subjected to molecular detection methods, but not controls. Also, serologic testing 
identified Fusobacterium varium as a potential contributor to the intestinal 
inflammation in UC. Interestingly, in-situ hybridization studies have shown anti-
inflammatory Lactobacillus spp. and Pediococcus spp. were absent in the patients’ 
samples suffreing from UC. Therefore, dysbiosis is a factor in the pathogenesis of UC”. 
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1.1.6 Miscellaneous Bacterial/Host Product in Colitis 
 
The human colon harbours both pathogenic and non-pathogenic bacteria. In 
deciphering the etiologic elements involved in colitis, several bacteria and their 
products have been thought to be involved in either the initiation or overall 
pathogenesis of the disease. Nitric oxide (NO) one of the bacterial metabolic products 
was considered to participate in human colitis related inflammation. Neut et al (1997) 
compared the quantity and quality of nitrate reducing bacteria in diversion colitis (colon 
inflammation occurring among patients undergoing ileostomy or colostomy) with 
healthy controls. The relative percentage of nitrate reducing bacteria showed 
statistically significant elevation among individuals suffering from diversion colitis.  
 
Indirect observation has also provided support for the role of bacterial populations in 
the induction of colitis. The therapeutic use of bacterial populations as probiotics, 
mainly Escherichia coli strain Nissle 1917, is acknowledged as one of the most important 
uses of bacteria (Konturek et al., 2009, Sha et al., 2014, Souza et al., 2016). It is believed 
that in healthy individuals their intestinal microflora occupies all the available space 
inhibiting colonization by pathogenic bacteria. Under certain conditions, when the 
normal intestinal microflora is disturbed it provides an opportunity for either the 
opportunistic or disease-causing bacteria to find an attachment place followed by 
colonization leading to disease like colitis and others.  
 
Johansson et al., (2014) have provided substantial evidence regarding the involvement 
of bacteria in UC. They proposed that the whole human sigmoid colon inner mucous 
layer, which is typically recalcitrant to microorganisms, becomes permeable providing 
access to the bacteria causing colitis and associated dysfunctions. These findings are 
mainly based on observations from a mouse model which revealed the presence of 
bacteria in epithelial areas supporting the idea of bacterial penetration. The breakage of 
colon mucus barrier and colitis has been supported by several studies (Chen et al., 
2014). The existing animal colitis models including the dextran sulphate colitis model 
(Johansson et al., 2010) and Muc2 deficient mice model closely match human colitis 
(Wenzel et al., 2014). Using these models no direct evidence exists to support barrier 
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crossing by the sulphate-reducing bacteria. However, this might be a very plausible 
mechanism to be explored in future studies for providing a proof of concept. 
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Section 2 
The contribution of sulphate reducing bacteria in UC 
 
1.2.1 Sulphate Reducing Bacteria in the colon 
 
The human gut microbiota helps in extracting nutrients and energy from our daily diet. 
A variety of dietary components not metabolized in the small intestine are metabolized 
by fermentation when they reach the colon, and this is driven by bacteria. Maintaining 
the redox balance is a major problem faced during fermentation. The H2 produced 
during the fermentation must be consumed, otherwise its high concentrations leads to 
several adverse effects such as the accumulation of toxic compounds like butyrate. 
Overcoming such toxicity by H2 consuming bacteria is likely to be a significant role in the 
gut. (Gibson et al. 1990; Macfarlane & Macfarlane, 2012). Approximately 30-50% of 
individuals in the West harbour bacteria capable of producing methane from H2 in their 
gut. These individuals have methanogenic bacteria in their large intestine converting 
hydrogen into methane and are called methanogenic individuals (Triantafyllou et al., 
2014). However, these are not the only bacteria capable of consuming hydrogen. 
 
In the human colon, the H2 consuming microbial population (hydrogenotrophic) can be 
split into three classes; methanogens, acetogens and sulphate reducing bacteria (SRB). 
This classification is based on the products they release upon utilizing hydrogen. The 
methanogens produce methane, acetogens acetate and SRBs H2S. and of the three 
classes the SRB are the most efficient in utilizing sulphate (Gibson et al., 1988a).  It has 
also been reported that the human colon mainly harbours Desulfovibrio of the class δ-
Proteobacteria, the main genus of SRB (Scanlan et al., 2009). Sulphate reducing bacteria 
(SRB) are a group of unrelated microorganisms that can utilize oxidized sulphur 
compounds, as final electron acceptors; during growth under anaerobic conditions. 
Through utilizing H2 SRB produce methane, acetate and H2S according to the following 
equation: 4 H2 + SO42- + H+ → HS- + 4 H2O (Plugge et al. 2011 ; Carbonero & Gaskins, 
2014). 
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In general, the SRB are a highly diverse group of microorganisms including 
Desulfovibrio, Desulfomicrobium, Desulfobulbus, Desulfobacter, Desulfococcus, 
Desulfosarcina, Desulfonema, Desulfotomaculum, and Thermodesulfobacterium.  The 
metabolic activities and characteristics of main key genera of SRB that present in the 
human colon are sumrise in Table 1.2.1. 
Table 1.2.1 The Characteristics and metabolic activities of some key genera of SRB in 
human colon 
Genus Characteristics and metabolic activities  
Desulfovibrio The most predominant genus in the large intestine (64–81%), 
commonly utilize lactate, ethanol, and hydrogen as electron donors 
for sulfate reduction. The SRB use sulfate as a terminal electron 
acceptor for respiration with typical electron donors consisting of H2, 
ethanol, lactate, succinate and other organic acids, with the 
concomitant production of H2S which is toxic to colonic epithelial 
cells leading to several colonic disease including UC (Wagner et al., 
1998, Carbonero et al., 2012) 
Desulfobacter  Desulfobacter utilizes only acetate as electron donor and oxidizes it to 
CO2 via the citric acid cycle only 9–16% of this group are present in 
human colon mucosa (Carbonero et al., 2012).  
Desulfobulbus Desulfobulbus present in the human intestinal mucosa in 5–8%. 
Desulfobulbus utilize propionate and hydrogen and can ferment 
organic materials under certain conditions (Kuever et al., 2005)  
Desulfomicrobium  Desulfomicrobium reduce sulfate to hydrogen sulfide. They oxidize 
simple organic compounds in the human intestine (lactate, pyruvate, 
ethanol, formate and hydrogen) incompletely, with the formation of 
acetate as an end product. They can grow using sulfate as an electron 
acceptor during sulfate anaerobic respiration. Desulfomicrobium are 
often found in the intestines of both humans and animals 
(Kushkevych, 2014). 
Desulfococcus  Desulfococcus are found as one of SRBs members that associated with 
mucosa in human colon. This group can oxidized organic compounds 
such as carbohydrates, fatty acids, alkanes, aromatic hydrocarbons 
completely to CO2 (Kushkevych, 2016).  
Desulfosarcina  One of the sulfate reducer that plays a crucial role in sulfur cycle.They 
can grow autotrophically with hydrogen gas as electron donor and 
CO2 sole carbon source. Desulfosarcina has been implicated to have 
role in colon cancer (Huycke & Gaskins, 2004).  
 
Bilophila 
 
Bilophila are common inhabitant of the human colon and has been 
reported as infective agent. Bilophila are differs from the other 
colonic associated members of Desulfovibrionaceae by not being able 
to reduce sulfate and the absences of desulfoviridin. In addition, this 
group are non-saccharolytic bacteria, which produce acetic acid as 
major and succinic and lactic acids as minor fermentation products 
from peptone-yeast broth. (Baron et al., 1989; Marchesi et al., 2016). 
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Desulfuromonas  Desulfuromonas are asporogenous bacteria that oxidize organic 
substrates completely to CO2. This group of bacteria use sulfur as an 
electron acceptor. It has been found that the growth of 
Desulfuromonas in human colon is associated with excessive protein 
ingestion (protein diet) as these metabolites products will promote 
the overgrowth of this group in human colon which may lead to the 
inflammation (Muyzer & Stams, 2008 ;Kushkevych,2013) 
 
 
SRB groups found in the gut are mainly of the genera Desulfobacter, Desulfovibrio, 
Desuflbulbus, Desulfomonas, Desulfomicrobium (Gibson, 1990). Reports have also shown 
that that among these five genera the Desulfovibrio are predominant in the human colon 
(Gibson et al., 1988c ; Willis et al., 1997). Desulfovibrio are characterized by the presence 
of a pigment, desulfoviridin which displays differential fluorescence; red in alkaline and 
blue-green in acidic under long wavelength UV 365 millimicron (Warren et al., 2005). 
Additionally, these bacteria are all anaerobic, Gram-negative bacilli. Two desulfovibrio 
species the D. piger and D. fairfieldensis were first identified in 1976 from human faeces. 
These species are unique to the human intestinal tract and have never been isolated 
from outside the human body (Gibson et al., 1988b). Desulfomonas pigra was the first 
SRB identified that was later renamed as Desulfovibrio piger (Loubinoux et al., 2002). 
Following this identification several other species belonging to the genera Desulfobacter 
and Desulfobulbus were also isolated and characterized (Gibson et al., 1993b). The 
presence of SRB in human faeces varies geographically, and may be associated with 
dietary habits or, perhaps, certain genetic factors. This presumption is based on a study 
reporting the differential carriage rates of SRB between the UK and South Africa faecal 
donors. With over 70% of UK stool samples containing SRB compared to only 15% of 
South African samples ( Section 1, Figure 1.1.1) (Gibson et al., 1988c) .  
 
1.2.2 Interaction of SRB with other organisms 
 
Co-existence of SRB with other organisms has been observed in natural and artificial 
environments. SRB can coexist and interact with several anaerobic bacteria through 
using an alternative electron donor or can compete by consuming the same substrate 
(Dar et al., 2008). A number of processes, such as conjugation, multicellular symbiosis, 
quorum sensing and niche adaption, combating host defence mechanisms, production of 
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secondary metabolites, benefit from inter- and intra-species co-operation (Williams et 
al., 2007). It is feasible that the interactions between different metabolic groups of 
bacteria in the colon may impact on human health, however before such a hypothesis 
can be formed it is necessary to have a greater knowledge about the exact nature of the 
bacterial populations and their possible interactions. 
 
1.2.3 Role of SRB in the aetiology of UC  
 
SRB are capable of metabolizing hydrogen as a source of energy and fall into the 
category of hydrogenotrophic bacteria. The H2S produced by SRB is considered a 
primary pathogenic mechanism in UC. The high production of acetate and H2S, both of 
which have a deleterious effect on the intestinal epithelial cells if they are not removed 
quickly (Kushkevych, 2014). The cells lining the colon can detoxify this gaseous 
material, however in UC patients this detoxification system is deteriorated so that H2S 
accumulates. This accumulation can lead to several other pathologies including an 
increase in the epithelial permeability and barrier function of the colon thus impacting 
its defensive and protective role, as well as inhibiting butyrate oxidation (Pitcher & 
Cummings, 1996). There are several strains of SRB present in the colon, however, some 
of these have demonstrated a relatively higher production of H2S identifying them as a 
potential nexus within the aetiology of UC. Kushkevych (2013) compared the production 
of H2S amongst SRB strains and revealed that Desulfovibrio sp. strain Vib-7 produced the 
highest concentration (up to 3.23 mM) of H2S, consuming 99% of sulphate presented in 
the medium. In vitro characterization of SRB isolates demonstrated that rates of H2S 
production were higher in SRBs isolated from UC patients compared to those obtained 
from healthy ones (0.55 versus 0.25 mM). Furthermore, faecal samples of UC patients 
mainly contain SRB of the genus Desulfovibrio (Gibson et al., 1991). 
 
Although the pathogenesis of UC remains poorly understood several studies have linked 
SRB with the development of UC. Loubinoux et al (2002) compared the presence of SRB 
in the faeces of patients with IBD to healthy volunteers and demonstrated that the 
amount of Desulfovibrio piger (formerly Desulfomonas pigra) was significantly increased 
in IBD patients (55%) when compared with healthy individuals (12%) or patients with 
other symptoms (25%) (p<0.05). A study comparing the levels of these groups of 
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bacteria in various parts of the colon of 25 healthy subjects and using sequence analyses 
of genus specific genes revealed that mucosa-associated SRBs were related to 
Desulfovibrio piger, Desulfovibrio desulphuricans and Bilophila wadsworthia (Nava et al., 
2012). 
 
It has been proposed that a higher dietary sulphate intake promotes SRB associated 
with UC, however, a study using Genome-wide transposon mutagenesis and insertion-
site sequencing, RNA-Seq, with mass spectrometry in a murine model revealed that 
“genes involved in hydrogen consumption and sulphate reduction are necessary for its 
colonization, varying dietary-free sulphate levels did not significantly alter levels of D. 
piger, which can obtain sulphate from the host in part via cross-feeding mediated by 
Bacteroides-encoded sulphatases” (Rey et al., 2013). 
 
As SRB play important roles associated with hydrogen removal in the intestines, it is 
unsurprising that they have been linked to UC syndrome (Levine et al., 1998; Jørgensen 
& Mortensen, 2001; Nyangale et al., 2012). The use of molecular techniques has aided 
the identification of pathogens, and techniques such as PCR have identified the relative 
richness of SRB in individuals with colitis issues (Zinkevich & Beech, 2000). 
 
1.2.4 Sulphate Reducing Bacteria, H2S, and Colitis – A potential Nexus 
 
SRB use sulphate as an electron acceptor in their energy supply pathway producing H2S 
as a metabolite (Attene-Ramos et al., 2007) (Figure 1.2.1). 
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Figure 1.2.1.Metabolic pathway used by SRBs to reduce sulphate (adapted Carbonero et 
al., 2012); APS: adenosine 5’-phosphosulfate 
 
H2S produced from SRB is hypothesized to disrupt mucin polymers of the gut 
epithelium. These polymers contain disulphide bonds and sulphide produced by SRB is 
thought to reduce these bonds, leading to breakage of mucus barrier thus allowing 
pathogenic bacteria access to the gut epithelium leading to the development of 
inflammation (Ijssennagger et al., 2016) (Figure 1.2.2). The penetration of hydrogen 
sulphide through the cell membrane is due to its high solubility in lipophilic solvents 
and it exerts an inhibitory effect on butyrate production (Rowan et al., 2009; Cuevasanta 
et al., 2012). Butyrate oxidation is the main source of energy the epithelial cells of the 
gut, when inhibited the resulting energy deficient environment leads to apoptosis of the 
cells and induction of inflammation ( Moore et al., 1997; Babidge et al., 1998). 
H2S has further deleterious effects on host cellular metabolism including activation of 
adenosine 5’-triphosphate (ATP) dependent potassium channels, inhibition of 
mitochondrial cytochrome c oxidase and induction of DNA damage (Szabó, 2007; Popov, 
2013). Higher concentrations of H2S in the millimolar range lead to oxidative stress 
through the formation of a complex with the ferric ion of cytochrome c oxidase, which 
ultimately inhibits cellular respiration (Caro et al., 2011). In support of this, a recent 
study by Beaumont et al (2016) reported that colonocyte exposure to low 
concentrations of the sulphide donor NaHS reversibly inhibited colonocyte 
mitochondrial oxygen consumption, concomitantly enhancing the expression of hypoxia 
inducible factor 1alpha (Hif-1alpha) gene along with inflammation-related genes such as 
those for inducible nitric oxide synthase (iNos) and interleukin-6 (Il-6). 
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It is important to mention here that the effect of H2S on bacterial cells are contrasting 
compared to host epithelial cells and is time and environment dependent (Wang , 2012).  
 
 
Figure 1.2.2. Sulphide as a Mucus Barrier-Breaker in IBD (Adapted from Ijssennagger et 
al., 2016) 
 
1.2.4 Genetic Diversity of SRB – 5’-phosphosulphate reductase (apsr1) and 
dissimilatory sulphite reductase (dsrAB) 
 
The SRB have two essential genes which allow them to utilise sulphate as a metabolite, 
adenosine 5’-phosphosulphate reductase (apsr1) and dissimilatory sulphite reductase 
(dsrAB). Both are highly conserved among SRB and have potential as biomarker. There 
are limited studies describing the role of both apsr1 and dsrAB in the overall pathogenic 
mechanisms of these bacteria. However, dsrAB was used to confirm SRB in colonic 
biopsy samples (Nava et al., 2012). Through utilizing dsrAB 1.9 kb amplicon a unique gel 
retardation-based technique, involving fingerprinting methodology, efficiently increases 
the chance of detecting rare and novel SRB (Wagner et al., 2005). Additionally, there are 
several interesting studies describing the role of the dsrAB gene in characterizing 
changes in the environment and various ecosystems (Perez-Jimenez et al., 2001; Perez-
Jimenez & Kerkhof, 2005). There are several ongoing metagenomics and molecular 
analysis to evaluate the role of gut-residing SRB in the pathogenesis of IBDs underway. 
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However, there is limited literature relevant to both these genes as far as their 
involvement in colitis disorders is concerned.   
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Section 3 
Molecular techniques for the detection and identification bacteria 
in human colon 
1.3.1 General Overview 
 
The human colon harbours hundreds of different species of bacteria (Poxton et al., 
1997). Earlier research on the detection of colonic bacteria mainly involved traditional 
culture techniques for the isolation of bacteria followed by their characterization. 
Analysis of the microbial community in the human gut was largely dependent on the use 
of enrichment procedures and the ability to grow strict anaerobes. The isolates were 
identified and characterized by various phenotypic methods. In a pioneering study, 
Moore & Holdeman (1974) analysed the faecal flora of 20 male Japanese-Hawaiians. The 
total number of different bacterial species was estimated to exceed 400, although the 
actual number of identified species was only 113. Subsequent studies confirmed the 
great diversity of intestinal bacteria. The Bacteroides, Bifidobacterium, Clostridium, 
Eubacterium, Fusobacterium, Lactobacillus, Peptostreptococcus, Ruminococcus and 
Streptococcus were the first dominant taxa identified (Eckburg et al., 2005; Martínez et 
al., 2013; Donaldson et al., 2016). Altough the exact diversity and function of the 
bacteria in human colon continue to be revealed; the role of these microbial 
communities in colonic health and disease has received considerable attention. It 
thought that certain bacteria inhabit the colon play a role in the onset of some colonic 
disease, whereas other bacteria are considered protective. The role of some key bacteria 
in the colon is shown in Table 1.3.1. 
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 Table 1.3.1.  The role of intestinal bacteria in human health and disease 
Bacterial genera Role of bacteria in the human colon 
 
Bacteroides 
A dominant genus present in the human colon as a normal microflora, however, causes disease if 
get into the bloodstream either through surgery or invades various tissues. Suggesting the role of 
these bacteria as an aetiological agent in infection diseases such as UC (Waidmann et al.,2003; 
Singh et al., 2013) 
Bifidobacterium The first bacteria to colonize the human colon and are believed to have positive benefits on their 
host health. They have important probiotic and protection role in the colon from pathogens 
invasion by competitive exclusion. They involved in the promoting of the immune system and in 
the digestion of energy substrates. (Toumi et al., 2013; Satish et al., 2017). 
Campylobacter Involved in IBD through producing toxins in the oral cavity. Enteric Campylobacter infections 
produce an inflammatory, bloody diarrhea (Man et al.,2010 ; Zhang et al.,2014) 
Clostridium Play a crucial role in colonic homeostasis through the interaction with the other bacterial 
populations. They provide specific and fundamental maintenance functions in the colon. 
However, some Clostridium species such as C. difficile is considered as the most important cause 
of infectious of the human colon; they linked to large bowel malignancies. Additionally has been 
associated with immunosuppression. These bacteria increased sharply among UC patients  
(Zhang et al.,2007 ; Marteau, 2009; Kolho et al., 2015; Autenrieth & Baumgart, 2017; Sokol et al., 
2017) 
Escherichia Commensal strains of Escherichia are involved in the homeostasis of human colon. However, in 
case of dysbiosis most beneficial bacteria are damaged, favouring the overgrowth of pathogenic 
strains that exert toxic effects on the colonic epithelium and causes chronic diarrhea. Some of 
Escherichia strains have been associated with IBD by promoting the inflammation leading to the 
development of colon cancer (Waidmann et al., 2003; Joossens et al., 2011) 
Faecalibacterium Faecalibacterium are one of the most abundant bacterial members in the human colon found in 
ileal, colonic, and rectal biopsies from healthy individuals. These organisms produce butyrate 
and have anti-inflammatory properties. Lower levels of these bacteria are associated with 
Crohn’s disease and ulcerative colitis (Martinez-Medina et al., 2006; Hansen et al., 2012; Machiels 
et al.,2014; Vrakas et al.,2017) 
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Lactobacillus 
 
Lactobacillus in the colon has a very important role in the host health promoting properties. They 
are commonly used as probiotics, which are known as live microorganisms that give a health 
benefit on the host by creating balanced microbial populations in human colon. In addition, 
protect the host against colonic infections and tumor by their antibacterial properties and 
immune system activation. (Ott et al., 2008) 
Peptostreptococcus Induces intracellular cholesterol biosynthesis and degrade complex indigestible compounds in 
the colon. However, they can become pathogenic to their host. Numbers of these organisms  were 
found  in IBD and Colorectal cancer patients  (Verma et al., 2010; Zhang et al.,2013) 
Ruminococcus Dominant members of the human intestinal bacteria that play a key role in the digestion of the 
complex carbohydrate present in the high fibre dietary to provide the energy that is necessary 
for their host. (Joossens et al., 2011) 
Eubacterium Eubacterium is considered as a key orgnasim within the human colon that has very important role 
in the intestinal metabolic balance with final impact on host health. They utilize glucose and 
ferment acetate and lactate, to form butyrate and hydrogen supporting the trophic interactions of 
microbes in the human colon (Engels et al, 2016). 
Fusobacterium 
 
Part of the normal flora of the human colon. However; Fusobacterium recently found to be in a 
high abundance in colon cancer patients suggesting that they may provide an important 
contribution in disease stages (Kostic et al., 2012). 
Streptococcus Part of the commensal human intestinal microbiota which involved in the physiological health by 
promoting the immunomodulatory functions  (Jandhyala et al., 2015). 
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Characterization of SRB was initially dependent on 1) phenotypic characteristics of 
bacteria involving nutritional aspects and morphology and 2) biochemical 
characterization, mainly the presence of desulphoviridin or lipid fatty acids. The advent 
of molecular techniques for evaluating bio-ecological microbial communities of the gut 
has provided a wealth of information beneficial for overall understanding the role of 
resident gut bacteria in human health and disease (Furrie, 2006).  
There are advantage and disadvantages to both the classical bacterial culturing 
techniques and more modern molecular techniques. The choice of techniques is 
dependent the question being addressed. For example, techniques involving 
fingerprinting are good for evaluating bacterial community structure; dot blots and 
fluorescent in situ hybridization are helpful to measure the density of a bacterial 
species. Whereas, techniques like microarrays can be used to identify pathogenesis 
mechanisms as well as for bacterial identification purposes. Molecular techniques based 
microbial diagnostic have emerged as an active discipline, and several commercial 
companies have developed tools for the identification and characterization of bacterial 
species (Namsolleck et al., 2004) (Figure 1.3.1) 
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Figure 1.3.1. Schematic diagram of molecular techniques used for colonic bacterial 
analysis (adapted from Muyzer & Smalla, 1998; Vaughan et al., 2000) 
 
 
1.3.2 Polymerase chain reaction Amplification (PCR) 
 
PCR was developed by Kary B. Mullis in 1983, and rapidly became a fundamental tool in 
molecular biology. Without specifically isolating the target bacteria; PCR can detect 
specific nucleic acid of individual bacterial species from a mixture of nucleic acids of 
different sources (Mullis, 1990). In theory, the products generated by PCR reflect the 
mix of microbial gene signatures present within a sample. Amplifying conserved genes 
with PCR like 16S rRNA obtained from a sample, is a widespread practice for studying 
colonic microbial ecology mainly because conserved genes are 1) universal in 
prokaryotes, 2) are functionally and structurally conserved, 3) are composed of both 
highly conserved and variable regions (Hugenholtz, 2002). An alternative is to use 
specially designed primers that exclusively target regions of DNA that encode functional 
genes, verifying the presence of specific metabolic pathways. Several primers are 
available that specifically target key species of colonic mucosa bacteria. PCR products 
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that result from amplifying DNA obtained from colonic samples are generally analysed 
by using 1) the clone library method, 2) DNA micro-arrays, 3) genetic fingerprinting or 
through a combination of any of these (Coenye & Vandamme, 2003; Frank et al., 2007). 
 
There are several types of PCR available to investigate populations of microbes both 
qualitatively and quantitatively. In addition to being able to detect the genetic signature 
of bacteria that cannot be cultivated by conventional means, the advantage of PCR 
techniques which includes real-time PCR, quantitative PCR is that the technology is very 
sensitive and demonstrates selectivity (Ott et al., 2004). 
 
1.3.3 16S rRNA Gene Sequencing and Phylogenetic analysis  
 
During the last decade, it has become apparent that there has been a significant 
miscalculation of the taxonomic and phylogenetic diversity of GIT microbiota. This 
situation arose from the combination of being unable to isolate and cultivate microbes 
together with the inability to identify new species. The technological development of 
using 16S rRNA gene sequences to identify and classify bacteria has transformed 
taxonomy. By comparing the rRNA sequence, taxonomists can determine the 
evolutionary relationships between specimens. The extent of sequence differences in 
different samples provides a form of measurement of evolutionary distance. Some 
regions in the rRNA molecules are highly conserved, whereas others display high 
degrees of variability. Evolutionarily closer samples demonstrate greater homology 
(Ritari et al., 2015). This method allows organisms to be differentiated at phylogenetic 
levels ranging from species to domain, with relationships visualised by creating a 
phylogenetic tree (Janda & Abbott, 2007).  
 
The 16S rRNA genes display a relatively slower rate of evolution making them ideal for 
use in phylogenies (Woese & Fox, 1977; Janda & Abbott, 2007). The usefulness of the 
16S rRNA in detecting clinically relevant bacterial species can be ascertained from the 
fact that there are more than three 16S database used for taxonomic classification of 
microbial species. Among these the ribosome database project (RDP) (Bacci et al., 2015), 
SILVA (Quast et al., 2013), and Greengenes (DeSantis et al., 2006) have received 
relatively more attention.  
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Today, a library of tens of thousands of 16S rRNA gene sequences is available; novel 
sequences that have been isolated can be compared to these known existing sequences 
making this technique an effective tool in the identification of novel human GIT bacteria 
(Lahti et al., 2014).  
 
The phylogenetic identification of cultures of hundreds of obligate anaerobes has been 
achieved by sequencing short fragments of amplified rDNA (approximately 500 bases); 
these sequences includes variable regions V1, V2 and V3 and V6 that are used for 
diagnosis. More than 90% of the organisms have easily been identified as belonging to 
recognised species, but many novel isolates remain unmatched (Schloss & Westcott, 
2011). Detailed phylogenetic analysis has demonstrated that these isolates belong to 
previously unknown species or genera with many new GIT species being officially 
recorded; meanwhile the research into the phenotypes of the unknown isolates 
continues (Li et al., 2014). It has been reported that 16S rRNA sequencing technology 
has been helpful mainly in the identification of bacteria with an unusual phenotypic 
profile, rare and hard to culture bacterial species. According to very conservative 
estimates; 29 bacterial species, out of 215 belonged to new genus, which were achived 
between 2001 and 2007 (Woo et al., 2008).  Additionally, the 16S rRNA technique has 
been helpful in defining the changes in bacterial characteristics over time. Therefore, it 
is important to mention here that one should be cautious in describing the data 
generated from the 16S rRNA sequencing strategy particularly in clinical settings 
(Christophersen et al., 2011; O'Sullivan et al., 2014).   
 
1.3.4 Denaturing Gradient Gel Electrophoresis (DGGE) 
 
Molecular methods that have been developed to study the microbial composition are 
referred to fingerprinting. A common feature of all molecular fingerprinting methods is 
that they depend upon multi-template PCR reactions to assess microbial community 
structures or ‘fingerprints’. Fingerprinting techniques have been widely applied to the 
ecology of colonic microbes; the methods are also proving invaluable to understanding 
the composition and dynamics of GIT microbes (Suchodolski et al., 2004). 
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Denaturing gradient gel electrophoresis (DGGE), introduced in 1993 by Muyzer et al. 
can be used to analyse the diversity of complex microbial ecosystems. This method, 
demonstrated in Figure 1.3.2, separates 16S rRNA fragments that have been amplified 
by PCR on polyacrylamide gels that contain a gradient of denaturing agents. Hetero- 
duplexes of different amplicons (with different G/C content) are migrated to different 
positions; thereby fragments of the same length but different sequences can be 
differentiated. The result is a pattern of bands in the gel with each band representing 
hypothetically, a single species. The bands separated through this methodology can then 
be identified through sequence analysis by extracting DNA fragments from the gel 
(Muyzer et al. 1993). A benefit associated with DGGE is several samples can be analyzed 
on a single gel run. In addition to the biases presented by the PCR technique and DNA 
extraction inadequacies, DGGE is also vulnerable to general biases related to sample 
handling, storage and type (Green et al. 2006). Furthermore, there are some DGGE 
specific limitations, including the co-migration of DNA fragments with different 
sequences and limited detection sensitivity for under-represented species where only 
the dominant species of the community are displayed. In addition, relatively small 
fragments of DNA can be difficult to separate, as are the molecules generated by the 
different rRNA operons of a single organism.  
 
Irrespective of its shortcomings and despite the advancement of high-throughput 
sequence analysis techniques, DGGE is the current best method available to obtain an 
accurate outline of the composition of a microbial communities; from this, sequence 
analyses can be explored in greater detail (Possemiers et al., . 2004; Vanhoutte et al., 
2004). 
CHAPTER 1: INTRODUCTION 
30 
 
 
Figure 1.3.2.  The principles of DGGE 
 
 
1.3.5 Pulsed field gel electrophoresis (PFGE) 
 
Pulsed field gel electrophoresis (PFGE) is a reliable and fast method to resolve DNA 
molecules larger than 30 kb in an electric field that periodically changes direction. This 
technique can be used to estimate genome size of a microorganism. (Alduina & 
Pisciotta., 2015). The PFGE fingerprinting method is commonly used by the 
epidemiologists for differentiating pathogenic bacterial strains from the non-pathogenic 
counterparts (Falsafi et al., 2014). In addition, it is also possible to use PFGE to compare 
the genome of bacterial species. The PGFE of linearized full-length chromosomal DNA of 
Desulfovibrio desulphuricans, Desulfovibrio vulgaris, and Desulfobulbus propionicus 
(Devereux et al., 1997). There are several studies describing the utility of PFGE for 
comparative studies of bacterial diversity (Said et al., 2010; Fendri et al., 2013; Castiaux 
et al., 2014). 
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1.3.6 Quantitative PCR (qPCR) 
 
Quantitative PCR (qPCR) technique is used for direct quantification of the number of 
bacteria present in a sample. qPCR uses fluorescent reporter molecules that can be 1) 
fluorescent dye-tagged probes made of sequence-specific oligonucleotides, together 
with a quencher (e.g. Molecular Beacons, TaqMan probes (hydrolysis probes) or 
(Scorpions). 2) Nonspecific DNA binding dyes, for example SYBR Green, which when 
bound to double-stranded DNA (dsDNA), emit fluorescence (Brukner et al., 2015).  
 
DNA binding dyes, such as SYBR Green present an easy to use, cost-effective 
visualisation tool and are a popular choice for optimising qPCR reactions. Fluorescence 
increases in proportion with the concentration of dsDNA, which presents the dye with 
more binding sites. This feature provides information about the accumulation of PCR 
products as the fluorescence signal increases in line with the augmented levels of dsDNA 
and this can be directly measured (Figure 1.3.3). SYBR Green is a reasonably 
straightforward method; however, non-specificity is a limitation that is inherent to 
assays that rely upon dyes binding to DNA. The binding of dye molecules that increases 
in parallel with the increase in dsDNA means that reaction specificity can only be 
governed by the primers (Giglio et al., 2003; Agrimonti et al., 2013). 
 
The other most commonly employed detection chemistry for qPCR is linear probes, such 
as TaqMan. As well as PCR primers, an oligonucleotide probe is incorporated into the 
reaction in this detection chemistry. Attached to the 5’ end of the probe is fluorescent 
reporter dye, such as FAM, and at the 3’ end is a quencher, for example TAMRA. TaqMan 
system developed by relies on the release and detection of a fluorescent signal following 
the cleavage of a fluorescent labelled probe by the 5-exonuclease activity of Taq 
polymerase. In the intact state, the fluorescent signal on the probe, such as 6-
carboxyfluorescein (6- FAM), is quenched by the proximity on the probe of a second dye, 
6-carboxy-tetramethylrhodamine (TAMRA). The rapid detection of fluorescence is 
achieved after each round of amplification as fluorescent dye is released(Figure 1.3.3) 
(Heid et al., 1996; Kang et al., 2007; Kubota et al., 2014; Wang et al., 2014). 
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qPCR allows for high throughput analysis of numerous samples. Provisional upon the 
creation of a universal probe for use with real-time PCR, conserved regions of 16S rRNA 
theoretically enable the detection and enumeration of all complex populations of 
bacteria (Farrelly et al., 1995). A functional gene specific for a given group or species to 
increase specificity was also applied in this technique (Nadkarni et al., 2002). qPCR has 
been used to identify and evaluate the distribution of faecal desulfovirbios in healthy 
samples also determining Desulfovibrio numbers in crypt-associated mucous (Fite et al., 
2004; Rowan et al., 2010). 
 
Figure 1.3.3. Comparison of and A) SYBR®-Green, B) TaqMan®- Based Detection 
Workflows Adapted from (Cao & Shockey, 2012) 
 
1.3.7 Microarray  
 
A biochip is a collection of miniaturized test sites (microarrays) arranged on a solid 
surface allowing in a single experiment to analyse the expression of thousands of genes, 
or the same gene from thousands of organisms in parallel.  
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Total DNA or RNA is isolated from clinical samples and then fragmented. The fragments 
are amplified by PCR and simultaneously labelled using labelled nucleotides (referred to 
as DNA arrays) or the fragments are directly labelled chemically (referred to as RNA 
arrays) and hybridized to oligonucleotide probes which immobilized on support matrix, 
termed probes. After that the immobilized probes are washed to remove excess product 
before the probe/target complex can be visualized with a fluorescent scanner 
(Namsolleck et al., 2004) (Figure 1.3.4).  
 
In standard oligonucleotide or cDNA microarray probes are organised directly on a solid 
surface. Either a collection of organised spotted probes immobilized on a solid surface 
like glass microscope slide, nylon membrane or silicon or alternatively a bead array 
which involves a collection of microscopic polystyrene beads, each with a specific probe. 
(Lyons, 2003; Mah et al., 2004;  Mocellin et al., 2005).  
 
2D solid substrate arrays rely on probes bound in a two-dimensional fashion directly to 
the surface. However, in 3D solid substrate arrays the probes are bound in multiple 
layers within a three-dimensional microdroplet. A 3D format increases the surface area 
and increase probe quantities, therefore increasing the sensitivity of the microarray 
(Tang et al., 2009; Bumgarner, 2013). 
 
A review of the literature indicates that micro-array systems have been used to analyse 
the diversity of bacterial populations based on their functional genes or the 16S rRNA 
gene (Cho & Tiedje 2001; Paliy et al., 2009). Microarrays have also previously been used 
in the study of the composition of bacteria present in the human colon (Wang et al., 
2004; Kim et al., 2005; Palmer et al., 2006).  
 
For characterization of bacterial composition several types of microarrays have been 
used. Genome arrays which are established using pure bacterial culture genomic DNA 
(Wu et al., 2004). Functional gene arrays which contain genes encoding key enzymes 
that are involved in the metabolic pathway of the bacteria which allow controlling any 
physiological changes within bacterial population (Wu et al., 2001). Phylogenetic 
oligonucleotide arrays are used for analysis of bacteria structure and variance and their 
probes are designed from rRNA sequence database (Loy et al., 2002). 
CHAPTER 1: INTRODUCTION 
34 
 
 
Figure 1.3.4.  Principle of the microarray technique (adapted from Namsolleck et al, 
2004). 
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Section 4 
The effect of antibiotics and honey on the growth of bacterial 
biofilms 
1.4.1 Bacterial biofilms  
 
Bacterial populations utilize several strategies to preserve their existence in adverse 
environments. One such strategy is the formation of bacterial biofilms in which a group 
of bacteria form a multicellular structure, protecting individuals through the production 
of extracellular polymeric substances (EPS) (Figure 1.4.1) (Kjelleberg et al., 2007). 
Whilst biofilms have been investigated those present on living tissues, and in particular 
those of the gut, have not been explored in detail (Dongari-Bagtzoglou, 2008). The 
human colon harbours a huge number of bacterial including both beneficial bacteria, 
and under certain circumstances pathological or opportunistic bacteria which can give 
rise to conditions such as UC (Sasaki and Klapproth, 2012). As far as the formation of 
biofilms in the colonic bacterial population is concerned, there have been relatively few 
studies ( Probert & Gibson, 2002; Macfarlane & Dillon, 2007; von Rosenvinge et al., 
2013). Whilst the usage of antibiotics for controlling a particular bacterial species within 
colon can be effective; they demonstrate reduced effect against bacterial biofilms and 
can impact on key metabolic activities, such as fermentation and enzyme synthesis 
(Newton et al., 2013). 
 
Figure 1.4.1 biofilm formation – 1. Cell adhesion 2.  Formation of micro colonies, 3. 
Accompanied by EPS production. 4. The formation and maturation5. The dispersion 
cells from biofilm (Kjelleberg et al., 2007). 
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1.4.2 The aspects of bacterial Quorum Sensing in the colon  
 
Quorum sensing (QS) is a mechanism that can regulate the bacterial colonization and 
the dissemination in the gut by coordinating gene expression and cell behaviour 
according to the population density of the gut bacteria (Yang and Jobin, 2014). This 
phenomenon involves bacterial release of various classes of signalling molecules, 
“autoinducers”, into their environment such as acyl-homoserine lactones (AHLs) (Fuqua 
et al., 1994). The accumulation of these autoinducer molecules then enable a single cell 
to sense the number of bacteria (cell density) and also measure the number 
(concentration) of the molecules within a population (Miller and Bassler, 2001; 
Thompson et al., 2015).  In this way, the bacteria share information about cell density 
and regulate individual gene expression by cell-to-cell communication (Rutherford and 
Bassler, 2012). When the signalling molecules attain a critical threshold concentration, 
the targeted QS genes are activated or repressed (Jacobi et al., 2012). 
The role of QS in the growth and survival of colonic bacteria is likely to be important. It 
is believed that upon colonization of the gut bacteria undergo metabolic changes where 
genes involved in transportation and the metabolism of carbohydrate and amino acid 
become highly induced (Yuan et al., 2008; Alpert et al., 2009). The colon microbiota is 
known to consist of a wide variety of bacteria with a variety of roles in the gut ranging 
from modulation of the immune system to protection against pathogens, and nutrient 
absorption (Poxton et al., 1997). The diversity of the colonic bacteria determine the 
state of the human gut, with a high diversity being associated with a healthy human gut. 
On the other hand, a reduction in diversity is associated with dysbiosis where an 
abnormal ratio of commensal and pathogenic bacterial species exists in the colon, 
favouring the emergence and augmentation of certain bacterial species in the gut which 
is considered to be the hallmark of the colonic disease, such as UC (Manichanh et al., 
2006; Bäckhed et al., 2012; Belizário and Napolitano, 2015). Because of the diversity and 
the increase in number of the bacteria inhabiting the colon there is a need for a survival 
mechanism that would enhance the growth in the presence of bacterial competition. QS 
could be such a mechanism. Bacteria motility, surface proteins biofilm formation, and 
virulence are also controlled by the secretion of QS signalling molecules which are 
released into the colon environment (Di Cagno et al 2011; Piras et al., 2012; Shao et al., 
2012; Thompson et al., 2015). It has been reported that chemicals mediating QS are also 
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pathogenic factors for certain bacterial species and that their levels define the relative 
bacterial number particularly in diseases like UC (Raut et al., 2013). Several studies have 
described the role of QS the in their pathogenesis. It is worth mentioning here that one 
of the emerging bacterial species appearing during the pathogenesis of UC was 
Enterococcus faecalis. According to these studies, microbes utilize several QS regulatory 
proteins including gelatinase, serine protease, enterocin O16 and cytolysin as the 
primary pathogenic attributes ( Zhou et al., 2016;  Ali et al., 2017). Among these various 
molecular moieties, gelatinase has been associated with the disruption of intestinal 
epithelial barriers thus providing pathogenic bacteria to invade intestinal barrier 
(Maharshak et al., 2015). Furthermore, data from animal model studies showed that 
bacterial invasion of intestinal barrier is dependent on the quorum-sensing 
transcriptional regulator SdiA and bacterial species lacking this regulatory protein have 
relatively lesser capability to penetrate into the deep layers of the gut (Sharma and 
Bearson, 2013; Sharma and Casey, 2014). The bacteria involved in UC are no exception 
to this control. These bacteria, amongst others, synchronize their social behavior, to 
communicate among themselves, and to regulate gene expression in response to their 
population density (Rutherford and Bassler 2012). In additiona, antibiotic treatment 
eliminates vulnerable bacteria from the bacterial population in the gut, leaving resistant 
bacteria to grow, multiply and perform their physiological functions. It is possible, 
therefore, that the acquired and intrinsic resistance to a variety of antibiotics in UC 
could be associated with QS mechanisms of the bacteria involved (Miller et al., 2014; Ali 
et al., 2017).   
 
1.4.3 Existing UC therapies  
 
The UC symptoms are mainly inflammation of the colon associated with diarrhoea with 
blood. Symptoms are mainly a refractory and hard to treat even with conventional 
medications. Mostly anti-inflammatory drugs prescribed like aminosalicylates and 
corticosteroids followed by a variety of immune system suppressors that reduce 
inflammation. The most prominent immunosuppressants in practice are azathioprine, 
mercaptopurine, cyclosporine, infliximab, adalimumab and golimumab and vedolizumab 
(Monterubbianesi et al., 2014; Rietdijk & D'Haens, 2014; Kim et al., 2015; Shahidi et al., 
2016). With our increasing understanding of the gut microbiome and the role of 
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bacterial biofilms colonic disease; it is timely to evaluate usage of antibiotics amongst 
UC patients. In treating UC clinicians must account for numerous factors when designing 
a therapeutic regime. It has been observed that alongside bacterial associated colitis, the 
Clostridium difficile secreted toxins (CD toxins) can also induce antibiotic-associated 
colitis, or pseudomembranous colitis (PMC) (Kawaratani et al., 2010). 
Two prominent antibiotics rifaximin and metronidazole are commonly prescribed to 
treat UC. However, the usage of metronidazole is controversial, whilst considered as a 
cost-effective drug which inhibits the nucleic acid synthesis by disrupting the DNA of 
microbial cells resulting in bacterial cell death with good activity against pathogenic 
anaerobic bacteria (Lofmark et al., 2010). Issues remain surrounding the generation of 
resistant bacteria involved in UC with a capability to produce nitroreductase (Rafii et al., 
2003). Because of this and due to other factors, including genetic susceptibility, and 
abnormal immune response potentially due to Clostridium difficile colonisation, 
metronidazole is often administered in conjuction with other agents. A case report 
suggested that vancomycin and metronidazole when administered in conjunction were 
helpful in overcoming refractory UC (Miner et al., 2005). A more in depth study of 
metronidazole-ciprofloxacin administration demonstrated that the antibiotic pairing 
transiently disrupted the colon bacterial population with selective disruption of 
bacterial biofilms associated with UC. The beneficial bacterial population return to 
normal within a week upon the cessation of antibiotic administration (Swidsinski et al., 
2008).  
Rifaximin is another antibiotic that selectively targets the microbial population involved 
in IBD acts by inhibiting RNA synthesis in susceptible bacteria by binding to the β-
subunit of bacterial RNA polymerase (Guslandi, 2011). This antibiotic has a very 
promising in vitro antimicrobial profile when compared with other antibiotics like 
ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin. A study 
comparing rifaximin with all these antimicrobial pharmacological agents revealed its 
inhibitory effect on 90% of the anaerobic bacterial strains evaluated in this study. 
Furthermore, the minimal inhibitory concentration was 0.25 microgram/ml comparable 
with teicoplanin and vancomycin, however, less than those of nitazoxanide and 
ampicillin-sulbactam (Finegold et al., 2009). Rifaximin is approved in the United States 
for the treatment of travellers’ diarrhoea and colonic infections. Due to its safety profile 
and beneficial impact on gastroenteritis and associated disorder, this antibiotic is 
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approved in more than 30 other countries to treat a variety of gastrointestinal disorders 
(Koo & DuPont, 2010). 
Rifaximin has shown very promising data, with remission in 59% of individuals with 
Crohn’s disease and 76% with UC (Guslandi, 2011). Promising results with rifaximin 
have also led to the development of rifaximin-extended intestinal release variants 
(Scribano, 2015) as well as a nano-suspension formulation instead of orally 
administered tablets (Newton & Kumar, 2016). IBD are associated with gut microbiota 
dysbiosis, and a review of existing studies suggested that, besides direct bactericidal 
effect, the rifaximin can also modulate the gut environment maintaining normal 
microflora (Newton & Kumar, 2016). However, these findings and the proposed 
mechanism of action of rifaximin are yet to be validated. 
 
1.4.4 Traditional medicine as a potential treatment for UC  
 
A wide variety of traditional medicines are also used to treat UC. The most popular 
include aloe Vera gel, wheat grass juice, Boswellia serrata, and bovine colostrum enemas 
(Ke et al., 2012). A proposed advantage of using herbal remedies is reduced side effects 
when compared with synthetic medicine. However, there is limited evidence about the 
efficacy of herbal medicine, although its use is widely accepted for herbal remedies due 
to relative safety and cost benefits. A series of clinical trials using herbal medicine in UC 
have also been reported (Salaga et al., 2014, Teschke et al., 2015, Triantafyllidi et al., 
2015). The use of honey as a natural remedy for UC is increasing. Natural honey showed 
highly promising results in protecting rodents from acetic induced colitis. Honey is 
composed of a mixture of sugars and as such the control in this study involved glucose, 
fructose, sucrose and maltose mixture showing no significant protective effect 
confirming that natural honey has certain essential elements inhibiting the induction of 
colitis (Mahgoub et al., 2002). 
 Intriguingly a similar antibacterial effect was observed with a natural product, honey, at 
a low concentration of 0.5 % (v/v). At this dose biofilm formation in enterohemorrhagic 
Escherichia coli O157: H7 was significantly reduced, without inhibiting the growth 
commensal E. coli K-12 biofilm formation (Lee et al., 2011). Follow-up studies compared 
Manuka honey (MH) alone or in combination with sulfasalazine a medicine used for 
colitis treatment. MH showed an additive effect when used as combination therapeutics 
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thus confirming its efficacy and safety profile without any interactions with a 
conventional drug (Medhi et al., 2008).  
 
Besides benefitting morphological and histological scores, biochemical parameters like 
lipid peroxidation were also improved with combination therapeutic utilizing MH 
(Medhi et al., 2008). The use of honey in the treatment of colitis has been reported both 
with the oral administration or rectal administration. A study compared the benefits of 
honey, prednisolone and disulfiram in the trinitrobenzene sulfonic acid induced colitis 
rat model. Intriguingly honey showed a higher potential to treat chronic colitis when 
compared with prednisolone (Bilsel et al., 2002). 
 
The emerging therapeutic potentials of honey in UC are due to its potential in 
overcoming inflammation and oxidative stress. A recent study has evaluated the benefits 
of using honey in dextran sodium sulfate (DSS) induced colitis model. The study 
revealed that honey-treated UC animals showed improvements in both microscopic and 
macroscopic scores. A significant down-regulation of oxidative, inflammatory and 
apoptotic markers manifest the beneficial impact of honey in UC (Nooh & Nour-Eldien, 
2016). This study supports further investigations into the effect of honey alone, or in 
combination with other conventional medications, to treat UC. 
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AIMS OF THE RESEARCH 
 
The exact causes of ulcerative colitis (UC) are unknown, with possible candidates being 
an autoimmune response, genetics and diet/environment. It is the contention of this 
thesis that the microflora of the colon plays an important role in the development of UC, 
in particular that the Sulfate Reducing Bacteria (SRB) are the primary etiological agent 
involved in UC. A sub-hypothesis of the current study is that the consumption of Mauka 
honey can be an effective approach in the control of possible UC-causing bacteria. The 
major hypothesis and the associated sub-hypothesis are linked with the following 
research questions: 
 Does bacterial diversity change in patients suffering from UC, with particular 
reference to SRBs? 
 Is there any link between SRB and the presence of specific bacterial population 
that can help in early detection of SRB?  
 Can the use of Manuka honey improve the efficiency of antibiotics in controlling 
the bacteria involve in UC?  
The overall aim of the study is to estimate the relative levels of SRB, compared to 
predominant species colonizing the mucosal surface of the human colon, in healthy and 
patients suffering from UC, and to design procedures for the detection and 
quantification of SRBs. 
Specific aims of the investigation were as follows:  
 Test bacterial DNA samples obtained from patients suffering from UC and 
healthy controls. 
 Identify existing oligonucleotide (DNA) probes for selected bacteria known to be 
implicated in the aetiology of UC; and designing de-novo probes where required. 
 Evaluate DNA probes using a cassette based approach for fine-tuning of biochips. 
 Test DNA probes for hybridization with bacterial DNA samples obtained from 
patients suffering from UC and healthy controls. 
  Evaluate a sensitive method for rapid enumeration of SRB 
 Investigate the influence of honey on the growth of SRB biofilms in the presence 
of antibiotics to determine whether this agent influences bacterial growth and 
activity. 
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Section 1 
 
Molecular characterisation of mucosa-associated bacterial 
communities from human colon 
 
2.1.1 Bacterial growth conditions 
 
The bacterial strains used in this study were Desulfovibrio alaskensis NCIMB 13491, 
Desulfovibrio indonensiensis NCIMB 13468, Desulfovibrio vulgaris (strain Hildenborough, 
NCIB 8303), Desulfovibrio vietnamensis DSMZ 10520, and Escherichia coli (BP) obtained 
from the University of Portsmouth, School of Pharmacy and Biomedical Sciences 
bacterial culture collection. The Desulfovibrio bacteria were used because they represent 
the main genus of SRB that found in the human colon and known to be implicated in UC. 
Moreover, unpublished data reported a level of serum antibody against D. indonensiensis 
in UC patients (Zinckivch, Unpublished). E. coli (BP) was used because previous 
experiments have shown that the presence of E. coli in the human colon correlates 
significantly with SRB presence (Zinckivch, Unpublished). 
SRB strains (Desulfovibrio sp.) were cultivated anaerobically in Vitamin Medium with 
iron (VMI medium) or Vitamin medium with reduced iron (VMR) at 37°C for 7 days. It 
has been found that these media supplemented with lactate and sulfate which can 
ofered a higher sensitivity of SRB detection (one to two orders of magnitude) (Zinkevich 
et al., 1996; Zinkevich & Beech, 2000). E. coli BP were cultivated aerobically at 37°C for 
18 h in either Lysogeny Broth (LB) medium which is the most commonly used a 
nutrient-rich medium for fast growth of E.coli (adapted from Bertani, 1951) (Fisher, 
UK); or in MacConkey Agar which is usually used for the differentiation and 
identification of enteric bacteria based on their lactose fermentation (MacConkey, 
1905).  The bacterial inoculum was adjusted for all experiments of approximately 2X108 
cells/ml for E. coli BP and 7X106 cells/ml for SRB. The composition of VMI, VMR, LB 
medium nutrient broth and MacConkey Agar is shown in Appendix 1. 
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2.1.1.1 Purification of genomic bacterial DNA 
 
Chromosomal DNA was extracted from bacterial cultured cells using QIAGEN DNeasy 
Blood and Tissue Kit (QIAGEN, UK) following the manufacturer’s instructions (DNeasy 
Blood and Tissue Handbook 07/2006 p.29-44). The bacterial cells harvested in 
eppendorf tubes (1.5 ml) by centrifugation at 13 000 x g for 10 min at room tempreture 
(Heraeus Fresco 21, Thermo Scientific, UK) and were resuspended in 180 μl of Tissue 
Lysis buffer (ATL buffer). 20 µl of Proteinase K was added to the samples and mixed 
thoroughly by vortexing and incubated at 56°C from 1-3 h until the samples completely 
lysed. The samples were vortexed occasionally (every hour). After incubation the 
samples were vortexed for 15 seconds before adding 200µl of Lysis buffer (AL buffer) 
and mixed thoroughly by vortexing. Then 200µl of 100% ethanol was added to the 
samples and mixed again thoroughly by vortexing. The mixture was placed into the 
DNeasy Mini Spin column (placed in a 2 ml collection tubes) and centrifuged at 6 000 x g 
for 1 min at room tempreture, the flow through was discarded and the DNeasy Mini Spin 
column was placed in a new collection tube. 500 µl of Wash buffer 1 (buffer AW1) was 
added to the column, which was then centrifuge at 6 000 x g for 1 min at at room 
tempreture, the flow through was discarded and the DNeasy Mini Spin column placed in 
a new collection tube. 500 µl of Wash buffer 2 (buffer AW2) was added to the column, 
which was then centrifuged at 13 000 x g for 3 min at room tempreture and the flow 
through was discarded. Finally, the DNA was eluted by placing DNeasy Mini Spin column 
in a clean 1.5 ml Eppendorf tubes after adding the 50 µl of Elution buffer (buffer AE) 
directly onto the centre of DNeasy membrane, incubated at room temperature for 1 min 
and then centrifuged at 6 000 x g for 1 min at room temperature.  
 
Bacterial DNA isolated following the sampling of specimens of colonic mucosa which 
were taken during colonoscopy from the proximal colon of one healthy individual and 
four patients suffering from UC. The samples were kept at -20°C until used (Zinkevich & 
Beech, 2000). These samples were provided by Dr. Zinkevich.  
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2.1.2 Polymerase chain reaction (PCR) 
 
Aliquots of 2-10 ng of DNA were added to a PCR master mixture and the volume 
adjusted to 25 µl or 50 µl with nuclease-free water (SIGMA). The PCR products were 
analysed by 0.9 or 1.2 % agarose gel electrophoresis. Standard PCR reactions were 
carried out in the RoboCycler® Gradient 96 (Stratagene, UK) or T100™ Thermal Cycler 
(Bio-Rad, UK). Touch down PCR reactions were carried out in the T100™ Thermal Cycler 
(Bio-Rad, UK). All primers used in this study were purchased from Life Technologies, 
UK. GoTaq® Green Master Mix was purchased from Promega, UK. 
 
2.1.2.1 PCR for bacterial 16S rRNA genes 
 
The V3, V4 and V5 region of the bacterial 16S rRNA gene was amplified using the 
primers pair 341F+GC and 907R (Table 2.1.1). Final reactions contained: 2x GoTaq® 
Green Master Mix and 10 µM of each oligonucleotide primers. Reactions for the V3, V4 
and V5 region were initially denatured at 94°C for 4 min; followed by a touch down PCR: 
20 cycles of 94°C for 1 min, 63-54 °C for 1 min and 72°C for 1 min followed by 15 cycles 
of 94°C for 1 min, 53°C for 1 min and 72°C for 1 min plus an additional 10-min cycle at 
72°C. 
Approximately 1.5kb of 16S rRNA gene was amplified using primers 8F and 1492R 
(Table 2.1.1). Final reactions contained: 2x GoTaq® Green Master Mix and 10 µM of 
each oligonucleotide primers. Reactions were initially denatured at 94°C for 2 min; 
followed by 30 cycles of 94°C for 30s, 55°C for 1 min and 72°C for 45s followed by a final 
extension step at 72°C for 15 min. 
 
2.1.2.2  PCR detection of SRB (for dsr, Desulfovibrio 16S rRNA and aps 
genes) 
 
The dsr, Desulfovibrio 16S rRNA and aps genes were amplified using the primers set 
DSR1F+,DSR-R, DSV691F, DSV826R and Aps F, Aps R respectively (Table 2.1.1). 
Reactions contained: 2x GoTaq® Green Master Mix and 10μM of each oligonucleotide 
primers. Reactions for the dsr were initially denatured at 95°C for 3 min; followed by 35 
cycles of 95°C for 15s, 67°C for 30s and 72°C for 30s followed by a final extension step at 
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72°C for 10 min. The reactions for the Desulfovibrio 16S rRNA gene were initially 
denatured at 95°C for 3 min; followed by 35 cycles of 95°C for 30s, 62°C for 1min and 
72°C for 45s followed by a final extension step at 72°C for 10 min. The reactions for the 
Aps gene were initially denatured at 95°C for 3 min; followed by 34 cycles of 95°C for 
15s, 59°C for 1min and 72°C for 1 min followed by a final extension step at 72°C for 10 
min. 
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Table 2.1.1. Sequence of primers used in PCR 
Primer Sequences of + and – Primers 
(nucleotide) 
Gene Target Reference 
8F 5'-AGAGTTTGATCCTGCCTCAG-3' 
 
 
 
 
 
Bacterial 
16S rRNA 
 
 
Turner et al., 
1999 
 1492R 5'-GGTTACCTTGTTACGACTT-3' 
 
341F+GC 
 
5’-
CGCCCGCCGCGCGCGGGCGGGGCGGGGGCA
CGGGGGGCCTACGGGAGGCAGCAG-3’ 
Muyzer et 
al., 1998 
 
907R 5’-CCGTCAATTCMTTTGAGTTT-3’ 
DSR1F+ 
 
5’-ACSCACTGGAAGCACGGCGG-3’ dsrA Kondo et al., 
2006 
DSR-R 5’ -GTGGMRCCGTGCAKRTTGG-3’ 
DSV691F 5′-CCGTAGATATCTGGAGGAACATCAG-3′ Desulfovibrio 
16S rRNA 
Fite et al., 
2004 
DSV826R 5′-ACATCTAGCATCCATCGTTTACAGC-3′ 
APS F 5’-CGCTGGCAGATGATGATCAA-3’ apsA This study  
APS R 5’-ATGCGGTTGGGCTCGTT-3’ 
Legend: R=G/A, Y=T/C, W=A/T, I = Inosine, S=G /C , M= A/C , K= G/T. 
 
2.1.2.3 Positive controls for PCR reactions 
 
Genomic DNA, extracted from laboratory type strains obtained from University of 
Portsmouth strains collections were used as positive controls and Nuclease free Water 
as negative controls for all PCR reactions. Details of laboratory type strains and 
microbial cultivation are given in subsection (2.1.1) and media composition in Appendix 
1. 
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2.1.3 Analysis of PCR products using agarose gel electrophoresis 
 
All the amplified PCR products (10 µl) were analysed on either 0.9 % (w/v) or 1.2% 
(w/v) agarose gel made by dissolving the appropriate amount of agarose (Sigma 
Chemical Ltd, UK) in 1xTAE (20 mM Tris acetate, 10 mM sodium acetate, 0.5 mM Na2-
EDTA) buffer. DNA molecular weight markers (1 kb DNA ladder and 100 bp, Promega, 
UK) were used for size determination of the PCR products. The gels were run in a 
horizontal electrophoresis chamber (Horizontal gel electrophoresis unit, Scie-Plas, UK). 
A voltage of 50 V was applied for the first 10 min and 140 V for the remaining 40 min. 
The gels were stained with the SYBR® Safe DNA gel stain (Life Technologies), (6 µl of 
stain added into 100 ml of agarose gel) and was photographed under UV light using 
molecular imager® Gel Doc™ XR+ Imaging system (BIORAD). 
 
2.1.4 Cloning: construction of genomic libraries and sequencing 
 
The total bacterial DNA extracted from biopsy sample was used as the template for PCR 
amplification of 16S rRNA and dsrA genes, which were subsequently cloned using 
pGEM®-T Easy Vector cloning system (Promega, UK) and TOPO® TA Cloning® Kit for 
Sequencing (life technologies, UK).  
 
2.1.4.1 Ligation of plasmid DNA and competent cells transformation  
 
The ligation reaction (final volume 10 µl) was prepared using 50 ng (1 µl) of pGEM®-T 
Easy vector, 5 µl  of 2X rapid ligation buffer, 3 µl of insert (PCR product) and 1 µl of T4 
DNA ligase. The molar ratio of vector to the insert of 1:3 was used as recommended by 
the manufacturer (technical manual no. 042). 
The ligation reactions were incubated at RT for 1 h then centrifuged and 2 µl of the 
ligation reaction was added to sterile 1.5 ml tube placed on ice. 50 µl of JM109 high 
efficiency competent cells (Messing et al., 1981) were carefully transferred to ligated 
mixture and incubated on ice for 20 min.  
 
The cells were heat-shocked for 50 seconds at 42°C in a water bath and were 
immediately returned to the ice for 2 min. Room temperature SOC medium (950 µl) 
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(Sigma, UK) was and cells were incubated at 37°C for 1.5 hours with aeration (~150 
rpm).  
100 µl of each transformation culture were plated onto LB/Ampicillin/IPTG/X-Gal 
plates in duplicate. The solid LB medium was supplemented with 100 µg ampicillin ml-
1, 100 µg X-Gal ml-1 and 0.5 mM IPTG. After incubation overnight at 37°C the plates 
were placed at 4°C overnight for better blue/white screening.  
TOPO cloning reaction (final volume 6 µl) was prepared according to manufacture 
instruction. 4 µl of PCR product, 1 µl of salt solution and 1 µl TOPO®TA vector, was 
mixed gently and incubated for 5 minutes at RT. 2 µl of the TOPO® cloning reaction was 
added to One Shot® TOP10 chemically competent cells (Life Technologies, UK), mixed 
gently and incubated on ice for 30 minutes. The cells were heat-shocked for 30 seconds 
at 42°C without shaking. The tube was immediately transferred to the ice for few 
minutes. 250 µl of room temperature S.O.C medium was added to the cells and shaked 
horizontally (200rpm) at 37°C. 100 µl of each transformation culture were plated onto 
LB/Ampicillin plates in duplicate and incubated overnight at 37°C . 
 
2.1.4.2 Purification of plasmid DNA  
 
The white bacterial colonies were picked from the plates and inoculated into sterile 
universal tubes containing 5 ml of LB supplemented with 100 µg/ml ampicillin (Fisher, 
UK) and incubated overnight at 37°C with aeration (~200 rpm).  
Recombinant plasmid DNA was purified using Zyppy™ Plasmid Miniprep Kit (Zymo 
Research, Irvine, CA) following the manufacturer’s instructions. 3 ml of E.coli LB culture 
harvested in Eppendorf tubes (1.5 ml) by centrifugation at 11 000 x g for 1 min 
(Heraeus Fresco 21, Thermo Scientific, UK). Bacterial cells were re-suspended in 600 µl 
water.  100 µl of 7X Lysis Buffer was added and mixed by inverting the tube 4-6 times 
until complete lysis was obtained. 350 µl of Neutralization Buffer was added and mixed 
by inverting the tube several times until the neutralization was completed. The samples 
were span at 11,000 x g for 4 minutes.  
The supernatant (~900 µl) was transferred into the Zymo-Spin™ IIN column without 
disturbing the cell debris pellet. The column centrifuged 11,000 x g for 15 seconds and 
flow through was discarded (this step was repeated until all supernatant has been 
loaded). 200 µl of Endo-Wash Buffer was added to the column and centrifuged for 30 
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seconds then 400 µl of Zyppy™ Wash Buffer and centrifuged for 1 minute.  Finally the 
plasmid DNA was eluted by placing Zymo-Spin™ IIN column into a clean 1.5 ml 
Eppendorf tube and then 30 µl of PCR grade H2O was added directly onto the 
membrane, incubated at RT for 1 min and then centrifuged at 11 000 x g for 1 min. 
Insertion of the PCR product of interest into the plasmid was verified by PCR using 
primers 8F and 1492R and DSR1F+ and DSR-R (Table 2.1.1) and by agarose gel 
electrophoresis analysis (subsection 2.1.3). 
 
2.1.4.3 Purification of PCR product and Sequencing 
 
Amplified PCR products of plasmid DNA (bacterial 16S rRNA and dsr genes) were 
purified using QIAquick® PCR purification kit (Qiagen, UK) following the 
manufacturer’s instructions (quick-start protocol, 09/2011 p.1-2) before to be sent to 
the GATC Biotech UK (Cambridge, UK) DNA sequencing service. 5 volumes of buffer PB 
was mixed with 1 volume of the PCR reaction applied onto the QIAquick column and 
centrifuged for 1 min. Flow through was discarded. The column was washed using 750 
µl buffer PE and centrifuged for 1 min. After flow through was discarded the QIAquick 
column was centrifuged once more for 1 min to remove residual wash buffer. Finally, 
the PCR product was eluted with 50 µl of ultra-pure water. Purified PCR products were 
sent for DNA sequencing (GATC Biotech, Cambridge, UK). The DNA fragments were 
identified by sequencing using PCR primers (subsections 2.1.2.1 and 2.1.2.2) and 
homology searches in BLAST of the GenBank. 
 
2.1.5 Denaturing Gradient Gel Electrophoresis (DGGE) 
 
PCR products (bacterial 16S rRNA gene) were separated on denaturing gradient gel 
(INGENYphorU, Ingeny International BV, The Netherlands). 30 µl of PCR products were 
loaded on 6% (w/v) polyacrylamide gel in 0.5x TAE buffer. The electrophoresis was run 
at 60°C using the gel containing 30% to 80% urea-formamide denaturing gradient 
(100% corresponded to 7M urea and 40% (v/v) formamide) increasing in the direction 
of electrophoresis. The gel was run for 15 min at 200 V and for 20 hours at 90 V. 
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After electrophoresis the gel was removed gently from the tank, placed in appropriate 
container and stained using 12 µl of SYBR Safe DNA gel stain (Life technologies, UK) in 
750 ml of double distilled water for 20 minutes in darkness, then rinsed thoroughly with 
distilled water. The gel was photographed under UV light using Alpha Innotech Gel 
Documentation System (Alpha Innotech Corporation, USA). 
 
2.1.6 DNA extraction from DGGE gels and Sequencing 
 
All bands were cut out from the DGGE gels using a sterile scalpel, transferred into a 
sterile 1.5 ml Eppendorf tubes containing 40 µl of ultra-pure water (Machado et al., 
2007). The samples were incubated for 24 h at 4°C, followed by 1 hour incubation at 
37°C. Samples were then centrifuged at 13 000 x g for 1 min (Heraeus Fresco 21, 
Thermo Scientific, UK). The supernatants (5 µl) were used for PCR re-amplification as 
described above (subsection 2.1.3.1). Re-amplified PCR products were purified using 
QIAquick® PCR purification kit (Qiagen, UK) (as described in subsection 2.1.4.3) and 
sent for DNA sequencing (GATC Biotech, Cambridge, UK). The DNA fragments were 
identified by sequencing using PCR primers (subsections 2.1.2.1) and homology 
searches in BLAST of the GenBank. 
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2.1.7 Phylogenetic analysis 
 
Sequences were aligned using Muscle as implemented in SeaView ver4.0 (Galtier et al., 
1996; Edgar, 2004). Phylogenetic trees were constructed using the maximum likelihood 
optimal criteria which are part of SeaView ver4.0. The Tamura and Nei 1993 (TN93) 
model was the substitution model employed using a rate category of 4. Trees were 
constructed using BioNJ method (Gascuel, 1997) with NNI tree searching operations. 
Support for nodes in the produced trees was estimated with a bootstrap analysis, 
implemented in SeaView ver4.0. A bootstrap search of 100 repetitions was used in this 
analysis. 
The DGGE gel was scored for the presence and absence of bands for each sample tested. 
A comparative table was constructed with band presence score as 1, and absence scored 
as 0. The comparative table was used to construct a matrix from which genetic distance 
was calculated according to the algoritm of Nei and Li (1979) as applied in PAUP* 4.0 
(Swofford, 2003). The genetic distance was used to construct a UPGMA tree.  
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Section 2 
Probe designing and testing 
2.2.1. DNA probes design 
 
The groups of colonic bacteria that can be involved in the etiology and pathogenesis of 
UC were used as targets for Probes design. The NCBI database 
(http://www.ncbi.nlm.nih.gov) was used to derive sequences for probe design 
(Appendix 3). The complete nucleotide sequences for each functional and structural 
gene were downloaded and saved in FASTA format. The sequences were loaded in 
SeaView software (Galtier et al., 1996). Region variations in the sequences were 
identified from multiple alignments generated by Clustalo (Sievers et al., 2011) or 
Muscle (Edgar, 2004). Based on final alignments, conserved parts of the sequences of 
each gene were chosen and used for probe designing using the Oligo 7 program 
(Rychlik, 2007). Published probes and an established rRNA-targeted oligonucleotide 
probe database named 'probeBase' (Loy et al., 2007) were also used for probe selection.  
 
The probe design meets the following well-established requirements:  
 Unique to the target agent. 
 The homogeneous predicted melting temperatures (Tm) of the probes. 
 The homogeneous length of oligonucleotides and for the developing array the 
probe size is preferentially limited to between 18 and 25 bases. 
 
Hybridization kinetics of nucleic acids is temperature dependent, and the specificity and 
efficiency depend on the hybridization temperature. One of the main problems with 
designing oligonucleotide microarrays is to achieve nearly identical melting 
temperatures for all probes on the array. There are several approaches for the 
equalizing of the probes hybridization ability. In the first stage, the oligonucleotide 
probes should be design with the same predicted melting temperature (Tm±2⁰C) by 
using one of the algorithms based on thermodynamic properties of nucleic acid duplex 
formation and dissociation in solution. Mainly all the algorithms are based on the 
nearest neighbour model (Breslauer et al., 1986).   
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The predicted Tm is calculated using Integrated DNA Techenlogy (IDT) OligoAnalyzer 
3.1program (http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/Default.aspx). 
For the Tm calculation, the program demands not only the oligonucleotide sequence, 
but the buffer conditions as well. Tm and consequently the hybridization temperature 
depend on the buffer composition. The length of each probe was established ranging 
from 18 to 25 bases. The GC content was calculated and only probes with GC content 
between 40 and 60% were selected for further analysis. The designed probes were 
synthesized and C6-Amine-group was inserted at 5´-end during the synthesis (Sigma- 
Aldrich, UK).  All designed probes were verified against the GeneBank nucleic acid 
database for specificity using the BLAST program (Altschul et al., 1990).  
 
2.2.2 Cassette construction for fine-tuning of biochips 
 
Cassette approach is a novel method used for evaluation designed probes in single 
reaction. The cassette comprising all of the probes in equimolar proportions for a quick 
reveal the probes unsuitable for inclusion in the biochip (Zinkevich et al., 2014). Single 
stranded (ss) DNA cassette was used as the targets for hybridization with the probes 
that were coupled to the matrix so that the hybridization capacity of each probes to be 
evaluated. The ss DNA cassette is a lineal array of sequences complimentary to the 
studied set of probes. Cy3 fluorescent dye was inserted at the 5´-end of the ss cassette 
during the synthesis. Each DNA cassettes was constructed to contain the four chosen 
oligonucleotides and were synthesized by Bioneer Corporation (Daejeon, Republic of 
South Korea). The size of the cassette was varied from 93 to 100 bp.   
 
2.2.3 Development of a biochip using dendrimeric matrix  
 
Ready to use dendrimeric matrix activated for the probes immobilization was provided 
by Dr Nelly Sapojnikova (I. Javakhishvili Tbilisi State University, Andronikashvili 
Institute of Physics). Dendrimeric matrix is formed by the microscopic glass slide 
treatment in a special manner (Anne-Marie et al., 2006). 
The oligonucleotide probes were immobilized onto the activated slides using spotting 
pins (V&P Scientific, Inc, San Diego, USA). 200 nl/spot of oligonucleotide probes with 
two replicate spots of each probe being applied to activated slides. Concentrations of 
oligonucleotide probes were 250 pmol/0.1µl in 1% Diisopropylethyl amine (DIEA) 
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reagentPlus®, 99% (Sigma-Aldrich, UK), in water. The slides were then incubated 
overnight in a humid chamber at 37⁰C and subsequently washed with nuclease-free 
sterile water then with 100 % ethanol. The surface of the glass slides with the 
immobilized probes was deactivated by treatment with a solution made of 6-amino-1-
hexanol 97% (50mM), (Sigma Adrich, UK) and DIEA (150 mM) in 20ml of anhydrous 
amine free N,N-dimethylformamide (DMF) molecular biology grade (Applichem, 
Germany) for 2 hours, in order to prevent the binding of the fluorescently labelled DNA 
with the matrix surface. Finally, the deactivated glass slides with the immobilized 
probes (biochips) were washed with DMF, acetone, water and dried. The biochips were 
then ready to be used in hybridization experiments and can be stored at 4ᵒC until use at 
least for 6 months. 
 
2.2.4 Hybridization 
 
The hybridization buffer for the ss-DNA cassette was SSARC (4xSSC [600 mM NaCl, 60 
mM Na-citrate], 7.2% (v/v) Na-sarcosyl). The solution of Cy3-labelled ss cassette (100 
pmol/µl) was prepared by dissolving the dry pellet in nuclease free water. The cassette 
quantity in the hybridization buffer was 100 pmol. The sample and the slide with 
immobilized probes were preheated to the hybridization temperature (45⁰C) using 
chilling/heating block (Cole-Parmer®,USA) for 5 minutes. The fluorescent samples 
solution was loaded onto the biochip and covered immediately with the cover slip. The 
final volume of the hybridization solution was 10 µl. The volume of the hybridization 
solution (10 µl) is from the calculation 2 µl per 1 cm2 of the covered square. The area 
under a cover slip was 2.2cm x 2.2cm=4.84 cm2.  
Before placing the biochip in the hybridization chamber (Arrayit, USA) 10 µl of nuclease-
free water was added to one of the grooves to keep 100 % humidity in the chamber 
during the hybridization reaction. The slide was immediately placed in the hybridization 
chamber covered by the chamber lid and sealed by screws (Figure 2.2.1). The 
hybridization proceeds at 45°C for 4 hours. Slide was removed from the hybridization 
chamber and immersed in the washing buffer 1 (2XSSC/0.2% SDS) in a Petri dish for 
removing the cover slip. Then the slide was placed in a Falcon tube for washing in buffer 
1 by shaking for 2 minutes on a shaker multi Bio 3D (BIOSAN, Latvia). Then the buffer 1 
was discarded and next wash was performed in the washing buffer 2 (0.2XSSC/0.2% 
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SDS) and the washing buffer 3 (0.2XSSC) subsequently on a shaker multi Bio 3D 
(BIOSAN, Latvia) for 2 minutes each at 30 rpm at room temperature. The slide was dried 
by centrifugation in a Microarray High Speed Centrifuge (ArrayIt, USA), and visualized 
using a Portable Imager 5000 (Aurora Photonic, USA) with 532 nm green Laser and 580 
nm filter. The signal intensity of each point on the biochip was calculated using 
MicroChip Imager software (Aurora Photonics, USA).  
 
 
Figure 2.2.1. Photograph for the hybridization chamber 
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2.2.5 Genomic DNA preparation for hybridization on a biochip 
 
DNA purified from the bacterial strains described in subsection 2.1.1 and the genomic 
DNA from biopsy samples subsection 2.1.1.1 was used in the hybridization procedure.  
2.2.5.1 DNA amplification 
 
Genomic DNA from bacteria and from biopsy samples were amplified using illustra™ 
GenomiPhi HY DNA Amplification Kit (GE Healthcare, Life Science, USA). 22.5 µl of 
sample buffer was added to 2.5 µl of 10 ng DNA and mixed thoroughly. The samples 
were heated at 95 ᵒC for 3 min and immediately chilled on ice. The master mix was 
prepared by combine 22.5 µl of reaction buffer and 2.5 µl of enzyme mix on ice .25 µl of 
prepared master mix was transferred to each cooled samples on ice. The samples were 
incubated at 30ᵒC for 4 hours. The reaction was stopped by incubation at 65°C for 10 
min and followed by immediate chilling on ice for 10 min. The extent of amplification 
was verified using 1.5% agarose gel in 1X TAE buffer. The amplified reactions were 
store at -20 °C until used.  
2.2.5.2 Purification of amplified products  
 
The amplified products were purified using PureLink Quick PCR Purification Kit 
(Invitrogen, USA).  Four volumes of PureLink® Binding Buffer (B2) with isopropanol 
was added to one volume of the amplified product and mixed well. The samples were 
loaded into the PureLink® Spin Column placed in collection tube. The column was 
centrifuged at 10,000 × g for 1 min at room temperature and the flow through was 
discarded. 650 µl of washing buffer with ethanol was added to the column and 
centrifuged at 10,000 × g for 1 min at room temperature and the flow through was 
discarded. The column was centrifuged again at maximum speed (13,000× g) at room 
temperature for 3 min. Finally, the DNA was eluted by placing the PureLink® Spin 
Column in a clean 1.5 ml Eppendorf tubes after that  50 µl elution Buffer (10 mM Tris-
HCl, pH 8.5) was added directly onto the centre of column , incubated at room 
temperature for 1 min and then centrifuged at 13, 000 x g for 2 min.  
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2.2.5.3 DNA Fragmentation  
 
The amplified purified products were fragmented using NEBNext® dsDNA 
Fragmentase® (New England biolabs, UK). The fragmentation reaction was prepared by 
mixing 1-3 µg of amplified purified products, 2µl 10X reaction buffer v2, 2µl of 
NEBNext® dsDNA Fragmentase and 4 µl of 200 Mm MgCl2. The volume was adjusted to 
20 µl by nuclease-free water. The reaction was incubated at 37°C for 25 min and the 
enzyme was inactivated by heating the reaction for 5 min at 65°C. 
The restirictase FastDigest SaqAI (Thermo Scientific, USA) was used for the 
fragmentation of the amplified purified products as well. . The fragmentation reaction 
was prepared by mixing 3 µg of amplified purified products, 3 µl 10xSaqAI Buffer, 3 µl of 
SaqAI enzyme. The volume was adjusted to 30 µl by nuclease-free water. The reaction 
was incubated at 37°C 30 min, and the enzyme was inactivated by heating the reaction 
for 5 min at 65°C. The digestion conditions were selected to form a range of fragment 
sizes from 50 to 200 bp. The fragments sizes were checked in 1.5 % agarose gel in 
1XTAE buffer. The fragmented DNA was purified using PureLink Quick PCR Purification 
Kit (Invitrogen, USA) as described in subsection 2.2.5.2 
 
2.2.5.4 DNA labelling and hybridization  
 
Fragmented DNA was labelling using BioPrime® Plus Array CGH Genomic Labelling 
System (Invitrogen, USA) Alexa Fluor® 555-labeled primers and nucleotides. For 
labelling reaction approximately 1 µg of fragmented DNA and 20 µl of  Alexa Fluor® 555 
Panomer™ 9(31 nmole was re-suspended in 110 µl of 2.5X Reaction Buffer)  were mixed 
and nuclease free water was added up to 44 µl, . The reaction was incubated at 95°C for 
10 minutes then chilled immediately on an ice and was protected from light, for 5 
minutes. One ice, 5 µl of 10X Nucleotide Mix with Alexa Fluor® 555-aha-dCTP and 1 µl 
Exo-Klenow Fragment were added to the mixture with DNA to reach the final volume 50 
µl, The isothermal amplification of DNA and simultaneous labelling in the samples 
proceeds at 37ᵒC for 8 hours.  The amplified and labelled products were purified using 
BioPrime® purification Module (Invitrogen, USA). 200 µl of Binding Buffer B2 was 
added to to each tube contained the labelled samples. The samples were loaded onto the 
PureLink™ Spin Column and centrifuged at 10,000×g for 1 minute, then flow-through 
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was discarded and the column was placed back in the tube. 650 µl of Wash Buffer W1 
was added to the column and centrifuged at 10,000×g for 1 minute, then flow-through 
was discarded and the column was placed back in the tube. The samples were spin at 
maximum speed (14,000 xg) for an additional 3 minutes to remove any residual wash 
buffer. Finally, the Spin Column was placed in a new, sterile amber collection tube and 
55 µl of elution buffer E1 was added to the centre of column, incubated at room 
temperature for 1 minute and centrifuged at maximum speed (14,000 xg) for 2 minutes. 
The yield of amplified labelled purified DNA was estimated by spectrophotometer 
(NanoDrop, Technologies Inc.).  The DNA was precipitated by adding 10 volumes of 2% 
LiClO4 in acetone for overnight at - 20°C. Centrifugation was performed to pellet DNA at 
14,000 x g for 30 min, the supernatant was discarded, and the pellet was washed with 1 
ml acetone, and then centrifuged at 14,000xg for 20 min. The pellet was dried on air or 
at 37°C 10-20 min until the red/pink colour was clearly visible. The pellet was dissolved 
in the hybridization buffer (1 M GuSCN (guanidine thyocianate), 5 mM EDTA, 50 mM 
HEPES (pH 7.5), 0.2 mg/ml BSA (bovine serum albumin) (Sigma, UK), then was heated 
at 95°C for 5 min followed by immediate chilling on ice for 2 min. The fluorescent 
samples solution was loaded onto the slide of immobilized probes and covered 
immediately with the cover slip. The cover slip was prepared by soaking in washing 
detergent for 20 min, and then extensively rinsed in distillate water; after that, the cover 
slip was soaked in the concentrated sulfuric acid for 20 min, and rinsed extensively in 
distillate water. Finally, the cover slip was rinsed in 95% ethanol and dry at 80°C. The 
area under a cover slip was 2.2cm x6.4cm=14.08 cm2; the volume of the hybridization 
buffer (30 µl) is calculated from 2 µl per 1 cm2.  Before placing the biochip in the 
hybridization chamber 10 µl of nuclease-free water was added to one of the grooves to 
keep 100 % humidity in the chamber during the hybridization reaction. The samples 
were hybridized at 25°C for 4 hours followed by washing in 4xSSC; 7.2 % Sarcosyl for 30 
sec. The slide was dried by centrifugation in a Microarray High Speed Centrifuge 
(ArrayIt, USA), and visualized using a Portable Imager 5000 (Aurora Photonic, USA) 
with 532 nm green Laser and 580 nm filter. The signal intensity of each point on the 
biochip was calculated using MicroChip Imager software (Aurora Photonics, USA).  
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Section 3 
Detection and quantification of sulphate reducing bacteria using 
microbiological and quantitative PCR techniques 
 
2.3.1 Bacterial culture preparation  
 
Desulfovibrio indonesiensis NCIMB 13468 were cultivated anaerobically in Vitamin 
Medium Reducing iron (VMR medium) at 37°C for 7 days. E. coli BP was cultivated 
anaerobically in VMR medium at 37°C overnight (~17-18 h). The bacterial inoculum 
was adjusted for all experiments of approximately 2X108 cells/ml for E. coli BP and 
7X106 cells/ml for D. indonesiensis. Seven days old culture of D. indonesiensis was used 
for subculturing D. indonesiensis in different time of growth for 7 days, 3 months and 1 
year in VMR and VMI media at 37 °C. The SRB growth stages divided into exponential 
phase, stable state and decline period. It has been found that the number of SRB 
increased rapidly (from day ~3-30) achieving the maximum in day seven. After that the 
growing process of SRB reached the stable state (~2-6 months) before it started the last 
stage which is the decline phase (Butlin et al., 1949; Zhang et al., 2011; Mahat et al., 
2015). In these experiments three growth stages (7days, 3 months and 1 year old 
culture) were used. This is meant to observe the stage by stage progress of SRB gene 
expression over time as well as to evaluate the ability of E.coli BP to induce the growth 
of SRB in low cell density. Each age of D. indonesiensis cultures (7 days, 3months, and 1 
year) were serially diluted in VMR and VMI media. 0.5ml of E. coli BP was inoculated to 
each dilution of  different age D. indonesiensis cultures and incubated anaerobically at 
37°C for 28 days and the growth of D. indonesiensis , was monitored every 24 hours 
visually for the production of black iron sulfide. The blackening of the medium is evidence 
of SRB growth in the medium (Vester  & Ingvorsen, et al., 1998). Viable count of E. coli 
BP was determined before co-culture with D. indonesiensis by ten-fold serially diluting 
0.1 ml of E.coli BP culture in 0.9 % NaCl; and plated on a freshly prepared MacConkey 
agar and incubation at 37°C. The colonies were counted and expressed as colony 
forming unit per ml of culture (cfu/ml). The composition of VMR, VMI and MacConkey 
agar is shown in Appendix 1.  
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Genomic DNA was extracted from 5ml of D. indonesiensis original culture cells which 
was used for serial dilution (of all ages) QIAGEN DNeasy Blood and Tissue Kit (QIAGEN, 
Germany) following the manufacturer’s instructions (as described in subsection 2.1.1.1).  
 
2.3.2 Purification of total bacterial RNA 
 
RNA was purified from D. indonesiensis original culture which were used for serial 
dilution (of all ages) using the QIAGEN RNeasy Mini kit according to the manufacturer’s 
instructions (RNAprotect bacteria reagent Handbook, 07/2001 p.13-35). Before 
proceeding to RNA purification 4 ml of D. indonesiensis culture were stabilized by adding 
1 volume of the culture to 2 volumes of RNAprotect bacteria solution placed in a 
reaction tube. The samples were mixed by vortexing for 5 seconds, incubated for 5 min 
at room temperature and centrifuged for 10 min at 5000x g (Heraeus Fresco 21, Thermo 
Scientific, UK). The supernatant was discarded. 200µl of TE buffer containing lysozyme 
(1mg/ml) was added to the samples and mixed by vortexing for 10 seconds then 
incubated for 5 min at room temperature. 700 µl of buffer RLT containing β-
Mercaptoethanol (10µl β-ME per 1ml buffer RLT), (sigma Aldrich, UK) was added to the 
samples and votexed vigorously then centrifuged at the maximum speed (13000xg) for 
2 min. The supernatant was collected in a new eppendorf tube and 500 µl of 100% 
ethanol was added to the lysate, mixed by votexing. The lysate containing ethanol was 
applied to RNeasy mini column placed in a 2ml collection tube and centrifuged for 15 
seconds at 8000x g. DNase digestion was performed during RNA purification using 
RNase-free DNase set (QIAGEN, UK). 350 µl of RW1 buffer was added into the RNeasy 
mini column and centrifuged for 15 seconds at 8000 x g and the flow through was 
discarded. 80 µl of DNase I incubation mixture was added into each RNeasy silica-gel 
membrane, and incubated in the room temperature for 15 min. 350 µl of buffer RW1 
was added into the RNeasy column , incubated at the room temperature for 5 min and 
centrifuged for 15 seconds at 8000 x g. The RNeasy column was transferred into new 
collection tube, washed by 500 µl RPE buffer and centrifuged for 15 seconds at 8000 x g 
and the flow through was discarded. RNeasy column was washed again with 500 µl RPE 
buffer and centrifuged for 2 min at 8000 x g. The RNeasy column was placed in new 2 ml 
collection tube and centrifuged for 1min at the maximum speed (14000 x g). Finally, 
RNA was eluted with 40 µl RNase free water onto the centre of RNeasy silica-gel 
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membrane was placed in a new 1.5 ml Eppendorf tube and centrifuged for 1 min at 8 
000 x g. 
 
2.3.2 .1 cDNA Synthesis  
 
Random primers (2.5 µl, 60 µM, Promega, UK) were annealed to RNA (10 µl, approx. 1-2 
µg) in a total volume of 15 µl at 70°C for 10 minutes and immediately placed on ice for 5 
minutes. 2.5 µl of 5x buffer for MMLV, 1µl of 10mM dNTP mix, 1µl RNase inhibitor, 4.5 µl 
of water and 1µl of MMLV reverse transcriptase (Promega, UK) were mixed and  added 
to each RNA/primer mixture; the total volume of each reaction was 25 μl. Reverse 
transcription was carried out at 37°C for 60 minutes. The reaction was stopped by 
heating for 15 minutes at 70°C. An equal volume of H2O was added to each cDNA. A 
negative control was included by omitting MMLV-RT from the reaction mixture. cDNA 
samples were stored at -20°C before real-time PCR analysis.  
 
2.3.3 Preparation of PCR fragment of the apsA and the  dsrA genes 
 
The apsA and dsrA genes fragments were used for standard curve generation for qPCR.  
PCR fragments were amplified (five tubes reactions; final volume of 50 µl) using 
genomic DNA of D. indonesiensis as a template as describes in subsection 2.1.2.2. The 
PCR products were verified in 1.2% agarose gel. The rest of PCR reactions of were 
combined and DNA was precipitated.  One tenth of the PCR products volume of 3M 
Sodium Acetate pH 5.2 was added (Sigma adrich, UK). 2.5 volumes of 100 % ethanol was 
added to the samples and placed in a -20°C overnight. DNA was precipitated by 
centrifugation at 14 000 x g for 10 min, washed twice with 400µl of 70% ethanol and 
centrifuged at 14 000 x g for 10 min each. After removal of ethanol the pelleted DNA was 
air dried and resuspended in 25 µl of nuclease free water. The DNA samples were mixed 
with 6X loading dye (Promega, UK) and analysed on 1.2 % agrose gel in 1 X TAE buffer 
(90 min, 100 V). The gel was photographed after staining as described in section 2.1.3.  
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2.3.4 Purification of DNA fragments from the agarose gel  
 
PCR fragments of dsrA gene (221 bp) and apsA gene (135 bp) were cut off from agarose 
gel and purified using QIAquick ® Gel Extraction kit (Qiagen, UK) according to the 
manufacturer's instructions (QIAquick Spin Handbook 04/2014 p24-25). 3 volumes of 
Buffer QG were added to 1 volume of gel slice (100 mg ~ 100 μl). The gel slice was 
incubated at 50°C for 10 min (until agarose has completely dissolved). The tube was 
vortexed occasionally. 1 gel volume of isopropanol was added to the sample and mixed 
thoroughly. The samples were applied to the QIAquick column, centrifuged for 1 min, 
washed with 500 µl of buffer QG, and then washed with 750 µl of buffer PE.  After 
centrifugation the flow-through was discarded. The column was centrifuged for an 
additional 1min at 14 000 x g to dry the column. DNA was eluted with 50 µl of Buffer EB 
(10mMTris·Cl, pH 8.5).  
 
2.3.5 Quantitative real-time PCR (Q PCR) 
 
All real-time experiments were performed on Stratagene Mx3005P (Agilent 
Technologies, UK). A quantitative real-time PCR assay targeting two functional genes of 
SRB dsrA and apsA was used to determine the copy numbers of these genes and finally 
enumerate the amount of SRB. Specific primers DSR-F1, DSR-R (Table 2.1.1) and 
TaqMan probe (6FAM) - 5’-CCGATAACRCYGCCGCCGTAACCGA - 3’ - (TAMRA) (Bourne et 
al., 2011) were used for dsrA gene. For the apsA gene; TaqMan assay using the primers 
APS-F, APS-R (Table 2.1.1) and the probe – (6FAM-5’ CGCATCATGGAGCGCATGTTCATC-
3’ - TAMRA); (This study).  
Standard curves for quantification of the dsrA and the apsA genes were constructed with 
10-fold dilutions of gel purified PCR fragments from 10-1 – 10-10. PCR reaction contained 
5 µl of 2 X Brilliant Q PCR master mix (Agilent, UK), 0.5 µl of 10 µM of the DSR or APS 
forward and reverse primers mix, 0.25 µl of 5 uM specific dsr or aps TaqMan probes, 2 µl 
of template, plus nuclease-free water to bring the total volume to 10 µl. The reaction 
condition for amplification was 95°C for 3 min followed by 40 cycles of 95°C for 15 sec, 
67°C for 30 sec and 72°C for 30 sec. All runs included a no template control (NTC). 
Standard curves were obtained by plotting the Ct (threshold cycle) values of 10-fold 
dilutions of the dsrA and the apsA fragments. Ct values for each well were calculated 
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using the manufacturer’s software. Three experiments in triplicate were performed for 
each gene. For data analysis, Ct and DNA quantity in ng were exported into a Microsoft 
Excel Word spread sheets. The copy number was calculated on the basis of the 
measured concentration of standard (ng/ µl), an average molecular mass of 660 for a 
base pair in a double-stranded DNA and the size of PCR fragment (221 bp for dsrA gene 
and 135 bp for apsA) and Avogadro’s number (6,02 x 1023 mol-1). Normality of data was 
assessed using the Shapiro-Wilk normality test. The data was found to be not normally 
distributed; therefore Kruskal-Wallis with Dunn’s multiple comparisons or Mann-
Whitney statistical tests were performed to compare the SRB g DNA copy numbers and 
the gene expression in different time of growth.  
2.3.6 Measurements of hydrogen sulfide (H2S) 
 
The serial dilution of a 7 days old D. indonesiensis culture was grown in either VMR or 
VMI medium at 37°C for 7 days. The last two vials of the serial dilution which gave 
positive indication of D. indonesiensis growth as pure and mixed culture with E. coli BP 
were used for measuring H2S concentration using H2S meter (Sensorcon, Inc. ,USA), 
with a lower detection limit of 1 ppm. Three independent experiments were done in 
triplicate. The averages of the 3 readings of each repeats were taken and the mean 
values were determined. Error bars indicate standard deviation. * indicate significance 
(p ≤ 0.05). 
2.3.7 Pulsed field gel electrophoresis (PFGE) 
 
The Pulsed Field Gel Electrophoresis (PFGE) was performed according to manufacture 
instruction (CHEF-DR®II pulsed field electrophoresis systems, instruction manual and 
application guide p12-23) with some minor modification adapted from (Devereux et al., 
1997; Ribeiro et al., 2009) See below. 
2.3.7.1 Preparation of Agarose Embedded Bacterial DNA 
 
The bacterial culture used in this study was D. indonesiensis and E.coli BP. D. 
indonesiensis was grown anaerobically in VMR medium at 37°C for 24h, 48h and 6 days 
and  E. coli BP aerobically in LB Broth for 4h at 37°C. 180 g/ml chloramphenicol (sigma 
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Aldrich, UK) was added to the bacterial cultures and continued to grow for 1 hour. A 
twenty-fold dilution of the above bacterial suspension was made and small amount of 
this suspension was placed on the hemocytometer for counting bacterial cells under 
light microscope with a 40 X objective. Approximately 5X10⁸ bacterial cells were taken 
for each ml of agarose plugs to be made. The cells were harvested from culture by 
centrifugation at 10,000 x g for 5 minutes at 4 °C. The pellet was washed twice with TE 
buffer(10 mM Tris-HCl and 1 mM EDTA, pH 8.0) (sigma, UK) then  the cells were 
resuspend in one-half the final volume of plugs to be made using Cell Suspension Buffer 
(10 mM Tris, pH 7.2, 20 mM NaCl, 50 mM EDTA) and the cell suspension were 
equilibrated to 50 °C. 2% of low melt agarose (CleanCut agarose, Biorad, US) was 
prepared and equilibrated to 50 °C in a water bath. The cell suspension combined with 
an equal volume of 2% CleanCut agarose and mixed gently but thoroughly. The 
cell/agarose mixtures were kept at 50 °C, and the mixture was transferred to plug molds 
which were placed initially on ice using sterile transfer pipettes. The agarose was 
allowed to solidify by placing the molds at 4 °C for 10–15 min. Using 50 ml of falcon 
tube, 5ml of lysozyme buffer was transferred (10 mM Tris, pH 7.2, 50 mM NaCl, 0.5% 
Brij 58, 0.2% sodium deoxycholate, 0.5% sodium lauryl sarcosine, 1 mg/ml lysozyme), 
(sigma, UK)  for each ml of agarose plugs. The solidified agarose plugs were pushed 
using the snap off tool with plug molds into the 50 ml centrifuge tube containing 
lysozyme buffer then the plugs Incubated for 1 hour at 37 °C without agitation. The 
lysozyme buffer was removed and the plugs was rinsed with 25 ml of 1x wash buffer 
(20 mM Tris, pH 8.0, 50 mM EDTA) (sigma, UK). 5 ml of Proteinase K Reaction Buffer 
(100 mM EDTA, pH 8.0, 0.2% sodium deoxycholate, 1% sodium lauryl sarcosine, 1 
mg/ml Proteinase K) (sigma, UK) was used for each ml of agarose plugs. The plugs were 
transferred to the tubes contain the Proteinase K Reaction Buffer then were Incubated 
at 50°C until the plug goes clear after 2 hours-overnight without agitation. The plugs 
were washed with sterile water twice, followed by 6 washes with 50 ml of 1X wash 
buffer (20 mM Tris, pH 8.0, 50 mM EDTA)(sigma, UK) 1 hour each at room temperature 
with gentle agitation. The plugs were kept in TE buffer and store at 4°C until used. 
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2.3.7.2 Restriction Enzyme Digestion of Plugs 
 
Tow restriction enzymes were used for plugs digestion PmeI which recognizes 
5’GTTT↓AAAC 3’ sites and NotI recognizes 5’GC↓GGCCGC 3’ sites (Thermo scientific, US). 
In a sterile 1.5 ml microcentrifuge tube one plug was placed with 1 ml of 1X Buffer B for 
PmeI or 1X Buffer H for Not I then were incubated at room temperature for 1 hour with 
gentle agitation. The buffer was aspirated off then 0.3 ml of fresh 1X Buffer was added 
and 50U of the restriction enzyme Pme I or Not I per 100 µl plug and was incubated at 
37°C for 2 hours. After the incubation time, the buffer was removed and 1 ml of 
UltraPure™ 0.5 X TBE Buffer (made from 10X stock  solution:1.0M Tris, 0.9M boric Acid, 
0.01M EDTA pH 8.0)(Invitrogen by Life Technologies, UK) was added and was incubated 
for 30 minutes at 37°C with gentle agitation.  
2.3.7.3 Casting the gel  
 
The gel was run using CHEF-DR® II Pulsed Field Electrophoresis Systems (Biorad, US). 
3 litters of 0.5X TBE was poured into in the electrophoresis chamber and the buffer was 
allowed to circulate at ~ 0.75 L/min to equilibrate to the desire temperature (14°C).  
The plugs were placed on each tooth of the comb then 1% Pulsed Field Certified™agrose 
gel (Biorad, USA) in 0.5X TBE was poured gently and allowed to solidify for 15 minutes. 
The comb was removed gently and the gel wells was filled with 1% agrose gel in 0.5X 
TBE allowed to solidified for 10 minutes and placed in the electrophoresis chamber 
containing 0.5X TBE. The run time was 22 h at 6 V/cm with a 60 to 120 second switch 
time ramp at an included angle of 120°. Three markers were used as as size standards in 
the gel; Lambda ladder 1000 kb, Saccharomyces cerevisiae 2200 kb and 
Schizosaccharomyces pombe 5.7 mb (Biorad, USA). 
 
2.3.7.4 Removing and staining the gel 
 
After the run was completed the gel was removed gently and slided off into 0.5µg/ml of 
SYBR® Safe DNA gel stain (Life Technologies) in 0.5 X TBE buffer and the gel was left in 
dark for 20 min then destained in 0.5 X TBE for 5min. Finally, the gel was photographed 
under UV light using molecular imager® Gel Doc™ XR+ Imaging system (BIORAD). The 
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genome size was estimated based on the observation of linearized chromosomal DNA 
which migrated into the agarose gel during PFGE.  
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Section 4 
 
The effect of Manuka honey and antibiotics on the growth of pure 
and mixed sulphate reducing bacterial biofilms 
 
2.4.1 Honey samples  
 
Manuka honey of different strength: UMF® 5+, UMF® 15+, UMF®25+ and (Comvita), as 
commercial honey (Rowse) were compared for their effects on biofilm formation. The 
methylglyoxal (MGO) content of Manuka honey is used to define the antimicrobial 
activity of this honey and is referred to as the unique Manuka Honey Factor (UMF®) 
(Mavric et al., 2008). All samples were diluted in VMR medium for use in all assays and 
stored in the dark at 4°C. All honey concentrations are expressed as % w/v. To 
distinguish the antimicrobial effect of honey from any osmotic effects of sugars, an 
artificial honey, simulating the sugar composition of honey, 30.5% glucose, 37.5% 
fructose and 1.5% sucrose dissolved in sterile water (Shannon et al., 1979) were also 
tested. 
 
2.4.2 Antibiotics 
 
The antibiotics used in this study included rifaximin and metronidazole (sigma aldrich, 
UK). The two antibiotics most commonly used as antimicrobial drugs in the treatment of 
patients suffering from UC (Wang  and  Yang , 2012). 
 
2.4.3 Bacterial growth conditions 
 
The bacterial strains which were used in this study were D. indonesiensis and E. coli BP.  
Approximately 2X108 cells/ml for E. coli BP and 7X106 cells/ml for D. indonesiensis had 
been used as adjusted inoculum for all the further studies. Both strains were 
subcultured anaerobically in VMR medium at 37oC. E.coli BP culture was ten-fold 
serially diluted in 0.9 ml of 0.9 % NaCl; then plated on MacConkey agar and incubated at 
37°C for 24 h for counting of viable bacterial cells before inoculation. The initial D. 
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indonesiensis inoculum size was determined using a haemocytometer. The result of 
counting was expressed as cells per millilitre (cells/ml). 
 
2.4.4 Preparation of honey samples  
 
Stock solution of the honey were prepared in VMR medium (w/v %). Honey solution 
was kept in closed jars in dark by covering the jars with aluminium foil. Prepared honey 
solution was placed in shaker incubator innova 4000 (New Brunswick Scientific, USA) at 
220 rpm for approximately 1 h at 37oC to obtain a homogenous solution. Aseptically, the 
prepared honey solution was then pre-filtered with 0.45μm Nalgene syringe pre-filters 
(Themo Scientific, USA) into new autoclaved-containers in order to purify the highly 
viscous solutions and prevent clogging of final filtration. Pre-filtrated honey solution 
was then subsequently filtered with sterile 0.22μm pore sized "Millex Syringe 
Filters"(Merck Chemicals Ltd.) into autoclaved glass vials and degassed under a stream 
of nitrogen (N2) for 30 mins, sealed and kept in the 4⁰C until further use.  
 
2.4.5 Determination of the Minimum Inhibitory Concentration (MIC) and 
Minimum Bactericidal Concentration (MBC) of honey and antibiotics  
 
The Minimum Inhibitory Concentration (MIC) which is the lowest concentration of an 
antimicrobial agent required to inhibit the visible growth of bacteria; and the Minimum 
Bactericidal Concentration (MBC) which is the lowest concentration of antimicrobial 
treatment that required to kill the bacteria was determined. The effect of honey, 
rifaximin and metronidazole alone and in combination against D. indonesiensis as pure 
and mixed culture with E. coli BP in biofilms were examined. These experiments were 
performed in different aspects. First, for the evaluation of the ability of the honey to 
prevent the biofilms formation; the honey concentrations were prepared in increments 
of 5 in the range of 0- 60 % (w/v) in VMR medium. D. indonesiensis was inoculated as 
pure and mixed culture with E.coli BP (approximately 106 cells/ml for D. indonesiensis 
and 108 cells/ml for E. coli BP) simultaneously with the honey and incubated 
anaerobically at 37⁰C for 7days.  After 7 days incubation the vials were treated carefully 
in order to not disrupted the biofilms. The supernatant solution was gently removed by 
syringe and the uniform biofilms that been adhere, colonize in the vials were rinsed by 
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0.5 ml of fresh VMI medium. 1 ml of the solution was transferred into fresh VMI medium 
and ten fold serial dilutions were performed. The media with cultures were incubated at 
37⁰C for 7days. The second experiment was performed to assess wither the honey was 
able to eradicate the already established biofilms. The culture of pure and mixed D. 
indonesiensis with E.coli BP was allowed to grow at 37⁰C for 6 days. Then different 
concentrations of honey (0- 60 % (w/v) were added to the bacterial cultures and 
incubated at 37⁰C overnight. The bacterial biofilms assessments were repeated as 
described above for all experiments. Third, the effect of antibiotics on the growth of 
pure and mixed D. indonesiensis biofilms was evaluated.  Antibiotics solutions were 
prepared from stock solutions of 25mg/ml and diluted to 256- 1 µg/ml (v/v) through 
doubling dilution in VMR medium. D. indonesiensis was inoculated as pure and mixed 
culture with E. coli BP in different concentrations of antibiotics alone and in 
combination then incubated anaerobically at 37⁰C for 7days before the biofilms were 
assed as described above. Fourth, the synergistic effect of honey and antibiotics was 
investigated. The concentration of Manuka UMF®15+ that inhibited the growth of pure 
and mixed D. indonesiensis biofilms was used to be tested with different concentrations 
of antibiotics to assess whether manuka honey will be able to improve the efficiency and 
reduce the MIC value of the antibiotics. Manuka UMF®15+ was used to be tested 
synergistically with antibiotics because it is commercially available. The volume of 
antibiotics necessary to achieve the required concentrations (256- 1 µg/ml (v/v) was 
aseptically added simultaneously into sterile vials containing the bacterial culture and  
the required Manuka UMF®15+ concentration in VMR medium then incubated 
anaerobically at 37⁰C for 7days.  In the fifth experiment, to evaluate whether manuka 
honey can inhibit the growth of biofilms therefore the antibiotics will have better effect 
on the weak biofilms. As described above the required Manuka UMF®15+ concentration 
in VMR medium were added simultaneously to the pure and mixed D. indonesiensis. The 
cultures were incubated with Manuka UMF®15+ at 37⁰C for for 6 days; then to achieve 
the required concentrations of the antibiotics combination; appropriate volume was 
added. The cultures were incubated overnight before the biofilms were assesd.  
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2.4.6 Preparation of Methylglyoxal (MGO) 
 
Methylglyoxal (MGO) is the major antibacterial component of Manuka honey. MGO is 
found in high concentration in the nectar of manuka flowers and belived to give manuka 
honey its antibacterial properties (Mavric et al., 2008). In order to assess the 
contribution role of MGO to the activity of Manuka honey this experiment was 
performed. MGO levels can be used to estimate the UMF based on the relationship 
between MGO and UMF identified previously (Adams et al., 2008; Cokcetin et al., 2016). 
MGO levels in Manuka honey found to be ranging from 38 to 1123 mg/kg. Manuka 
UMF®15+ was predicted to has the mnimum MGO content of approximately 514 mg/kg 
(Adams et al., 2008; Atrott and Henle, 2009; Roberts et al., 2015). MGO (40 % solution in 
water (w/w) (Sigma-Aldrich, UK) was diluted in VMR medium to obtain the equivalent 
concentrations of MGO content in Manuka UMF®15+ (ranging from 0-0.25% v/v). D. 
indonesiensis was inoculated as pure and mixed culture with E.coli BP in the different 
concentrantions of MGO and incubated for 7 days at 37°C before the biofilms were assed 
as described in section 2.4.5. In all experiments the mean values were estimated from 
five independent experiements. All values are presented as mean standard deviation. 
Normality of data was assessed using the Shapiro-Wilk normality test.  In all instances 
the data was found to be not normally distributed. As such Kruskal-Wallis with Dunn’s 
multiple comparisons or Mann-Whitney statistical tests were performed to compare the 
differences between treatments and among honey samples on the pure and mixed D. 
indonesiensis biofilms as required.  
. 
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Section 1 
Analysis of Biopsy DNA samples using 16S rRNA and DSR genes 
sequences 
 
It has been widely excepted that the bacteria that colonize the human colon play a 
fundamental role in the human physiology however, little is known about the bacterial 
composition that colonize mucosal surfaces in the human colon. In this investigation the 
bacterial composition of the colonic mucosa associated bacteria were characterised for 
microbial identification and phylogeny construction. Rapid molecular fingerprinting 
analysis based on 16S rRNA and DSR genes including DGGE and sequencing were used 
to detect and identified bacteria in samples obtained from patients suffering from UC 
and healthy individual. 
 
3.1.1 PCR for bacterial 16S rRNA genes 
 
The 16S rRNA gene is used frequently as a target for many assays, and universal PCR 
primers are routinely used for species identification (Weisburg et al., 1991). To confirm 
that bacterial DNA has been successfully extracted and to exclude the presence of 
inhibitors of the PCR reaction, the universal bacterial 16S rRNA primers were used as a 
positive PCR amplification control (subsection 2.1.2.1). PCR gels demonstrating the 
presence of bacterial DNA are depicted in Figures 3.1.1 and 3.1.2.  
The 16S rRNA PCR products of the correct size (550 bp and 1500 bp) for DNA extracted 
from the colonic mucosa of healthy volunteer and patients suffering from UC showed 
that all the extracted DNA products were efficiently PCR amplifiable in all samples, 
which indicated that bacteria were always present and that the PCR were conducted 
without significant amounts of inhibitors in biopsy samples. Negative controls yielded 
no bands, which demonstrated that contaminants were not present. In addition, the fact 
that no band occurred in all samples examined confirmed that PCR reagents were free of 
contaminants. 
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Figure 3.1.1. A photograph of agarose gel showing the PCR amplified products of 
16SrRNA gene (550 bp) with primers: 341F+GC and 907R. Lane 1: PCR products of 
Patient 1 suffering from UC; lane 2: PCR products of Patient 2 suffering from UC; lane 3: 
PCR products of Patient 3 suffering from UC ; lane 4: PCR products of Patient 4 suffering 
from UC;  lane 5: PCR products of Healthy volunteer; lane 6: 1 kb DNA Ladder; lane 7: 
Negative control; lane 8: DNA D. alaskensis 
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Figure 3.1.2. A photograph of agarose gel showing the PCR amplified products of 
16SrRNA gene (1500 bp) with primers: 341F+GC and 907R. Lane 1: PCR products of 
Patient 1 suffering from UC  ; lane 2: PCR products of Patient 2 suffering from UC; lane 
3: PCR products of Patient 3 suffering from UC ; lane 4: PCR products of Patient 4 
suffering from UC;  lane 5:PCR products of Healthy volunteer; lane 6: 1 kb DNA Ladder; 
lane 7: Negative control; lane 8: DNA D. alaskensis 
 
Highly specific primers for Desulfovibrios 16S rRNA gene were used to confirm the 
presence of the genus of Desulfovibrio in the samples. The result showed strong PCR 
positivity of the expected size and mucosa associated Desulfovibrio were present in all of 
UC tissues and in healthy volunteer (Figure 3.1.3). The microbiota present in the colon 
has been mostly described from faeces samples, which do not accurately represent the 
mucosa-associated microbiota (Zoetendal et al., 2002; Eckburg et al., 2005). Therefore, 
little is known about the diversity and ecology of mucosa-associated SRB in the human 
colon. This study provides some information on the molecular characterization of 
abundant of microbes that are associated with the colonic mucosa of healthy human and 
UC suffers. These observations confirmed that Desulfovibrio were the predominant SRB 
populations and that they were found associated with the mucosa throughout the large 
intestine in both UC sufferers and healthy individual, supporting previous evidence that 
indicated Desulfovibrio was the dominant genus of SRB found in human colon (Gibson et 
al., 1988a; Loubinoux et al., 2002; Stewart et al., 2006; Kushkevych, 2014).  
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Figure 3.1.3. A photograph of agarose gel showing the PCR amplified products of 
desulfovibrios 16S rRNA gene (135 bp) with primers: DSV691F and DSV826R. Lane 1: 
PCR products of Patient 1 suffering from UC ; lane 2: PCR products of Patient 2 suffering 
from UC; lane 3: PCR products of Patient 3 suffering from UC ; lane 4: PCR products of 
Patient 4 suffering from UC;  lane 5: 100 bp DNA Ladder; lane 6: Negative control; lane 
7: PCR products of DNA D. vulgaris; lane 8: PCR products of Healthy volunteer 
 
To further analyze the SRB population in biopsy samples of UC and healthy volunteer, 
genomic DNAs from these samples were amplified using the dsr primers set DSR1F+and 
DSR-R. All samples tested yielded unambiguously a positive result and distinct 
amplicons of the right size were obtained and that indicated the presence of SRB in all 
samples (Figures 3.1.4). DSR gene involved in dissimilatory sulphate reduction pathway 
in SRB is evolutionarily conserved among SRB, including delta proteobacteria and was 
selected as the preferred marker for SRB. (Wagner,1998; Ben-Dov et al.,, 2007). 
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Figure 3.1.4. A photograph of agarose gel showing the PCR amplified products of dsrA 
gene (221 bp) with primers: DSR1F+and DSR-R Lane 1: PCR products of Patient 1 
suffering from UC ; lane 2: PCR products of Patient 2 suffering from UC; lane 3: PCR 
products of Patient 3 suffering from UC ; lane 4: PCR products of Patient 4 suffering 
from UC;  lane 5: 100 bp DNA Ladder; lane 6: Negative control; lane 7: PCR products of 
DNA D. vulgaris; lane 8: PCR products of Healthy volunteer 
 
Functional marker genes encoding key enzymes of characteristic of SRB metabolic 
energy pathways, such as sulfate reduction, have been found to be useful in the 
detection of microorganisms belonging to different ecophysiological classes in complex 
microbial assemblages from diverse habitats in faeces samples. However, no 
information exists about the diversity of functional genes of SRB in colonic mucosa 
associated bacteria (Gibson et al., 1991; Fite et al., 2004; Wagner et al., 2005; Frank et 
al., 2007; Christophersen et al., 2011; Rey et al., 2013).  
 
Perhaps, in order to generate information on microflora of the colon, a molecular 
approach was taken, involving PCR, Cloning, Sequencing and DGGE-PCR analysis, to 
provide a structural and functional analysis of the colon from healthy and UC patients. 
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3.1.2 DGGE analysis of microbial communities in the biopsy samples 
 
It is evident that there is a strong association between UC and colonic mucosa 
microflora. However, the entire picture remains unclear. Using molecular techniques, to 
analyze the bacteria existing in colonic mucus that were considered to be influencing the 
inflammation of UC helped to clarify the relationship between colonic inflammation and 
microflora diversity in UC. PCR-DGGE approach has been used extensively to analysis 
human microbiota and was found that this approach is a useful tool for comparing 
complex microbial community profiles present in human colonic samples (Scanlan et al., 
2006; Kinross et al., 2008). 
The 16S rRNA gene profiles of the bacterial collections associated with biopsies were 
generated by PCR coupled with DGGE. The PCR amplified products of 16S rRNA gene 
(550 bp) were analysed with DGGE for the visualisation of DNA bands representing 
dominant bacterial species in the samples. DGGE allows separation of DNA fragment 
mixtures of equal length depending on their sequence. To some extent the community 
profiles originating in the patients suffering from UC resembled each other as far as the 
16S rRNA band numbers and migration patterns are concerned. However, significant 
differences in the healthy volunteer sample profile were observed. Examples of profiles 
are shown in Figure 3.1.5.  
 
The high-density bands which represent the dominant microbial populations showed 
the differences in microbial structure of the various biopsy samples.  The differences in 
localization of dominant bands in the adjacent lanes suggested that there were various 
degrees of changes and differences in the microbial community structure between UC 
patients and healthy control and, even within UC patients.  
 
The DGGE patterns obtained from each sample contained a number of bands at 
relatively different positions and with differing intensities. The community profiles of 
samples obtained from UC patients number one and two (Fig. 3.1.5, lanes 1 and 2) 
showed relatively few strong bands (1-3), while the profile of the samples from UC 
patient number 3 and 4 (Fig 3.1.5, lanes 3 and 4) had between 5-7 dominant bands with 
a greater number of weaker bands. In contrast, the lane (Fig. 3.1.5., lane 6) containing 
amplicons from the healthy patient displayed up to 9 bands, representing the presence 
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of at least 9 different bacterial phylotypes. This suggests that there has been a reduction 
in diversity for UC patients compared with healthy one. Several bands were shared 
between all samples, and these included bands 2, 4, 10, 15 and 24. The bands 1,7,13 and 
19 were present in UC patient 1, 3, 4 and healthy control. However, these bands were 
absence in UC patient 2.  Band 5 and 12 were present only in UC patients 3 and 4, while 
band 11 was unique to UC patient 3 (Figure 3.1.5). 
 The lower band counts found in the UC patients indicate the possible absence or 
reduction in the abundance of specific bacterial classes amongst their predominant 
bacteria compared with healthy control (Figure 3.1.5). DGGE analyses in this 
investigation showed that the richness of UC patient’s profiles was lower compared to 
healthy individual. These results collectively are consistent with many comparative 
studies of colonic microbiota of patients with UC and non-UC controls, confirming that 
changes occur in the microbial communities in UC patients colon when compared to 
healthy individuals (Frank et al., 2007; Arumugam et al., 2011; Rigottier-Gois, 2013). 
This was subsequently confirmed by sequencing and biochip analysis (Section 2).  
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Figure 3.1.5.  DGGE profile demonstrating diversity of bacterial populations in biopsy 
samples obtained from healthy volunteer and patients suffering from UC based on PCR 
products of 550 bp of bacterial 16S rRNA. Lane 1: UC Patient 1, Lane 2: UC Patient 2, 
Lane 3: UC Patient 3, Lane 4: UC Patient 4, Lane 5: Negative control, Lane 6: healthy 
volunteer 
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The dendrogram in Figure 3.1.6 was constructed based on DGGE banding similarity 
patterns, and clearly shows that the banding profiles from all of the patients biopsy 
samples formed a single clade, supported by a bootstrap value of 75%.  Within this 
patient cluster two other clusters formed, one composed of patient 1 with 2 (cluster I) 
and the other containing  patients 3 with 4 (cluster II), supported by bootstrap values of 
80% and 81% respectively. The banding profile from the healthy individual grouped 
outside from the main cluster. This result showed the distinct separation of patients 
suffering from UC and healthy individual thus indicating a difference in the composition 
of the intestinal microbiota present in both group.  
 
 
 
Figure 3.1.6. UPGMA dendogram showing similarity of DGGE profiles of microbial 
communities in all colonic biopsy samples of UC patients and healthy control used in 
this study. Bands from each sample were coded and a UMPGA tree was produced using 
the distance algorithm described by Nei and Li (1979) and executed in PAUP* 4.0. P1: 
UC patient number 1, P2: UC patient number 2 , P3: UC patient number 3 , P4: UC patient 
number 4 , H: healthy individual.  
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The strength of a PCR-DGGE analysis is that it is able to show the changes in structure of 
dominant bacterial communities between different environments by simple changes in 
the banding profiles. The bands can be identified after they have been re-amplified and 
sequenced by performing a BLAST analysis using the target sequence against a 
database, such as GenBank. 25 bands, identified in Fig. 3.1.6, were excised, re-amplified 
and sequenced. Although 25 bands were excised, not all were successfully sequenced. 
The results of 16S rRNA gene sequencing of DGGE-bands is shown in (Table 3.1.1). Only 
4 bands were successfully sequenced. There are a number of reasons why the majority 
of bands failed to generate a sequence: (1) insufficient DNA for sequencing, (2) 
contamination of the extracted DNA with inhibitors, (3) degradation of the extracted 
DNA so that the primers fail to anneal, and (4) the band may contain heterogeneous 
DNA fragments that give indistinct sequences (Sekiguchi et al., 2001; Sun et al., 2013). In 
addition to this, some PCR fragments may not separate during DGGE so that they form 
indistinct smears of other separated PCR fragment (Kisand & Wikner, 2003). The 
sequences from the 4 bands were matched with those from Escherichia coli (98% 
match) for band 5, and Enterobacter aerogenes (99% match) for band 13, both of which 
were present in the UC patients. The other sequences from bands 23 and 25, derived 
from a healthy individual, matched those from an uncultured Ruminococcus species 
(98% match) and Eggerthella lenta (99% match) resepectively. Both of these species are 
Gram-positive gut inhabiting, anaerobic bacteria. Eggerthella species have been 
implicated in systematic bacteremia (Lau et al., 2004), and are candidates for 
involvement in UC, and the cause of liver and anal abscesses. Although the sample size 
here is small, the results suggest that the microflora of UC patients is different to that of 
a healthy person, with it having a lower diversity and, potentially, species that differ 
considerably.  
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Table 3.1.1. Sequencing results of bacterial 16S rRNA from the bands cut from DGGE gel 
Band(s)* Closest relative % Identity Accession no 
5 Escherichia coli 1303 98% |HE616528.1| 
13 Enterobacter aerogenes EA1509E 99% |FO203355.1| 
23 Uncultured Ruminococcus sp. M6-41  98% gb|EU530431.1| 
25 Eggerthella lenta strain W02018C 99% KP944193.1 
*Bands are numbered as indicated on the DGGE gels shown in Figure 3.1.5 
 
3.1.3 Diversity analysis of PCR products of bacterial 16S rRNA and dsr 
genes by sequencing 
 
Analysis of amplified bacterial 16S rRNA gene provides in depth exploring of bacterial 
diversity from complex bacterial communities. In this investigation, bacterial diversity 
of the mucosal biopsies from 4 UC patients and one healthy control were compared by 
analysis of PCR-amplified 16S rRNA clone libraries. A total of 250 clones from the 
mucosal biopsies were sequenced (control 100 clones; UC patient1 25 clones; UC 
patient2 25 clones; UC patient3 50 clones; UC patient4 50 clones) to obtain an overall 
estimation of bacterial diversity present in both groups.  
 
 The 16S rRNA sequence data from the healthy individual identified bacteria pre-
dominantly from families including Enterobacteriaceae, Bacterioidaceae, Clostridiacease, 
Coriobacteriaceae, Ruminococcaceae, Eggerthellaceae, Lactobacilaceae and 
Porphyromonoadaceae. All the four colitis patients had sequences from the 
Enterobacteriaceae (Figure 3.1.7) and no other. The 16S rRNA have been used in several 
studies to evaluate the bacterial diversity of the mucosal biopsies from different parts of 
the gastrointestinal tract (GIT) like human jejunum, ileum, colon as well as the rectum. A 
study focusing on evaluating the diversity of human GIT revealed that upon sequencing 
347 clones bacteria from various phyla including Firmicutes, Bacteroidetes, 
Proteobacteria, Fusobacteria, Verrucomicrobia, and Actinobacteria were observed within 
one healthy individual (Wang et al., 2005). It was intriguing to note in this study that 
microbial population varies from different parts of the colonic mucosa. For example 
jejunum, ileum, colon, and rectum have highly diverse bacterial population. This 
suggests that the differences of microbial population can occur within the patient.  
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However, other studies showed that the major group of bacteria were similar 
throughout the different parts of the colon between the individuals (Eckburg et al., 
2005; Costello et al., 2009 ; Momozawa et al., 2011)  
 
 
Figure 3.1.7. A histogram demonstrating the Family level of bacterial composition 
present in healthy patient and patients suffering from UC (16S rRNA gene) 
 
This data shown (Figure 3.1.7) which obtained from this study clearly demonstrate that 
colitis leads to an imbalance in colon microbial population strengthening the population 
of Enterobacteriaceae, whereas, bacteria from all other families had vanish among colitis 
individuals. Since imbalance of normal colonic bacterial population is precondition for 
colon inflammation (Gophna et al., 2006). Higher abundance of Enterobacteriaceae, in 
UC patients has also been reported previously (Kotlowski et al., 2007). 
Enterobacteriaceae have been observed to be active in inflammatory environments; the 
pathogenic bacteria can start the inflammation process in genetic susceptibility people, 
weakening the mucosal lining by the production of high concentration of butyric acid. 
This leads to activation of the immune system provoking an attack on the mucosa cells, 
causing a shift in the colonic commensal microbiota that favours members of the 
Enterobacteriaceae (Ohkusa et al., 2003; Nedialkova et al., 2014). The imbalance of 
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microbial population in the colon leads to a metabolic imbalance which inflames the 
colonic mucosa which may result in changing of bacterial composition (Ott et al., 2004).  
A reduction of bacteroidetes was also observed in UC microbiota which comes in line 
with our findings. However, this study found also that there was an increase in clostridia 
in UC patients ( Hansen et al., 2011) 
Regarding the relative abundance of various bacterial families present in the healthy 
colon, it was observed that Bacteroidaceae was the most abundant bacterial family in 
the colon of the healthy patient, having a 48% share of the total, followed by members 
from the Clostridiaceae (16%), the Ruminococcaceae (13%), the Enterobacteriaceae 
(12%), and the Coriobacteriaceae (8%). Three other families, Eggerthellaceae, 
Porphyromonadaceae and Lactobacilaceae had sequences representing 1% of the total. 
It is interesting to note that colitis patients having disrupted this balance of various 
bacterial families and have 100% predominance of bacteria from Enterobacteriaceae 
family.         
Several studies have compared the bacteria present in patients with active UC and non 
UC patients.  Nishikawa et al (2009) shown that there was a loss of bacterial belonging 
to Clostridia associated with active colitis. Ríos-Covián et al (2016) indicated that 
species from Bacteriodes and Firmcute promote good health in the colon by producing 
long chain fatty acid, which are an essential source of energy for epithelial cells lining 
the colon. It is possible that after the inflammation and damaging the mucosa layer of 
the colon, these bacteria may be depleted which result of the reduction of this bacterial 
group during active UC disease. 
 
A reduction of bacterial diversity has been observed in other studies. Walujkar et al 
(2014) using 16S rRNA gene sequences reported dysbiosis and dysanaerobiosis in 
microbial populations of patients suffering mild to server UC, with an overall decrease in 
the proportion of obligate anaerobes and an increase in facultative anaerobes and some 
aerobes. This study also aligns well with data generated from other studies that suggest 
a reduction in the diversity of the colonic mucosa associated bacterial microflora (Ott et 
al., 2004). The mechanisms causing this imbalance remain unknown. 
 
The features of a healthy colon include low oxygen concentrations and the presence of 
anaerobic bacteria in great numbers. The decrease of obligate anaerobes observed in 
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this study, including Bacteroidetes, Clostridium, Ruminococcus present in the colon of a 
healthy individual, and the shift to facultative anaerobes, members of the 
Enterobacteriaceae in the colons of patients suffreing from UC, can be explained by  
increases in the levels of oxygen, which will kill the obligate anaerobes allowing 
facultative anaerobes to take over  (Lind Due et al., 2003; Lupp et al., 2007, Rigottier-
Gois, 2013) 
 
Based on the information generated from sequences of 16S rRNA the next step was to 
identify relative key species of each bacterium among UC patients and healthy control. 
The healthy individual gut microbiome is highly complex. It has several species of 
bacteria. However, the ulcerative colitis patients mainly harbor bacteria from 
Enterobacteriaceae family. The major species of Enterobacteriaceae in the colon of 
colitis patients varied amongst the patients. A breakdown for relative levels of each 
bacterial species in healthy is shown in Table 3.1.2. In the healthy individual 16S RNA 
gene sequences from Bacteriodes frgilis were recovered at a frequency of 14% followed 
by 10% for Bacteroides dorei, Bacteroides vulgatus (8%), Ruminococcus torques (6%), 
Clostridum ramosum (4%) and Clostridum saccharogumia , Clostridum cocleatum , 
Clostridum spiroforme and Barnesiella intestinihominis each with (3%) while the other 
sequences represented the species Enterobacter aerogenes, Lactobacillus aogosae, 
Faecalibacterium prausnitzii, Eggerthella lenta, klebsiella pneumoniae at a frequency of 
1%.  
Although all of the bacterial sequences from the colons of the UC patients represented 
species of the Enterbacteriaceae, there were not a single common bacterial species 
found among all the four patients. The majority of 16S rRNA gene sequences recovered 
from UC patient 1 belonged to Citrobacter species, with 29% of the sequences belonging 
to Citrobacter freundii, 10% to Citrobacter murliniae, and 8% each to Citrobacter braakii, 
Citrobacter werkmanii and Enterobacter aerogenes in addition to other species displayed 
in Table 3.1.2.  
 
16S rRNA sequences from UC patient 2 were found to have identities similar to some of 
the common species found in UC patient 1, although the relative levels varied. These 
included matches for Citrobacter freundii and Enterobacter aerogenes, each representing 
22% of the sequences recovered, Citrobacter braakii, representing 19%, Raoultella 
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ornithinolytica (13%), Kluyvera cryocrescens (11%) in addition to other species 
including Klebsiella pneumoniae, Lelliottia amnigena, Acinetobacter calcoaceticus, 
Citrobacter murliniae and Klebsiella oxytoca all showed in Table 3.1.2.  
 
UC patient 3 showed a different profile to all of the other UC patients. UC patient 3 had 
sequence matches for five species, 48% of which were for Escherichia coli followed by 
28% for Shigella sonnei and 10% for Serratia marcescens, and 7% each for Shigella 
flexneri, Shigella boydii (Table 3.1.2). Sequences from UC patient 4 matched those from 
Enterobacter aerogenes (24% of the total), Raoultella ornithinolytica (22%), Kluyvera 
cryocrescens (19%), Citrobacter freundii (12%) followed by the presence of Citrobacter 
braakii, Klebsiella oxytoca and Yokenella regensburgei at 4% each with other more 
species all showed in Table 3.1.2. 
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Table 3.1.2. The species level of bacterial composition present in the colon of UC patients and healthy control (16S rRNA) 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Bacteroides fragilis 14% - - - - 
Bacteroides dorei 10% - - - - 
Bacteroides vulgatus 8% - - - - 
Ruminococcus torques 6% - - - - 
Clostridium ramosum 4% - - - - 
Clostridium spiroforme, C.cocleatum , C.saccharogumia, C.hathewayi 3% - - - - 
Clostridium leptum, C. lavalense, C.asparagiforme, C. bolteae, C. 
clostridioforme, C.citroniae,  C.coccoides, C. aldenense 
1% - - - - 
Ruminococcus productus, R. gnavus 1% - - - - 
Bacteroides merdae, B. eggerthii, B. gallinarum, B. clarus, B. uniformis 1% - - - - 
Odoribacter splanchnicus 1% - - - - 
Butyricimonas paravirosa, Butyricimonas faecihominis, Butyricimonas virosa 1% - - - - 
Barnesiella intestinihominis 3% - - - - 
Blautia hansenii, Blautia stercoris 1% - - - - 
Lactobacillus rogosae 1% - - - - 
Adlercreutzia equolifaciens 1% - - - - 
Asaccharobacter celatus 1% - - - - 
Gordonibacter faecihominis,G. pamelaeae 1% - - - - 
Enterorhabdus mucosicola, E. caecimuris 1% - - - - 
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Table 3.1.2 cont.  
 
 
 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Parvibacter caecicola 1% - - - - 
Denitrobacterium detoxificans 1% - - - - 
Slackia faecicanis 1% - - - - 
Faecalibacterium prausnitzii 1% - - - - 
Averyella dalhousiensis 1% - - - - 
Kluyvera ascorbate 1% - - - - 
Hungatella effluvii 1% - - - - 
Erwinia billingiae 1% - - - - 
Raoultella ornithinolytica 1% 4% 13% - 22% 
Pantoea agglomerans 1% - - - 3% 
Lelliottia amnigena 1% - 1% - - 
Eggerthella lenta,Eggerthella sinensis,Eggerthella hongkongensis 1% - - - - 
Enterobacter soli 1% - - - - 
Klebsiella oxytoca - - 2% - 4% 
Citrobacter youngae  - 3% - - - 
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Table 3.1.2 cont.  
 
 
 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Escherichia coli - - - 48%- - 
Shigella sonnei - - - 28% - 
Serratia marcescens - - - 10% - 
Citrobacter freundii 1% 29% 22% - 12% 
Citrobacter murliniae - 10% 5% - - 
Citrobacter braakii 1% 8% 19% - 4% 
Citrobacter werkmanii - 8% - - 3% 
Enterobacter aerogenes 1% 8% 22% - 24% 
Kluyvera cryocrescens 1% 6% 11% - 19% 
Kluyvera intermedia - 2% - - - 
klebsiella pneumoniae 1% - 1% - - 
Shigella flexneri - - - 7% - 
Shigella boydii - - - 7% - 
Raoultella terrigena - 2% - - 3% 
Raoultella planticola - - - - 1% 
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Table 3.1.2 cont.  
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Yokenella regensburgei - 1% - - 4% 
Enterobacter asburiae - 2% - - 1% 
Acinetobacter calcoaceticus - 2% 4% - - 
Enterobacter cloacae - 4% - - - 
Enterobacter  ludwigii - 3% - - - 
Cedecea neteri, Cedecea lapagei - 1% - - - 
Leclercia adecarboxylata - 1% - - - 
Escherichia vulneris - 1% - - - 
Pantoea eucalypti - 1% - - - 
Proteus mirabilis - 1% - - - 
Enterobacter hormaechei - 2% - - - 
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Among the four UC patients, each has certain unique bacterial species suggesting 
pathogenesis of diseases varies from individual to individual. Although the species differ 
between patients, similar genera are present in 3 of the patients (Figure 3.1.8). Genera 
of Citrobacter, Enterobacter, Kluyvera and Roultella are present in patients 1, 2 and 4.  In 
contrast, patient 3 has less diversity, dominated by genera of Escherichia and Shigella. 
Healthy control was dominated by high proportion of Bactriodes , Ruminococcus and 
clostridium and low level of Kluyvera, Roultella and Citrobacter when compared with UC 
patients.   
 
Becker et al (2015) highlighted the unmet need to identify bacterial species involved in 
UC. The authors stated “It is currently unclear whether the composition of the microbial 
flora or individual bacterial strains or pathogens induces or supports the pathogenesis of 
UC. Further research will be necessary to carefully dissect the contribution of individual 
bacterial species to this disease and to ascertain whether specific modulation of the 
intestinal microbiome may represent a valuable further option for future therapeutic 
strategies.” Although this study was a pilot in nature, it does identify bacterial 
populations involved in colitis disorders at the genus and family level and highlights the 
need for future genomic studies to understand better diseases associated with human 
colonic mucosa. 
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 Figure 3.1.8. Proportion of bacterial genera present in the colon of UC patients and healthy control (16S rRNA). 
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In the literature various species have been sporadically identified as being involved in 
colitis. According to Kaakoush et al (2014) bacteria from Campylobacter species are 
involved in colitis disorders. Among the various bacteria adherent and invasive 
Escherichia coli, Helicobacter, Fusobacteria, and Campylobacter species have also been 
identified (Bohr et al., 2004; Conte et al., 2006; Minami et al., 2009; Mukhopadhya et al., 
2011; Thomson et al., 2011). Data have started to emerge to indicate that the bacterial 
genotype has a significant role in its invasiveness to gut (Kaakoush et al., 2014). Murine 
model data further revealed that it is not only the presence of a particular bacterial 
species that is important but it is the interaction of microbes with other species present 
in the gut that determine the pathogenic aspects (Liang et al., 2014). A study by Winter 
and Baumler (2014) agreed with our findings at the molecular level. According to this 
study, high levels of facultative anaerobic bacteria mainly from the Enterobacteriaceae 
family were involved in inflamed colon. In addition, Ahmed et al (2007) concluded that 
pro-inflammatory bacterial species such as Shigella, Citrobacter were associated with 
the early stages of inflammation, as possible bacterial operators that can drive colitis to 
colon cancer in patients suffering from UC. It may be important to recognise that several 
types of inflammatory pathways that could manifest, which could be influenced by 
different bacteria. Lapthorne et al (2015), in an animal study, noticed a reduction in the 
Enterobacteriaceae family bacteria associated with colonic disorders. This study 
confirms these observations associating members of the Enterobacteriaceae with colitis, 
particularly, Citrobacter and Shigella species, as well as recording that dysbiosis in 
colonic mucosa is generally characterized by bacterial reduction in diversity and 
decrease of obligate anaerobes in parallel with increase facultative anaerobes or the 
presences of unusual aerobes bacteria. 
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In the current study, primary interest was to detect SRB in samples of healthy control 
and patients suffering from UC and to estimate if there is any difrences or the precense 
of specific SRB species in both groups. SRB 16S rRNA gene sequences were not detected  
in this study. This might be because these bacteria were not present in high enough 
quantities as aresult of their slow growth. In order to detect SRBs, a different target 
gene was used which is specific to SRBs. In next set of experiments primer specific for 
dissimilatory sulfite reductase gene was used to amplify dsr gene of healthy and UC 
patients DNA then PCR products cloned. A total of 30 clones from the mucosal biopsies 
were sequenced (control 7 clones; UC patient1 6 clones; UC patient2 7 clones; UC 
patient3 5 clones; UC patient4 5 clones). The sequences were compared with database 
sequences. As shown in Figure 3.1.9, SRB of five different families were identified. These 
include Desulfovibrionaceae, Desulfohalobiaceae, Desulfomicrobiacease, 
Desulfobacteraceae, Desulfonatronaceae, and Syntrophobacteraceae. Importantly, all 
four colitis patients revealed a loss of the Desulfonatronaceae bacterial family. 
Furthermore, bacteria from Syntrophobacteraceae family were only present in patient 2 
and 4. Based on the data from Figure 3.1.9, it is not possible to make any conclusive 
statement, except that members of the Desulfovibrionaceae and Desulfomicrobiaceae are 
present in healthy and all UC patients and Desulfontronaceae was only present in 
healthy control and was absence in all UC patients. The microbiome diversity appears to 
be the major issue encountered by patients with colitis disorders.
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Figure 3.1.9. A histogram demonstrating the Family level of SRB composition present 
in healthy patient and patients suffering from UC (dsrA gene) 
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Sequences from Desulfovibrionaceae, Desulfobacteraceae and Desulfomicrobiaceae were 
the most abundant of SRB groups present in the samples, including samples from 
patients with UC and the healthy individual and which were recovered with similar 
frequencies in general. The exception being sequences from patient 1 which showed the 
absence of Desulfobacteraceae . 
 
The gut microbiome is highly diverse in nature, and overall bacterial population varies 
between individuals. A dietary habit of the people and environmental factors affects the 
composition of bacterial populations. The diversity of SRBs, however, is limited to two 
families and 2 main genera. In total, sequences from 14 genera were detected from the 
patients and the healthy individual. The presence of sequences from two genera, 
Desulfovibrio and Desulfomicobium, were recovered from all patients and the healthy 
individual. All of the other genera were present in one, two, three or four of the 
individuals sampled. The greatest number of species recovered, according to the dsr 
sequences, was found within the Desulfovibrio. Sequences representing 18 Desulfovibrio 
species were recovered from the healthy individual. In three of the four patients, this 
number increased to 20, 27 and 28 (Figure 3.1.10). Only in patient 1 did the number of 
Desulfovibrio species sequences drop, to 5. The diversity of SRBs in this individual was 
greatly reduced compared to the other patients, reflecting the dominance of 7 species in 
total. Sequences from the other genus present in all of the individuals matched 
Desulfomicrobium species. The healthy individual had sequences representing 3 species 
of Desulfomicrobium. This number increased in two UC patients, stayed the same in one 
and decreased in the other (Figure 3.1.10). 
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Figure 3.1.10. Distribution of genera from heathy and UC patients. The numbers above 
each histogram represents the number of species identified as Desulfovibrio from each 
patient. 
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The levels and diversity of SRB in UC patient 1 are of interest. The clinical data relevant 
to disease severity and how long the patient has been suffering from the disease was 
not described for the patients. In future, it will be quite intriguing to link bacterial 
population particularly SRB with the UC pathogenic aspect and disease stage. It is a 
quite possible that the levels and type of bacteria species might be defining factors in 
the disease outcomes. In comparing with health control, it is quite evident that existing 
population of SRB was significantly elevated in this patient, although the diversity was 
low. However, the other three individuals also manifested emergence of new bacterial 
species. 
 
The healthy individual had dsr sequences representing a complex and diverse SRB 
population with no significant increase for any specific species. The sequence identities 
recovered from UC patient 1 are shown in Table 3.1.3, along with those from the other 
patients. Seven species of bacteria were identified including Desulfohalobium retbaense 
(15%), Desulfomicrobium salsuginis (15%), Desulfovibrio burkinensis (14%), 
Desulfovibrio intestinalis (14%), Desulfovibrio carbinolicus (14%), Desulfovibrio 
magneticus (14%), and Desulfovibrio desulfuricans (14%). Twenty-one new sequences 
were recovered from the rest of the patients (2 to 4), representing 21 new species. The 
diversity from patients 2, 3 and 4 resembled that of the healthy individual. The largest 
group of sequences representing single species were recovered from UC patient 2, and 
these were for Desulfovibrio gigas and Desulfovibrio hydrothermalis, both representing 
7% of the total sequences recovered. 
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Table 3.1.3 The level of SRB species present in the colon of UC patients and healthy individual (dsr gene) 
 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Desulfovibrio africanus 7% - 5% 4% 4% 
Desulfovibrio intestinalis 6% 14% 5% 3% 4% 
Desulfovibrio gabonensis 6% - 2% 1% 3% 
Bilophila wadsworthia 6% - 5% 1% 4% 
Desulfovibrio vulgaris 4% - 2% 1% 3% 
Desulfovibrio piger 4% - 5% 1% 3% 
Desulfovibrio desulfuricans 4% 14% 5% 3% 3% 
Desulfovibrio fructosivorans 3% - - 1% 1% 
Desulfovibrio fairfieldensis 3% - 2% 1% 3% 
Desulfovibrio simplex 3% - - 1% 3% 
Desulfovibrio burkinensis 3% 14% 2% 4% 3% 
Desulfovibrio oxyclinae 3% - 2% 3% 3% 
Desulfovibrio oceani 3% - - 1% 1% 
Desulfovibrio magneticus 3% 14% 2% 4% 3% 
Desulfovibrio halophilus 2% - 2% 3% 3% 
Desulfovibrio longus 2% - - 1% 1% 
Desulfovibrio aminophilus 2% - - 3% 1% 
Desulfovibrio termitidis 1% - 2% 3% 3% 
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Table 3.1.3 cont 
 
 
 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Desulfovibrio carbinolicus 2% 14% 3% 4% 3% 
Desulfovibrio alkalitolerans 1% - - 3% 1% 
Desulfovibrio alaskensis 2% - 3% 3% 1% 
Desulfovibrio piezophilus - - 5% 3% 4% 
Desulfovibrio portus - - 2% 1% 3% 
Desulfovibrio hydrothermalis - - 7% 1% - 
Desulfovibrio gigas - - 7% 4% 4% 
Desulfovibrio zosterae - - 3% 3% 1% 
Desulfovibrio salexigens - - 5% 1% 3% 
Desulfovibrio aespoeensis - - 3% - 1% 
Desulfovibrio acrylicus - - - 3% 1% 
Desulfovibrio aerotolerans - - - 3% 1% 
Desulfovibrio carbinoliphilus - - - 3% 1% 
Desulfovibrio cuneatus - - - 3% 1% 
Desulfohalobium retbaense 1% 15% - 3% 1% 
Desulfomicrobium salsuginis 1% 15% 3% 3% 3% 
Desulfosalsimonas propionicica 1% - - 3% 1% 
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Table 3.1.3 cont 
 
 
  
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Desulfonatronospira thiodismutans 2% - - - - 
Desulfatibacillum alkenivorans 3% - - 1% 3% 
Desulfococcus oleovorans 4% - 2% - 1% 
Desulfomicrobium apsheronum 1% - - 2% - 
Desulfatitalea tepidiphila 2% - - - - 
Desulfonatronovibrio halophilus 2% - - - - 
Desulfomicrobium aestuarii 1% - - 3% 1% 
Desulfonatronum thioautotrophicum 1% - - - - 
Desulfonatronum lacustre 1% - - - - 
Desulfatibacillum aliphaticivorans 3% - - 1% 1% 
Desulfobacter vibrioformis 3%  2% - - 
Desulfobacter postgatei 2% - 2% - 1% 
Desulfobacter latus 2% - 2% - 1% 
Thermodesulforhabdus norvegicus - - 3% - 1% 
Desulfosarcina variabilis - - 3% - 2% 
Desulfomicrobium escambiense - - 2% 2% 3% 
Desulfomicrobium baculatum - - 2% 2% 1% 
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Table 3.1.3 cont 
 
 
 
 
Bacterial species Healthy control UC patient1 UC patient2 UC patient3 UC patient4 
Desulfomicrobium thermophilum - - - 3% 2% 
Desulfomicrobium orale - - - 3% 2% 
Desulfomicrobium salsuginisstrain - - - - 2% 
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The number of dsr sequences that represented a single species totaled 36 for the 
healthy individual, 7 for patient 1, 31 for patient 2, 42 for pateint 3 and 47 for pateint 4. 
This confusing data is simplified if the number of genera for each individual is 
considered. The healthy individual had sequences representing 11 genera, whereas the 
UC patients had 4, 7, 6 and 9 for patients 1, 2, 3 and 4 respectively. A reduction in 
diversity for each individual patient. This reduction coincides with an increase in the 
propotion of sequences representing the genus Desulfovibrio. In the healthy individual, 
53% of sequences recovered belonged to Desulfovibrio, this proportion increased to 
71% and 70% in patients 1 and 3, and to 66% and 67% in patients 4 and 2.        
 
Sequences representing 32 species of Desulfovibrio were recovered from all individuals. 
Of these, only 5 sequences were present in the healthy individual and UC patients, and 
these represented the species Desulfovibrio intestinalis, Desulfovibrio desulfuricans, 
Desulfovibrio burkinensis, Desulfovibrio carbinolicus and Desulfovibrio magnetus (Figure 
3.1.11). Sequences present in the healthy individual and three of the patients included 
those presenting the species Desulfovibrio fairfieldensis, Desulfovibrio termitidis, 
Desulfovibrio alaskensis and Desulfovibrio halophilus. Sequences representing species 
only found in three of the UC suffers included: Desulfovibrio piger, D. piezophilus, D. 
gigas, D. zosterae, and D. salexigens. The only other species present as a dsr sequence in 
the healthy individual and three of the UC patients was Bilophila wadsworthia.
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Figure 3.1.11. Species of Desulfovibrio present in a healthy individual and four UC suffers
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Jia et al (2012) reported that distribution of SRB was reduced among patients suffering 
from UC. This study concluded that for a healthy functioning colon two bacterial species 
were needed, Desulfovibrio piger and B. wadsworthia, where their presence was noted at 
levels of 93.5% in the healthy control group. In the present study, a slightly different 
response was observed. There was a reduction in diversity of SRBs at the genera level 
associated with UC, possibly at the expense of an increase in the diversity of one genus, 
Desulfovibrio. Desulfovibrio piger sequences were not present in the healthy individual 
but those for Bilophila wadsworthia were. In UC patient 1, which exhibited the greatest 
diversity loss, B. wadsworthia was absent, but it was present in the other three UC 
patients. This study suggests that it is, perhaps, the loss of diversity at the genera level 
that is important in the development of UC, allowing one group of SRBs to become 
dominant.  
 
There are several studies describing dysbiosis, but these have produced different sets of 
information about the bacterial populations. Ott et al (2004) studied the dynamics of 
the mucosa-associated flora in the UC patients using 16S rRNA sequences, reporting the 
loss of bacterial diversity including Prevotella sp, Porphyromonas sp, however, none of 
the bacteria described in this study were reported in the UC patients. It is quite possible, 
that the amplification strategies as well as the quality of DNA also impact the overall 
recovery of bacterial species for 16S rRNA and these findings still awaits confirmation 
with future studies. No SRB sequences were detected in the current study when the 16S 
rRNA gene was targeted.  
 
Although 16S rRNA is widely used for bacterial species characterization from 
environments, it is possible that some species sequences are missed in such studies, 
particularly those from rare or low abundant species.  Targeting functional genes in PCR 
amplifications may be the only option to get conclusive information about rare bacterial 
species. There are several reports highlighting this issue. Salzman et al (2002) studied 
the characterization and presence of Lactobacillus acidophilus from mouse small 
intestine, large intestine and faeces. 16S rRNA gene sequences were helpful in the 
identification of this particular bacterium, but also picked out certain other bacterial 
species. Similarly, there are several other reports in the literature in which gene-specific 
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PCR has been the final resort in the characterization of bacterial species (Parra et al., 
1991; Spierings et al., 1992; Gloux et al., 2011).  
The major focus of interst in this study was on sulfate reducing bacteria, and to our 
surprise, it was not possible to get a reliable picture of sulfate reducing bacteria in the 
UC and healthy individual using 16S rRNA gene sequences. However, a gene specific 
PCR involving dsr gene was selected to find out their potential contributions in UC. 
 
This study based on combining 16S rRNA bacterial identification strategy combined 
with specific gene for SRB (dsr gene) utilization in evaluating the relative levels of colon 
microbiota about UC has opened up a new avenue of research. It has identified that 
bacterial diversity changes dramatically in UC sufferers at several levels; there is an 
overwhelming increase in the number of species from the Enterobacteriaceae, and an 
increase of species from Desulfovibrio. 
 
3.1.4 Phylogenetic analysis  
 
The sequences of 16S rRNA and dsrA genes obtained by cloning and sequencing were 
used for Phylogenetic analysis construction. All sequences and their closest relatives 
were aligned using Muscle implemented in Seaview (Galtier et al., 1996; Edgar, 2004) 
(Appendices 2). Based on the sequence result from 16S rRNA; the majority of the 
inhabitants of the colon of UC patient and healthy control belonged to Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria. These bacteria have been recorded as 
present in healthy colon by other studies, supporting our findings (Eckburg et al., 2005; 
Huse et al., 2012). Phylogenetic analyses were performed for each of these bacterial 
groups, with the significance of each clade estimated by bootstrapping.  
The taxa in the Firmicutes 16S rRNA Phylogenetic tree (Figure 3.1.12) divide into three 
deeply branched clades, named Group-A, Group-B, and Group-C. Group-C contained 
members of the class Negativicutes and sequences from clones were absent from this 
group. Within Group-B, representing class Bacilli and Clostridia, 5 out of 27 clones from 
the healthy colon sample (K53, K55, K23, P81, and P68) were grouped with sequences 
from Clostridium ramosum.  Most of the clones, 22 out of 27 clones from the healthy 
control sample, belonged to the larger group, Group-A. Within the Group-A, 2 clones 
(K24 and K31) were grouped with Clostridium lavalense and 2 clones (C_P2100 and K8) 
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with sequences from Hungatella hathewayi. 7 clone sequences (p87, p28, p69, p21, p67, 
k10, and k5) formed a distinct clade that was closely related to Ruminococcus torques 
sequences. 2 clones (K29 and P24) had sequences that grouped with sequences from 
Clostridium nexile. 2 clone sequences (K30 and K50) formed a clade with those from 
Ruminococcus gnavus. 2 clones (P41 and P47) formed their own clade, which was 
closely related to Subdoligranulum variabile sequences. 5 clones (K53, k55, k23, p81, 
and p68) were clustered with Clostridium raosum. Clostridia species participate in 
immune homeostasis, inhibition of autoimmunity and harmful inflammation to colonic 
mucosa, and they also contribute to the overall maintenance of colon function, however, 
it still unknown if the reduction of Clostridia species in the colon can lead to chronic 
inflation in UC patients (Frank et al., 2007; Rajilic et al., 2007). Clones K25, P76, K13, 
K52, and K32 were classified as Blautia coccoides, Eubacterium eligens, Clostridium 
leptum, Faecalibacterium prausnitzii, Flavonifractor plautii respectively; which may 
indicate that these clones are belonging to these bacteria. 
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Figure 3.1.12. A maximum likelihood phylogenetic tree (model TN93) showing the 
relationships between derived 16S rRNA gene sequences of known taxa belonging to 
Firmicutes and those of random clones from healthy control; the support value 
estimated with 100 bootstrap replicates using PhyML. Bootstrap values which above 50 
only shown 
CHAPTER 3: RESULTS AND DISCUSSION 
110 
 
Both S. variabile and Faecalibacterium prausnitzii are abundant in the healthy human 
colon and they have an important function in human health and protection against 
pathogenic bacteria (Nava et al., 2005).  
 
The taxa representing the order Bacteroidales formed a maximum likelihood tree 
(Figure 3.1.13) that divided into four deeply branched clades named group-A to group-
D. Most of the clones, 37 out of 43 Bacteroidales clones from healthy control sample, 
belonged to the larger group, group-A. The Bacteroidales, an order within the phylum 
Bacteroidetes, contains four families including the Bacteroidaceae, the 
Porphyromonaceae, the Rikenellaceae, and the Prevotellaceae. Members of the 
Bacteroidales have been shown to predominate and occupy a vital niche at the colonic 
mucosal surface, which gives these bacteria the ability to interact with the host and 
therefore they have role(s) in the human health either beneficial or detrimental 
(Hooper et al., 2003; Mazmanian et al., 2005). Within the group-A, containing general 
Bacteroides taxa, clones and reference taxa formed seven independent sub-clades 
termed BF1, BF2, BA1, BV, BD, BU, and BA2. Sequences from 14 out of 43 clones (p45, 
p46, k26, p44, p82, p25, p64, k4, p89, k16, k51, k6, p49, and p26) formed clades with 
BF1 and BF2 subgroups with various B. fragilis strains.  Sub-clade BA1 comprised 6 
sequences out of 43 clones (k2, k3, k1, p78, p212, k28), which was basal to clades BF1 
and BF2. Blast searching results showed k2 and k3 clones had 99% sequence 
homologies with B. fragilis, as did sequences from clones p78, p212 and k28 at 97%, 
96% and 98% homology matches respectively. It would appear that clades BF1, BF2 and 
BA1 contain strains of B. fragilis, with the exception k1 clone, which had 99% sequence 
homology with that from Bacteroides clarus. Poxton et al (1997) found mucosa 
associated B. fragilis in the colon representing 42% of total bacteroides isolated, which 
is in agreement with the high frequency of this species in healthy human colon of this 
study.  
 
Clade BV contained 5 clone sequences (k54, p85, p48, p83, p86) with representatives of 
B. vulgatus sequences at a basal location, while clade BD containing 7 clone sequences 
(k22, p29, p66, p62, p88, p65, p710) with a basal B. dorei sequence.  The taxonomic 
affiliation of the BA2 clade, which contains 4 clone sequences (p77, k27, p61, and p410) 
only, was hard to infer from the tree. The blast searching results showed that the 
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sequence from clone P410 had 96% sequence identity with that from B. uniformis. 
Whereas, the sequence from clone P61 had 99% sequence homology with that from B. 
fragilis. Clones k27 and p77 were closely related to B. vulgatus. Clade BA2 is sister to 
clade BU, which contained 1 clone (p412) and many B. uniformis strains.  In this study 
the dominating species including B. thetaiotaomicron, B. vulgatus, B. uniformis and B. 
fragilis which were observed to be commonly present in the healthy control sample 
came in line with other studies (Frank et al., 2007;Noor et al., 2010; Sekirov et al., 2010). 
The protection role of B. vulgatus and B. ovatus against the development of colitis and 
intestinal inflammation has previously been demonstrated (Waidmann et al., 2003; 
Conte et al., 2006; Hudcovic et al., 2009).  
 
The remaining 3 clades (group B, group C and group D) all contained clone sequences. 
In general, group-B contained members of the Parabacterioides and clone k15, which 
grouped with the 16S rRNA sequence from Parabacteroides merdea. Group-C contained 
member of the Barnesiella as a sister group to three clones (P211, P611, p210) where 
sequences from Barnesiella viscericola represented to nearest taxonomic relation. Basal 
to this main clade was the sequence from clone L31 and Barnesiella intestinihominis. 
Group-D contained members of the Butyricimonas and clone p27, which formed a clade 
with the sequence from Butyricimonas virosa. This species has been recorded before as 
being a member of the human colonic mucosa, and reinforces the usefulness of 16S 
rRNA sequences to provide a rapid identification of environmental bacteria, providing a 
broader understanding of unknown bacteria present in mucosa of human colon (Toprak 
et al.,  2015; Mehta et al., 2015; Enemchukwu et al., 2016).  
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Figure 3.1.13. A maximum likelihood phylogenetic tree (model TN93) showing the 
relationships between derived 16S rRNA gene sequences of known taxa belonging to 
Bacteroidetes and those of random clones from healthy control; the support value 
estimated with 100 bootstrap replicates using PhyML. Bootstrap values which above 50 
only shown 
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The 16S rRNA phylogenetic tree of Proteobacteria in healthy control sample (Figure 
3.1.14) appeared divided into two major branches named Group-A, Group-B, containing 
the Gamma Proteobacteria and the Delta Proteobacteria, as an outgroup.  Group A 
comprised members of the orders Pseudomonadales and Enterobacterales, and two 
clones from the healthy control sample (P79 and P610) which grouped inside of the 
Enterobacterales subgroup, closely related to the sequences of Enterobacter aerogenes. 
Enterobacter aerogenes is recognised as part of the normal intestinal flora, however 
under certain conditions these bacteria have been found to infect the human colon and 
lead to several symptoms that can cause debilitation of the host colon that leads to 
inflammation (Grimont & Grimont, 2006). 
 
Figure 3.1.14. A maximum likelihood phylogenetic tree (model TN93) showing the 
relationships between derived 16S rRNA gene sequences of known taxa belonging to 
Proteobacteria and those of random clones from healthy control; the support value 
estimated with 100 bootstrap replicates using PhyML. Bootstrap values which above 50 
only shown 
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The last bacterial group from the healthy individual was the Actinobacteria and the 
phylogenetic tree for this is shown in Figure 3.1.15. It contained three major branches 
Group-A, Group-B, and Group-C corresponding to the Coriobacteriia, Bifidobacteriales, 
and Actinobacteri. Within the Group-A, one clone (K14) from healthy control sample 
formed a clade with Eggerthella lenta. E. lenta found as member of normal bowel 
mucosa their presence contributes to the host defense through the anti-inflammation 
activity that certain E. lenta strains have however their pathogenicity is not as low as 
previously suggested (Kageyama et al., 1999; Saunders et al., 2009; Longman & Littman, 
2015).  
 
Figure 3.1.15. A maximum likelihood phylogenetic tree (model TN93) showing the 
relationships between derived 16S rRNA gene sequences of known taxa belonging to 
Actinobacteria and those of random clones from healthy control; the support value 
estimated with 100 bootstrap replicates using PhyML. Bootstrap values which above 50 
only shown 
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Sequences recovered from UC suffers gave homology matches to members of the 
Enterobacteriaceae, and a phylogenetic tree (Figure 3.1.16) based on maximum 
likelihood analysis was constructed using clone rRNA sequences and public available 
reference sequences for this group. The clone sequences from all patients suffering from 
UC grouped into three distinct groups termed Group-A, Group-B, and Group-C.  Group-A 
contained 11 clone sequences (C_23/24, C_23/32, C_A1A6, C23/22, C23/33, C_A1A17, 
C_A1A20, C_A1A15, C_A1A11, C_A1A18, and C_A1A14), which formed a clade with 
sequences from Escherichia coli. The clones belonged to Group-A , were all from patient 
3. Group-B contained 10 clone sequences formed a clade with those from Citrobacter 
freundii and these sequences were from patients 2 and 4. Group-C contained 7 clones 
from patient 1 and patient 2 and these sequences also formed a clade with sequences 
from Citrobacter freundii. Several studies have observed imbalances in the bacteria 
present in the colon of patients suffering from UC such as the increase of certain group 
of bacteria (Proteobacteria) which was observed this study (Ott et al., 2004; Frank et al., 
2007; Packey& Sartor., 2009). The taxonomic differences between control and UC 
patients were distinguished in this study and our results are similar in terms of the 
reduction the reduction of biodiversity of Firmicutes, Bacteroidetes and Actinobacteria 
in patients of UC and an increase in members of Gamma Proteobacteria was also 
observed (Sokol & Seksik, 2010).  
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Figure 3.1.16. A maximum likelihood phylogenetic tree (model TN93) showing the 
relationships between derived 16S rRNA gene sequences of known taxa belonging to 
Proteobacteria and those of random clones from patients suffering from UC the support 
value estimated with 100 bootstrap replicates using PhyML. Bootstrap values which 
above 50 only shown 
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SRB belong to the mucosa associated bacteria of both humans and animals (Cummings 
et al., 2003), and 67- 91% of all dominant SRB species are belonging to Desulfovibrio 
genus (Kushkevych, 2013). A pathogenic role in UC disease may came from this genus of 
SRB, however not one 16S rRNA sequence for these species was detected from healthy 
or UC patients. One reason that could explain this absence at the 16S rRNA level is the 
rarity of SRB cells, sequences from which might be out-completed in PCR amplifications 
by those from commoner species.  In order to characterise the SRBs present in the 
human colon, a different gene was targeted, one that would be present pre-dominantly 
in SRB cells – the dissimilatory sulfite reducatase (dsr) gene.  Dissimilatory sulfate 
reduction and the production of hydrogen sulphide by SRB in the human colon have 
been proposed as one of the main causes of colonic mucosa inflammation (Rowan et al., 
2009). Previous studies on the diversity of SRB in complex microbial communities such 
as human colon have been based on 16SrRNA gene analysis (Deplancke et al., 2000; 
Nava et al., 2012; Kushkevych, 2014). The dsr gene has been widely used as ideal 
phylogenetic marker gene for assessing the diversity of SRB in complex environments, 
other than the human colon (Wagner et al., 1998; Loy et al., 2004; Nakagawa et al., 
2004).  
The dsr gene phylogenetic tree (Figure 3.1.17) was constructed from an alignment of 
taxa including dsr sequences from cloned PCR products.  A maximum likelihood tree 
divided the taxa into five deeply branched clades named group-A to group-E.  The 
Group-A, Group-B, Group-C, Group-D, and Group-E clades corresponding to the 
Desulfovibrionales, Desulfobacterales, Desulfovibrionales, Desulfarculales, and 
Syntrophobacterales taxonomic lineage respectively. The dsr gene clone sequences were 
from both healthy (clones F1, F4, F6, and E5) and UC patients (clones A7, B8, B6, C4, 
C11, C1, D4, D12, and D5) and all were placed inside the larger clade, the Group-A for 
the Delsulfovibrionales, but not at the same location. All the clone sequences from 
healthy control samples were clustered together, and were closely related to 
Desulfovibrio aminophilus and Desulfovibrio longus. All the clone sequences from three 
patient samples were clustered together with Desulfovibrio alaskensis G20, a gram-
negative mesophilic sulfate-reducing bacterium. The presence and increased members 
of the genus of Desulfovibrio subspecies (Specifically, strains of D. piger and D. vulgaris) 
were reported as human opportunistic pathogen in UC patients (Gibson et al., 1990; 
Zinkevich & Beech, 2000; Rowan et al., 2009; Rowan et al., 2010).  
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Figure 3.1.17. Deltaproteobacteria maximum-likelihood (model TN93) dsr gene based 
phylogenetic tree. The tree reflected the relative placement of the dsr gene clones from 
healthy control and patients suffering from UC among sulfate-reducing 
Deltaproteobacteria. Numbers placed above the branches were the support values 
estimated with 100 bootstrap replicates using PhyML. Bootstrap values which above 50 
only shown 
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Based on the phylogenetic analysis obtained from this study distinct bacterial taxa 
accounted the differences between healthy control and UC patients the overall bacterial 
profile showed a major shifts in the bacterial taxa that discriminated mucosal 
communities in healthy control and UC patients samples. The ability of 16S rRNA gene 
to distinguish SRB species was limited however the functional gene, dsr, was able to 
distinguish ecologically distinct bacterial populations (Kondo et al., 2006). 
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Section 2 
Design of a Biochip for screening of mucosa associated bacteria in 
healthy and colitis patients 
 
The low-density biochips have been developed to analyse a relatively small number of 
genes. A notable example being the usage of a biochip to monitor the common intestinal 
pathogenic bacteria (Jin et al., 2005). These multi target biochips are possibly ideal for 
detecting pathogens that interact to produce symptoms and as such would be of great 
use for rapidly screening the bacterial populations of the colonic mucosa in UC. In this 
chapter a set of oligonucleotide probes targeting some of bacteria known to be involved 
on UC was designed. The hybridization potential of each probe was evaluated using 
cassette method (Zinkevich et al., 2014); and subsequently the probes were used to 
design biochips for bacterial detection and identification on healthy and UC patients 
samples. 
 
3.2.1 Oligonucleotide probe design 
 
The colonic bacteria, which are likely to be implicated in the etiology and pathogenesis 
of UC, were selected and the DNA probes for targeting these bacterial genes were 
designed. The selection of these bacteria was based on previous studies as well as on 
the analysis of biopsy samples of healthy individual and UC patients from this thesis 
(Cummings et al., 2003; Sasaki & Klapproth, 2012; Kushkevych, 2013; Matsuoka & 
Kanai, 2015). Additional probes obtained from ProbeBase an rRNA-targeted 
oligonucleotide probe database were also included in the analysis (Loy et al., 2007). 
Designed and published probes shown in Table 3.2.1 and Table 3.2.2. 
The probes were designed from the alignments of species- or genus-specific variable 
regions. The sequences of selected marker genes for a range of taxa were obtained from 
NCBI. Alignment maps were generated to allow for the detection of conserved 
sequences which would allow for the generation of taxa probes. All probes were 
checked for their specificity and taxon coverage by BLAST searches against the GenBank 
database. Probe length is important to modulate specificity and sensitivity, with longer 
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probes (40-70 mer) are less specific but more sensitive; whereas, shorter probes (> 20 
mer) can differentiate SNPs in target sequences (Relógio et al., 2002). 
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Table 3.2.1. List of design probes  
 
Probe name Targeted bacteria Gene name Probe sequence(5’-3’) Tm °C 
Dslpig Desulfovibrio piger dissimilatory sulfite reductase beta-subunit-dsrB TCAAAAAGAATTTCGGCAAGTGGCT 56.1 
Dslgig Desulfovibrio gigas Sulfate adenylyltransferase-sat CCTGAAGATCGAAGAAAAGTACG 55.7 
Dsbub Desulfobulbus Sulfate adenylyltransferase-sat GATCATTATTTCGTCAAAGAGAACG 54.4 
Dsbac Desulfobacter Sulfate adenylyltransferase-sat AAGATCGCTATTGAAGTATGTGACG 56.1 
Dslsp Desulfovibrio sp adenosine-5'-phosphosulfate reductase alpha- 
subunit-aprA 
TCATGATCAACGGTGAATCCTACAA 56.1 
Dsldes Desulfovibrio 
desulfuricans 
dissimilatory sulfite reductase  alpha –subunit- 
dsrA 
CAAGTACTATCACAGCAAATTCCTG 56.1 
Desfot Desulfotomaculum Sulfate adenylyltransferase-sat CTGAAGAATACAAAGGTGTTTACCT 54.4 
S1 SRB dissimilatory sulfite reductase  alpha –subunit-dsrA TAAGTTCTACACCTCCGAATACCT 55.9 
Ent1 Enterobacteriaceae β-galactosidaes-β-gal   TATTCGATTTCTGATAAGAGCGTGG 56.1 
EC E. coli β-galactosidaes-β-gal GGAAAACACCTAACGCATATTAACG 56.1 
Bacfr Bacteriodes  fragilis Neuraminidase gene-nanH GACAAGGATTCTACCAGCTTTATAC 56.1 
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Table 3.2.1.  Cont. 
Probe name Targeted bacteria Gene name Probe sequence(5’-3’) Tm °C 
Bacsp Bacteriodes  sp beta-isopropylmalate 
dehydrogenase -leuB 
TGTATTTCGGTGAGAAGTATCAGGA 56.1 
Cldif Clostridium difficile Toxin Clostridium difficile gene- 
TcdC  
GTGAAGCGTTCTTAGTCAATACACT 56.1 
Clsp1 Clostridium sp [Fe-Fe]-hydrogenases- hydA GGGGATAGCTAGTGGATTTAGTATA 56.1 
Fusv Fusobacterium varium Fusobacterium adhesin A-fadA TAACTATAAAGTATCAGGAGGGCTT 54.4 
Fusnu Fusobacterium nucleatum Fusobacterium adhesin A-fadA GATTTAATGAAGAAAGAGCACAAGC 54.4 
Fusne Fusobacterium necrophorum Fusobacterium adhesin A-fadA CTATTATTTCGGTCAAAGTTCCACA 54.4 
Ent2 Enterobacteriaceae β-galactosidaes-β-gal GGCTGAACAACAAGAAGATTTACAC 56.1 
Clsp2 Clostridium sp [Fe-Fe]-hydrogenases- hydA GACCGTATAAGAGATAACTATGAAG 54.4 
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Table 3.2.2. List of published DNA probes 
 
 
Probe name Targeted bacteria Gene name Probe sequence(5’-3’) Tm °C Reference 
Rum Ruminococcus 16SrRNA 
 
CCA ATT GGA AAC GAT TGT TAA TAC C 54.4 Harmsen et al.,  2002 
Bif Bifidobacterium CATCCGGCATTACCACCC 56.9 Reichardt et al., 2011 
Lac Lactobacillus CCG TCA ACC CTT GAA CAG TT 55.2 Demaneche et al., 2008 
SR2 SRB aprA GGCCTGTCCGCCATCAATA 57.1 Zinkevich & Beech, 
2000 
 
16S Bacteria  16S rRNA CCTACGGGAGGC AGCAG  55 Muyzer et al.,1993 
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Probes used in this study vary between 18 and 25 oligigonucleotides in length. The 
probes with similar Tm values (Tm±2°C) were also considered. The identical 
hybridization behaviour of the oligonucleotide probes immobilized onto a solid surface 
have to be achieved and controlled. Five cassettes were constructed. Each cassette 
contains four of the chosen oligonucleotide probes and functions as the target DNA in 
hybridisation reactions with the biochip were constructed. Therefore, appropriate and 
poorly performing probes can be rapidly identified in the hybridization reactions. The 
composition of the ss cassettes is shown in Figure 3.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: RESULTS AND DISCUSSION 
126 
 
Cassette 1- 5’- piger (25/56.1)* gigas (23/55.7) * Desulfovibrio sp (25/56.1)* SRB1 
(24/55.9) *- 3’ 
Cassette 1 - SEQUENCE 
5’TCAAAAAGAATTTCGGCAAGTGGCTCCTGAAGATCGAAGAAAAGTACGTCATGATCAACG
GTGAATCCTACAATAAGTTCTACACCTCCGAATACCT3’ 
Cassette 1_COMPL  
5’ CY3-
AGGTATTCGGAGGTGTAGAACTTATTGTAGGATTCACCGTTGATCATGACGTACTTTTCTTC
GATCTTCAGGAGCCACTTGCCGAAATTCTTTTTGA 3’ (97 bp) 
________________________________________________________________________ 
Cassette 2 -5’- Desulfobulbus (25/54.4)* Desulfobacter (25/56.1)* Desulfovibrio 
desulfuricans (25/56.1)* Desulfotomaculum (25/54.4)*- 3’ 
Cassette 2 – SEQUENCE 
5’ GATCATTATTTCGTCAAAGAGAACGAAGATCGCTATTGAAGTATGTGACG 
CAAGTACTATCACAGCAAATTCCTGCTGAAGAATACAAAGGTGTTTACCT 3’ 
Cassette 2_COMPL  
5’ CY3-
AGGTAAACACCTTTGTATTCTTCAGCAGGAATTTGCTGTGATAGTACTTGCGTCACATACTT
CAATAGCGATCTTCGTTCTCTTTGACGAAATAATGATC’3 (100 bp) 
_____________________________________________________________ 
Cassette 3 -5’ Enterobacteriaceae (25/56.1)* E.coli (25/56.1)* Bacteriodes  fragilis 
(25/56.1)* Bacteriodes  sp (25/56.1)*-3’ 
Cassette 3 – SEQUENCE 
5’ TATTCGATTTCTGATAAGAGCGTGG GGAAAACACCTAACGCATATTAACG 
GACAAGGATTCTACCAGCTTTATAC TGTATTTCGGTGAGAAGTATCAGGA’3 
Cassette 3_COMPL  
5’ CY3-
TCCTGATACTTCTCACCGAAATACAGTATAAAGCTGGTAGAATCCTTGTCCGTTAATATGCG
TTAGGTGTTTTCCCCACGCTCTTATCAGAAATCGAATA’3 (100 bp) 
______________________________________________________________________ 
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Cassette 4 -5’ Clostridium difficile (25/56.1)* Clostridium sp (25/56.1)* Fusobacterium 
varium (25/54.4)* Bifidobacterium (18/56.9)*’3 
Cassette 4 – SEQUENCE 
5’ GTGAAGCGTTCTTAGTCAATACACTGGGGATAGCTAGTGGATTTAGTATA 
TAACTATAAAGTATCAGGAGGGCTTCATCCGGCATTACCACCC ’3 
Cassette 4_COMPL  
5’ CY3-
GGGTGGTAATGCCGGATGAAGCCCTCCTGATACTTTATAGTTATATACTAAATCCACTAGCT
ATCCCCAGTGTATTGACTAAGAACGCTTCAC’3 (93 bp) 
_________________________________________________________________________ 
Cassette 5 -5’ Fusobacterium nucleatum (25/54.4)* Ruminococcus (25/54.4) 
*Fusobacterium necrophorum (25/54.4)* Lactobacillus (20/55.2)* ’3 
Cassette 5 – SEQUENCE 
5’ GATTTAATGAAGAAAGAGCACAAGCCCAATTGGA AACGATTGTTAATACC 
CTATTATTTCGGTCAAAGTTCCACACCGTCAACCCTTGAACAGTT’3  
Cassette 5_COMPL  
5’ CY3-
AACTGTTCAAGGGTTGACGGTGTGGAACTTTGACCGAAATAATAGGGTATTAACAATCGTTT
CCAATTGGGCTTGTGCTCTTTCTTCATTAAATC’3 (95 bp) 
______________________________________________________ 
Figure 3.2.1. The composition of the ss cassettes 
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3.2.2 Fine-tuning of biochips using cassette approach  
 
A critical step in biochips design is the evaluation of probes, which are going to be used 
on a biochip. These probes have to satisfy several requirements such as a uniform 
melting temperature (Tm) and being a similar size so that their signal intensities are 
comparable under the same hybridization conditions.  Whilst in silico modelling of 
biochip probes is developing rapidly there is often a large difference between the 
theoretical and real world activity of probes. Approximately a quarter of probes are 
non-specific when in situ (Hager, 2006). Determination of individual probe efficacy can 
be time consuming and a novel cassette method for the rapid evaluation of probe 
efficacy has been developed (Zinkevich et al., 2014).  
 
This methodology was adapted to investigate the role of SRB in the development of UC. 
Glass or other silica derivatives are typically used as the base material for microarrays 
as they are chemically resistant and display good optical character. However, they 
feature a limited DNA binding capacity resulting in a low-density surface coverage. 
Various techniques have been used to improve binding efficacy, for example the 
polyacrylamide gel pads coupled with 3-methyluridine probes (Zinkevich et al., 2014). 
For this study a dendrimeric matrix was used which allows for a higher loading of 
probes, promotes improved hybridization and are more robust allowing for several 
hybridization, de-hybridization cycles (Caminade et al., 2006). Probes to detect bacterial 
species or genera identified from the published literature as potentially playing a role in 
UC were designed.  
 
Single stranded (ss) cassettes were used as the targets for the hybridization with the 
probes coupled into the dendrimeric matrix. The cassettes present the lineal set of 
sequences complimentary to the probes. The Cy3 fluorescent dye was inserted at 5´-end 
of each cassette during the synthesis.  
 
Five cassettes were used to evaluate the hybridization potential of each probe. The 
cassettes were composed of four probes; and the size of cassettes varied from 93 to 100 
bp. The hybridization behaviours of the probes targeting Desulfovibrio piger, 
Desulfovibrio gigas, Desulfovibrio sp and SRB were assessed using cassette N1. All of the 
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probes showed comparable hybridization capacities (Figure 3. 2.2), indicating that each 
of these probes were suitable for inclusion in the biochip.  
 
 
Figure 3.2.2. Schematic diagram and the results of the designed cassette N1 
hybridization as signal to noise (S/N) ration. The purple circles are the probes position 
markers the gray circles are the probes. The arrangement of the probes was as follows: 
A1, A2, A3, A4,B1,C1,D1, E1 – Probes position markers; B2,C2 – Dslpig for Desulfovibrio 
piger ;D2,E2 – Dslgig for Desulfovibrio gigas ;B3,C3 – Dslsp for Desulfovibrio sp; D3,E3 – 
S1 for SRB; B4,C4 -16S Negative control;  D4,E4 – were left empty to give background 
signal. 
 
Four probes for the identification of Desulfobulbus, Desulfobacter, Desulfovibrio 
desulfuricans and Desulfotomaculum included in cassette N2. Only two of these probes 
for Desulfobulbus and Desulfotomaculum exhibited similar hybridization profiles 
however the probes for Desulfobacter and Desulfovibrio desulfuricans failed to detect 
their antisense (Figure 3. 2.3) 
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Figure 3.2.3. Schematic diagram and the results of the designed cassette N2 
hybridization as signal to noise (S/N) ration. The purple circles are the probes position 
markers the gray circles are the probes. The arrangement of the probes was as follows: 
A1, A2, A3, A4, B1, C1, D1, E1 – Probes position markers; B2, C2 – Dsbub for  
Desulfobulbus; D2, E2 – Dsbac for Desulfobacter; B3, C3 – Dsldes for Desulfovibrio 
desulfuricans; D3, E3 – Desfot for  Desulfotomaculum; B4, C4 -16S Negative control;  D4, 
E4 – were left empty to give background signals. 
 
The probes for Enterobacteriaceae, Escherichia coli, Bacteriodes fragilis and Bacteriodes 
sp. in cassette N3 reveal the same binding capacity while the probe for Bacteriodes sp. 
failed to give any signal (Figure 3. 2.4). 
 
Figure 3.2.4. Schematic diagram and the results of the designed cassette N3 
hybridization as signal to noise (S/N) ration.   The purple circles are the probes position 
markers the gray circles are the probes. The arrangement of the probes was as follows: 
A1, A2, A3, A4, B1, C1, D1, E1 – Probes position markers; B2, C2 –Ent1 for 
Enterobacteriaceae; D2, E2 –EC for E.coli; B3, C3 – Bacfr for Bacteriodes  fragilis; D3, E3 –
Bacsp for Bacteriodes  sp; B4, C4 -16S Negative control;  D4, E4 – were left empty to give 
background signals. 
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The hybridization efficiency of the probes for Clostridium sp, and Bifidobacterium in 
cassette N4 was the same. The probes for Clostridium difficile and Fusobacterium varium 
failed to hybridize with its single-stranded compliment (Figure 3. 2.5). 
 
Figure 3.2.5. Schematic diagram and the results of the designed cassette N4 
hybridization as signal to noise (S/N) ration.  The purple circles are the probes position 
markers the gray circles are the probes.The arrangement of the probes was as follows: 
A1, A2, A3, A4, B1, C1, D1, E1 – Probes position markers; B2, C2 – Cldif for Clostridium 
difficile; D2, E2 –Clsp1 for Clostridium sp; B3,C3 –Fusv for Fusobacterium varium; D3, E3 
–Bif for Bifidobacterium; B4, C4 -16S Negative control;  D4, E4 – were left empty to give 
background signals. 
 
The probes in cassette N5 showed comparable hybridization capacities except for probe 
Lactobacillus which gave negative result (Figure 3.2.6).  
 
Figure 3.2.6. Schematic diagram and the results of the designed cassette N5 
hybridization as signal to noise (S/N) ration. The purple circles are the probes position 
markers the gray circles are the probes. The arrangement of the probes was as follows: 
A1, A2, A3, A4, B1, C1, D1, E1 – Probes position markers; B2, C2 –Fusnu for 
Fusobacterium nucleatum; D2, E2 –Rum for Ruminococcus; B3, C3 –Fusn for 
Fusobacterium necrophorum; D3, E3 –Lac for Lactobacillus; B4, C4 -16S Negative 
control; D4, E4 – were left empty to give background signals. 
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The 6 probes (for Desulfobacter; Desulfovibrio desulfuricans; Bacteriodes sp; Clostridium 
difficile; Fusobacterium varium and Lactobacillus) which failed to produce any 
hybridization signal were reordered and were tested again. The biochip experiment is a 
multi-stage process in which the accuracy of each individual step may influence the 
target detection. Therefore, to exclude the possibility of the influence of other factors 
caused the detection failure, such as the probe design or the human factor; the probes 
were reorder as separate sets. The newly synthesized probes showed comparable 
hybridization signal with other probes (Figure 3.2.7). This indicated that the negative 
results obtained with the first set of the probes occurred due to the error during the 
synthesis. The probe manufacturing errors were reported previously that it is very 
common (Jonathan et al., 1997; McGall et al., 1997; Jakubek & Cutler, 2012).  Another 
possibility is that the chips often may have different binding properties if these matrixes 
manufactured on different days (batch effect). However, several fundamental 
observations of microarray behaviour remain poorly understood (Hong et al., 2008). 
 
As a result most of the probes exhibited comparable hybridization signals and were 
characterized by the mean S/N ratio=7 (dashed line) (Figure 3.2.7). Only probes for 
Desulfobacter, Desulfotomaculum, Enterobacteriaceae and Clostridium sp were slightly 
out of the mean range ±SD. The probes, S/N ratio which were higher than the mean S/N 
of the majority of the probes; were re-design and tested against DNA obtained from 
patients suffering from UC and healthy individual.  
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Figure 3.2.7. Schematic diagram and the analysis of the designed cassettes 
hybridization with biochip. The results of the hybridization as signal to noise (S/N) 
ration. The data presented are mean values±SD. 
 
Panel A. Schematic diagram represents the arrangement of the probes on the biochip. 
The probes were spotted in duplicate. The red circles are the probes position markers. 
B2, C2- Dslpig for D. piger; B3, C3- Dsbub for Desulfobulbus; B4, C4- Ent1 for 
Enterobacteriaceae; B5, C5- Cldif for C. Difficile, B6, C6- Fusnu  for F. nucleatum; D2, E2- 
Dslgig for D. gigas ; D3, E3- Dsbac for  Desulfobacter; D4, E4- EC for E.coli; D5, E5- Clsp1 
for Clostridium sp.; D6, E6- Rum for Ruminococcus; F2, G2- Dslsp for Desulfovibrio sp; F3, 
G3- Dsldes for D. desulfuricans; F4, G4- Bacfr for B. fragilis; F5, G5- Fusv for F. varium; F6, 
G6- Fusn for F. necrophorum; H2, I2- S1 for SRB; H3, I3- Desfot for Desulfotomaculum; 
H4, I4- Bacsp for Bacteriodes sp.; H5, I5- Bif for Bifidobacterium; H6, I6-Lac for 
Lactobacillus. 
 
Panel B.  The analysis of the designed cassettes represents the results of the 
hybridization as signal to noise (S/N) ratio. 1- S1 for SRB; 2- Dslsp for Desulfovibrio sp; 
3- Dslpig for D. piger;  4- Dslgig for D. gigas; 5- Dsldes for D. desulfuricans; 6- Dsbub for 
Desulfobulbus; 7- Dsbac for Desulfobacter; 8- Desfot for Desulfotomaculum; 9- Ent1 for 
Enterobacteriaceae; 10- EC for E.coli; 11- Bacsp for Bacteriodes  sp.; 12- Bacfr for B.  
fragilis; 13- Clsp1 for Clostridium sp; 14- Cldif for C. difficile; 15- Rum for Ruminococcus; 
16- Fusv for F. varium; 17- Fusnu  for F. nucleatum; 18- Fusn for F. necrophorum;19- Bif 
for Bifidobacterium; 20- Lac for Lactobacillus 
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3.2.3 Analysis of DNA samples of healthy control and patients suffering 
from UC using biochip  
 
The designed biochip was used to study the bacterial profiling using DNA purified from 
biopsy samples of healthy individual and patients suffering from UC. DNA of healthy 
individual and patients suffering from UC were prepared for hybridization with the 
biochip by amplification, fragmentation and labelling. Peaks equal and above a S/N of 2 
were counted as positive samples. 
The biochip for healthy individual sample analysis was constructed using 23 probes in 
duplicate.  
Probes 1 and 2 targeted SRB while probes 3-9 targeting specific SRB species. Probes 10 
and above target other bacteria which may have a role in the development of UC. Probes 
10 and 11 targeted Enterobacteriaceae species generically and probes 15 and 16 
targeted Clostridium species.  
In the healthy control, DNA produced high levels of the fluorescent signal intensity for 
the probes targeting D. piger and Enterobacteriaceaee family members (Probe 2 which 
was re-designed but not Probe 1) were detected. Low levels of SRB (Probe 1 and 2), E. 
coli, Bacteriodes sp., Bacteriodes fragilis , Clostridium sp1 (Probe 1; but not probe 2 which 
was re-designed) and Fusobacterium nucleatum were detected (Figure 3.2.8). The 
obtained results showed the presence of these bacterial species in healthy individual 
sample.  The weak or absence of hybridization signal (probes 3, 5-10, 17-19, 23) could 
mean either the absence of the appropriate group of bacteria in the studied sample or 
very low presentation of these bacteria. 
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Figure 3.2.8. Schematic diagram and the hybridization analysis of the DNA obtained 
from healthy individual.  The hybridization results represented as signal to noise (S/N) 
ratio. 
Panels A. Schematic diagram represents the arrangement of the probes on the biochips 
of healthy individual sample. The probes were spotted in duplicate. The red circles are 
the probes position markers. B2, C2- S1 for SRB1; B3, C3- SR2 for SRB; B4, C4- Dslsp for 
Desulfovibrio sp; B5, C5- Dslpig for D. piger; B6, C6- Dslgig for D. gigas; D2, E2- Dsldes for 
D. desulfuricans; D3, E3- Dsbub for Desulfobulbus; D4, E4- Dsbac for  Desulfobacter; D5, 
E5- Desfot  for Desulfotomaculum; D6, E6- Ent1 for Enterobacteriaceae; F2, G2- Ent2 for  
Enterobacteriaceae; F3, G3- EC for E.coli; F4, G4- Bacsp for Bacteriodes sp.; F5, G5- Bacfr 
for  B.  fragilis; F6, G6- Empty; H2, I2- Clsp1 for Clostridium sp.; H3, I3- Clsp2 for 
Clostridium sp.; H4, I4- Cldif for C. Difficile; H5, I5- Rum for Ruminococcus; H6, I6- Fusv 
for F. varium; J2, K2- Fusnu for F. nucleatum; J3, K3- Fusn for F. necrophorum; J4, K4- Bif 
for Bifidobacterium; J5, K5- Lac for Lactobacillus. 
 
Panel B.  The analysis of the designed probes represents the results of the hybridization 
as signal to noise (S/N) ratio. 1- S1 for SRB; 2- SR2 for SRB; 3- Dslsp for Desulfovibrio sp; 
4- Dslpig for D. piger; 5- Dslgig for D. gigas; 6- Dsldes for D. desulfuricans; 7- Dsbub for 
Desulfobulbus; 8- Dsbac for Desulfobacter; 9- Desfot for Desulfotomaculum; 10- Ent1 for 
Enterobacteriaceae; 11- Ent2 for Enterobacteriaceae; 12- EC for E.coli; 13- Bacsp for 
Bacteriodes sp.; 14- Bacfr for B.  fragilis; 15 - Clsp1 for Clostridium sp; 16: Clostridium 
sp2; 17- Cldif for C. difficile; 18- Rum for Ruminococcus; 19- Fusv for F. varium; 20- 
Fusnu  for F. nucleatum; 21- Fusn for F. necrophorum; 22- Bif for Bifidobacterium; 23- 
Lac for Lactobacillus. 
 
The biochip for UC patients’ samples analysis was constructed using 23 probes in 
duplicate. UC patient 1 sample all bacteria were detected in this sample with the 
exception of Desulfobulbus and Bacteriodes sp, Clostridium sp (Probe 1 but not Probe 2) 
and Clostridium difficile. SRB 1, SRB 2, D. piger, Desulfobacter, Enterobacteriaceaee 
CHAPTER 3: RESULTS AND DISCUSSION 
136 
 
(Probe 1 but not Probe 2), and Fuscobacterium varium were detected at high levels 
comparing with other probes (Figure 3.2.9). 
 
 
Figure 3.2.9. Schematic diagram and the hybridization analysis of the DNA obtained 
from UC patient 1. The hybridization results represented as signal to noise (S/N) ratio. 
 
Panels A. Schematic diagram represent the arrangement of the probes on the biochips 
of UC patient 1 sample. The probes were spotted in duplicate. The red circles are the 
probes position markers.B2, C2- Dslpig for D. piger; B3, C3- Dslsp for Desulfovibrio sp; 
B4, C4- Ent2 for  Enterobacteriaceae; B5, C5- Cldif for C. Difficile; B6, C6- Fusn for F. 
necrophorum; B7, C7- SR2 for SRB2; D2, E2- Dslgig for D. gigas; D3, E3- Dsldes for D. 
desulfuricans; D4, E4- EC for E.coli; D5, E5- Clsp1 for Clostridium sp.; D6, E6- Rum for 
Ruminococcus; D7, E7- Ent1 for Enterobacteriaceae; F2, G2- Dsbub for Desulfobulbus; F3, 
G3- Desfot  for Desulfotomaculum; F4, G4- Bacfr for  B.  fragilis; F5, G5- Fusv for F. 
varium; F6, G6- Bif for Bifidobacterium; F7, G7- Clsp2 for Clostridium sp.; H2, I2- Dsbac 
for  Desulfobacter; H3, I3- S1 for SRB1; H4, I4- Bacsp for Bacteriodes sp.; H5, I5- Fusnu 
for F. nucleatum; H6, I6- Lac for Lactobacillus; H7, I7- S1 for SRB 
 
Panel B. The analysis of the designed probes. The hybridization results represented as 
signal to noise (S/N) ratio. 1- S1 for SRB; 2- SR2 for SRB; 3- Dslsp for Desulfovibrio sp; 4- 
Dslpig for D. piger; 5- Dslgig for D. gigas; 6- Dsldes for D. desulfuricans; 7- Dsbub for 
Desulfobulbus;8- Dsbac for Desulfobacter; 9- Desfot for Desulfotomaculum; 10- Ent1 for 
Enterobacteriaceae; 11- Ent2 for Enterobacteriaceae; 12- EC for E.coli; 13- Bacsp for 
Bacteriodes  sp.; 14- Bacfr for B.  fragilis; 15- Clsp1 for Clostridium sp; 16: Clostridium 
sp2; 17- Cldif for C. difficile; 18- Rum for Ruminococcus; 19- Fusv for F. varium; 20- 
Fusnu  for F. nucleatum;21- Fusn for F. necrophorum; 22- Bif for Bifidobacterium; 23- Lac 
for Lactobacillus;24-S1 for SRB.  
 
 
 
In UC patient 2 sample; SRB (Probe 1 but not 2), Desulfovibrio sp, D. piger, D. gigas, 
Desulfobacter, Bacteriodes sp., Bacteriodes fragilis, Desulfotomaculum, 
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Enterobacteriaceae (Probe 1 not 2) and Lactobacillus were detected at high levels of 
hybridization signals. However, low levels of Clostridium sp. were detected (Figure 
3.2.10). 
 
 
Figure 3.2.10.  Schematic diagram and the hybridization analysis of the DNA obtained 
from UC patient 2. The hybridization results represented as signal to noise (S/N) ratio. 
 
Panels A. Schematic diagram represent the arrangement of the probes on the biochips 
of UC patient 2 sample. The probes were spotted in duplicate. The red circles are the 
probes position markers.B2, C2- Dslpig for D. piger; B3, C3- Dslsp for Desulfovibrio sp; 
B4, C4- Ent2 for  Enterobacteriaceae; B5,C5- Cldif for C. Difficile; B6,C6- Fusn for F. 
necrophorum; B7,C7- SR2 for SRB2; D2,E2- Dslgig for D. gigas; D3,E3- Dsldes for D. 
desulfuricans; D4,E4- EC for E.coli ;D5,E5- Clsp1 for Clostridium sp.; D6,E6- Rum for 
Ruminococcus; D7,E7- Ent1 for Enterobacteriaceae; F2,G2- Dsbub for Desulfobulbus; 
F3,G3- Desfot  for Desulfotomaculum; F4,G4- Bacfr for  B.  fragilis; F5,G5- Fusv for F. 
varium; F6,G6- Bif for Bifidobacterium; F7,G7- Clsp2 for Clostridium sp.; H2,I2- Dsbac for  
Desulfobacter; H3,I3- S1 for SRB1; H4,I4- Bacsp for Bacteriodes sp.; H5,I5- Fusnu for F. 
nucleatum; H6,I6- Lac for Lactobacillus; H7,I7- S1 for SRB 
 
Panel B. The analysis of the designed probes represents the results of the hybridization 
as signal to noise (S/N) ratio. 1- S1 for SRB; 2- SR2 for SRB; 3- Dslsp for Desulfovibrio sp; 
4- Dslpig for D. piger; 5- Dslgig for D. gigas; 6- Dsldes for D. desulfuricans; 7- Dsbub for 
Desulfobulbus;8- Dsbac for Desulfobacter; 9- Desfot for Desulfotomaculum; 10- Ent1 for 
Enterobacteriaceae; 11- Ent2 for Enterobacteriaceae; 12- EC for E.coli; 13- Bacsp for 
Bacteriodes  sp.; 14- Bacfr for B.  fragilis; 15- Clsp1 for Clostridium sp; 16: Clostridium 
sp2; 17- Cldif for C. difficile; 18- Rum for Ruminococcus; 19- Fusv for F. varium; 20- 
Fusnu  for F. nucleatum;21- Fusn for F. necrophorum; 22- Bif for Bifidobacterium; 23- Lac 
for Lactobacillus;24-S1 for SRB.  
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In UC patient 3 high levels of fluorescent signal of the probes detecting SRB, D. piger and 
D. gigas were observed. However, low levels of Desulfobulbus, Enterobacteriaceae 
(Probe 1), Fuscobacterium nucleatum and Bifidobacerium were detected (Figure 3.2.11). 
 
 
Figure 3.2.11. Schematic diagram and the hybridization analysis of the DNA obtained 
from UC patient 3. The hybridization results represented as signal to noise (S/N) ratio. 
 
Panels A. Schematic diagram represent the arrangement of the probes on the biochips 
of UC patient 3 sample. The probes were spotted in duplicate. The red circles are the 
probes position markers.B2, C2- Dslpig for D. piger; B3, C3- Dslsp for Desulfovibrio sp; 
B4, C4- Ent2 for  Enterobacteriaceae; B5,C5- Cldif for C. Difficile; B6,C6- Fusn for F. 
necrophorum; B7,C7- SR2 for SRB2; D2,E2- Dslgig for D. gigas; D3,E3- Dsldes for D. 
desulfuricans; D4,E4- EC for E.coli ;D5,E5- Clsp1 for Clostridium sp.; D6,E6- Rum for 
Ruminococcus; D7,E7- Ent1 for Enterobacteriaceae; F2,G2- Dsbub for Desulfobulbus; 
F3,G3- Desfot  for Desulfotomaculum; F4,G4- Bacfr for  B.  fragilis; F5,G5- Fusv for F. 
varium; F6,G6- Bif for Bifidobacterium; F7,G7- Clsp2 for Clostridium sp.; H2,I2- Dsbac for  
Desulfobacter; H3,I3- S1 for SRB1; H4,I4- Bacsp for Bacteriodes sp.; H5,I5- Fusnu for F. 
nucleatum; H6,I6- Lac for Lactobacillus;H7,I7-S1 for SRB  
 
Panel B. The analysis of the designed probes represents the results of the hybridization 
as signal to noise (S/N) ratio. 1- S1 for SRB; 2- SR2 for SRB; 3- Dslsp for Desulfovibrio sp; 
4- Dslpig for D. piger; 5- Dslgig for D. gigas; 6- Dsldes for D. desulfuricans; 7- Dsbub for 
Desulfobulbus;8- Dsbac for Desulfobacter; 9- Desfot for Desulfotomaculum; 10- Ent1 for 
Enterobacteriaceae; 11- Ent2 for Enterobacteriaceae; 12- EC for E.coli; 13- Bacsp for 
Bacteriodes  sp.; 14- Bacfr for B.  fragilis; 15- Clsp1 for Clostridium sp; 16: Clostridium 
sp2; 17- Cldif for C. difficile; 18- Rum for Ruminococcus; 19- Fusv for F. varium; 20- 
Fusnu  for F. nucleatum;21- Fusn for F. necrophorum; 22- Bif for Bifidobacterium; 23- Lac 
for Lactobacillus;24-S1 for SRB.  
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In UC patient 4 sample SRB (with both probes), D. piger, D. gigas and Desulfobacter were 
detected at high levels comparing with low levels of hybridization signals of 
Enterobacteriaceae, Fusobacterium nucleatum and Fuscobacterium necrophorum (Figure 
3.2.12).  
 
Figure 3.2.12. Schematic diagram and the hybridization analysis of the DNA obtained 
from UC patient 4. The hybridization results represented as signal to noise (S/N) ratio. 
 
Panels A. Schematic diagram represent the arrangement of the probes on the biochips 
of UC patient 4 sample. The probes were spotted in duplicate. The red circles are the 
probes position markers.B2, C2- Dslpig for D. piger; B3, C3- Dslsp for Desulfovibrio sp; 
B4, C4- Ent2 for  Enterobacteriaceae; B5,C5- Cldif for C. Difficile; B6,C6- Fusn for F. 
necrophorum; B7,C7- SR2 for SRB2; D2,E2- Dslgig for D. gigas; D3,E3- Dsldes for D. 
desulfuricans; D4,E4- EC for E.coli ;D5,E5- Clsp1 for Clostridium sp.; D6,E6- Rum for 
Ruminococcus; D7,E7- Ent1 for Enterobacteriaceae; F2,G2- Dsbub for Desulfobulbus; 
F3,G3- Desfot  for Desulfotomaculum; F4,G4- Bacfr for  B.  fragilis; F5,G5- Fusv for F. 
varium; F6,G6- Bif for Bifidobacterium; F7,G7- Clsp2 for Clostridium sp.; H2,I2- Dsbac for  
Desulfobacter; H3,I3- S1 for SRB1; H4,I4- Bacsp for Bacteriodes sp.; H5,I5- Fusnu for F. 
nucleatum; H6,I6- Lac for Lactobacillus; H7,I7-S1 for SRB  
 
Panel B. The analysis of the designed probes represents the results of the hybridization 
as signal to noise (S/N) ratio. 1- S1 for SRB; 2- SR2 for SRB; 3- Dslsp for Desulfovibrio sp; 
4- Dslpig for D. piger; 5- Dslgig for D. gigas; 6- Dsldes for D. desulfuricans; 7- Dsbub for 
Desulfobulbus; 8- Dsbac for Desulfobacter; 9- Desfot for Desulfotomaculum; 10- Ent1 for 
Enterobacteriaceae; 11- Ent2 for Enterobacteriaceae; 12- EC for E.coli; 13- Bacsp for 
Bacteriodes  sp.; 14- Bacfr for B.  fragilis; 15- Clsp1 for Clostridium sp; 16: Clostridium 
sp2; 17- Cldif for C. difficile; 18- Rum for Ruminococcus; 19- Fusv for F. varium; 20- 
Fusnu  for F. nucleatum;21- Fusn for F. necrophorum; 22- Bif for Bifidobacterium; 23- Lac 
for Lactobacillus;24-S1 for SRB.  
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When comparing the samples, several key trends are visible (Figure 3.2.13). Pan-SRB 
probes 1 and 2 detected SRB in all samples, however in UC patients 1 and 4 this was 
highly elevated compared to healthy individual sample. The probe for D. piger was 
detected in all samples and at elevated levels in the healthy control individual. 
Conversely, the probes for D. gigas and Desulfobacter sp were detected in all UC patients 
samples, albeit at low levels in some UC patients, but they were not detected in the 
control sample. Whilst no other specific SRB were detected in the control sample it was 
not possible to discern a trend due to a high degree of variation in UC patient samples. 
The presence of D. piger was unsurprising as it has previously been described as the 
most common SRB present in the human colon (Scanlan et al., 2009, Rey et al., 2013). 
The converse trend was observed with D. gigas and Desulfobacter sp in this instance no 
hybridization signal was detected in the control sample whereas a consistent level 
signal was detected in all UC patients samples. There are no reports in the literature of 
D. gigas or Desulfobacter sp specifically being associated with UC so this is a potential 
novel finding. An interesting possibility is that the reduction in D. piger and increase in 
D. gigas and Desulfobacter sp may be linked through mechanisms unknown, 
contribution to the dysbiosis associated with UC. In addition, other explanations of the 
association of D. gigas with UC patients samples  that D. gigas may has physiological 
features  that cause  inflammation or participate in the prolongation of chronic 
inflammatory or may these species are preferred by inflammation condition in UC 
patients (Rowan et al., 2010).  However, investigation of sufficient number of samples 
would be required to make a proper conclusion. 
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Probe Target Healthy UC1 UC2 UC3 UC4 
S1 SRB       
SR2 SRB       
Dslsp Desulfovibrio sp.      
Dslpig D. piger      
Dslgig  D. gigas      
Dsldes Desulfovibrio desulfuricans      
Dsbub Desulfobulbus      
Dsbac Desulfobacter      
Desfot Desulfotomaculum      
Ent1 Enterobacteriaceaee       
Ent2 Enterobacteriaceaee       
EC  E. coli      
Bacsp  Bacteriodes sp.      
Bacfr  Bacteriodes fragillis      
Clsp1 Clostridium sp      
Clsp2 Clostridium sp      
Cldif Clostridium difficile      
Rum Ruminococcus      
Fusv Fuscobacterium varium      
Fusnu Fuscobacterium nucleatum      
Fusne Fuscobacterium 
necrophorum 
     
Bif  Bifidobace ium      
Lac Lactobacillus      
Key 
>2  2-4  4-6  6-8  8+  
 
Figure 3.2.13. Heat map of bacteria detected in the samples of healthy individual and 
UC patients. Cells are coloured according to the S/N ratio calculated for each sample and 
probe as per the key provided. 
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The probes assessing Enterobacteriaceaee displayed a marked difference, with a strong 
detection with Enterobacteriaceaee probe 1 in UC patients 1, 2 and 3 samples but not UC 
patient 4 and control, whereas Enterobacteriaceaee probe 2 detected in the healthy 
control sample at a high level, and only in UC patient 1 , 2 and 4 at a low level. These 
data suggest that the pan-Enterobacteriaceae probes were detecting different, non-
overlapping populations. Enterobacteriaceae have been associated with UC previously, 
although specific strains have not (Lavelle et al., 2015). These findings suggest that 
investigation into specific species of Enterobacteriaceae may prove useful in 
determining if certain species display a protective or deleterious effect in UC. 
Clostridium difficile colonization can induce antibiotic-associated colitis (Kawaratani et 
al., 2010). However, there was no noticeable trend in the detection of C. difficile with 
specific probes in all samples analysed. Interestingly similar amount of Clostridium 
genera with non-specific probes was detected in UC patients 1 and 2 as well as healthy 
control sample in the case of the latter suggesting that the generic probes did not detect 
C. difficile. Whilst C. difficile is undoubtedly pathogenic and able to induce colitis 
however these species was not detected in all samples tested in this study. Therefore, it 
is not possible to draw strong conclusions from the data obtained. As Clostridium genera 
were detected in the healthy control it is possible that non-pathogenic genera displaces 
the C. difficile in control sample. However, investigation of sufficient number of samples 
would be required to make a proper conclusion. 
One other key difference between the control and UC patient samples was the detection 
of Fuscobacterium nucleatum probe in all UC patients except UC patient 2. The probe for 
Fuscobacterium necrophorum was detected in UC patients samples together with 
presence of the Fuscobacterium varium probe in UC patient 1 and UC patient 2 with 
notable increase on UC patient 1. Members of the Fusobacterium genus, including 
Fuscobacterium nucleatum, F. necrophorum, and Fuscobacterium varium which have 
been detected in the studied samples, have been reported by previous studies as 
gastrointestinal bacteria that have a significant role on UC (Ohkusa et al. 2003; Legaria 
et al., 2005; Afra et al., 2013; Tahara et al., 2015). Although Fuscobacterium varium is 
conserved generally to be a rare bacterium and found to be correlated with UC in a 
minority cases around the world, the present study findings was in conjunction with 
previous studies which demonstrated the F. varium have long been associated with the 
development of UC. 
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All samples tested in this study displayed differences in the heterogeneity of resident 
bacteria, which may conform to the hypothesis that UC arises from dysbiosis 
(Cummings et al., 2003). A loss of protective bacteria such as Lactobacilli and 
Bifidobacteria was also proposed as a mechanism in the pathogenesis of UC, however 
this was not shown in the studied samples. Indeed, all UC patients displayed a marked 
increase in the detection of Bifidobacteria and Lactobacillus was detected only in UC 
patient 1 and 2 in high level. The increasing level of Lactobacillus in UC patients was 
previously reported (Wang et al., 2014). The presence of Bifidobacteria and the high 
level of Lactobacillus in UC patients samples could be explained that these bacteria have 
a role in defence through the promotion of a mucous secretion which will help to 
protect colonic epithelial cells from pathogenic bacteria during inflammation (Mack et 
al., 2003).  
Together this suggests that whilst UC may be linked to bacteria, it is not currently 
possible to identify a single bacterial species or change that is associated with UC. 
Elevated levels of SRB bacteria detected in UC patients 1 , 3 and 4  suggests that SRB 
may play a role in the development of UC, but low level results of SRB in patient 2 
suggests that this may be limited to a subset of cases. The analysis of the patients 
samples for the presence of main bacterial species or groups that may have role on UC 
pathogenesis  by biochip showed that hybridization signals are absent for some probes. 
This may indicate that either the absence of the appropriate target group of bacteria in 
the studied samples or their low abundance.  
The biochip/cassette methodology used in this study would provide an ideal framework 
to rapidly and accurately assess bacteria associated with UC in patient samples. In 
future studies it would be worthwhile incorporating of multiple probes specific to 
species of Enterobacteriaceae as the changes in the level of hybridization signals of 
these bacteria were potentially the most novel finding of these experiments.  
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Section 3 
Detection and quantification of SRB using microbiological 
and quantitative PCR techniques 
 
The role of SRBs, particularly Desulfovibrio species, in etiology of UC has been widely 
suggested. SRBs are toxic to human epithelial intestinal cells chiefly because they 
produce H2S, which damage the colonic mucosa layer leading to inflammation (Medani 
et al., 2011; Chan & Wallace, 2013; Kushkevych, 2014). In order to extend 
understanding further from these reports and to control SRB effects, a rapid method to 
quantification and detect SRB colonisation is needed. Unfortunately, this has posed a 
huge challenge. This is largely because of low recovery rate of SRB making it difficult to 
recognize the early stages of infection. In this study rapid method for detection and 
quantification of Desulfovibrio species was developed. 
 
3.3.1 The growth of different age of Desulfovibrio species culture in VMR 
and VMI media  
 
Strains of Desulfovibrio species are frequently recovered at a greater frequency (when 
Escherichia coli is present, even when the SRB is present at low cell densities (102-
103cells/ml) (Zinkevich, unpublished data). This suggests that a relationship might exist 
between the two organisms. When both species are co-cultured together their growth 
behaviour changes (Bharati et al., 1980), the growth yield constant increases and sulfate 
is reduced accompanied by the total consumption of formate, lactate and alcohol. Co-
culture of SRBs with methanogens and dehalorespiring bacteria are well-known 
examples of syntrophism (Drzyzga et al, 2001). The relationship with Escherichia coli 
appears to lead to enhanced growth of the SRB (generation time for this organisms is 
usually greater than 3-8 days) (Rabus et al., 1993; Galushko et al., 1999; Gerardi, 2003; 
Ingvorsen et al., 2003). This can, potentially, provide a rapid detection of the sulphate 
reducer by stimulating its growth. SRBs often operate at low cell densities and have a 
slow growth (- > 28 days) which could be changed by co-culturing with E. coli so that 
detection can be recorded earlier. 
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For these experiments, the effect of E.coli BP on the growth of different age cultures (7 
days, 3 months and 1-year old) of Desulfovibrio indonesiensis was assessed. 10-fold 
serial dilutions of 7-day old D. indonesiensis cultures were incubated in VMR media. Two 
groups of experiments were designed:  (1) where E. coli BP was added into each dilution 
of D. indonesiensis, and (2) where no E.coli BP was added to the dilution. The growth of 
D. indonesiensis was monitored daily for 28 days and the SRB was detected by the 
production of the metal sulphide in culture. The blackening of the medium was 
indication of SRB growth in the medium (Andrade, et al., 2000).  
 
The results showed that the addition of E.coli BP to the culture induced the growth of D. 
indonesiensis. The growth of pure D. indonesiensis was observed in the first 5 dilutions 
only, whereas in the presence of E. coli BP growth of D. indonesiensis was observed up to 
10-10 (Table 3.3.1, Figure 3.3.1). These results indicate, that E. coli BP induces D. 
indonesiensis growth or acts as an enhancer that activates dormant SRB. This result 
suggests that inclusion of E. coli increase the detection of SRB which otherwise would 
have stayed undetected due to their extremely low density.  
 
Table 3.3.1. Comparison of 7 days old D. indonesiensis culture growth efficiency in VMR 
medium with and without of E. coli BP.  The symbol (+) means growth of D. indonesiensis 
represented by blackening of the medium, and (-) means no growth. Several 
independent experiments were done in triplicate. 
 
 
7 days old 
culture used for 
inoculation 
Dilution in VMR medium 
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + + + + + - - - - - - - 
D. indonesiensis 
+ E.coli  BP 
+ + + + + + + + + + - - 
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Figure 3.3.1. Growth of 7days old D. indonesiensis culture in VMR medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonesiensis, (B) Growth of D. 
indonesiensis with E.coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
 
To test whether E.coli BP can activate dormant SRB cells older cultures of D. 
indonesiensis were used. When a 3 months old D. indonesiensis culture was used the 
growth induction was observed as well. However, the difference between pure SRB 
growth (10-1) and growth of SRB in the presence of E. coli BP (10-5) was 4 orders of 
magnitude (Table 3.3.2, Figure 3.3.2). Although the detection level had dropped; it is 
worth noting that there is a difference in detection level between D. indonesiensis with 
or without the addition of E. coli BP.  
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Table 3.3.2. Comparison of 3 months old D. indonesiensis culture growth efficiency in 
VMR medium with and without of E. coli BP.  The symbol (+) means growth of D. 
indonesiensis represented by blackening of the medium, and (-) means no growth. 
Several independent experiments were done in triplicate. 
 
          
          
 
Figure 3.3.2. Growth of 3 months old D. indonesiensis culture in VMR medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonesiensis, (B) Growth of D. 
indonesiensis with E.coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
A similar result was obtained when a 1-year old pre-culture of D. indonesiensis was used 
as the inoculum for the serial dilution in the presence or absence of E. coli BP (Table 
3.3.3, Figure 3.3.3). Interestingly, this result showed that D. indonesiensis could still be 
detected even though the culture was 1 year old. Although both groups, had growth it 
  
3 months old 
culture used for 
inoculation 
Dilution in VMR medium  
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + - - - - - - - - - - - 
D. indonesiensis 
+E.coli  BP 
+ + + + + - - - - - - - 
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was evident that the addition of E. coli enhanced the level of detection of D. indonesiensis 
significantly when compared to the group without. This result further suggests that E. 
coli plays a very important role in re-activating SRBs. This result is consistent with the 
previous results obtained when the 7-day and the 3-month old inoculates were used, 
implying that E. coli BP may be acting as a growth inducer or activator, thereby making 
the SRB cells detectable. All three experiments showed that although D. indonesiensis 
was detectable without the inclusion of E. coli, its addition greatly increased the lower 
level of detection.  
 
Table 3.3.3. Comparison of 1 year old D. indonesiensis culture growth efficiency in VMR 
medium with and without of E. coli BP.  The symbol (+) means growth of D. indonesiensis 
represented by blackening of the medium, and (-) means no growth. Several 
independent experiments were done in triplicate. 
 
 
 
 
 
 
 
 
 
  
1 year old culture 
used for inoculation 
Dilution in VMR medium 
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + - - - - - - - - - - - 
D. indonesiensis 
+E.coli BP 
+ + + + - - - - - - - - 
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Figure 3.3.3. Growth of 1 year old D. indonesiensis culture in VMR medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonesiensis, (B) Growth of D. 
indonesiensis with E.coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
Species of Desulfovibrio have a requirement for inorganic iron to stimulate growth 
(Postgate, 1965; Gibson, et al., 1999).  The amount of inorganic iron present in the 
medium used, VMR, to culture D. indonesiensis previously was 0.05 g of iron (II) 
sulphate heptahydrate (FeSO4.7H2O). It is feasible that increasing this quantity of iron in 
the media will further promote growth. If this can be achieved, then the level of 
detection might be increased. For this reason, the inorganic iron in the medium was 
increased to 0.5 g (medium VMI). The experiments to characterise the relationship 
between E. coli BP and D. indonesiensis were repeated using VMI medium.  
 
The cultures of D. indonesiensis used aged for 7 days, 3 months and 1 year, as before, 
and growth assessed with and without E.coli BP. A difference in the growth of the 7-day 
old culture of D. indonesiensis in VMI medium was observed when E.coli BP was 
included in the dilution series (Table 3.3.4, Figure 3.3.4). The addition of E. coli BP 
greatly enhanced the ability to detect D. indonesiensis at greater dilutions. A result that 
was similar to the one obtained when VMR medium was used except that detection was 
made at a greater dilution. However, the difference between the levels of detection for 
the co-culture and monoculture was the same in both sets of experiments. It can be 
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concluded that the increase of inorganic iron to the medium does promote growth of the 
SRB but does not influence the effect that E.coli has on growth.  
 
Table 3.3.4. Comparison of 7 days old D. indonesiensis culture growth efficiency in VMI 
medium with and without of E. coli BP.  The symbol (+) means growth of D. indonesiensis 
represented by blackening of the medium, and (-) means no growth. Several 
independent experiments were done in triplicate. 
 
 
 
 
Figure 3.3.4. Growth of 7 days old D. indonesiensis culture in VMI medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonesiensis, (B) Growth of D. 
indonesiensis with E.coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
When the age of the D. indonesiensis culture was increased to 3 months a similar result 
was obtained. The level of detection of the monoculture and co-culture improved, but 
the difference between the treatments did not, which remained at the 104 level (Table 
3.3.5, Figure 3.3.5).  
  
7 days  old culture 
used for inoculation 
Dilution in VMI medium 
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + + + + + + - - - - - - 
D. indonesiensis +E. 
coli BP 
+ + + + + + + + + + - - 
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 Table 3.3.5. Comparison of 3 months old D. indonesiensis culture growth efficiency in 
VMI medium with and without of E. coli BP.  The symbol (+) means growth of D. 
indonesiensis represented by blackening of the medium, and (-) means no growth. 
Several independent experiments were done in triplicate. 
 
  
3 months old culture 
used for inoculation 
Dilution in VMI medium 
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + + - - - - - - - - - - 
D. indonesiensis + 
E.coli BP 
+ + + + + + - - - - - - 
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Figure 3.3.5. Growth of 3 months old D. indonensiensis culture in VMI medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonensiensis, (B) Growth of D. 
indonensiensis with E.coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
The difference in detection levels between the two media was not observed when a 1-
year old culture of D. indonesiensis was used as the inoculum. (Table 3.3.6 and Figure 
3.3.6). There was no increase in the level of detection of D. indonesiensis with or without 
the inclusion of E. coli when either medium was used. This presumably reflects the 
physiological state of the older culture, where fewer cells capable of responding to the 
increased iron levels exist. Nevertheless, the co-cultures with E. coli BP retained their 
enhanced level of detection ability; this result strongly suggests a role for E.coli in 
increasing the detection of SRB in that E.coli has a commensal effect which improves the 
efficiency of growth of SRB at a low density of cells.  
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Table 3.3.6. Comparison of 1 year old D. indonesiensis culture growth efficiency in VMI 
medium with and without of E. coli BP.  The symbol (+) means growth of D. indonesiensis 
represented by blackening of the medium, and (-) means no growth. Several 
independent experiments were done in triplicate. 
 
 
 
 
Figure 3.3.6. Growth of 1 year old D. indonesiensis culture in VMI medium in the 
presence and absence of E.coli BP. (A) Growth of pure D. indonesiensis, (B) Growth of D. 
indonesiensis with E. coli BP. The black precipitate at the bottom of the vials indicates 
SRB growth. 
 
The growth experiments described above indicate that there is a significant relationship 
between E. coli BP and SRBs. The addition of E. coli greatly enhanced the lower level of 
detection of D. indonesiensis when compared to growth without E. coli BP in all the ages 
of D. indonesiensis pre-cultures tested (7 days old, 3 month’s old and 1 year old pre-
cultures). This suggests that co-culturing SRB with E. coli provides a method to recover 
aged SRB cultures and sustain their growth. Both SRB and E. coli have been reported to 
  
1 year   old culture 
used for inoculation 
Dilution in VMI medium 
-1 -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -12 
D. indonesiensis + - - - - - - - - - - - 
D. indonesiensis 
+E.coli BP  
+ + + + - - - - - - - - 
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be involved in UC etiology, and the relationship exhibited between the two may be a 
survival mechanism.  
The experiments described in this section indicate the influence of E.coli on SRB growth 
and the role for E. coli as an inducer of SRB growth. This is probably because E. coli may 
be producing a substance(s) capable of either enriching the medium or supporting the 
growth of SRB by an unknown mechanism. The inclusion of E.coli in the culture medium 
for SRB increases detection level, thereby improving identification and quantification of 
SRB, and enhancing the chance of having cells physiologically capable of growth for 
further investigation (Gibson et al., 1991; Kushkevyeh & Moroz, 2012). Additionally, the 
inclusion of E.coli may improve the growth of SRB because it is a facultative anaerobe, 
and as such it is possible that it makes use of the traces of oxygen available in the 
environment, which will aid the growth of SRB, which are obligate anaerobes. E.coli has 
an iron (II) transport system and its ability to obtain this crucial element for 
fundamental living processes (Kammler et al., 1993). This may be the critical factor that 
allowed the survival and growth of E.coli to continue and therefore improve the 
efficiency of SRB growth.  
3.3.2 Quantification of D. indonesiensis culture using q PCR 
 
Viable SRB cell counts are believed to be underestimated when standard synthetic 
enumeration media is used. Improved count estimates are produced when natural 
media are used (Vester & Ingvorsen, 1998), presumably because of the presence of 
additional nutrients not found in synthetic media, however it is not always convenient 
to use natural media. Most enumeration methods using culture are evaluated by the 
production of a black ferrous sulfide precipitate. This provides a useful method for 
detection but an inaccurate one for quantification and it is time consuming. The slow 
growth rates of SRBs and their low cell densities add to the problems associated with 
their enumeration. Therefore, there is a need to identify the best method to quantify 
SRB for experimental purposes. The accurate quantification of genes and their 
transcripts allow an exact measurement of microbial activity and, possibly, phylogenetic 
identity (Neretin et al 2003). Real time or qPCR is a specific quantification method that 
accurately evaluates the number of bacteria in a culture by estimating the number of 
transcripts or DNA molecules directly in an environment that can be amplified by PCR 
(Wagner et al., 2005; Barton & Fauque, 2009; Christophersen et al., 2011).  
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Dissimilatory sulfite reductase (DSR) and adenosine phosphosulfate reductase (APS) 
are key enzymes in sulfate reduction pathways present in SRBs. Estimation of the copy 
number for the genes and transcripts for these enzymes can be related to the number of 
cells in culture. Such an approach can be used to confirm the results obtained in the 
previous section regarding the age of the culture and its activity. 
The genomic DNA and total RNA were extracted from the samples taken from the 
original culture of different ages used for serial dilution (7 days, 3 months and 1year) 
and analyzed by qPCR. A series of tenfold dilutions of the target amplicons were 
analyzed in parallel with DNA and RNA samples for estimations of absolute abundance 
of dsrA and apsA. Ct values in each dilution were measured in triplicate using qPCR with 
the apsA primers-probe set to generate the standard curve. Ct values were plotted 
against the logarithm of their initial template (in ng). Efficiency of PCR for apsA was 
99.3% with R2 = 0.995 and for dsrA was 100.3% with R2 = 0.992; both the reaction 
efficiencies and the R values indicated the validity of the standard curves. (Figure 3.3.7; 
Figure 3.3.8). 
 
 
Figure 3.3.7. Standard curve for apsA gene 
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Figure 3.3.8. Standard curve for dsrA gene 
 
The dsrA and the apsA copy numbers were expressed as number of SRB cells per ml of 
D. indonesiensis culture, taking into account dilution factors and the volume of nucleic 
acid extract. All calculations were based on the assumption that an average of one dsrA  
gene copy (Klein et al., 2001; Kondo et al., 2008) and only one apsA  (Friedrich, 2002) 
gene copy per SRB cell.  
 
For genomic DNA samples (Table 3.3.7), 2.13 x1011 cells/ml were revealed in a 7-day 
old culture, based on the detection of  dsrA copies in genomic DNA isolated from these 
cells. SRB cultures that were 3 months old contained 6.9 x1010 cells/ml, while the 1-year 
old culture gave 2.85 x1010 cells/ml. Quantification of the cells in different age SRB 
cultures based on the detection of the apsA copy numbers in genomic DNA showed that 
the greatest cell count was found in the 7-day old culture at 4.40 x 1011 cells/ml, 
followed by the 3-month old culture at 1.68 x1011 cells/ml and the least was for the 1-
year oldlture at 7.68 x1010 cells/ml (Table 3.3.7). The same trend was shown for both 
genes - the older SRB culture contained the fewest number of cells.  
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Table 3.3.7.  Quantification of the dsrA and ApsA genes in genomic DNA purified from 7 
days old D. indonesiensis cultures using TaqMan qPCR. Experiment and statistical 
analysis was based on several independent experiments.  
 
The age of 
D. indonesiensis 
culture 
The copy number of dsrA and apsA genes  
per ml of D. indonesiensis culture  
dsr A Aps A 
7 days 2.13 x1011 4.40 x 1011 
3 months 6.9 x1010 1.68 x1011 
1 year 2.85 x1010 7.68x1010 
 
Furthermore, according to Kruskal-Wallis analysis (Table 3.3.8) there was a significant 
difference in the copy number for the dsrA gene detected in genomic DNA between the 
7-day and 1 year old cultures (P = 0.0005). On the other hand (Table 3.3.8) a 
comparison of the of the copy number of aps gene detected in genomic DNA showed 
significant difference between 7days and 3 month old cultures (P = 0.0373) and 7 days 
and 1 year cultures (P = 0.0023). However, when comparing 3 months and 1 year old 
cultures there was no significant was observed.     
 
Table 3.3.8. A comparison of the copy number of dsrA and apsA genes detected in 
genomic DNA isolated from 7 days, 3months and 1 year old D. indonesiensis cultures 
using Kruskal-Wallis statistic test based on ten replicates. Asterisks indicate significant 
differences (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
 
Comparison Significant P Value 
dsrA 
7 Days vs. 3 Months No 0.1348 
7 Days vs. 1 Year Yes 0.0005 (***) 
3 Months vs. 1 Year No 0.2813 
ApsA  
7 Days vs. 3 Months Yes 0.0373 (*) 
7 Days vs. 1 Year Yes 0.0023 (**) 
3 Months vs. 1 Year No 0.9418 
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Detection of dsrA and apsA transcripts in total RNA isolated from the different age of 
SRB cultures showed the same trend - a higher cell numbers in the 7-day old culture 
with 1.43 x 1010 (dsr A) and 6.37 x 109 (aps A) cells/ ml of D. indonesiensis culture when 
compared to the 2.85 x 109 (dsr A) and 6.98 x 108 (aps A) present in the 3-month old 
culture (Table 3.3.9).  The Mann-Whitney test statistic suggested that there was a 
significant different between the 7-day old and 3-month old cultures of D. indonesiensis 
culture for both genes (dsr A, P=0.0018 and Aps A, P=0.0079) (Table 3.3.10). This may be 
due to the age of the inoculum of the cultures and the number of viable cells present.  
Older cultures would be expected to have fewer viable cells.  
 
Table 3.3.9. Quantification of the dsrA and ApsA genes in RNA purified from 7 days, 3 
months old D. indonesiensis cultures using TaqMan qPCR. Experiment and statistical 
analysis was based on several independent experiments.  
 
The age of 
D. indonesiensis 
culture 
The copy number of dsrA and apsA genes  
per ml of D. indonesiensis culture  
dsr A aps A 
7 days 1.43 x 1010 6.37 x 109 
3 months 2.85 x 109 6.98 x 108 
 
 
Table 3.3.10. A comparison of the copy number of dsrA and apsA genes detected in 
transcripts in total RNA isolated from 7 days and 3 months old D. indonesiensis cultures 
using Mann-Whitney test statistic based on ten replicates of dsr and aps genes. Asterisks 
indicate significant differences (** P ≤ 0.01). 
 
Comparison Significant P Value 
dsrA 
7 Days vs. 3 Months YES 0.0018 (**) 
ApsA  
7 Days vs. 3 Months YES 0.0079 (**) 
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3.3.3 Quantification of Hydrogen sulfide produced by D. indonesiensis 
grown with and without E. coli BP  
 
SRB are known to produce toxic hydrogen sulfide (H2S) in the gastrointestinal tract of 
humans and animals (Reis et al., 1992). It is also believed that only very little of the H2S 
is produced by dissimilatory sulfate reduction, which is integrated in to the cell for cell 
synthesis, while the rest is expelled into the environment (Singh & Lin, 2015). The 
production of hydrogen sulfide by D. indonesiensis was estimated in order to correlate it 
to the production of ferrous sulfide. In the experiment a 7-day old culture of D. 
indonesiensis was diluted serially in VMR medium and cultured with and without E. coli 
BP, and the H2S concentration was measured in the vial with the lowest level of 
detection (positive for culture of D. indonesiensis). This was the 10-5 dilution without the 
addition of E.coli BP and the 10-10 dilution when D. indonesiensis was cultured with E.coli 
BP. The average concentration of H2S present in the D. indonesiensis and E. coli culture 
was 131 ppm, which was 3 times greater than the concentration (51 ppm) measured in 
the D. indonesiensis culture, despite the difference in dilution (Figure 3.3.9). The 
presence of E.coli BP with D. indonesiensis enhanced the H2S production when compared 
to D. indonesiensis alone culture. Both data sets resulted in the same gap difference in 
the detection of growth of the original experiment, a magnitude of 5 (-5 to -10). The 
difference made by the addition of E. coli; this result indicates that E.coli is capable of 
enhancing growth in SRB.  
 
Figure 3.3.9. The concentration of H2S of 7 days D. indonesiensis culture with and 
without E. coli BP. three independent experiments were done in triplicate. The data 
presented are mean values ± SD. Asterisks indicate significant differences (* P ≤ 0.05). 
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Previous studies have shown that in order to determine the etiology of SRB in 
gastrointestinal diseases, it is important to accurately estimate its cell growth 
(Christophersen et al., 2011). Therefore in the process of determining the best method 
of measuring and quantifying the number of cell growth of Desulfovibrio in a culture, 
the use of qPCR was examined in this study.  
 
The qPCR data obtained from a 7-day old pre-culture and its serially diluted post-
cultures in the vials labeled 10-1 to 10-12 resulted in a similar data to those obtained 
when levels of detection in growth medium was examined. The qPCR data in this 
chapter correlated with the growth data in corresponding vial. This result thus showed 
that when the dsrA and aps -TaqMan qPCR were used, the number of SRB cells 
estimated per ml of cultures had an impressive correlation with the data of culture 
obtained from 7 days old D. indonesiensis. This result therefore supports previous data 
that showed that qPCR is an accurate and time saving method of measuring and 
quantifying Desulfovibrio (Christophersen et al., 2011; Neretin et al., 2003).   
 
The H2S level in vials result in serially diluting a 7 day old pre-culture D. indonesiensis 
with and without E.coli supports previous reports that H2S is a key product resulting 
from the metabolic processes of SBR (Christophersen et al., 2011).  Studies have also 
shown that H2S is toxic to human colon; extreme levels of H2S coupled with profuse 
levels of SRB have also been implicated in patients having UC (Gibson et al., 1991; 
Roediger et al., 1993; Gardiner et al., 1995; Christl et al., 1996; Pitcher et al., 2000). The 
findings obtained from this study showed the differences of concentration average level 
of H2S in D. indonesiensis co-cultured with E. coli BP. The difference was greatly 
increased ~3-folds in concentration when compared to D. indonesiensis alone which 
suggest that E. coli BP supporting the growth of D. indonesiensis and therefore increase 
the H2S production. During the metabolic activity, E. coli produces Lactate which is one 
of the substrates used by SRB Desulfovibrio in the gut for metabolism (Barbetti et al., 
1988; Vernia et al., 1988; Bourriaud et al., 2005; Marquet et al., 2009; Kushkevych and 
Moroz, 2012). Although, the presence of sulfate and lactate in the gut increases cell 
growth, it also results in enhanced production of acetate and hydrogen sulfide which 
are toxic to humans (Gibson et al., 1993b; Marquet et al., 2009; Rey et al., 2013).  
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Culture technique allows detecting the SRB growth in the presence of E. coli BP in low 
dilutions comparing with the growth of SRB only. This suggests an underestimation of 
SRB growth in agreement with other reports (Gibson et al., 1987; Levine et al., 1998; 
Jørgensen, 2009). Using the dsrA-apsA TaqMan qPCR the number of SRB cells was 
estimated and that was in a good correlation with the data of culture techniques. The 
inclusion of E. coli BP in the culture medium for these SRB allows a faster identification 
of their presence. 
 
3.4 Genome Sizes of D. indonesiensis estimated by Pulsed-Field Gel 
Electrophoresis  
 
The genome size of D. indonesiensis was estimated by Pulsed-Field Gel Electrophoresis 
(PGFE). The size was determined from the estimation of the migration of the full-length 
bands relative to the sizes of DNA standard fragments. PFGE is an analytical tool 
employed in estimating the actual genome size of bacteria; this method separates the 
bacteria DNA into several chromosomes of various sizes that can be measured (Römling 
et al., 1992; Boyle et al 1993; Devereux et al., 1997; Klaassen et al., 2002; Fernández-
Cuenca, 2004). Interestingly, PFGE resolves DNA fragments into several megabases 
between 0.6 and 10 Mb thus making it easier to evaluate and also map out the bacterial 
genomes physically (Römling et al., 1992).  
 
In the past researchers have been able to use PFGE to identify other family members of 
a bacterium genus. When accurately interpreted these data and structure could be used 
in genetic engineering, drug and vaccine discovery and other areas of Molecular Biology 
and Biotechnology (Kullen & Klaenhammer 2000; Klaassen et al., 2002; Fernández-
Cuenca, 2004). It is however worth noting that this method may not be effective in 
resolving some bacterial chromosomes and in some instances the DNA degrades (Kato 
et al 1996; Izumiya et al 1997; Liesegang & Tschäpe, 2002). To solve this problem some 
workers recommended the use of thiourea which has the ability to neutralize the 
nucleolytic peracid derivative of Tris buffer produced at the anode during 
electrophoresis, thereby preventing DNA degradation but this method was not effective 
for all bacterial species (Ray et al., 1995; Silbert et al., 2003). However, over the years 
the use of Restriction endonuclease was discovered and tested. This involves cleaving 
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the bacterial chromosome with a restriction endonuclease that has a 6 bp or 8 bp 
recognition site (genome finger printing), resulting in about three to one hundred DNA 
fragments that are resolvable on the PFGE gel (Pfaller et al., 1992; Römling et al., 1992). 
Summation of these fragments allows an estimation of the genome size. For this section, 
the bacterial cultures used were D. indonesiensis and E. coli BP, as these were used in the 
detection studies. 
 
Figure 3.3.10 shows the PGFE gel with the following samples loaded in corresponding 
wells/lane as labelled below: Lanes (1) Schizosaccharomyces pombe ladder; (2) lambda 
ladder (3) D. indonesiensis DNA digested with PmeI; (4) D. indonesiensis DNA; (5) D. 
indonesiensis DNA digested with NotI; (6) Saccharomyces cerevisiae ladder size range; 
(7) E.coli DNA digested with PmeI; (8) E.coli DNA; (9) E.coli DNA digested with NotI.  
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Figure 3.3.10. Pulsed-field gel sizing of SRB genomes from (a) D. indonesiensis and (b) 
E.coli: Lanes (1) Schizosaccharomyces pombe size range 3.5-5.7 Mb; (2) lambda ladder 
size range 0.05–1 Mb  ;(3) D. indonesiensis digested – PmeI; (4) D. indonesiensis ; (5) D. 
indonesiensis digested-NotI; (6) Saccharomyces cerevisiae ladder size range 240-2200 
Kb; (7) E.coli digested – PmeI; (8) E.coli; (9) E.coli digested – NotI;(10) D. indonesiensis. 
Sizes of selected DNA standards (BIO-RAD DNA Size Markers–Yeast Chromosomal; BIO-
RAD DNA Size Markers lambda and BIO-RAD DNA Size Markers–S. pombe Chromosomal 
DNA) are indicated. 
 
Table 3.3.11 below showed the estimation of the total genome observed. E.coli was used 
as control in this experiment largely because it has a known genomic size (Lukjancenko 
et al., 2010).  
 
Table 3.3.11. Estimated gel size Measurement of the genomes from (a) D. indonesiensis 
and (b) E.coli: (3) D. indonesiensis digested – PmeI; (5) D. indonesiensis digested-NotI; 
(7) E.coli digested – PmeI; (8) E.coli; (9) E.coli digested – NotI.  
 
 
 
 
 
 
 
 
Lane 3 5 8 9 
Fragments 392 181 2100 2150 
 512 1673 1600 1600 
 1965 1695 405 378 
     
Total (Mb) 2869 3549 4105 4128 
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DNA degradation was observed when samples were analyzed by electrophoresis 
without restriction digestion, as seen in the D. indonesiensis genomic DNA (lane 4 
above). The reason for the degradation was unclear but this may probably be due the 
large size of the genome or to the nucleolytic peracid derivatives formed by Tris buffer 
at the anode during electrophoresis thus, supporting observations from other research 
workers (Ray et al., 1995). The restriction enzymes PmeI and NotI were selected and 
used individually to digest genomic DNA from SRB and E.coli and the resultant 
fragments were separated by PFGE (Figure 3.3.10). The electrophoretic profiles and 
genome fingerprinting results above showed three DNA fragments on Lane 3- SRB 
digested – PmeI of a total genome size ~2.5 Mb (392 kb, 512 kb and 1965 kb 
respectively). Lane 5- SRB digested-NotI resulted in a total genome size of ~3.5 Mb (181 
kb, 1673 kb and 1695 kb respectively), Lane 8- E. coli resulted in a total genome size of 
~4.1 Mb (2100 kb, 1600 kb and 405 kb respectively) while Lane 9- E.coli digested – NotI 
resulted in a total genome size of ~4.1 Mb (2150 kb, 1600 kb and 378 kb respectively). 
From the results of this study, the D. indonesiensis estimated genome size obtained 
above showed a very close similarity to those obtained in previous research work 
where the genome sizes of Desulfovibrio desulfuricans, Desulfovibrio vulgaris, and 
Desulfobulbus propionicus were estimated to be 3.1, 3.6, and 3.7 Mb, respectively 
(Devereux et al., 1997).  
 
The results obtained in this section thus indicates that Pulse Field Gel Electrophoresis 
accurately estimates the genome size of bacteria after the DNA has first been digested 
with restriction enzymes; with the restriction enzymes preventing DNA degradation 
during electropghoresis (Pfaller et al., 1992; Römling et al., 1992; Boyle et al 1993; 
Devereux et al., 1997; Klaassen et al., 2002; Fernández-Cuenca, 2004). 
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Section 4 
The effect of antibiotics and Manuka honey on the growth of 
sulfate reducing bacterial biofilm 
 
A biofilm is a microbial community formed within a complex matrix where bacteria and 
other microbes co-exist and support the growth of each other (Costerton et al., 1995; 
Jackson et al., 2002a). In adapting to their way of life, these bacteria have developed 
intricate methods of growing and surviving by attaching themselves to and inhabiting 
solid surfaces (Costerton et al., 1995, 1999; Jackson et al., 2002 a,b). Biofilms protects 
bacteria from damaging circumstances, the effect of which is widespread universally 
through all environments allowing biofilms to escalate bacterial infections making them 
difficult to treat (Römling & Balsalobre, 2012). Previous reports have highlighted the 
difficulty in treating chronic and difficult-to-treat infections caused by the bacterial 
inhabitants of the colon; a source of concern here is related to one of the advantages of 
that biofilms provide their ability to evade attacks from the human immune system 
(Dongari-Bagtzoglou, 2008; Macfarlane et al., 2011; Willem, 2015). Antimicrobial 
efficiency of Manuka honey which is produced from manuka tree (Leptospermum 
scoparium) in New Zealand is known to supersede other honey and its effectiveness is 
attributed to a joint action of methylglyoxal (MGO) and other compounds which give it 
an extra antiseptic and therapeutic property against several antibiotic resistance 
microorganisms. The MGO content of Manuka honey is used to define the antimicrobial 
activity of this honey and is referred to as the unique Manuka Honey Factor (UMF®) 
(Molan & Russell, 1988; Mavric et al., 2008; Maddocks et al., 2012). In the previous 
sections, it was observed that UC was associated with a change in bacterial diversity 
favoring members of the Enterbacteriaceae and the Desulfovibrio. Furthermore, it was 
demonstrated that a relationship between E. coli and Desulfovibrio indonesiensis existed, 
where co-culturing the SRB with E. coli enhanced its growth. Therefore, does the use of 
manuka honey in combination with antibiotics can help in controlling the bacteria 
involved in UC ?  
In this section Manuka honey with different UMF number was compared with the 
commercial honey for their efficacy against E. coli BP and D. indonesiensis microbes both 
of which are associated with UC. Effect of honey against pure and mixed of these 
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bacteria was examined on the biofilm formation as well as disruption of the existing 
biofilms. The effect of two commonly used antibiotics for UC rifaximin and 
metronidazole was also examined in the presence and absence of honey. 
 
3.4.1 The MIC and MBC values of different Manuka honey on D. 
indonesiensis in pure culture and mixed culture with E. coli BP 
 
The growth characteristics of D. indonesiensis and E. coli BP before treatment with 
honey and antibiotics were determined. The growth of E. coli for all experiments ranged 
between 1.95X107 to 2X108 cells/ml after 18 hours incubation at 37C; while the 
growth for D. indonesiensis was 3.5X105 to 7X106 cells/ml after 6 days incubation at 37 
C.  
Minimum inhibitory concentrations (MIC values) and minimum bactericidal 
concentration (MBC values) were determined for D. indonesiensis biofilms cultured with 
and without E.coli BP when treated with different concentrations of Manuka honey 
(UMF® 5+, UMF® 15+ and UMF® 25+) , artificial honey and commercial honey. Here, the 
honey was added simultaneously with the D. indonesiensis biofilm with and without E. 
coli; and incubated for 7 days after which the inhibitory effect of honey on biofilm 
formation was examined. Although artificial honey has the same amount of sugars 
presented in the honey; it exhibited no effect on the growth of pure and mixed D. 
indonesiensis biofilms with E. coli BP. This result clearly suggested that sugar content is 
not the only antibacterial factor however there might be other mechanisms than the 
high osmotic pressure are involved in the inhibition of bacterial growth (Nassar et al., 
2012). 
The data shown in Figure 3.4.1 gives the mean MIC values for D. indonesiensis, in single 
and mixed culture, when incubated simulataneously with 4 different honeys, Manuka 
UMF®5+, Manuka UMF®15+, Manuka UMF®25+ and commercial honey. Differences in 
MIC values exist between treatments and between single culture or mixed biofilms.    
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Figure 3.4.1. The MIC values for E. coli and D. indonesiensis grown as pure and mixed 
population (the honey was added simultaneously with culture and then incubated 
for 7 days) when treated with Manuka honey UMF® 5+, UMF® 15+, UMF® 25+ and 
commercial honey. The MIC values are the average from 5 independent experiments 
and are displayed with standard deviation. Asterisks indicate significant differences (* P 
≤ 0.05; ** P ≤ 0.01). 
 
 
Significant differences between treatments were observed when assessed via Kruskal-
Wallis test with Dunn’s multiple comparisons (Table 3.4.1) for MIC values for the SRB 
when in single or mixed culture. The differences between the mean MIC values when 
the SRB in single or mixed culture was treated with different grades of Manuka honey 
showed some inconsistencies. The mean MIC value for all of the treatments increased 
when D. indonesiensis was cultured with E. coli, however none of these differences were 
significant according (Table 3.4.1). Successive treatments with higher grades of Manuka 
honey, whether the SRB was in single or mixed culture, resulted in lower mean MIC 
values although significance not detected indicating some differences in susceptibility to 
Manuka honey (Table 3.4.1). However, a significant effect was observed when 
comparing the UMF®15+ and UMF®25+ single biofilms to the commercial honey single 
and mixed biofilms (UMF®15 vs CH P value of 0.009, UMF®15 vs CH Mix value of 0.003 
& UMF®25+ vs CH value of 0.005, UMF® 25+ vs CH Mix value of  0.002). 
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Similarly, no significant difference between the means was found for the SRB in single 
or mixed culture when the treatments were for Manuka UMF®15+ and UMF®25+ (MIC 
values from 14% to 12% respectively).  However, when the mean MIC values for UMF® 
5+ and UMF® 25+ treatments were compared there was a significant difference 
between these two concentrations (UMF®25+ had a lower MIC value) indicating that 
both cultures had a greater susceptible to higher grades of Manuka honey. The mean 
MIC value for all of the treatments increased when D. indonesiensis was cultured with E. 
coli, however not all of these differences were significant according to Kruskal-Wallis 
test statistics (Table 3.4.1). Comparison of the means for the mixed and single culture 
biofilms treated with commercial honey (42% and 46% respectively) were not 
significantly different at P = > 0.9999. Similarly, the difference between the mean MIC 
values was not significant for D. indonesiensis in either biofilm when treated with 
Manuka UMF®5, UMF®15+ and UMF®25 (Table 3.4.1). 
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Table 3.4.1: A comparison of the MIC values obtained when different concentrations of 
Manuka and commercial honey were applied using Kruskal-Wallis test statistics. Only 
comparisons which reached significance are shown. Asterisks indicate significant 
differences (** P ≤ 0.01). 
 
Comparison Significant p-value 
UMF®5+ vs. UMF®5+ mix No > 0.9999 
UMF®5+ vs. UMF®15+ No > 0.9999 
UMF®5+ vs. UMF®15+ mix No > 0.9999 
UMF®5+ vs. UMF®25+ No > 0.9999 
UMF®5+ vs. UMF®25+ mix No > 0.9999 
UMF®5+ vs. CH No 0.6890 
UMF®5+ vs. CH mix No 0.3041 
UMF®5+ mix vs. UMF®15+ No 0.3980 
UMF®5+ mix vs. UMF®15+ mix No > 0.9999 
UMF®5+ mix vs. UMF®25+ No 0.2703 
UMF®5+ mix vs. UMF®25+ mix No > 0.9999 
UMF®5+ mix vs. CH No > 0.9999 
UMF®5 mix vs. CH mix No > 0.9999 
UMF®15+ vs. UMF®15+ mix No > 0.9999 
UMF®15+ vs. UMF®25+ No > 0.9999 
UMF®15+ vs. UMF®25+ mix No > 0.9999 
UMF®15+ vs. CH Yes 0.0090 (**) 
UMF®15+ vs. CH mix Yes 0.0027 (**) 
UMF®15+ mix vs. UMF®25+ No > 0.9999 
UMF®15+ mix vs. UMF®25+ mix No > 0.9999 
UMF®15+ mix vs. CH No 0.4291 
UMF®15+ mix vs. CH mix No 0.1805 
UMF®25+ vs. UMF®25+ mix No > 0.9999 
UMF®25+ vs. CH Yes 0.0053 (**) 
UMF®25+ vs. CH mix Yes 0.0015 (**) 
UMF®25+ mix vs. CH No 0.5974 
UMF®25+ mix vs. CH mix No 0.2598 
CH vs. CH mix No > 0.9999 
 
 
In these situations, the addition of E. coli to the biofilm appears to have increased the 
resistance of D. indonesiensis to the inhibitory effects of the Manuka honey. A number of 
possibilities could explain these results. The apparent reduction in susceptibility of the 
SRB cells to the antimicrobial component of honey could have happened because their 
contact with it had been reduced. In the mixed culture, a greater number of E. coli cells 
would have been present to interact with the antimicrobial agent, preventing 
interaction with the SRB cells. E. coli cells in culture are sensitive to the active 
ingredient in Manuka honey, perhaps more so than other bacteria, and they are 
particularly sensitive to the higher grades of honey (Badawy et al., 2004; Adebolu, 2005; 
Wilkinson & Cavanagh, 2005; Mandal & Mandal, 2011). Another possibility is that the 
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E.coli biofilm provides protection against the uptake of the antimicrobial agent. It has 
been reported that these biofilms exhibit a greater resistance to antibiotics because 
E.coli changes its expression of the rpoS gene, which codes for one of the sigma factors 
(sigma 38) of RNA polymerase. This controls stationary phase genes and protects the 
cell against stress. Genes activated at this time include sodC – the gene that codes for 
superoxide dismutase, and gor – glutathione reductase (Corona-Izquierdo & Membrillo-
Herna’ndez 2002; Schembri et al., 2003; Ito et al 2009). Presumably the reduction in 
activity against D. indonesiensis results from some degree of protection afforded by the 
presence of another bacterium. In this respect it can be considered that the difference in 
the inhibitory effect is due to complementary activity of the two species taken together 
(Cooper et al., 1999).  
The mean MBC values for D. indonesiensis biofilms cultured with and without E.coli 
when treated with Manuka honey of different grades and commercial honey, which was 
added simultaneously with the inoculum and cultured for 7 days, are shown in the 
histogram in Figure 3.4.2. 
 
 
Figure 3.4.2.  The MBC values for E. coli and D. indonesiensis grown as pure and mixed 
population (the honey was added simultaneously with culture and then incubated 
for 7 days) when treated with Manuka honey UMF®5+, UMF®15+, UMF®25+ and 
commercial honey. The mean MBC values were calculated from 5 independent repeat 
experiments and shown with standard deviation. Asterisks indicate significant 
differences (* P ≤ 0.05; ** P ≤ 0.01). 
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The pattern for the MBC values was similar to the one observed for MIC values, although 
the values were marginally greater, which was expected. No significant difference was 
observed within or between Manuka honey treatments with the exception of UMF®5 
mixed SRB and E. coli culture compared to UMF® 25+ pure SRB  (P = 0.021) ;UMF® 15+ 
compared to commercial honey on pure SRB culture  (P =0.0211); UMF® 15+ compared 
with commercial honey on mixed culture (P =0.0017); UMF® 25+ with compared with 
commercial pure SRB culture (P=0.0035) and UMF® 25+ pure SRB culture with 
compared with commercial honey (P=0.0002)   (Table 3.4.2).  
 
Table 3.4.2: A comparison of the MBC values obtained when different concentrations of 
Manuka and commercial honey were applied using Kruskal-Wallis test statistics. Asterisks 
indicate significant differences (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
Comparison Significant p-value 
UMF®5+ vs. UMF®5+ mix No > 0.9999 
UMF®5+ vs. UMF®15+ No > 0.9999 
UMF®5+ vs. UMF®15+ mix No > 0.9999 
UMF®5+ vs. UMF®25+ No 0.8417 
UMF®5+ vs. UMF®25+ mix No > 0.9999 
UMF®5+ vs. CH No > 0.9999 
UMF®5+ vs. CH mix No 0.5915 
UMF®5+ mix vs. UMF®15+ No 0.1025 
UMF®5+ mix vs. UMF®15+ mix No > 0.9999 
UMF®5+ mix vs. UMF®25+ Yes 0.0211 (*) 
UMF®5+ mix vs. UMF®25+ mix No > 0.9999 
UMF®5+ mix vs. CH No > 0.9999 
UMF®5+ mix vs. CH mix No > 0.9999 
UMF®15+ vs. UMF®15+ mix No > 0.9999 
UMF®15+ vs. UMF®25+ No > 0.9999 
UMF®15+ vs. UMF®25+ mix No > 0.9999 
UMF®15+ vs. CH Yes 0.0211 (*) 
UMF®15+ vs. CH mix Yes 0.0017 (**) 
UMF®15+ mix vs. UMF®25+ No > 0.9999 
UMF®15+ mix vs. UMF®25+ mix No > 0.9999 
UMF®15+ mix vs. CH No > 0.9999 
UMF®15+ mix vs. CH mix No 0.2369 
UMF®25+ vs. UMF 25 mix No > 0.9999 
UMF®25+ vs. CH Yes 0.0035 (**) 
UMF®25+ vs. CH mix Yes 0.0002 (***) 
UMF®25+ mix vs. CH No 0.7854 
UMF®25+ mix vs. CH mix No 0.1272 
CH vs. CH mix No > 0.9999 
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The mean MBC values for D. indonesiensis present in biofilms varied when it was 
present alone or with E.coli. In all cases the MBC values were greater when the SRB was 
in a mixed biofilm although this effect never reached significance (Table 3.4.2). 
When the grade of Manuka honey was increased to UMF® 15+, the mean MBC value was 
reduced compared to UMF®5+ for both cultures (Figure 3.4.2); with the pure D. 
indonesiensis biofilm having 16 % MBC mean value and the D. indonesiensis with E. coli 
BP mixed having 23 % MBC mean value although the difference was not significant 
according to Kruskal-Wallis test statistics (Table 3.4.2), this suggests that increase in 
concentration of honey increases the susceptibility of both cultures but the inclusion of 
E. coli further emphasizes the resistance of D. indonesiensis to the treatments. 
Treatment with a higher UMF® 25+ Manuka honey resulted in a much lower MBC mean 
value when compared to UMF® 5+ and UMF® 15+ (Figure 3.4.2); which was statistically 
significant between the single UMF®25+ and the mixed UMF®5+ biofilm cultures (Table 
3.4.2) according to Kruskal-Wallis test statistics. Treatment of the D. indonesiensis 
biofilm resulted in a 13.8 % mean value and the mixed culture showed a 21.4 % mean 
value, suggesting that the MBC value is dependent on the concentration of the Manuka 
honey where the higher the grades of the honey results in a lower MBC value.  
The inclusion of E. coli BP enhanced the resistance of D. indonesiensis to these 
treatments. On the other hand, treatment with the commercial honey resulted in an 
increased MBC mean value for both cultures when compared to their mean values 
obtained when Manuka honey were used. The mean MBC values for D. indonesiensis 
alone or with E. coli BP, were 45% and 53% respectively, with the difference between 
these not being statistically significant (Table 3.4.2); this data also showed that the 
addition of E. coli BP decreased the sensitivity of the mixed biofilm to honey thus, the 
slightly higher MBC values of D. indonesiensis with E. coli BP when compared to the pure 
D. indonesiensis.  
In order to determine whether Manuka honey could disrupt established biofilms, the 
honey was added to preformed biofilms before MIC and MBC values were estimated. D. 
indonesiensis biofilms and D. indonesiensis with E. coli biofilms were formed after 6 days 
growth, when various honey treatments (Manuka UMF ®5+, Manuka UMF®15+, Manuka 
UMF®25+ and commercial honey) were applied to the biofilms followed by overnight 
incubation. The mean MIC values for D. indonesiensis were estimated for each treatment 
(Figure 3.4.3). The pattern observed was similar to the one obtained when honey was, 
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added to the growing cultures, except that the mean MIC values were greater. The mean 
MIC value decreases with the different Manuka honey treatments, with the lowest 
values being observed for the highest-grade honey applied to the SRB biofilm.   
 
 
Figure 3.4.3. The MIC value of Manuka UMF® 5+, UMF® 15+, UMF® 25+ and commercial 
honey for E. coli and D. indonesiensis grown as pure and mixed population (the honey 
was added after incubating the culture for 6 days). The mean values were calculated 
form 5 independent experiments and shown with standard deviation. Asterisks indicate 
significant differences (* P ≤ 0.05; ** P ≤ 0.01). 
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Table 3.4.3: A comparison of the MIC values obtained when different concentrations of 
Manuka and commercial honey were applied using Kruskal-Wallis test statistics. 
Asterisks indicate significant differences (** P ≤ 0.01). 
Comparison Significant p-value 
UMF®5+ vs. UMF®5+ mix No > 0.9999 
UMF®5+ vs. UMF®15+ No > 0.9999 
UMF®5+ vs. UMF®15+ mix No > 0.9999 
UMF®5+ vs. UMF®25+ No 0.8016 
UMF®5+ vs. UMF®25+ mix No > 0.9999 
UMF®5+ vs. CH No > 0.9999 
UMF®5+ vs. CH mix No > 0.9999 
UMF®5+ mix vs. UMF®15+ No 0.0767 
UMF®5+ mix vs. UMF®15+ mix No > 0.9999 
UMF®5+ mix vs. UMF®25+ Yes 0.0019 (**) 
UMF®5+ mix vs. UMF®25+ mix No 0.1743 
UMF®5+ mix vs. CH No > 0.9999 
UMF®5+ mix vs. CH mix No > 0.9999 
UMF®15+ vs. UMF®15+ mix No > 0.9999 
UMF®15+ vs. UMF®25+ No > 0.9999 
UMF®15+ vs. UMF®25+ mix No > 0.9999 
UMF®15+ vs. CH No > 0.9999 
UMF®15+ vs. CH mix No 0.0767 
UMF®15+ mix vs. UMF®25+ No 0.4172 
UMF®15+ mix vs. UMF®25+ mix No > 0.9999 
UMF®15+ mix vs. CH No > 0.9999 
UMF®15+ mix vs. CH mix No > 0.9999 
UMF®25+ vs. UMF®25+ mix No > 0.9999 
UMF®25+ vs. CH No 0.0701 
UMF®25+ vs. CH mix Yes 0.0019 (**) 
UMF®25+ mix vs. CH No > 0.9999 
UMF®25+ mix vs. CH mix No 0.1743 
CH vs. CH mix No > 0.9999 
 
Table 3.4.3 showed a comparison of the different treatments used in this experiment for 
both biofilms according to Kruskal-Wallis test statistics. The MIC mean values of D. 
indonesiensis alone were only significant for UMF®5+ mixed compared to UMF®25+ 
single (P= 0.002) although a trend of decreasing MIC with increasing Manuka 
concentration as observed. The mean MIC values for the SRB alone at UMF®25+ are 
significantly different compared to the values obtained for commercial honey with a 
mixed biofilm, with the Manuka honey producing the lower values (P = 0.002). 
In other words, the only successful treatment of the SRB in mixed culture was with the 
highest grade of Manuka honey, where the mean MIC was 37%. 
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This contrast with a previous study where the reported percentage of honey needed to 
completely prevent the growth of Proteus mirabilis and E. coli in biofilms was between 
6-6.5 % v/v (Willix et al. 1992; Ahmed et al. 2014). This concentration was lower than 
that obtained in this study for the tested honeys. These differences probably due to the 
different of antibacterial activity of honey of different batch or the differences in the 
tested bacteria and tested methods.  
 
 
Figure 3.4.4. The MBC value of Manuka UMF® 5+, UMF® 15+, UMF® 25+  Manuka 
honey and commercial honey for E. coli BP and D. indonesiensis grown as pure and 
mixed population (the honey was added after incubated the culture for 6 days). The 
mean values were calculated from 5 independent experiments and shown with 
standard deviation. Asterisks indicate significant differences (* P ≤ 0.05) 
 
 
The mean MBC values for D. indonesiensis in pure and mixed pre-formed biofilms when 
treated with different grades of honey are shown in Figure 3.4.4. In general, the mean 
values have increased from those observed when the honey was included with the 
growing culture (Figure 3.4.2), and they were greater than the mean MIC values (Figure 
3.4.3). The pattern observed was similar to the previous susceptibility results, where 
greater mean MBC values were observed for the SRB in mixed culture and decreasing 
mean MBC values recorded for the higher grades of Manuka honey (values of 47%, 37% 
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and 37% for pure culture biofilms treated with Manuka UMF®5+, UMF®15+ and 
UMF®25+ respectively, and 57%, 45% and 41% for mixed cultures treated with Manuka 
UMF®5+, UMF®15+ and UMF®25+ respectively). The greatest mean MBC values (52% 
and 57% for the SRB in pure and mixed culture respectively) were for the cells in 
biofilms treated with commercial honey.  
 
Table 3.4.4. A comparison of the MBC values obtained when different concentrations of 
Manuka and commercial honey were applied using Kruskal-Wallis test statistics. 
Asterisks indicate significant differences (* P ≤ 0.05). 
Comparison Significant p-value 
UMF ®5+ vs. UMF®5+ mix No > 0.9999 
UMF®5+ vs. UMF®15+ No > 0.9999 
UMF®5+ vs. UMF®15+ mix No > 0.9999 
UMF®5+ vs. UMF®25+ No > 0.9999 
UMF®5+ vs. UMF®25+ mix No > 0.9999 
UMF®5+ vs. CH No > 0.9999 
UMF®5+ vs. CH mix No > 0.9999 
UMF®5+ mix vs. UMF®15+ Yes 0.0156 (*) 
UMF®5+ mix vs. UMF®15+ mix No 0.9377 
UMF®5+ mix vs. UMF®25+ Yes 0.0103 (*) 
UMF®5+ mix vs. UMF®25+ mix No 0.1047 
UMF®5+ mix vs. CH No > 0.9999 
UMF®5+ mix vs. CH mix No > 0.9999 
UMF®15+ vs. UMF®15+ mix No > 0.9999 
UMF®15+ vs. UMF®25+ No > 0.9999 
UMF®15+ vs. UMF®25+ mix No > 0.9999 
UMF®15+ vs. CH No 0.3626 
UMF®15+ vs. CH mix Yes 0.0156 (*) 
UMF®15+ mix vs. UMF®25+ No > 0.9999 
UMF®15+ mix vs. UMF®25+ mix No > 0.9999 
UMF®15+ mix vs. CH No > 0.9999 
UMF®15+ mix vs. CH mix No 0.9377 
UMF®25+ vs. UMF®25+ mix No > 0.9999 
UMF®25+ vs. CH No 0.2644 
UMF®25+ vs. CH mix Yes 0.0103 (*) 
UMF®25+ mix vs. CH No > 0.9999 
UMF®25+ mix vs. CH mix No 0.1047 
CH vs. CH mix No > 0.9999 
 
Comparison of the mean MBC values for D. indonesiensis treated with the different 
honeys using the Kruskal-Wallis test statistic (Table 3.4.4) revealed differences with the 
various treatments. The trends were the same for the single culture and mixed culture 
biofilms. Significant differences between the means were observed for the Manuka 
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UMF®5+ on mix SRB culture and UMF®15+ on pure SRB  (P = 0.016) and UMF®25+ (P = 
0.010), and the UMF®15+ and UMF®25+ on pure SRB culture compared with the 
commercial honey on mixed SRB biofilms (P = 0.0156 and 0.010 respectively) (Table 
3.4.4) 
The susceptibility of D. indoneseisis to Manuka honey when present in an existing 
biofilm, pure or mixed, was less than when the honey was added to the cells prior to the 
establishment of the biofilm. The mean MIC and MBC values were greater for every 
treatment, although there was still greater susceptibility when the higher grades of 
honey were used. Presumably the increase in MIC and MBC mean values reflects that 
greater permeability barriers exist when the biofilm is established, and that higher 
concentrations of honey are needed to disrupt the biofilm.  Previous studies have shown 
honey’s ability to prevent the formation as well as elimination of established biofilms 
(Cooper et al., 2010; Lu et al., 2014). In agreement with previous studies the results 
obtained from this investigation showed that the effective concentration of honey 
needed to prevent biofilm formation is lower than the concentration required to disrupt 
an established biofilm (Allen et al., 1991; Probert & Gibson, 2002; Lin et al., 2011). 
Manuka UMF®25+ was more effective at interrupting the growth and survival of 
matured biofilm when compared to other concentrations of honey tested. This is result 
agrees with previous studies by Sherlock et al (2010), who showed in their study that 
the biofilm formation of E.coli  is inhibited by Manuka honey UMF®25+ at 
concentrations ≥ 12.5%. 
3.4.2 The susceptibility of D. indonesiensis in pure culture and mixed 
culture with E. coli BP when treated with Manuka honey and antibiotics 
 
The susceptibility of D. indonesiensis to Manuka honey supplemented with antibiotics 
was assessed to explore whether application of the honey improves the prevention of 
SRB biofilm establishment or disruption. The antibiotics chosen for study were rifaxmin 
and metronidazole, both of which are frequently used in the treatment of UC (Guslandi, 
2011; Miner et al., 2005). Rifaxmin is a semi-synthetic antibiotic that binds to the Beta 
sub-unit of RNA polymerase, preventing transcription. It is used as a treatment against 
traveller’s diarrhoea, caused by E. coli, irritable bowel syndrome and hepatic 
encephalopathy. Metronidazole is a nitroimidazole that inhibits DNA synthesis by 
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disrupting DNA. This only happens when the antibiotic is reduced, which takes place in 
anaerobic cells. It, therefore, has little effect against human cells or aerobic bacteria.  
The susceptibility of the SRB was tested against these antibiotics given singularly and in 
mixtures with and without Manuka UMF®15+ honey. 
The MIC values for D. indonesiensis in pure and mixed cultures after they had been 
treated with the antibiotics rifaximin, metronidazole, and combinations of these with 
and without honey (Figure 3.4.5). The greatest effect of these antibiotics was on the 
pure cultures of D. indonesiensis when they were given individually or in combination, 
and when the honey was added, either at the beginning of growth or after 6 days. The 
greatest mean MIC value was 230.4 µg/ml, which was obtained when the SRB was in 
mixed culture treated with either rifaxmin, metronidole or a combination of both. The 
mean MIC values dropped considerably to 57.6, 22.4 and 22.4 µg/ml respectively when 
treated with rifaxmin, metronidole and a combination of both. In this study these 
antibiotics were combined in order to reduce the occurrence of antibiotic resistance to 
rifaximin and metronidazole. Combination of antibiotics agents used in this way form a 
synergy that increases the antimicrobial properties. The increased sensitivities to the 
antibiotics provide the best way to eradicate both test bacteria, which are involved in 
the etiology and pathogenesis of UC (Burke, 1997; Ohge et al., 2003; Rowan et al., 2009; 
Leibovici et al., 2010;  Mirsepasi-Lauridsen et al., 2016). However, what was observed is 
that these two bacteria were able to increases their chance of survival at high 
concentrations of both antibiotics even in combination when were grown together.  
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Figure 3.4.5. The MIC value of rifaximin, metronidozole alone and in combination, 
rifaximin+ metronidozole in the presence of Manuka UMF® 15+ (the antibiotics and 
honey were added simultaneously to the cultures), rifaximin+ metronidozole in the 
presence of Manuka UMF® 15+ (the antibiotics were added after 6 days incubation 
with Manuka UMF® 15+). Mean values were estimated from 5 independent 
experiments and are shown with standard deviation. Asterisks indicate significant 
differences (* P ≤ 0.05; ** P ≤ 0.01). 
 
According to Kruskal-Wallis test statistics (Table 3.4.5), although a large difference 
existed between the mean MIC values for D. indonesiensis in pure culture than mixed 
with E. coli BP when they were grown simultaneously with rifaximin or metronidazole 
alone and in combination, these values were not significant. The pure D. indonesiensis 
culture was sensitive to these antibiotics while the mixed culture showed high 
resistance probably because the co-culturing both bacteria enhances resistance via a 
number of mechanisms (Cooper et al., 1999; Wilkinson & Cavanagh, 2005; Mittal et al., 
2015). These include speed with which they develop extracellular polymeric matrix as 
well as altered activity of metabolic enzymes and the growth rate leading to a shift from 
the TCA cycle to fermentation-dervied energy acquisition, endogenous oxidative stress 
and their ability to transfer genes which enables them to develop resistance to the 
therapeutic agents (Bradshaw et al., 1996; Shimizu, 2014).  
When D. indonesiensis and cultures of D. indonesiensis and E. coli were treated with 
rifaximin, metronidazole and Manuka honey 15+, added simultaneously to the culture, 
the difference between the mean MIC value for the SRB in the two cultures were again 
different but not significantly so according to the Kruskal-Wallis test statistics (Table 
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3.4.5). The mean MIC value was lowest when D. indonesiensis was in pure culture, with 
the smallest value being 14.4µg/ml.   
Table 3.4.5. A comparison of the MIC values obtained when different concentrations 
antibiotics and UMF®15+ were applied Kruskal-Wallis test statistics. Asterisks indicate 
significant differences (** P ≤ 0.01; *** P ≤ 0.001). 
 
Treatment Significant p-value 
Rif. vs. Rif. mix No > 0.9999 
Rif. vs. Met. No > 0.9999 
Rif. vs. Met. mix No > 0.9999 
Rif. vs. Rif. + Met. No > 0.9999 
Rif. vs. Rif. + Met. mix No > 0.9999 
Rif. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Rif. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. vs. UMF®15+ treated cells with Subs. Rif. + Met. No 0.5913 
Rif. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. mix vs. Met. No 0.1223 
Rif. mix vs. Met. mix No > 0.9999 
Rif. mix vs. Rif. + Met. No 0.1223 
Rif. mix vs. Rif. + Met. mix No > 0.9999 
Rif. mix vs. Rif. + Met. + UMF®15+ Yes 0.0167 (**) 
Rif. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0006 (***) 
Rif. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Met. vs. Met. mix No 0.1223 
Met. vs. Rif. + Met. No > 0.9999 
Met. vs. Rif. + Met. mix No 0.1223 
Met. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Met. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. No > 0.9999 
Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Met. mix vs. Rif. + Met. No 0.1223 
Met. mix vs. Rif. + Met. mix No > 0.9999 
Met. mix vs. Rif. + Met. + UMF®15+ Yes 0.0167 (**) 
Met. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0006 (***) 
Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. + Met. vs. Rif. + Met. mix No 0.1223 
Rif. + Met. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Rif. + Met. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. + Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. No > 0.9999 
Rif. + Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. + Met. mix vs. Rif. + Met. + UMF®15+ Yes 0.0167 (**) 
Rif. + Met. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. + Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0006 (***) 
Rif. + Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. + Met. + UMF®15 vs. Rif. + Met. + UMF®15 mix No > 0.9999 
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Treatment Significant p-value 
Rif. + Met. + UMF®15 vs. UMF®15 treated cells with Subs. Rif. + 
Met. 
No > 0.9999 
Rif. + Met. + UMF®15+ vs. UMF®15+ treated cells with Subs. Rif. + 
Met. mix 
No > 0.9999 
Rif. + Met. + UMF®15+ mix vs. UMF®15+ treated cells with Subs. 
Rif. + Met. 
No 0.0947 
Rif. + Met. + UMF®15+ mix vs. UMF®15+ treated cells with Subs. 
Rif. + Met. mix 
No > 0.9999 
UMF®15+ treated cells with Subs. Rif. + Met. vs. UMF®15+ treated 
cells with Subs. Rif. + Met. mix 
No 0.8500 
 
 
Differences in mean MIC values between the treatments were observed that were 
statistically significant according to Kruskal-Wallis tests (Table 3.4.5). 
Considering the susceptibility of the SRB to the antibiotics alone, the mean MIC value 
recorded was 22.4 µg/ml for metronidazole, which was not significantly different to the 
mean MIC value of 57.6 µg/ml for rifaximin. Similarly, when the two antibiotics were 
combined in a treatment, the mean MIC value (22.4 µg/ml) was not significantly 
different to that for rifaximin alone or metronidazole alone. The mean MIC value for D. 
indonesiensis fell to 14.4 µg/ml when Manuka UMF®15 honey was included with the 
dual antibiotic treatment of the pure biofilm, however this was not significantly 
different to the metronidazole or rifaximin and metronidazole treatments. The mean 
MIC values for D. indonesiensis changed considerably when the biofilm contained E. coli 
as well as the SRB. The value, 230.4 µg/ml, did not change for treatments with rifaximin, 
metronidazole or the mixture, but dropped significantly to 76.8 µg/ml for the treatment 
with the honey (Table 3.4.5). Interestingly, the addition of honey influenced the MIC 
value for the SRB in mixed culture only. 
Increased sensitivity of D. indonesiensis to the honey and antibiotic treatment was 
achieved by prolonged incubation of the SRB, grown with E.coli, with Manuka UMF®15 
honey for 6 days before the addition of rifaximin and metronidazole. For the pure 
culture biofilm, the mean MIC value for the SRB decreased to 4.8 µg/ml, whereas the 
mean value dropped to 44.8 µg/ml for the mixed biofilm. This reduction for single 
cultures was significant compared to previous treatments with rifaximin and 
metronidazole in mixed cultures (Table 3.4.5). It is feasible, under these circumstances, 
that the honey is preventing the formation and establishment of the biofilm which, in 
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turn, reduces the protection it provides, and increases the sensitivity of the cells to the 
antibiotics, when they are applied.    
 
Figure 3.4.6. The MBC value of rifaximin, metronidozole alone and in combination, 
rifaximin+ metronidozole in the presence of Manuka UMF® 15+ (adding the 
antibiotics and honey simultaneously), rifaximin+ metronidozole in the presence of 
Manuka UMF® 15+ (adding antibiotics after 6 days of incubation with Manuka 
UMF® 15+). The mean values were estimated from 5 independent experiments and are 
shown with standard deviation. Asterisks indicate significant differences (** P ≤ 0.01). 
 
 
The mean MBC values for D. indonesiensis in pure or mixed cultures with E. coli treated 
with the antibiotics, singularly and in combination, with and without Manuka UMF®15+ 
honey are shown in Figure 3.4.6. The overall pattern observed was similar to the one 
described for mean MIC values.  The mean values when the SRB biofilms were treated 
with rifaximin and metronidazole were 51.2 and 70.4 µg/ml, which were not 
significantly different according to Kruskal-Wallis test statistics (Table 3.4.6), while the 
value when the antibiotics were used in combination was 57.6 µg/ml, which was also 
not significantly different to the ones obtained for the rifaximin or metronidazole 
treatments. The MBC values decreased to 14.4 and 7.2 µg/ml when the combined 
antibiotic treatment included Manuka honey UMF®15+ and when the cells were treated 
with Manuka UMF®15+ honey prior to combined antibiotic treatment. Both of these 
treatments produced mean MBC values that were significantly different to the values 
obtained with the other treatments (Table 3.4.6).  
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Table 3.4.6.  A comparison of the MBC values obtained when different concentrations 
antibiotics and UMF®15+ were applied using Kruskal-Wallis test statistics. Asterisks 
indicate significant differences (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
 
Treatment Significant p-value 
Rif. vs. Rif. mix No > 0.9999 
Rif. vs. Met. No > 0.9999 
Rif. vs. Met. mix No 0.6438 
Rif. vs. Rif. + Met. No > 0.9999 
Rif. vs. Rif. + Met. mix No 0.6438 
Rif. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Rif. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. vs. UMF®15+ treated cells with Subs. Rif. + Met. No > 0.9999 
Rif. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. mix vs. Met. No > 0.9999 
Rif. mix vs. Met. mix No > 0.9999 
Rif. mix vs. Rif. + Met. No > 0.9999 
Rif. mix vs. Rif. + Met. mix No > 0.9999 
Rif. mix vs. Rif. + Met. + UMF®15+ Yes 0.0112 (*) 
Rif. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0017 (**) 
Rif. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No 0.6844 
Met. vs. Met. mix No > 0.9999 
Met. vs. Rif. + Met. No > 0.9999 
Met. vs. Rif. + Met. mix No > 0.9999 
Met. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Met. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. No 0.8698 
Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Met. mix vs. Rif. + Met. No 0.6638 
Met. mix vs. Rif. + Met. mix No > 0.9999 
Met. mix vs. Rif. + Met. + UMF®15+ Yes 0.0044 (**) 
Met. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0006 (***) 
Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No 0.3526 
Rif. + Met. vs. Rif. + Met. mix No 0.6638 
Rif. + Met. vs. Rif. + Met. + UMF®15+ No > 0.9999 
Rif. + Met. vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. + Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. No > 0.9999 
Rif. + Met. vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No > 0.9999 
Rif. + Met. mix vs. Rif. + Met. + UMF®15+ Yes 0.0044 (**) 
Rif. + Met. mix vs. Rif. + Met. + UMF®15+ mix No > 0.9999 
Rif. + Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. Yes 0.0006 (***) 
Rif. + Met. mix vs. UMF®15+ treated cells with Subs. Rif. + Met. mix No 0.3526 
Rif. + Met. + UMF®15+ vs. Rif. + Met. + UMF®15+ mix No 0.2704 
Rif. + Met. + UMF®15+ vs. UMF®15+ treated cells with Subs. Rif. + 
Met. No > 0.9999 
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Treatment Significant p-value 
Rif. + Met. + UMF®15+ vs. UMF®15+ treated cells with Subs. Rif. + 
Met. mix No > 0.9999 
Rif. + Met. + UMF®15+ mix vs. UMF®15+ treated cells with Subs. Rif. 
+ Met. No 0.0596 
Rif. + Met. + UMF®15+ mix vs. UMF®15+ treated cells with Subs. Rif. 
+ Met. mix No > 0.9999 
UMF®15+ treated cells with Subs. Rif. + Met. vs. UMF®15+ treated 
cells with Subs. Rif. + Met. mix No > 0.9999 
 
 
 
The mean MBC values increased when the treatments were against mixed culture 
biofilms of D. indonesiensis and E. coli. When rifaximin was used the mean value was 
204.8 µg/ml, which increased to 230.4 µg/ml when metronidazole was used. When the 
antibiotics were used in combination the mean MBC value was 230.4 µg/ml. All of these 
values were not significantly different according to Kruskal-Wallis test statistics (Table 
3.4.6). The mean values dropped to 115.2 µg/ml when Manuka honey UMF®15+ was 
included in the treatment, and to 44.8 µg/ml when the cells were treated with Manuka 
honey UMF®15+ before antibiotic treatment.  
The differences between the mean MBC values for the SRB in pure or mixed culture 
biofilms were not significantly different when each treatment was compared (Table 
3.4.6). However, there was a trend of the mixed biofilms having greater MIC and MBC 
mean values than those for D. indonesiensis alone, indicating that the SRB strain was less 
susceptible to the antibiotics and antibiotics/Manuka honey combinations when in 
mixed culture.  
 
A similar pattern of significance, as described for figure 3.4.5, when comparing mixed 
cultures with rifaximin and metronidazole to single cultures with honey was observed. 
With a significant reduction for all values observed following the addition of Manuka 
honey. The lowest MBC values were obtained when Manuka honey UMF®15+ was used 
to treat the cells in either the pure or mixed biofilm before antibiotic treatment. 
Desulfovibrio species and E. coli have been reported to be sensitive to rifaximin and 
metronidazole (Huang & DuPont, 2005; Finegold et al., 2009; Löfmark et al., 2010), and 
this appears to be true for D. indonesiensis, however it also appears that the SRB 
becomes less susceptible to both antibiotics when it is co-cultured with E. coli. How this 
sensitivity is altered is unknown, but there does appear to be a relationship between 
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these organisms as both grow together in the human colon and they have both been 
implicated in the pathogenesis of UC (Burke & Axon, 1987; Pitcher et al., 2000). E. coli 
strains have a known ability to increase the cell density of other organisms by 
producing a signalling factor (Scott, 2002). This signalling factor may be part of a 
quorum sensing system or the production of an auto-inducer for growth. If the growth 
of the SRB is stimulated by the presence of E. coli, it is possible that this could lead to the 
greater production of hydrogen sulfide, which might act against the antibiotics.     
 
In order to determine if the inhibitory effect of Manuka honey was due to its 
antimicrobial agent, Methylglyoxal (MGO) (Adams et al., 2008; Mavric et al., 2008; 
Müller et al., 2013), rather than some other compound found in the honey, the effect of 
MGO on the pure and mixed cultures was examined.  
 
 
 
Figure 3.4.7. The MIC value of Methylglyoxal (MGO) of D. indonesiensis as pure and 
mixed culture with E.coli BP. The mean values were estimated from 5 independent 
experiments and are shown with standard deviation. Asterisks indicate significant 
differences (** P ≤ 0.01). 
 
The mean MIC value for D. indonesiensis in pure culture was 0.08% v/v which increased 
to 0.19% v/v when the SRB was co-cultured with E. coli (Figure 3.4.7).  This indicated 
that MGO had an antimicrobial effect on the pure and the mixed culture of D. 
indonesiensis. The difference in MIC level between the pure D. indonesiensis and D. 
indonesiensis co- cultured with E. coli BP was statistically significant according to Mann-
Whitney test statistics (P = 0.008) (Table 3.4.7). 
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Table 3.4.7. A comparison of the MIC values obtained when different concentrations of 
Methylglyoxal (MGO) were applied using Mann-Whitney test statistics. Asterisks 
indicate significant differences (** P ≤ 0.01). 
 
Comparison Significant p-value 
MGO: SRB vs SRB + EC Yes 0.008 (**) 
 
The pattern recorded here was similar to the one observed with Manuka honey, where a 
decrease in susceptibility occurred when the SRB was co-cultured with E. coli. This 
result thus agreed with previous research work showed that the antimicrobial activity 
of Manuka honey against bacterial cultures is due to the presence of the unique MGO as 
the active antimicrobial component in Manuka honey (Adams et al., 2008; Müller et al., 
2013) 
 
 
 
Figure 3.4.8. The MBC value of Methylglyoxal (MGO) of D. indonesiensis as pure and 
mixed culture with E.coli BP. Mean MBC values were estimated from 5 independent 
experiments and are shown with standard deviation. Asterisks indicate significant 
differences (* P ≤ 0.05). 
 
 
The mean MBC values of MGO for D. indonesiensis in pure and mixed culture were 0.14% 
v/v and 0.23% v/v respectively (Figure 3.4.8), mirroring the pattern observed for the 
mean MIC values of MGO and Manuka honey. The difference between the two values 
was significant according Mann-Whitney analysis (P = 0.047) (Table 3.4.8). The 
magnitude of change, however, was not as great as observed for the Manuka honey.  
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Table 3.4.8.  A comparison of the MBC values obtained when different concentrations 
of Methylglyoxal (MGO) were applied using Mann-Whitney test statistics. Asterisks 
indicate significant differences (* P ≤ 0.05). 
 
Comparison Significant p-value 
MGO: SRB vs SRB + EC Yes 0.047 (*) 
 
The present study showed that Manuka honey both inhibits as well as disrupts existing 
biofilms both in pure and mixed culture of Desulfovibrio with and without E. coli. The 
effectiveness of this increased with the higher UMF grade of Manuka honey. The 
protection of the SRB by E. coli was observed by a reduction in its susceptibility, 
recorded as increases in mean MIC and MBC values.  The effectiveness of any treatment 
with the antibiotics rifaximin and metronidazole is enhanced if Manuka honey 
UMF®15+ is applied prior to their delivery.  It was also shown that the believed active 
ingredient in Manuka honey, methylglyoxal, inhibited D. indonesiensis in a similar way 
observed by treatment with Manuka honey, suggesting that this is indeed the active 
component. 
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The primary aims of the work described in this thesis were to compare and contrast the 
diversity of bacteria present in the colon of healthy people with that from patients 
suffering from ulcerative colitis with specific reference to SRBs, develop a system to 
enhance the detection of SRBs in natural systems, and to assess the susceptibility of 
Desulfovibrio indonesiensis, cultured alone and co-cultured with Escherichia coli, to 
Manuka honey. 
 
The colon harbours a complex microbial ecosystem, reaching densities of 109- 1012 
cfu/ml (Blaut & Clavel, 2007) that provides anaerobic fermentative of resistant 
starches, dietary fibres and unabsorbed sugars and alcohols, as well as proteins to 
generate short chain fatty acids, acetate, propionate, and butyrate as well as peptides 
and amino acids. Lactic acid, ethanol, succinic acid and formate are important 
intermediates in this breakdown. In addition to these compounds, branch chain fatty 
acids, ammonia, hydrogen sulfide, amines, phenols, indoles and mercaptanes are also 
formed. This requires the cooperative action of different microbial groups. It has been 
estimated that there are approximately 500 different species present in the colon, of 
which 75% are believed to be uncultrable (Duncan et al., 2007). Although great 
diversity of bacterial species and groups exists, dependent upon diet and health, 
approximately 60-80% of colonic or faecal bacteria belong to either the Cytophaga-
Flavobacterium-Bacteroides (CFB) group or to the low GC Firmicutes. The remaining 
20-25% is often represented by members of the Bacteriodetes and 3-5% by high GC 
content Actinomycetes. Proteobacteria usually form a minor component of the colon 
microflora.         
 
In this study a number of molecular techniques were employed to assess the molecular 
diversity of bacteria from the colon of healthy people and UC suffers. These included 
PCR-DGGE, and the cloning and sequencing of 16S rRNA gene fragments, the dsr gene 
fragments from colon derived DNA.  PCR/DGGE profiles were used initially as a rapid 
method to compare the bacterial diversity associated with UC patients and healthy 
individual samples and the result showed that there was a change in microbiota 
composition associated with the disease. 
The 16S rRNA sequences from the healthy person provided a broad diversity that 
included members from the Bacteriodaceae, Clostridiaceae, Coriobacteriaceae, 
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Ruminococcaceae, Eggerthellaceae, Lactobacilaceae, Porphyromonadaceae, and the 
Enterobacteriaceae, with the greatest proportion being members of the Bacteriodaceae 
followed by the Clostridiaceae and Ruminococcaceae. The frequency of 
Enterobacteriaceae was approximately 12 %, which is greater than previously reported 
(Duncan, et al., 2007) but it is clear that this group is not one of the pre-dominant ones. 
This level of diversity is consistent with previous reports (Eckburg et al., 2005; Rajilić-
Stojanović, 2007; Bik et al., 2010) and reflects the metabolic complexity expected of 
bacteria present in the colon. In contrast, the mucosal bacterial community of the colon 
from UC patients was not so diverse, with a total reduction in bacteria belonging to the 
Firmicutes and Bacteriodetes and an increase in the number belonging to the 
Enterobacteriaceae, in particular species of Citrobacter and Enterobacter.  
 
It is tempting to speculate that the observed dysbiosis in the microflora from UC 
patients maybe characteristic, and could be used as an initial marker for diagnosing the 
UC disease, however not all studies report such a reduction. Hansen et al (2011) 
reported a reduction in alpha diversity of colonic bacteria for suffers of Crohn’s Disease 
(CD) but not for those with ulcerative colitis. In this study, 37 patients (13 with CD, 12 
with UC and 12 healthy) had mucosal biopsies, from which DNA was extracted and 
sequenced for 16S rRNA gene spanning V3 to V6 regions. Sequences representing 
members of the Proteobacteria represented 10 % of the total for UC patients, which was 
higher than that for CD patients and healthy people but the proportion for Firmicutes 
and Bacterioidetes remained the same. In the present study biopsies from 4 patients 
were analysed, which is less than the number examined in Hansen et al (2011). It is 
possible that if a greater number of samples were analysed the recorded change in 
diversity might have been less. Lennon et al (2014) reported that the mucus gel layer in 
UC suffers is thinner than that of healthy people. This reduction of the layer is 
accompanied by an increase of bacteria that can degrade the gel, such as species of 
Rumminococcus, and the reduction in butyrate producing bacteria. The degradation of 
the mucus layer releases other compounds that support the growth of other bacteria, 
such as SRBs through the release of oxidised sulphur compounds.       
 
The reduction in 16S rRNA molecular diversity in UC patients reported in the current 
study clearly showed an increase in the proportion of Enterobacteriaceae at the expense 
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of other bacteria commonly associated with a healthy functioning colon; however it did 
not show the presence of any SRB sequences. Sulfate reducing bacteria have been 
implicated in UC condition through the production of hydrogen sulphide (Pitcher & 
Cummings, 1996; Rowan et al., 2009). The presence of hydrogen sulfide in the colon 
(Jørgensen & Mortensen, 2001; Linden et al., 2010); Bacteria degradation of cysteine 
and methionine results in the formation of hydrogen sulfide, presence as HS- at neutral 
pH, and the build up of this in the colon is toxic, inhibiting butyrate oxidation. Hydrogen 
sulfide can also be generated by the oxidation of lactate, ethanol, succinate and H2 when 
sulfate is reduced by SRBs. Oxidised forms of sulfur are present in foods, and these can 
act as the substrate for sulfide production. The absence of 16S rRNA gene sequences for 
any SRB does not mean that they were not present in the biopsy samples, it is possible 
that they were present but at low densities. Under these conditions, bacteria present at 
greater cell densities would be always preferentially detected. In order to test whether 
SRB were present in the mucosa biopsies different target genes were chosen.     
 
Dissimilatory sulphite reductase (DSR) is a key enzyme produced by SRBs, and the dsr 
AB genes make suitable targets for detection of these bacteria ( Dar et al., 2007). Few 
studies have been conducted to detect mucosa associated SRBs in the colon of UC 
patients (Zinkevich & Beech, 2000; Fite et al., 2004), most studies have limited the 
detection of SRBs to faeces. Although the targeting of dsr A gene, including real time 
PCR, to detection SRBs has been used in healthy human fecal (Christophersen et al., 
2011), it has not been used to detect them in colonic mucosa of UC patients. A variety of 
morphologically and nutritionally different SRBs have been isolated from human faeces, 
which belong to 5 genera with Desulfovibrio being the pre-dominant genus (Gibson et 
al., 1988c). The recovery of dsr A gene sequences from the 4 biopsies of UC patients 
revealed a diverse range of Desulfovibrio species, including Desulfovibrio intestinalis, 
Desulfovibrio desulfuricans, Desulfovibrio burkinensis, Desulfovibrio carbinolicus, 
Desulfovibrio magneticus, but with limitations for other SRB genera.  
 
The detection of Desulfovibrio species directly with mucosal biopsy samples agrees with 
the study of Loubinoux et al. (2002) where it was observed that the incident of SRBs 
(specifically Desulfovibrios) was higher in the faeces of IBD (CD and UC) patients than 
healthy indivuals. It is also in agreement with (Rowan et al., 2010) who used laser 
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capture microdisection and PCR to show that the Desulfovibrio increased in colonic 
mucosal biopsies from acute and chronic UC patients, It would appear that the mucosal 
layer undergoes a dysbiosis in UC patients where the proportion of Enterobacteriaceae 
and the number of Desulfovibrio species increases. 
 
A possible link between SRB and colonic epithelial inflammation has been suggested, as 
a result of hydrogen sulphide production but with little supporting evidence (Rowan et 
al., 2009). Desulfovibrio sp are well documented as possible causative agent of UC and in 
some extreme cases they may cause clone cancer in the individual. This makes 
investigate the role of SRB important bacteria of interest. However, the growth of SRB is 
slow and making the early detection these bacteria at low cell density very difficult after 
their recovery from natural habitats (human colon) and therefore controlling these 
bacteria is important. 
 
The detection of SRBs and their control was investigated by the development of a 
biochip to allow rapid screening and by identifying dietary additions for which SRBs 
have susceptibility. The challenging step in biochip design is the selection of probes 
with identical hybridisation characteristics. A novel cassette based methodology, which 
allowed for a rapid validate the de-novo designed probes and those which identified 
from the literature for fine-tuning of biochips, was used (Zinkevich et al., 2014) to 
assess the biochip. After probe evaluation, DNA from four UC biopsies and one healthy 
control were hybridised against the biochip to assess changes in bacterial population 
number and heterogeneity. It was not possible to identify a particular species or genera 
of bacteria that had a significant association with UC or confirm the role for SRB, 
although this may be due to the relatively small samples number of the study. However, 
several key trends were identified which may prove useful for further research. Possible 
variations in levels of Enterobacteriaceae were detected between UC patients and the 
control. Additionally, a potentially novel change in the relative amounts of D. piger and 
D. gigas were detected between UC patients and the control. Whilst, unable to identify a 
pathological mechanism in the literature this novel description requires further 
investigation. To summarize; whilst unable to identify a single species or genera of 
bacteria which underlies the eaitology of UC, this project has advanced the field and 
identified several possible strands of future development. Namely, more detailed 
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investigation into identifying particular Enterobacteriaceae species along with further 
investigation into the interaction between D. piger and D. gigas may prove informative. 
However, the precise role of SRB in UC remains unclear. Additionally, the novel, rapid 
biochip/cassette based screening method represents proof of concept study and should 
prove useful to expand the sample size of this research, for further validation to confirm 
the clinical usefulness of this test and also for other researchers for UC diagnosis before 
any test could be rolled out. As our understanding of the dysbioisis associated with UC 
expands, a methodology to rapidly optimize probes for simultaneous detection bacterial 
species and genera from UC patient samples will prove invaluable.  
 
Previous observation have shown that there is substantial association between SRBs 
and E. coli in the gut (Unpublished), where SRB always seem to be associated with the 
presence of enteric bacteria, such as E. coli, in colonic mucosa tissue. In addition to this 
it has been observed that the colonic bacteria E.coli can induce the recovery and growth 
of SRBs from the colon at low cell density. Co-culturing of SRBs with E. coli might 
provide a method to enhance its growth so that early detection of these bacteria can be 
made. SRB may play an important role in the eitology of UC and the key to 
understanding the role of SRB in UC could be in determining the real quantity of SRB 
between UC and non UC patients. The results obtained in this study take a closer look at 
their relationship and further emphasizes the effect of E. coli on the aiding the growth 
and survival of SRBs and how they can exist together in the colon as model in vitro.   
 
SRBs are well known to act co-operatively with other organisms as a result of their need 
to act synergistically when searching for exogenous electron acceptors (Walker et al., 
2009). The nature of the relationship between E. coli and SRBs is believed to one where 
the enteric stimulates the growth of the SRB. This is not unusual, E.coli has been 
described to enhance growth of other organisms, such as Chorella (Higgins et al., 2015).  
Co-culturing of Desulfovibrio indonesiensis with Escherichia coli BP resulted in increased 
levels of detection of the SRB. The strain of E.coli, recovered from an UC biopsy sample, 
was able to promote the growth of the SRB from aged pre-cultures, even when the SRB 
was present in low densities. This growth study was supported by changes in the levels 
of dsrA and apsA transcripts in the cultures detected by qPCR.  
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This observation is novel and has not been previously reported, and the co-culturing 
appears to give a novel way to detect SRBs.    
 
The control of SRBs can be achieved by treatment with antibiotics. However the mucosa 
associated bacteria are able to form biofilms which increases their chance of survival at 
high concentrations of antibiotics. This may be a contributing factor to the observation 
that UC patients receiving antibiotic treatment do not necessarily show any 
improvements in their condition. The low level of success in using antibiotics to treat UC 
suffers may be improved if the biofilm associated with the mucosal layer could be 
disrupted prior to treatment. The use of honey to do this was an option here, because 
honey has been widely used in treating bacterial infection (Badawy et al., 2004;  Mandal 
& Mandal, 2011; Maddocks et al., 2013). No such investigation examining the effect of 
honey on the bacteria involved in UC and mixed biofilms in combinations with 
antibiotics has previously been reported.  
 
The effect of Manuka honey of various strengths with and without rifaximin and 
Metronidazole antibiotics on the growth of D. indonesiensis alone and with E. coli was 
examined. It was observed that the addition of honey to pure biofilm D. indonesiensis 
reduced its MIC and MBC values in comparison to D. indonesiensis with E. coli, and that 
the strength of this reduction was associated with the higher grades of Manuka honey, 
in particular UMF®25+. It was shown also that the addition of the antibiotics to the 
bacterial culture after incubation with Manuka honey improved the antibiotics effect on 
the growth of pure D. indonesiensis biofilms and slightly for mixed D. indonesiensis with 
E.coli biofilms. The honey was able to inhibit the development of biofilms rather than 
inhibit the growth of establish biofilms this finding suggest that after early detection of 
bacteria causing the disease the honey before starting the antibiotics course will 
improve the efficiency of antibiotics used for treating the condition. This study thus 
showed that although co-culturing of SRB with E. coli increases the detection level of 
SRB in culture making isolation, identification quantification effective, it also increases 
its resistance to antimicrobials thus, increasing their survival  
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In conclusion, SRB has been linked to UC as possible causes by numbers of 
investigations, but whether these bacteria are causative agents, or other bacteria such 
as E. coli taking an advantage of changes in the gut intestinal bacteria and promoting the 
SRB growth; will be the main challenge for the future research. 
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Ulcerative colitis is a well characterized medical condition associated with bacterial 
dysbiosis, where changes in the intestinal bacterial population influence an individual’s 
health (Chen et al., 2017). It is possible that the establishment of a particular bacterial 
community is a predisposing factor for this disorder. Previous work has focussed on 
evaluating dynamic changes in the microbiome of the colon or identifying the 
predominant species present. Individual dietary habits can influence the microflora of 
the colon, and may have implications for the overall pathogenicity of the disease. The 
present study consisted of two separate, yet contextually highly relevant, studies 
investigating the role of sulfate reducing bacteria in the overall pathogenesis of the UC 
and the role that Manuka honey might have on the colon resident bacterial populations 
when used to treat SRBs. Kumamoto (2016) has previously reported that rare gut 
microbes might have a significant role in the inflammatory bowel disease. This study 
mainly considered the fungal population, but data presented in this thesis suggests that 
it may be equally true for the bacterial population. Here, the crucial role of SRB as 
producers of hydrogen sulfide fits well with the notion that microbes with a low 
population density might have a significant impact on the pathogenesis of UC disease. 
The microbial population changes observed in this study revealed that members of the 
Enterobacteriaceae predominated the colon in UC suffers, reflecting an overall reduction 
in bacterial diversity, while there was also an increase in species of Desulfovibrio. 
Although a reduction in bacterial diversity has been previously observed in UC suffers, 
the link between the enterics and SRBs has not been reported, particularly the induction 
of Desulfovibrio species growth in the presence of Escherichia coli. Nevertheless, to make 
these findings more meaningful, there is a need for further study relevant to this aspect.  
 The samples obtained for this study were colonic biopsies from a healthy 
individual or UC suffers. Furture work should focus on samples from inflamed 
and non-inflamed regions of biopsies from the same patient, and from patients 
who are in the same stage of the disease. This would allow the identification of 
specific strains that might be associated with the development of the disease. 
 Biopsy samples from different colonic regions of the same patient and taken at 
different stages of the disease would also allow an assessment how SRB profiles 
can change, and if there is link between particular SRB strains and bacterial 
population with UC pathogenesis. 
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 The potential relationship, commensal or symbiotic, between SRBs and E.coli 
needs to be investigated further. This is probably best approached by studying 
the association of bacterial strains, isolated from UC suffers, in animal model 
systems. By growing the strains together in vitro or in germ free animal models it 
would be possible to check whether they could induce inflammation to the model 
tissue, allowing this information to be translated to a clinical settings.  
 The co-culture of SRB strains with different organisms isolated from UC patient 
at different disease stages might allow the identification of their interactions 
leading to colonisation, and the reduction in bacterial diversity. This approach 
might answer the questions whether different strains of SRB can transmit the 
disease phenotype and if some bacteria can improve or prevent the disease. 
 H2S is the major byproduct of SRB growth that affects the mucosa layer of human 
colon leading to the inflammation. It is suspected that anything that promotes 
SRB growth will lead to an increase in the concentration of hydrogen sulphide 
production. This needs to be tested in situ. 
 The reduction in bacterial diversity associated with UC has been reported on a 
number of occasions (Zoetendal et al., 2002; Ott et al., 2004 ;Rigottier-Gois, 2013; 
Wang et al., 2014; Carding et al., 2015), however the reduction observed in this 
study was extreme, resulting in only members of the Enterobactericeae and 
Desulfovibrio being present from UC biopsies. This may reflect a low sequence 
sampling effort or that the change in diversity is progressive. In addition to this, 
the relationship between E. coli and Desulfovibrio species, described in this 
thesis, suggests a mechanism for the diversity reduction observed in the SRB 
group. The possible progressive nature in the reduction of diversity at the 
general and specific levels can be investigated further by evaluating the 
relationship between diet and the microbial diversity of UC sufferers at different 
levels of the disease. 
 The use of Manuka honey and its impact on controlling bacterial population 
existing in the form of biofilms is intriguing and is of future research interest. For 
the future direction clinical trials worth to conducted to evaluate the beneficial 
impact of Manuka honey with and without antibiotics among patients suffering 
from UC.
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Appendix 1: Growth media composition 
 
Growth media composition used in this study is described below.  
 Vitamin Medium, Vitamin Medium with iron and Vitamin medium  
with reduced iron (VM, VMI, VMR medium)  
Medium was prepared as follows (composition per litre) (Table A.1.1). 
Table A.1.1: VM, VMI and VMR medium composition. 
 
Compound g/liter 
Potassium dihydrogen phosphate 
(KH2PO4) 
 
 
0.5 g 
Ammonium chloride (NH4Cl) 
 
1 g 
Sodium sulphate (Na2SO4) 4.5 g 
Calcium chloride (CaCl2∙2 H2O) 0.04 g 
MgSO4∙7 H2O 0.06 g 
FeSO4∙7 H2O 0.004 g* 
Sodium citrate (Na3C6H5O7∙2 H2O) 0.3 g 
NaCl 25.0 g 
Casamino acids 
 
2.0 g 
Tryptone  
 
2.0 g 
Sodium lactate (NaC3H5O3) 6.0 g 
 
* FeSO4∙7 H2O for VMI medium 0.5 g and for VMR  0.05 g 
Medium pH was adjusted to 7.5 by adding NaOH. Sterile trace elements (1 ml stock 
solution) (Table A.1.2) and 1 ml sterile vitamin stock solution (Table A.1.3) were added 
to the medium. 10 ml vials were filled with a medium prepared. The medium was 
subsequently degassed with an O2 free-N2 flux to achieve anaerobic condition, the vial  
was covered with a stopper and crimp with aluminum and autoclaved for 30 min at 
121°C. 
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Table A.1.2: Modified Wolfe’s mineral elixir (per liter). 
Compound g/liter 
C6H9NO6  
 
1.5 g 
MgSO4∙7 H2O 3.0 g 
MnSO4∙ H2O 0.5 g 
NaCl 1.0 g 
FeSO4∙7 H2O 0.1 g 
CoSO4∙7 H2O 0.1 g 
NiCl2∙6 H2O 0.1 g 
 
CuCl2∙2 H2O 0.1 g 
 
ZnSO4∙7 H2O 0.1 g 
 
CuSO4∙5 H2O 0.01 g 
 
AlK(SO4) ∙12 H2O 0.01 g 
 
H3BO3 0.01 g 
 
NaMoO4∙2 H2O 0.01 g 
 
Na2SeO4 0.001 g 
 
The pH was adjusted to 6,5 to 7 then Distilled water was added up to 1L. 
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Table A.1.3: Vitamin stock solution.  
   Vitamins  Weight 
Vitamin C, ascorbic acid 10 g 
Vitamin B1, thiamine 60 mg 
Vitamin B2, riboflavin 20 mg 
Vitamin B12 5 mg 
Vitamin B3, nicotinic acid 50 mg 
Vitamin B5, D-pentanthonic acid 60 mg 
Vitamin B6, pyridoxime 61 mg 
Vitamin H , d-biotin 1 mg 
Distilled water 100 ml 
 LB medium  
LB Medium was prepared as follows (composition per litre) (Table A.1.4).  
 
Table A.1.4: Composition of LB medium. 
Compound Weight 
Sodium Chloride 10 
Yeast Extract 5 
Tryptone 10 
 
The pH for medium was adjusted to 7.2 using 5M NaOH; then autoclaved at 121°C for 30 
minutes. 
 MacConkey agar 
     Table A.1.5: Composition of MacConkey agar. 
Compound Weight 
MacConkey agar powder 52 
Distilled  H2O Up to 1L 
 
The MacConkey agar was dissolved; then autoclaving at 121⁰C for 30 minutes. 
Approximately 20 ml of MacConkey agar was poured into each Petri dish. 
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Appendix 2: Phylogenetic analysis 
 
 
Table A.2.1. Accession numbers of 16SrRNA sequences used for Bacteriodes phylogenic 
tree construction  
 
Bacteria Accession number 
Bacteroides thetaiotaomicron (ATCC 29148) 16S ribosomal RNA L16489.1 
Bacteroides vulgatus 16S ribosomal RNA gene, partial sequence M58762.2 
Bacteroides vulgatus strain mpk genome CP013020.1 
Bacteroides fragilis gene for 16S ribosomal RNA, partial cds, 
strain: JCM 17586 
AB618792.1 
Bacteroides dorei strain Z5 16S ribosomal RNA gene, partial 
sequence 
KJ145327.1 
Bacteroides uniformis gene for 16S ribosomal RNA, partial 
sequence, strain: EFEL002 
AB908393.1 
Parabacteroides distasonis gene for 16S ribosomal RNA strain: 
JCM 1294 
AB640686.1 
Parabacteroides goldsteinii strain JCM13446 16S ribosomal RNA 
gene 
EU136697.1 
Bacteroidetes bacterium Smarlab 3301186 16S ribosomal RNA 
gene 
AY538684.1 
B.ovatus 16S rRNA (ATCC 8483T) X83952.1 
Barnesiella viscericola strain C46 16S ribosomal RNA gene NR_041508.1 
Uncultured Bacteroidetes bacterium clone M0035_096 16S 
ribosomal RNA gene 
EF071264.1 
Butyricimonas virosa strain MT12 16S ribosomal RNA gene NR_041691.1 
Parabacteroides merdae 16S ribosomal RNA gene EU722738.1 
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Table A.2.1.Cont 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteria Accession number 
Bacteroides sp. WAL 10018 16S ribosomal RNA gene, partial sequence AY608696.1 
Bacteroides salyersiae strain JCM 12988 16S ribosomal RNA gene, 
partial sequence 
NR_112942.1 
Uncultured Bacteroidetes bacterium clone M0011_019 16S ribosomal 
RNA gene, partial sequence 
EF071259.1 
Bacteroides thetaiotaomicron strain VPI-5482 16S ribosomal RNA gene NR_074277.1 
Bacteroides nordii strain JCM 12987 16S ribosomal RNA gene, partial 
sequence 
NR_112939.1 
Bacteroides sp. Marseille-P2653 partial 16S rRNA gene, strain Marseille-
P2653 
LT558803.1 
Bacteroides distasonis 16S ribosomal RNA M86695.1 
Bacteroides sp. WH2 16S ribosomal RNA gene, partial sequence AY895180.1 
Bacteroides uniformis ATCC 8492 16S ribosomal RNA gene, complete 
sequence 
L16486.1 
Uncultured Bacteroides sp. clone RML172 16S ribosomal RNA gene, 
partial sequence 
KU161522.1 
Bacteroides uniformis strain ZL1 16S ribosomal RNA gene, partial 
sequence 
gb|JN873344.1 
Bacteroides sp. WH302 16S ribosomal RNA gene, partial sequence AY895184.1 
B.fragilis 16S rRNA (ATCC 25285T) X83935.1 
B.caccae 16S rRNA (ATCC 43185T) X83951.1 
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Table A.2.1.Cont 
Bacteria Accession number 
Uncultured Bacteroidetes bacterium clone LI3-81 16S 
ribosomal RNA gene 
GU956524.1 
Barnesiella intestinihominis strain JCM 15079 16S 
ribosomal RNA gene 
NR_113073.1 
Bacteroides fragilis gene for 16S ribosomal RNA, strain: 
JCM 17587 
AB618793.1 
Barnesiella intestinihominis strain JCM 15079 16S 
ribosomal RNA gene 
NR_113073.1 
Bacteroides fragilis gene for 16S ribosomal RNA, strain: 
JCM 17587 
AB618793.1 
Uncultured Bacteroides sp. clone RML151 16S ribosomal 
RNA gene 
KU161501.1 
Bacteroides vulgatus strain W05002A 16S ribosomal RNA 
gene 
KP944149.1 
Bacteroides vulgatus strain 39a-cc-B-5824-ARE 16S 
ribosomal RNA gene, partial sequence 
KR364743.1 
Bacteroides fragilis strain DNF00264 16S ribosomal RNA 
gene, partial sequence 
KU726649.1 
Bacteroides uniformis strain 19006C 16S ribosomal RNA 
gene, partial sequence 
KP944146.1 
Uncultured Bacteroides sp. clone RML172 16S ribosomal 
RNA gene, partial sequence 
KU161522.1 
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                  *       700         *       720         *       740         *       760         *       780         *       8        
AY608696.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
NR_112942. : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
EF071259.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCACACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
NR074277.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
NR112939.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGTTACTGACACTGAGGCTCGAAAGTGTGGGTATCAAAC  
LT558803.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
M86695.1   : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCCAAGCCATTACTGACGCTGATGCACGAAAGCGTGGGGATCAAAC  
AY895180.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTACTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
L16486.1   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATC-AAC  
KU161522.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
JN873344.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
AY895184.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTAGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
X83935.1   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
X83951.1   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
L16489.1   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
M58762.2   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAG-CTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
CP013020.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
AB618792.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
KJ145327.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
AB908393.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
NR126194.1 : GGCGGAACAAGTGAAGTAGCGGTGAAATGCTTAGATATCACTTGGAACCCCGATAGCGAAGGCAGCTTCCCAGGCTCGATCTGACGCTGATGCGCGAGAGCGTGGGTAGCGAAC  
AB640686.1 : GGCGGAATGCGTGGTGTAGCGGTGAAATGCTTAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCCAAGCCATGACTGACGCTGATGCACGAAAGCGTGGGGATCAAAC  
EU136697.1 : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACTCCGATTGCGAAGGCAGCTTACTAAACTATAACTGACACTGAAGCACGAAAGCGTGGGGATCAAAC  
AY538684.1 : GGCGGAACAAGTGAAGTAGCGGTGAAATGCTTAGATATCACTTGGAACCCCGATAGCGAAGGCAGCTTCCCAGGCTCGATCTGACGCTGATGCGCGAGAGCGTGGGTAGCGAAC  
X83952.1   : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTAGACTG--ACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
NR041508.1 : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGCAACGGACGCTGAGGCACGAAAGCGTGGGGATCGAAC  
EF071264.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
NR041691.1 : GGCGGAACAAGTGAAGTAGCGGTGAAATGCATAGATATCACTTGGAACCCCGATAGCGAAGGCAGCTTCCCAGGCTCGTTCTGACGCTGATGCGCGAGAGCGTGGGTAGCGAAC  
EU722738.1 : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACTCCGATTGCGAAGGCAGCTTACTAAACCATAACTGACACTGAAGCACGAAAGCGTGGGGATCAAAC  
GU956524.1 : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGCGACAGACGCTGAGGCACGAAAGCGTGGGTGTCGAAC  
NR_113073. : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGAAACAGACGCTGAGGCACGAAAGCGTGGGTATCGAAC  
AB618793.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
KU161501.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
KP944149.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
KR364743.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
KU726649.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
KP944146.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
KU161522.1 : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
K1         : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
K4         : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
k16        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
k22        : GGCAGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
k28        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
k51        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
k54        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAACTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
p25        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
p26        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
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p64        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
p65        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAACTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
p66        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
p78        : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
p710       : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_k2       : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_k3       : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_k6       : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_k15      : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACTCCGATTGCGAAGGCAGCTTACTAAACCATAACTGACACTGAAGCACGAAAGCGTGGGGATCAAAC  
C_k26      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACCGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_k27      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_L31      : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGAAACAGACGCTGAGGCACGAAAGCGTGGGTATCGAAC  
C_P29      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P44      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P45      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P46      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P48      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAACTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P49      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P61      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P62      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P77      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P82      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P83      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P85      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAACTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P86      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAGCTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P88      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCCTGCTAAACTGCAACTGACATTGAGGCTCGAAAGTGTGGGTATCAAAC  
C_P89      : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_PP210    : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGCGACAGACGCTGAGGCACGAAAGCGTGGGTATCGAAC  
C_P211     : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGCGACAGACGCTGAGGCACGAAAGCGTGGGTATCGAAC  
C_P212     : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P410     : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P412     : GGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTTGCTGGACTGTAACTGACGCTGATGCTCGAAAGTGTGGGTATCAAAC  
C_P611     : GGCGGAATGCGTGGTGTAGCGGTGAAATGCATAGATATCACGCAGAACCCCGATTGCGAAGGCAGCCTGCTAGGGTGCGGCAGACGCTGAGGCACGAAAGCGTGGGTATCGAAC  
C_P27      : GGCGGAACAAGTGAAGTAGCGGTGAAATGCATAGATATCACTTGGAACCCCGATAGCGAAGGCAGCTTCCCAGGCTCGATCTGACGCTGATGCGCGAGAGCGTGGGTAGCGAAC  
             GGCgGAAttcGTGgtGTAGCGGTGAAATGCtTAGATATCACgaaGAACtCCGATtGCGAAGGCAGC   Ct   ctg aaCtGAC  TGA GCtCGAaAGtGTGGGtatCaAAC        
 
Figure A.2.1. Alignment showing the 16SrRNA sequences of known taxa from database belonging to Bacteriodes and those of random 
clones from healthy control.
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Table A.2.2. Accession numbers of 16SrRNA sequences used for Firmicutes phylogenic 
tree construction
Bacteria Accession number 
Clostridium leptum 16S ribosomal RNA M59095.1 
Clostridium sp. MB2-A37 16S ribosomal RNA gene KT935669.1 
Uncultured Clostridium sp. b2-173 16S ribosomal RNA gene gb|JX576090.1 
Ruminococcus bromii strain L2-63 16S ribosomal RNA gene gb|EU266549.1 
Clostridium sp. JCD partial 16S rRNA gene, isolate JCD HG726040.1 
Clostridium boltei partial 16S rRNA gene, strain 16351 AJ508452.1 
Clostridium lavalense strain CCRI-9929 16S ribosomal RNA gene EF564278.1 
Clostridium asparagiforme strain N6 16S ribosomal RNA gene NR_042200.1 
Ruminococcus sp. 14565 partial 16S rRNA gene, strain 14565 AJ315980.1 
Ruminococcus albus 16S ribosomal RNA gene AF079847.1 
Clostridium sp. YIT 12069 gene for 16S rRNA AB491207.1 
Ruminococcus flavefaciens strain JM1 16S ribosomal RNA gene AY445595.1 
Ruminococcus sp. NML 00-0124 16S ribosomal RNA gene EU815223.1 
Clostridium orbiscindens strain AIP162.06 16S ribosomal RNA gene EU541435.1 
Clostridium sp.  gene for 16S ribosomal RNA AB622833.1 
Clostridium bartlettii strain WAL 16138 16S ribosomal RNA gene AY438672.1 
Uncultured Clostridium sp. clone 5.17h43 16S ribosomal RNA gene JN679181.1 
APPENDICES 
250 
 
Table A.2.2. Cont   
Bacteria Accession number 
Clostridium sp. TM-40 gene for 16S rRNA AB249652.1 
Faecalibacterium prausnitzii A2165 a  16S rRNA gene AJ270469.2 
Uncultured Faecalibacterium sp. M4-59 16S ribosomal RNA gene EU530347.1 
Uncultured Faecalibacterium sp. M4-28 16S ribosomal RNA gene EU530316.1 
Clostridium celerecrescens strain AIP 148.09 16S ribosomal RNA gene JQ246092.1 
Clostridium sp. K10 gene for 16S rRNA AB610561.1 
Clostridium lavalense 16S rRNA gene, strain Marseille-P2117 LT223652.1 
Clostridium hathewayi strain 1313 16S ribosomal RNA gene NR_036928.1| 
Clostridium citroniae strain RMA 16102 16S ribosomal RNA gene NR_043681.1 
Blautia coccoides strain DSM 29138 16S ribosomal RNA gene KU196081.1 
Blautia producta strain JCM 1471 16S ribosomal RNA gene NR_113270.1 
Clostridium nexile 16S rRNA gene, strain DSM 1787 X73443.1 
Flavonifractor plautii gene for 16S rRNA sequence, strain: MT42 AB693937.1 
Hungatella hathewayi strain R4 16S ribosomal RNA gene KU234408.1 
Ruminococcus gnavus gene for 16S ribosomal RNA AB910745.1 
Coprococcus eutactus gene for 16S ribosomal RNA D14148.1 
Gemella haemolysans ATCC 10379 16S ribosomal RNA gene L14326.1 
Gemella morbillorum strain 2917B 16S ribosomal RNA gene NR_025904.1 
Gemella sp. oral clone ASCF12 16S ribosomal RNA gene AY923143.1 
Uncultured Gemella sp. DSD10 16S ribosomal RNA gene AY672072.1 
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Table A.2.2. Cont  
Bacteria Accession number 
Roseburia hominis A2-183 16S rRNA gene, type strain A2-183T AJ270482.2 
Parvimonas micra ATCC 33270 16S ribosomal RNA gene AF542231.1 
Peptostreptococcus sp. oral clone FJ023 16S ribosomal RNA gene AY349390.1 
Eubacterium ventriosum strain ATCC 27560 16S ribosomal RNA gene L34421.2 
Eubacterium hallii strain ATCC 27751 16S ribosomal RNA gene L34621.2 
Coprococcus catus gene for 16S rRNA AB038359.1 
Eubacterium siraeum strain ATCC 29066 16S ribosomal RNA gene L34625.2 
Roseburia intestinalis 16S rRNA gene, strain L1-82 AJ312385.1 
Roseburia inulinivorans 16S rRNA gene, type strain A2-194T AJ270473.3 
Eubacterium eligens 16S ribosomal RNA L34420.1 
Clostridium sp. 14774 16S rRNA gene, strain 14774 AJ315981.1 
Butyrate-producing bacterium A2-166 16S rRNA gene AJ270489.1 
Butyrate-producing bacterium A2-175 16S rRNA gene AJ270485.2 
Roseburia faecis strain M6/1 16S ribosomal RNA gene AY804149.1 
Ruminococcus obeum ribosomal RNA (16S rRNA) gene L76601.1 
Ruminococcus torques gene for 16S ribosomal RNA isolate: GIFU 12126 D14137.1 
Subdoligranulum variabile 16S rRNA gene, type strain BI 114T AJ518869.1 
Butyrate-producing bacterium L2-6 16S rRNA gene AJ270470.2 
Dorea formicigenerans strain ATCC 27755 16S ribosomal RNA gene L34619.2 
 
 
 
 
Table A.2.2. Cont  
Bacteria Accession number 
Dialister sp. E2_20 16S ribosomal RNA gene AF481209.1 
Uncultured Dialister sp. clone oral taxon JKAS-116 16S ribosomal RNA 
gene 
JX548458.1 
Anaerostipes hadrus 16S ribosomal RNA gene AY305319.1 
Eubacterium rectale 16S ribosomal RNA L34627.1 
Faecalibacterium prausnitzii strain ATCC 27768 AJ413954.1 
L.lactis ribosomal RNA encoding 16S ribosomal RNA, transfer RNA X64887.1 
Lactococcus lactis subsp. lactis strain NM152-3 16S ribosomal RNA 
gene 
HM218600.1 
Streptococcus mitis 16S ribosomal RNA gene AF003929.1 
Streptococcus sp. 2418 16S ribosomal RNA gene JN590018.1 
Streptococcus oralis Uo5 strain Uo5 16S ribosomal RNA NR_102809.1 
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                       *       820         *       840         *       860         *       880         *       900         *          
M59095.1   : GAAGTAGAGG-TAGGCGGAATT-CCCNGTGTAGCGGT-AAATGCGTAGAGATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCTTT-AACTGACGCTGAAGCA  
KT935669.1 : GAAGTAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGAAATGCGTAGAGATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGGCTTT-AACTGACGCTGAGGCA  
JX576090.1 : GAAGTAGAGG-CAGGTGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGAGATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCA  
EU266549.1 : GAAGTAGAGG-CAGGCGGAATT-CCCCGTGTAGCGGTGAAATGCGTAGAGATGG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCA  
HG726040.1 : GAAGTAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGAAATGCGTAGAGATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCTTT-AACTGACGCTGAGGCA  
AJ508452.1 : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGTTGAGGCT  
EF564278.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
NR_042200. : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
AJ315980.1 : GAAGTAGAGG-CAGGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCT  
AF079847.1 : GAAGTAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-TCAGTGACGAA-GGC-GGCTTACT-GGGCTTT-AACTGACGCTGAGGCT  
AB491207.1 : GAAGTAGAGG-CAGGCGGAATT-CCGAGTGTAGCGGTGAAATGCGTAGATATTC-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-TACTGACGCTGAGGCT  
AY445595.1 : GAAGTAGAGG-TAAGCGGAATT-CCTGGTGTAGCGGTGAAATGCGTAGATATCA-GGAGGAACA-CCGGTGGCGAA-GGC-GGCTTACT-GGGCTTT-TACTGACGCTGAGGCT  
EU815223.1 : GAAGTAGAGG-TTGGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-TCAGTGGCGAA-GGC-GGCCAACT-GGGCTTT-TACTGACGCTGAGGCT  
EU541435.1 : GCTGGAGAGG-CAATCGGAATT-CCGTGTGTAGCGGTGAAATGCGTAGATATAC-GGAGGAACA-CCAGTGGCGAA-GGC-GGATTGCT-GGACAGT-AACTGACGCTGAGGCG  
AB622833.1 : GCTGGAGAGG-CAATCGGAATT-CCGTGTGTAGCGGTGAAATGCGTAGATATACGGAGGGAACA-CCAGTGGCGAA-GGCGGGATTGCTGGGACAGT-AACTGACGCTGAGGCG  
AY438672.1 : GCAGGAGAGG-AGAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTAGCGAA-GGC-GGCTCTCT-GGACTGT-AACTGACGCTGAGGCA  
JN679181.1 : GCAGGAGAGG-AGAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTAGCGAAGGGC-GGCTCTCT-GGACTGT-AACTGACGCTGAGGCA  
L76600.1   : GAAGTAGAGG-CAGGCGGAATT-CCCCGTGTAGCGGTGAAATGCGTAGAGATGG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCA  
EU530308.1 : GAAGTAGAGG-CAGGCGGAATT-CCCCGTGTAGCGGTGAAATGCGTAGAGATGG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCA  
EU728796.1 : A-AGTAGAGG-CAGGCGGAATT-CCCCGTGTAGCGGTGAAATGCGTAGAGATGG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGGCTTT-AACTGACGCTGAGGCA  
M59112.2   : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CNAGTGGCGAA-GGC-GACTTACT-GGACGAT-AACTGACGTTGAGGCT  
X76747.1   : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGTTGAGGCT  
HM008264.1 : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGTTGAGGCT  
AF262238.1 : GTCGGAGAGG-CAGGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGACGAT-GACTGACGTTGAGGCT  
AF028349.1 : GTCGGAGAGG-CAGGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGACGAT-GACTGACGTTGAGGCT  
AB117566.1 : GTCGGAGAGG-CAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTGCT-GGACGAT-GACTGACGTTGAGGCT  
JN713312.1 : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
NR036800.1 : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
HM235650.1 : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
X73441.1   : GCAGGAGAGG-ATCGTGGAATT--CCTGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGGTCT-GGCCTGT-AACTGACGCTCATTCC  
AY699288.1 : GCAGGAGAGGAATCGTGGAATTCCCATGTGTAGCGGTGAAATGCGTAGATATATGGGAGGAACA-CCAGTGGCGAAGGGC-GACGATCT-GGCCTGCAAACTGACGCTCAGTCC  
NR119286.1 : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGT-AACTGACGCTCAGTCC  
FJ538172.1 : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
AB249652.1 : GCATCAGAGG-ATCGCGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GGCGGTCT-GGGGTGC-AGCTGACGCTCAGTCC  
AJ270469.2 : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
EU530347.1 : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
EU530316.1 : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
JQ246092.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
AB610561.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
LT223652.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
NR036928.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
NR043681.1 : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGTTGAGGCT  
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KU196081.1 : GCCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGGT-AACTGACGTTGAGGCT  
NR113270.1 : GCCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGGT-AACTGACGTTGAGGCT  
X73443.1   : GTCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-CACTGACGTTGAGGCT  
AB693937.1 : GCTGGAGAGG-CAATCGGAATT-CCGTGTGTAGCGGTGAAATGCGTAGATATAC-GGAGGAACA-CCAGTGGCGAA-GGC-GGATTGCT-GGACAGT-AACTGACGCTGAGGCG  
KU234408.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
JQ271545.1 : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
AB910745.1 : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
D14148.1   : ACAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GACTTACT-GGACTGC-TACTGACACTGAGGCA  
L14326.1   : GCAGGAGAGA-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTTT-GGCCTGT-AACTGACACTGAGGCG  
NR025904.1 : GCAGGAGAGA-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTTT-GGCCTGT-AACTGACACTGAGGCG  
AY923143.1 : GCAGGAGAGA-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTTT-GGCCTGT-AACTGACACTGAGGCG  
AY672072.1 : GCAGGAGAGA-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAGGAACACCCAGTGGCGAA-GGC-GGCTTTTT-GGCCTGT-AACTGACACTGAGGCG  
AJ270482.2 : GTCGGAGGGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-TACTGACGCTGAGGCT  
AF542231.1 : GAAGGAGAGG-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAATA-CCGGTGGCGAA-GGC-GACTTTCT-GGACTTT-TACTGACGCTCAGGTA  
AY349390.1 : GAAGGAGAGG-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAATA-CCGGTGGCGAA-GGC-GACTTTCT-GGACTTT-TACTGACGCTCAGGTA  
L34421.2   : GTCGGAGGGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCGGTGGCGAA-GGC-GGCTTACT-GGACGAT-TACTGACGCTGAGGCT  
_L34621.2  : ACAGGAGAGG-CAGGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTGCT-GGACTGT-TACTGACACTGAGGCA  
AB038359.1 : TCAGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGA-CAATGACGCTGAGGCT  
L34625.2   : GAAGTAGAGG-CAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTGCT-GGCTTTT--ACTGACGCTGAGGCT  
AJ312385.1 : GTCGGAGGGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-TACTGACGCTGAGGCT  
AJ270473.3 : GTCGGAGGGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGCTGAGGCT  
L34420.1   : GCAGGAGGGG-TGAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTCACT-GGACTGT-AACTGACACTGAGGCT  
AJ315981.1 : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGT-AACTGACGCTCAGTCC  
AJ270489.1 : ACAGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACTGA-AACTGACACTGAGGCA  
AJ270485.2 : TCAGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAG-GGCGAA-GGC-GGCTTACT-GGACTGA-CAATGACGCTGAGGCT  
AY804149.1 : GTCGGAGGGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGCTGAGGCT  
L76601.1   : GCCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGGT-AACTGACGTTGAGGCT  
D14137.1   : GT-GGAGAGG--TAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
AJ518869.1 : AGTGCAGAGG-TAGGTGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GACCTACT-GGGCACC-AACTGACGCTGAGGCT  
_AJ270470. : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCA-TGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
L34619.2   : GTCGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGC-TACT-GGACGAT-GACTGACGTTGAGGCT  
AF481209.1 : ATCGGAGAGG-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAAGAACA-CCGGTGGCGAA-GGC-GACTTTCT-GGACGAA-AACTGACGCTGAGGCG  
JX548458.1 : ATCGGAGAGG-AAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGAGATTA-GGAAGAACA-CCGGTGGCGAA-GGC-GACTTTCT-GGACGAA-AACTGACGCTGAGGCG  
AY305319.1 : GCAGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-TCAGTGGCGAA-GGC-GGCTTACT-GGACTGA-AACTGACACTGAGGCA  
L34627.1   : GTCGGAGGGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-AACTGACGCTGAGGCT  
AJ413954.1 : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
X64887.1   : GCAGGAGAGG-AGAGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCGGTGGCGAA-AGC-GGCTCTCT-GGCCTGT-AACTGACACTGAGGCT  
HM218600.1 : GCAGGAGAGG-AGAGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCGGTGGCGAA-AGC-GGCTCTCT-GGCCTGT-AACTGACACTGAGGCT  
AF003929.1 : GCAAGAGGGG-AGAGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCGGTGGCGAA-AGC-GGCTCTCT-GGCTTGT-AACTGACGCTGAGGCT  
JN590018.1 : GCAAGAGGGG-AGAGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCGGTGGCGAA-AGC-GGCTCTCT-GGCTTGT-AACTGACGCTGAGGCT  
NR102809.1 : GCAAGAGGGG-AGAGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCGGTGGCGAA-AGC-GGCTCTCT-GGCTTGT-AACTGACGCTGAGGCT  
p76        : GCAGGAGGGG-CAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTGCT-GGACTGT-AACTGACACTGAGGCT  
K8         : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
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k10        : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
k13        : GAAGTAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGAAATGCGTAGAGATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCTTT-AACTGACGCTGAGGCA  
k50        : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAACGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
k52        : AGTGCAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACC-AACTGACGCTGAGGCT  
k53        : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
k55        : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
p21        : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
p67        : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
C_k5       : GCTGGAGAGG-CAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
C_k23      : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
C_k24      : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
C_k29      : GTCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-CACTGACGTTGAGGCT  
C_k30      : GTCGGAGAGG-AAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTTCT-GGACGAT-GACTGACGTTGAGGCT  
C_k31      : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
C_k32      : ACTGGAGAGG-CAGACGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGTCTGCT-GGACAGC-AACTGACGCTGAGGCG  
C_P24      : GTCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGAT-CACTGACGTTGAGGCT  
C_P41      : GGTGTAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACT-AACTGACGCTGAGGCT  
C_P47      : GGTGTAGAGG-TAGGCGGAATT-CCCGGTGTAGCGGTGGAATGCGTAGATATCG-GGAGGAACA-CCAGTGGCGAA-GGC-GGCCTACT-GGGCACT-AACTGACGCTGAGGCT  
C_P68      : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
C_P69      : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
C_P81      : GCAGGAGAGG-ATCGTGGAATT-CCATGTGTAGCGGTGAAATGCGTAGATATAT-GGAGGAACA-CCAGTGGCGAA-GGC-GACGATCT-GGCCTGC-AACTGACGCTCAGTCC  
C_P87      : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
C_P2100    : GCAGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACTGT-AACTGACGTTGAGGCT  
C_P28      : GCTGGAGAGG-TAAGTGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACAGT-AACTGACGTTGAGGCT  
C_k25      : GCCGGAGAGG-TAAGCGGAATT-CCTAGTGTAGCGGTGAAATGCGTAGATATTA-GGAGGAACA-CCAGTGGCGAA-GGC-GGCTTACT-GGACGGT-AACTGACGTTGAGGCT  
             g  g AGaGg  a g GGAATT cC  GTGTAGCGGTgaAAtGCGTAGAtAT   GgagGAAcA ccagtggCGAA gGC Ggc t cT GG c     acTGACg TgAggc         
 
Figure A.2.2. Alignment showing the 16SrRNA sequences of known taxa from database belonging to Firmicutes and those of random 
clones from healthy control.
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Table A.2.3. Accession numbers of 16SrRNA sequences used for Proteobacteria 
phylogenic tree construction for healthy control 
 
 
 
 
Bactria Accession number 
Pseudomonas aeruginosa PAO1 chromosome NC_002516.2 
Citrobacter freundii 16S rRNA gene, isolate MBRG 7.3 AJ514240.1 
Escherichia coli CFT073  NC_004431.1 
Escherichia coli O157:H7 EDL933 NC_002655.2 
K.pneumoniae 16S rRNA gene X87276.1 
Salmonella bongori strain BR 1859 16S ribosomal RNA 
gene 
AF029227.1 
Y.enterocolitica (serotype 0:3) for 16S rRNA X68674.1 
Enterobacter aerogenes strain BAC006 16S ribosomal 
RNA gene 
KU161309.1 
Enterobacter sp. ChroAq 66 16S ribosomal RNA gene KU951452.1 
Enterobacter xiangfangensis strain SDI-37 16S 
ribosomal RNA gene 
KT021517.1 
Enterobacter cloacae strain KLHD_03 16S ribosomal 
RNA gene 
KU158291.1 
Citrobacter sp. UIWRF1269 16S ribosomal RNA gene KR189389.1 
Citrobacter braakii strain 519C1 16S ribosomal RNA 
gene 
KT764983.1 
Enterobacter sp. AR15 16S ribosomal RNA gene HM027902.1 
Escherichia coli strain B10 16S ribosomal RNA gene KU870318.1| 
Escherichia coli str. K-12 substr. MG1655 strain K-12 
16S ribosomal RNA 
NR_102804.1 
Escherichia coli strain ATCC 43893 16S ribosomal 
RNA  
HM194886.1 
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Table A.2.3. Cont 
 
Bacteria Accession number 
Citrobacter freundii gene for 16S ribosomal 
RNA strain: JCM 24066 
AB548831.1 
Klebsiella pneumoniae strain QLR-2 16S 
ribosomal RNA gene 
KM096434.1 
Campylobacter coli 16S ribosomal RNA M59073.1 
E. coli genomic sequence  M87049.1 
Bilophila wadsworthia ribosomal RNA 
(rRNA) gene 
L35148.1 
Bilophila wadsworthia strain CCUG 32349 
16S ribosomal RNA gene 
KU749296.1 
Shigella sonnei strain AK102 insertion 
sequence IS1012 
KU255074.1 
Escherichia coli strain SYW001 16S 
ribosomal RNA gene, partial sequence 
EF620921.1 
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                       *       820         *       840         *       860         *       880         *       900         *          
NC002516.2 : GAATTTCCTGTGTAGCGGTGAAATGCGTAGATATAGGAAGGAACACCAGTGGCGAAGGCGACCACCTGGACTGATACTGACACTGAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
AJ514240.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCA-GTGCG-AAAGCGTGGGGAGCAAACAGG  
NC004431.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
NC002655.2 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
_X87276.1  : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
AF029227.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
X68674.1   : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KU234408.1 : GAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACTGTAACTGACGTTGAGGCTCG-AAAGCGTGGGGAGCAAACAGG  
KU161309.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KU951452.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KT021517.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KU158291.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KR189389.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KT764983.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
HM027902.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KU870318.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KU255074.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
EF620921.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
NR_102804. : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
HM194886.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
AB548831.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
KM096434.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
M59073.1   : GAATTGGTGGTGTAGGGGTAAAATCCGTAGAGATCACCAAGAATACCCATTGCGAAGGCGATCTGCTAGAACTCAACTGACGCTAA--TGCGTAAAGCGTGGGGAGCAAACAGG  
M87049.1   : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
L35148.1   : GAATTCCAGGTGTAGGAGTGAAATCCGTAGATATCTGGAGGAACACCGGTGGCGAAGGCGGCCACCTGGACGGTAACTGACGCTGAGGTGCG-AAAGCGTGGGTAGCAAACAGG  
KU749296.1 : GAATTCCAGGTGTAGGAGTGAAATCCGTAGATATCTGGAGGAACACCGGTGGCGAAGGCGGCCACCTGGACGGTAACTGACGCTGAGGTGCG-AAAGCGTGGGTAGCAAACAGG  
p79        : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
C_P610     : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCG-AAAGCGTGGGGAGCAAACAGG  
             GAATTccagGTGTAGcgGTgAAATgCGTAGAgATctggAgGAAtACCggTgGCGAAGGCGgccccCTgGAc aagACTGACgcTcAggtgCG AAAGCGTGGGgAGCAAACAGG        
 
 
Figure A.2.3. Alignment showing the 16SrRNA sequences of known taxa from database belonging to Proteobacteria and those of 
random clones from healthy control.
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Table A.2.4. Accession numbers of 16SrRNA sequences used for Actinobacteria 
phylogenic tree construction 
  
Bacteria Accession number 
Corynebacterium durum 16S ribosomal RNA Z97069.1 
Uncultured Corynebacterium sp. 24BA82 16S 
ribosomal RNA gene 
FJ976416.1 
Bifidobacterium adolescentis 16S ribosomal 
RNA gene 
AY305304.1 
Bifidobacterium sp. TM-7 gene for 16S rRNA AB218972.1 
Bifidobacterium coryneforme strain ATCC 
25911 16S ribosomal RNA gene 
NR044690.2 
Bifidobacterium sp. MRM 5.9 16S ribosomal 
RNA gene 
KP718941.1 
Bifidobacterium breve strain KB 90 16S 
ribosomal RNA gene 
AY513711.1 
Uncultured Bifidobacterium sp. clone 
ACW_P1 16S ribosomal RNA gene 
HM046575.1 
Bifidobacterium minimum strain 20E 16S 
ribosomal RNA gene 
KC787351.1 
Actinomyces graevenitzii 16S rRNA gene, 
strain CCUG 27294T 
AJ540309.1 
Corynebacterium sundsvallense 16S rRNA 
gene, strain CCUG 36622 
Y09655.1 
Actinomyces odontolyticus 16S rRNA X53227.1 
Eubacterium aerofaciens gene for 16S rRNA AB011816.1 
Eggerthella lenta gene for 16S ribosomal RNA 
strain: JCM 10766 
LC145578.1 
Eggerthella sp. SDG-2 16S ribosomal RNA 
gene 
EF413638.1 
 
Table A.2.4.Cont  
Bacteria Accession number 
Slackia heliotrinireducens strain JCM 14554 16S 
ribosomal RNA gene 
NR_113176.1 
Gordonibacter pamelaeae strain 7-10-1-b 16S 
ribosomal RNA gene 
NR_102934.1 
Adlercreutzia equolifaciens gene for 16S 
ribosomal RNA strain: FJC-A10 
AB306660.1 
Eggerthella lenta strain W02018C 16S 
ribosomal RNA gene 
KP944193.1 
Adlercreutzia equolifaciens gene for 16S rRNA 
strain: MT4s-5 
AB693938.1 
Gordonibacter faecihominis strain CAT-2 16S 
ribosomal RNA gene 
KF785806.1 
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              460         *       480         *       500         *       520         *       540         *       560         *        
Z97069.1   : GGTGACGGTACCGTGGAGAAGAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTGTCCGGATTTACTGGGCGTAAAGAGCTCGTAGGTGGTG  
FJ976416.1 : GGTGACGGTACCGTGGAGAAGAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTGTCCGGATTTACTGGGCGTAAAGAGCTCGTAGGTGGTG  
AY305304.1 : GGTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGGGCTCGTAGGCGGTT  
AB218972.1 : GGTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGGGCTCGTAGGCGGTT  
NR044690.2 : AGTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGC-AGCGTTATCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGTT  
KP718941.1 : AGTGAGTGTACC-CGTTGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGTT  
AY513711.1 : GTTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGGGCTCGTAGGCGGTT  
HM046575.1 : AGTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGATTTATTGGGCGTAAAGAGCTCGTAGGCGGTT  
KC787351.1 : AGTGAGTGTACC-TTTCGAATAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGTT  
AJ540309.1 : GTTGAGGGTACC-TGGATAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCT  
_Y09655.1  : TGTGACGGTAGG-TTGAGAAGAAGCACCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTT  
X53227.1   : GGTGACGGTAG--TGGGTAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGC-AGCGTTGTCCGGAATTATTGGGCGTAAAGGGCT--TAGGCGGT-  
AB011816.1 : CAAGACTGTACC-TGCAGAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGTAGGCGGCC  
LC145578.1 : TTCGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTATCCGGATTCATTGGGCGTAAAGAGCGCGTAGGCGGCC  
EF413638.1 : TTCGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTATCCGGATTCATTGGGCGTAAAGAGCGCGTAGGCGGCC  
NR113176.1 : CATGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGCAGGCGGCC  
|NR102934. : -GTGACGGTACC-TGCAGAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGTAGGCGGCC  
AB306660.1 : ---GACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGTAGGCGGCC  
_KP944193. : TTCGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTATCCGGATTCATTGGGCGTAAAGAGCGCGTAGGCGGCC  
AB693938.1 : -TAGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGTAGGCGGCC  
KF785806.1 : -TTGACGGTACC-TGCAGAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCGAGCGTTATCCGGATTCATTGGGCGTAAAGCGCGCGTAGGCGGCC  
k14        : TTCGACGGTACC-TGCAGAAGAAGCTCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGAGCGAGCGTTATCCGGATTCATTGGGCGTAAAGAGCGCGTAGGCGGCC  
                GA  GTAcc t   gAA AAGC CCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGG GC AGCGTT TCCGGA T AtTGGGCGTAAAG GC cgtAGGcGG          
 
 
Figure A.2.4. Alignment showing the 16SrRNA sequences of known taxa from database belonging to Actinobacteria and those of 
random clones from healthy control.
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Table A.2.5. Accession numbers of 16SrRNA sequences used for Proteobacteria 
phylogenic tree construction for UC patients 
 
Bacteria Accession number 
Pseudomonas aeruginosa PAO1 chromosome NC_002516.2 
Citrobacter freundii 16S rRNA gene, isolate MBRG 7.3 AJ514240.1 
Escherichia coli CFT073 NC_004431.1 
Escherichia coli O157:H7 EDL933 NC_002655.2 
K.pneumoniae 16S rRNA gene X87276.1 
Salmonella bongori strain BR 1859 16S ribosomal RNA 
gene 
AF029227.1 
Y.enterocolitica (serotype 0:3) 16SS rRNA X68674.1 
Enterobacter aerogenes strain BAC006 16S ribosomal 
RNA gene 
KU234408.1 
Enterobacter sp. ChroAq 66 16S ribosomal RNA gene KU951452.1 
Enterobacter xiangfangensis strain SDI-37 16S ribosomal 
RNA gene 
KT021517.1 
Enterobacter cloacae strain KLHD_03 16S ribosomal 
RNA gene 
|KU158291.1 
Citrobacter sp. UIWRF1269 16S ribosomal RNA gene KR189389.1 
Citrobacter braakii strain 519C1 16S ribosomal RNA 
gene 
KT764983.1| 
Enterobacter sp. AR15 16S ribosomal RNA gene HM027902.1 
Escherichia coli strain B10 16S ribosomal RNA gene KU870318.1| 
Shigella sonnei strain AK102 insertion sequence IS1012 KU255074.1 
Escherichia coli strain SYW001 16S ribosomal RNA 
gene 
EF620921.1 
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Table A.2.5. Contd. 
  
Bacteria Accession number 
Escherichia coli str. K-12 substr. MG1655 strain 
K-12 16S ribosomal RNA 
NR_102804.1 
Escherichia coli strain ATCC 43893 16S 
ribosomal RNA gene 
HM194886.1 
Citrobacter freundii gene for 16S ribosomal RNA 
strain: JCM 24066 
AB548831.1 
Klebsiella pneumoniae strain QLR-2 16S 
ribosomal RNA gene 
KM096434.1 
Campylobacter coli 16S ribosomal RNA M59073.1 
E. coli genomic sequence M87049.1 
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                  *       700         *       720         *       740         *       760         *       780         *       8        
C_23/22_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_23/24_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_23/32_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_23/33_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_26/36_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_26/41_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_B13U_UC_ : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A6_UC_ : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A11_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A14_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A15_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A17_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A18_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_A1A20_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_B1B3_UC_ : GAATTNCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_B1B16_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_6_UC_P1  : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_7_UC_P1  : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_19/14_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_19/20_UC : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_1A_UC_P1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA1_UC_P : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA4_UC_P : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA5_UC_P : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA7_UC_P : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA10_UC_ : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_AA20_UC_ : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
C_BB5_UC_P : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
NC002516.2 : GAATTTCCTGTGTAGCGGTGAAATGCGTAGATATAGGAAGGAACACCAGTGGCGAAGGCGACCACCTGGACTGATACTGACACTGAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
_AJ514240. : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCA-GTGCGAAAGCGTGGGGAGCAAACAGGA  
NC004431.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
NC002655.2 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
X87276.1   : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
AF029227.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
X68674.1   : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KU161309.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KU951452.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KT021517.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
|KU158291. : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KR189389.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KT764983.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
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HM027902.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KU870318.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KU255074.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
EF620921.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
NR_102804. : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
HM194886.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
AB548831.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
KM096434.1 : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
_M59073.1  : GAATTGGTGGTGTAGGGGTAAAATCCGTAGAGATCACCAAGAATACCCATTGCGAAGGCGATCTGCTAGAACTCAACTGACGCTAATGCGT-AAAGCGTGGGGAGCAAACAGGA  
M87049.1   : GAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGA  
             GAATTccagGTGTAGcGGTgAAATgCGTAGAgATctggAgGAAtACCggTgGCGAAGGCGgcCccCTgGAc aagACTGACgCTcAgGtGcgAAAGCGTGGGGAGCAAACAGGA        
 
 
 
Figure A.2.5. Alignment showing the 16SrRNA sequences of known taxa from database belonging to Proteobacteria and those of 
random clones from UC Patients.
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Table A.2.6. Accession numbers of dsr sequences used for Deltaproteobacteria 
phylogenic tree construction for UC patients and healthy individua
Bacteria Accession number 
Desulfomicrobium sp. MSL97 dsrA gene for 
dissimilatory sulfite reductase alpha subunit 
AB373130 
Desulfomicrobium sp. MSL95 dsrA gene for 
dissimilatory sulfite reductase alpha subunit 
AB373129 
Desulfomicrobium sp. MSL94 dsrA gene for 
dissimilatory sulfite reductase alpha subunit 
AB373128 
Desulfomicrobium sp. MSL93 dsrA gene for 
dissimilatory sulfite reductase alpha subunit 
AB373127 
Desulfomicrobium sp. MSL65 dsrA gene for 
dissimilatory sulfite reductase alpha subunit 
AB373124| 
Desulfomicrobium escambiense dsrA, dsrB 
genes for sulfite reductase alpha and beta 
subunits 
AB061531 
Desulfomicrobium salsuginis dsrA gene 
ADR28 
AM493693.1 
Desulfomicrobium baculatum dsrA, dsrB 
genes for sulfite reductase alpha and beta 
subunits 
AB061530 
Desulfomicrobium baculatum DSM 4028 CP001629 
Desulfococcus oleovorans Hxd3 strain DSM 
6200 dissimilatory sulfite reductase alpha 
subunit (dsrA) and dissimilatory sulfite 
reductase beta subunit (dsrB) genes 
AF418201.1 
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Table A.2.6.Cont  
Bacteria Accession number 
Desulfococcus oleovorans Hxd3 strain DSM 6200 
dissimilatory sulfite reductase alpha subunit (dsrA) and 
dissimilatory sulfite reductase beta subunit (dsrB) genes 
AF482464 
Desulfococcus oleovorans Hxd3 CP000859.1 
Desulfatibacillum alkenivorans dissimilatory sulfite 
reductase alpha subunit (dsrA) and dissimilatory sulfite 
reductase beta subunit (dsrB) genes 
AY504426 
Desulfatibacillum aliphaticivorans strain CV2803 
dissimilatory sulfite reductase 
AY215506.1 
 
Desulfatibacillum aliphaticivorans dissimilatory sulfite 
reductase alpha subunit 
AY215505.1 
Desulfosarcina sp. SD1 dissimilatory sulfite reductase 
alpha subunit (dsrA) and dissimilatory sulfite reductase 
beta subunit (dsrB) genes, partial cds 
FJ416306.1 
Desulfosarcina variabilis dissimilatory sulfite reductase 
alpha subunit (dsrA) and dissimilatory sulfite reductase 
beta subunit (dsrB) genes 
AF191907 
Desulfosarcina variabilis dissimilatory sulfite reductase 
alpha subunit (dsrA) gene 
AF360643.1 
Desulfobacter latus dissimilatory sulfite reductase alpha 
subunit (dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
U58124.2 
Desulfobacter vibrioformis dissimilatory sulfite redutase AJ250472 
Desulfobacter postgatei 2ac9 strain DSM 2034 
dissimilatory sulfite reductase alpha subunit (dsrA) and 
dissimilatory sulfite reductase beta subunit (dsrB) genes 
AF418198.1 
 
Table. A.2.6.Cont 
Bacteria Accession number 
Desulfobacterium cetonicum dissimilatory 
sulfite reductase alpha subunit (dsrA) and 
dissimilatory sulfite reductase beta subunit 
(dsrB) genes 
AF420282 
Desulfohalobium retbaense DSM 5692 CP001735.1 
Thermodesulforhabdus norvegicus 
dissimilatory sulphite reductase 
AJ277293.1 
Desulfovibrio africanus dissimilatory sulfite 
reductase alpha subunit (dsrA) and 
dissimilatory sulfite reductase beta subunit 
(dsrB) genes 
AF271772.1 
Desulfovibrio africanus dsrA, dsrB genes for 
sulfite reductase alpha and beta subunits 
AB061535.1 
Desulfovibrio africanus subsp. uniflagellum 
strain dissimilatory sulfite reductase alpha 
subunit and dissimilatory sulfite reductase 
beta subunit genes 
EU716165 
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Table. A.2.6.Cont 
Bacteria Accession number 
Desulfovibrio africanus str. Walvis Bay NC_016629.1 
Desulfovibrio alaskensis G20, complete 
genome 
CP000112.1 
Desulfovibrio alkalitolerans DSM 16529 ctg3 NZ_ATHI01000026.1 
Desulfovibrio carbinolicus strain DSM 3852 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase 
beta subunit (dsrB) genes 
AY626026 
Desulfovibrio desulfuricans subsp. 
desulfuricans dissimilatory sulfite reductase 
A subunit gene, partial cds 
AY820828 
Desulfovibrio desulfuricans strain F28-1 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase 
beta subunit (dsrB) genes 
DQ092635.1 
Desulfovibrio desulfuricans dissimilatory 
sulfite reductase alpha subunit (dsrA) and 
dissimilatory sulfite reductase beta subunit 
(dsrB) genes 
AF273034 
Desulfovibrio desulfuricans subsp. 
desulfuricans dissimilatory sulfite reductase 
subunit A (dsrA) gene, partial cds 
AY015495 
 
Table. A.2.6.Cont 
Bacteria Accession number 
Desulfovibrio fairfieldensis strain CCUG 45958, 
complete genome 
CP014229 
Desulfovibrio gabonensis strain DSM 10636 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
AY626027 2 
Desulfovibrio gigas DSM 1382 = ATCC 19364 CP006585 
Desulfovibrio halophilus strain DSM 5663 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
AF482461.1 
Desulfovibrio intestinalis dsrA, dsrB genes for 
sulfite reductase alpha and beta subunits 
AB061539 
Desulfovibrio intestinalis strain DSM 11275 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
AF418183 
Desulfovibrio magneticus RS-1 DNA AP010904 
Desulfovibrio oxyclinae strain DSM 11498 AY626033.1 
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dissimilatory bisulfite reductase alpha subunit 
(dsrA) gene 
Desulfovibrio piezophilus C1TLV30 FO203427.1 
Desulfovibrio piger ATCC 29098 strain DSM 749 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
AF482462 
Desulfovibrio portus dsrA gene for dissimilatory 
sulfite reductase alpha subunit 
AB373125 
Desulfovibrio salexigens DSM 2638 CP001649 
Desulfomonile tiedjei DSM 6799 CP003360 
 
Table. A.2.6.Cont 
Bacteria Accession number 
Desulfovibrio sp. CME3 dissimilatory sulfite 
reductase alpha subunit (dsrA) gene 
AF360649 
Desulfovibrio sp. dissimilatory sulfite reductase 
alpha subunit gene 
DSU58116 
Desulfovibrio sp. enrichment culture clone 83 
dissimilatory sulfite reductase (dsrAB) gene 
HM800739 1 
Desulfovibrio sp. J2, complete genome CP014206 
Desulfovibrio sp. LVS-10 partial rA gene for 
dissimilatory sulfite reductase alpha subunit, 
strain LVS-10 
AM494494 
Desulfovibrio sp. LVS-13 gene for dissimilatory 
sulfite reductase alpha subunit, strain LVS-13 
AM494495 
Desulfovibrio sp. LVS-21 partial rA gene for 
dissimilatory sulfite reductase alpha subunit 
AM494497 
Desulfovibrio sp. sul5 dissimilatory sulfite 
reductase subunit A (dsrA) and dissimilatory 
sulfite reductase subunit B (dsrB) genes 
KJ801800.1 
Desulfovibrio sp. wp6 dissimilatory sulfite 
reductase subunit A (dsrA) and dissimilatory 
sulfite reductase subunit B (dsrB) genes 
KJ801801 
Desulfovibrio termitidis dsrA, dsrB genes for 
sulfite reductase alpha and beta subunits 
AB061542.1 
Desulfovibrio termitidis HI1 strain DSM 5308 
dissimilatory sulfite reductase alpha subunit 
(dsrA) and dissimilatory sulfite reductase beta 
subunit (dsrB) genes 
AF418185 
Desulfovibrio vulgaris subsp. vulgaris 
dissimilatory sulfite reductase subunit A 
DQ826729 
Desulfovibrio vulgaris RCH1 CP002297.1 
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Table. A.2.6.Cont 
Bacteria Accession number 
Desulfovibrio vulgaris DP4 CP000527 
Desulfovibrio vulgaris subsp. vulgaris str. 
Hildenborough 
AE017285 
Desulfovibrio vulgaris dissimilatory sulfite reductase 
alpha 
U16723.1 
Desulfovibrio zosterae strain DSM 11974 
dissimilatory sulfite reductase alpha subunit (dsrA) 
and dissimilatory sulfite reductase beta subunit (dsrB) 
genes 
AY626028.2 
Desulfovibrio simplex dsrA, dsrB genes for sulfite 
reductase alpha and beta subunits 
AB061541 
Desulfovibrio fructosivorans dsrA, dsrB genes for 
sulfite reductase alpha and beta subunits 
AB061538 
Desulfovibrio aerotolerans dissimilatory sulfite 
reductase alpha subunit (dsrA) and dissimilatory 
sulfite reductase beta subunit (dsrB) genes 
AY749039.1 
Desulfovibrio aminophilus strain DSM 12254 
dissimilatory sulfite reductase alpha subunit (dsrA) 
AY626029 
Desulfovibrio simplex dissimilatory sulfite reductase 
alpha 
U78738 
Desulfovibrio aespoeensis Aspo-2 CP002431 
Desulfovibrio longus dsrA, dsrB genes for sulfite 
reductase alpha and beta subunits 
AB061540 
Desulfarculus baarsii DSM 2075 CP002085 
Desulfovibrio fructosivorans JJ strain DSM 3604 
dissimilatory sulfite reductase alpha subunit (dsrA) 
AF418187 
Desulfobacula toluolica Tol2 FO203503 
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              *       240         *       260         *       280         *       300         *       320         *       340          
AB373130   : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTACGTGTGGCCCAGCCTTCCGGCATGTACTACACTTCCGAA  
AB373129   : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTACGTGTGGCCCAGCCTTCCGGCATGTACTACACTTCCGAA  
AB373128   : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTACGTGTGGCCCAGCCTTCCGGCATGTACTACACTTCCGAA  
AB373127   : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTACGTGTGGCCCAGCCTTCCGGCATGTACTACACTTCCGAA  
_AB373124| : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTACGTGTGGCCCAGCCTTCCGGCATGTACTACACTTCCGAA  
AB061531   : ------------------------------------------ATGTTCCCCGGCGTTGCTCATTTTCATACCATCCGTGTCGCTCAGCCCGCGGGCATGTACTACACCACGGAG  
AM493693.1 : ------------------------------------------ATGTTCCCCGGCGTTGCTCATTTTCATACCATCCGTGTCGCTCAGCCCGCGGGCATGTACTACACCACGGAG  
_AB061530  : -ATGGCGGCGGCGTTATCGGCCGTTACTGTGACCAGCCCCAGATGTTCCCCGGTGTTGCTCATTTCCACACCGTTCGTGTCGCTCAGCCTGCGGGCATGTACTACACGACTGAT  
CP001629   : TATGGCGGCGGCGTTATCGGCCGTTACTGTGACCAGCCCCAGATGTTCCCCGGTGTTGCTCATTTCCACACCGTTCGTGTCGCTCAGCCTGCGGGCATGTACTACACGACTGAT  
AF418201   : ------------------------------------------------------------------------ATGCGCGTGGCCCAGCCCGCGGGCAAGTTCTACACCACCAAG  
_AF482464  : ------------------------------------------------------------------------ATGCGCGTGGCCCAGCCGC---GCAAGTTCTACACCACCAAG  
CP000859   : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCCAGCAGTTTCCCGGCGTGGCTCACTTTCACACCATGCGCGTGGCCCAGCCCGCGGGCAAGTTCTACACCACCAAG  
_AY504426  : ------------------------------------------ATGTTCCCGGGCGTTGCTCACTTTCACACCATCCGCGTGAACCAGCCCGCCGGTAAGTTCTACAACACCGAA  
AY215506.1 : ------------------------------------------ATGTTCCCGGGCGTTGCTCACTTTCACACCATCCGCGTGAACCAGCCCGCCGGTAAGTTCTACAACACCGAA  
AY215505   : ------------------------------------------ATGTTCCCGGGCGTTGCTCACTTTCACACCATCCGCGTGAACCAGCCCGCCGGTAAGTTCTACAACACCGAA  
FJ416306   : ------------------------------------------------------------------------ATGCGTATCAACCAGCCCGGCGGAAAATACTACACCACTGAT  
AF191907   : ------------------------------------------------------------------------ATGCGTATCAACCAGCCTGGCGGGAAATACTATACCTCCGAT  
AF360643   : ------------------------------------------------------------------------ATGCGTATCAACCAGCCTGGCGGGAAATACTACACCACCGAT  
DLU58124   : ------------------------------------------------------------------------ATGCGTGTAAACCAGCCCTGCGGTAAATATTACAGCACTGAA  
_AJ250472  : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCAAACTGTTCCCCGGTGTTGAACATTTTCACACCATGCGCGTAAATCAGCCCTGCGGTAAGTACTACAGCACAGAA  
_AF418198  : ------------------------------------------------------------------------ATGCGTGTAAACCAGCCTTGCGGTAAATACTATAGCACCGAG  
_AF420282  : -ATGGCGGTGGTGTTATCGGTCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCCCACTTTCATACCATGCGCATCAACCAGCCCGGCGGCAAATATTACACCACCGAG  
_CP001735. : TATGGTGGCGGCGTTATCGGCCGGTACTGTGATCAGCCGGAAATGTTCCCCGGCGTGGCCCACTTCCACACCATGCGTGTCAACCAGCCTGCCGGCAAGTACTACACCAGTGAG  
AJ277293.1 : TACGGCGGCGGCGTTATCGGACGATACTGCGACAGACCCGACCTGTTTCCCAATGTTGCCCATTTCCACACGATGCGTGTTAATCAGCCGGCAAGCAAGTTTTACACTACCGAC  
AF269147   : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTGGCTCACTTCCACACCGTCCGCGTGGCTCAGCCCTCCGGTAAGTACTACTCCACCGAA  
_CP003221  : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACATGCCCCAGCAGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCGTCCGGCAAGTACTACACGACCAAG  
AF327308   : ---------------------------------ATGCCCCAGCAGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCGTCCGGCAAGTACTACACGACCAAG  
AB061535   : ------------------------------------------ATGTTCCCCGGCGTGGCTCACTTCCACACCATGCGTGTGGCCCAGCCTGCGGGCAAGTACTACAACAGCAAG  
AF271772   : ---------------------------------ATGCCCCAGCAGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCGTCCGCGAAGTACTACACGACCAAG  
EU716165   : ---------------------------------ATGCCCCAGCAGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCGTCCGGCAAGTACTACACGACCAAG  
____NC_016 : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACATGCCCCAGCAGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCGTCCGGCAAGTACTACACGACCAAG  
CP000112.1 : TACGGCGGCGGCGTTATCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
NZ_ATHI010 : TACGGCGGCGGCGTCATCGGCCGTTACTGTGACGTTCCCAAGCAGTTCCCGGGCGTGGCCCACTTCCACACCGTCCGCGTCAACCAGCCCGGCGGCAAGTACTACACCACCGAG  
_AB061536  : ------------------------------------------ATGTTCCCCGGCGTCGCGCACTTCCACACCGTGCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCGCCGAA  
_AY626026  : ------------------------------------------ATGTTCCCCGGCGTCGCGCACTTCCACACCGTGCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCGCCGAT  
____DQ0926 : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGCAAGTACTACCACAGCAAG  
AF273034   : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGCAAGTACTACCACAGCAAG  
AY015495   : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGCAAGTACTACCACAGCAAG  
_DQ450464  : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTGGCGCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGCAAGTACTACCACAGCAAG  
CP014229   : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCGAACAGTTCCCCGGCGTGGCCCACTTCCACACCATGCGTGTGGCCCAGCCCGCCGGCAAATACTATGACACCAAG  
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_CP006585  : TACGGTGGCGGCGTCATTGGTCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTGGCGCACTTCCACACTGTCCGTCTGGCCCAGCCTGCAGCCAAGTATTACACGGCTGAG  
AF482461.1 : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCATACCGTTCGCGTGGCTCAGCCNGCCGGTAAGTTCTACACCACCAAG  
AB061539   : ------------------------------------------ATGTTCCCCGGCGTGGCTCACTTCCACACCATGCGTGTGGCCCAGCCTGCGGGCAAGTACTACAACAGCAAG  
AF418183   : ------------------------------------------ATGTTCCCCGGCGTGGCTCACTTCCACACCATGCGTGTGGCCCAGCCTGCGGGCAAGTTCTACAACAGCAAG  
AP010904   : TACGGCGGCGGCGTCATCGGCCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTCGCGCACTTCCACACCGTGCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCGCCGAT  
AY626033.1 : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCATACCGTTCGCGTGGCTCAGCCCGCCGGTAAGTTCTACACCACCAAG  
FO203427   : TACGGCGGCGGCGTTATTGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCTCACTTCCACACTGTTCGCGTGGCTCAGCCCATGGGCATGTGGTACAAGACCGAC  
AF482462   : ------------------------------------------------------------------------ATGCGTGTGGCCCAGCCCGCTGCCAAATACTACCACACCAAA  
_CP001649  : TACGGCGGCGGCGTTATCGGTCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTTGCACACTTTCACACCGTTCGTGTTGCACAGCCCACCGCTAAGTACTACACCACCGAG  
DSU58116   : ------------------------------------------ATGTTCCCCGGCGTGGCGCACTTCCATACCGTTCGCATGGCTCAGCCCGCCGGTAAGTTCTACACCACCAAG  
HM800739_1 : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCGCCGAA  
CP014206   : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCGCAGATGTTCCCCGGCGTTGCTCACTTCCACACCGTCCGCGTGGCTCAGCCCAACGGCAAGTGGTACAACACCAAG  
AM494494   : ------------------------------------------ATGTTCCCCGGTGTGGCCCACTTCCACACCATGCGTGTGGCTCAGCCTTCGGGCAAGTACTACCACAGCAAG  
AM494495   : -ATGGCGGCGGCGTTATCGGCCGCTACTGTGACCAGCCCGAAATGTTCCCCGGCGTCGCCCACTTCCATACGGTTCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCACCGAG  
AM494497   : ------------------------------------------ATGTTCCCCGGCGTGGCTCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGCAAGTACTACCACAGCAAG  
_KJ801800  : ------------------------------------------ATGTTCCCCGGCGTGGCCCACTTCCACACCGTCCGCCTGGACCAGCCCTCGGGCAAGTACTACACTTCCGAG  
KJ801801   : ------------------------------------------ATGTTCCCCGGCGTGGCTCACTTCCACACCATGCGTGTGGCCCAGCCTTCCGGTAAGTACTACCACAGCAAG  
CP002297   : TACGGCGGCGGCGTCATCGGCCGTTACTGTGACCAGCCCGAAAAGTTCCCCGGCGTGGCGCACTTCCATACCGTGCGCGTGGCCCAGCCTTCCGGCAAGTACTACTCTGCCGAC  
CP000527   : TACGGCGGCGGCGTCATCGGCCGTTACTGTGACCAGCCCGAAAAGTTCCCCGGCGTGGCGCACTTCCATACCGTGCGCGTGGCCCAGCCTTCCGGCAAGTACTACTCTGCCGAC  
AE017285   : TACGGCGGCGGCGTCATCGGCCGTTACTGTGACCAGCCCGAAAAGTTCCCCGGCGTGGCGCACTTCCATACCGTGCGCGTGGCCCAGCCTTCCGGCAAGTACTACTCTGCCGAC  
DVU16723   : TACGGCGGCGGCGTCATCGGCCGTTACTGTGACCAGCCCGAAAAGTTCCCCGGCGTGGCGCACTTCCATACCGTGCGCGTGGCCCAGCCTTCCGGCAAGTACTACTCTGCCGAC  
AB061541   : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTTGCTCACTTCCACACCATGCGTGTGGCCCAGCCCGCGGGCAAGTTCTACCACACCAAG  
AB061538   : TATGGCGGCGGCGTTATCGGCCGCTACTGTGACCAGCCCGAGATGTTCCCCGGCGTGGCCCATTTTCATACGGTTCGTGTGGCCCAGCCCTCCGGCAAGTACTACACCACCGAG  
AY749039   : TACGGCGGCGGCGTCATCGGACGTTACTGCGACCAGCCCGAAATGTTCCCGGGTGTGGCCCACTTCCACACCGTTCGTCTGGCCCAGCCCTCCGGCAAGTACTACACCGCCGAT  
_AY626029  : TACGGCGGCAGCGTCATCGGCCGTTACTGCGACCAGCCCCAGATGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCCTCCGGCCTGTACTACAAGACCGAC  
_U78738    : TACGGCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCGAAATGTTCCCCGGCGTTGCTCACTTCCACACCATGCGTGTGGCCCAGCCCGCGGGCAAGTTCTACCACACCAAG  
CP002431   : TACGGCGGCGGCGTTATCGGTCGTTACTGTGACCAGCCCCAGATGTTCCCCGGCGTGGCTCACTTCCACACCGTGCGTGTTGCCCAGCCCATGGGCATGTGGTACAACACCGAG  
AB061540   : TACGGCGGCGGCGTCATCGGTCGTTACTGCGACCAGCCTGAGATGTTCCCCGGCGTGGCCCACTTCCACACCGTGCGCGTGAACCAGCCCTCCGGCAAATTCTACACCACCGAA  
CP002085   : TATGGCGGAGGCGTCATCGGCCGTTATTCCGACGTCCCCAACCTTTTCCCTGGCGTCGAACACTTCCACACCGTGCGCGTCAACCAGCCCGCGTCCAAGTTCTACAAGACCGAG  
FO203503   : TATGGCGGTGGCGTTATCGGTAGATATTGTGATCAGCCTCAGGCATTTCCAGGTGTTGAGCATTTTCATACAATGCGTGTAAACCAGCCTGCAGGTAAGTATTATACAACTGAT  
CP003360   : TACGGCGGAGGGATCATCGGAAGATACTGCGATCAGCCGCAGCAGTTCCCTGGTGTTGCTCATTTCCATACTGTTCGTGTGAACCAGCCCTCAAGCAAGTATTACACCACCAAG  
F4         : ----GCNGCGGCGTTNTCGGCCGTTACTGCGACCAGCCCCAGCAGTTCCCCGGCGTGGCGCATTTCCATACCGTGCGCGTCAACCAGCCCTCGGGCAAGTACTACACCAGCGAA 
F6         : ----GCGGCGGCGTTATCGGCCGTTACTGCGACCAGCCCCAGCAGTTCCCCGGCGTGGCGCATTTCCATACCGTGCGCGTCAACCAGCCCTCGGGCAAGTACTACACCAGCGAA  
E5         : -------GCGGCGTTATCGGCCGTTACTGCGACCAGCCCCAGCAGTTCCCCGGCGTGGCGCATTTCCATACCGTGCGCGTCAACCAGCCCTCGAGCAAGTACTACACCAGCGAA  
C4         : ----GNGGCGGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
C11        : ----GNGGCGGCGTTA-CGGCCGTTACTGTGACCAGCCCGGAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAGCCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
D4         : ----GCGGCNGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
D12        : ----GCGGCGGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
A7         : ------GGCGGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
B8         : ----GCGGCGGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
C1         : ----GNGGCGGCGTTNTCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
C_B6       : TACGGCGGCGGCGTTATCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
C_D5       : TACGGCGGCGGCGTTATCGGCCGTTACTGTGACCAGCCCGAAATGTTCCCCGGCGTGGCACATTTCCACACCGTCCGCGTGAACCAGCCTGCAGGTAAGTTCTACACCTCCGAA  
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F1         : ------GGCNGCGTTNTCGGCCGTTACTGCGACCAGCCCCAGCAGTTCCCCGGCGTGGCGCATTTCCATACCGTGCGCGTCAACCAGCCCTCGGGCAAGTACTACACCAGCGAA  
                                                         gttccccggcgt gc ca tt ca acc T CG gT   cCAGCC  c gg aagT cTAca   cc A         
                                                                                                                                     
 
 
 
Figure A.2.6. Alignment showing the dsr sequences of known taxa from database belonging to Deltaproteobacteria and those of random 
clones from healthy control and UC patients. 
APPENDICES 
272 
 
 
   
                    *       360         *       380         *       400         *       420         *       440         *              
AB373130   : TACCTGCGTCACGTCTGCGACCTGTGGGAAATGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTTCTTCTTGGCACCACGACCCCGCAGCTGGAAGAA  
AB373129   : TACCTGCGTCACGTCTGCGACCTGTGGGAAATGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTTCTTCTTGGCACCACGACCCCGCAGCTGGAAGAA  
AB373128   : TACCTGCGTCACGTCTGCGACCTGTGGGAAATGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTTCTTCTTGGCACCACGACCCCGCAGCTGGAAGAA  
AB373127   : TACCTGCGTCACGTCTGCGACCTGTGGGAAATGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTTCTTCTTGGCACCACGACCCCGCAGCTGGAAGAA  
_AB373124| : TACCTGCGTCACGTCTGCGACCTGTGGGAAATGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTTCTTCTTGGCACCACGACCCCGCAGCTGGAAGAA  
AB061531   : TTCCTGAAGCAGCTCTGCGATCTTTGGGAAATGCGCGGTTCCGGCCTGACCAACATGCACGGCGCCACCGGCGACATCGTGTTGTTGGGCACCACTACTCCCCAGCTGGAAGAG  
AM493693.1 : TTCCTGAAGCAGCTCTGCGATCTGTGGGAAATGCGCGGTTCCGGCCTGACCAACATGCACGGCGCCACCGGCGACATCGTGTTGTTGGGCACCACTACTCCCCAGCTGGAAGAG  
_AB061530  : TTCCTGAAGCAGCTCTGCGACCTGTGGGATATGCGCGGCTCCGGTTTGACCAACATGCATGGCGCCACCGGCGACATCGTGCTTCTGGGAACAACCACTCCTCAGCTGGAAGAA  
CP001629   : TTTCTGAAGCAGCTCTGCGACCTGTGGGATATGCGCGGCTCCGGTTTGACCAACATGCATGGCGCCACCGGCGACATCGTGCTTCTGGGAACAACCACTCCTCAGCTGGAAGAA  
AF418201   : TACCTCAATGACCTGTGCGACCTGTGGGAGTTCCGGGGCAGCGGCCTGACCAACATGCACGGCTCCACCGGCGACATCATCTTCCTGGGCACCACCACGCCCCAGCTGGAAGAG  
_AF482464  : TACCTCAATGACCTGTGCGACCTGTGGGAGTTCCGGGGCAGCGGCTGCACCAACATGCACGGCTCCACCGGCGACATCATCTTCCTGGGCACCTCCACGCCCCAGCTGGAAGAG  
CP000859   : TACCTCAATGACCTGTGCGACCTGTGGGAGTTCCGGGGCAGCGGCCTGACCAACATGCACGGCTCCACCGGCGACATCATCTTCCTGGGCACCACCACGCCCCAGCTGGAAGAG  
_AY504426  : TGGCTCCGCAATCTTTGCGATCTGTGGGAATTCCGCGGCTCCGGCATCACCAACATGCACGGTTCCACGGGCGACATCGTCTTTTTGGGAACCGTCACCGAGCAGCTCGAGGAA  
AY215506.1 : TGGCTCCGCAATCTTTGCGATCTGTGGGAATTCCGCGGCTCCGGCATCACCAACATGCACGGTTCCACGGGCGACATCGTCTTTTTGGGAACCGTCACCGAGCAGCTCGAGGAA  
AY215505   : TGGCTCCGCAATCTTTGCGATCTGTGGGAATTCCGCGGCTCCGGCATCACCAACATGCACGGTTCCACGGGCGACATCGTCTTTTTGGGAACCGTCACCGAGCAGCTCGAGGAA  
FJ416306   : TTTCTGAAAAAACTCTGCGATCTGTGGGAGTTCCGCGGTTCCGGCATCACCAACATGCACGGTTCTACCGGTGACATCATCTTTATCGGCACCTCCACTCCGCAGTTGGAAGAA  
AF191907   : TTTCTGAAAAAACTGTGTGACCTGTGGGAGTTCCGCGGCTCCGGCATCACCAATATGCACGGCTCCACCGGTGACATCATTTTTATCGGTACCTCCACCCCGCAGTTGGAAGAA  
AF360643   : TTTCTGAAAAAACTGTGTGACCTGTGGGAGTTCCGCGGCTCCGGCATCACCAATATGCACGGCTCCACCGGTGACATCATTTTTATCGGTACCTCCACCCCGCAGTTGGAAGAA  
DLU58124   : TATCTCAGACAACTGACTGACCTGTGGGATTTCAGGGGTTCCGGCGTAACCAATATGCATGGCGCCACCGGGAATATCATCCTGCTGGGTACCACCACTCCCCAGTTGGAAGAA  
_AJ250472  : TACTTGAGAAAACTGACGGATCTGTGGGACTTCAGAGGTTCCGGAGTTACCAATATGCATGGCGCCACCGGCGATATCATTCTTCTGGGTACCACCACTCCCCAGCTTGAAGAA  
_AF418198  : TATCTTAGACAATTGACTGAGCTGTGGGACTTCAGGGGCTCCGGAATTACCAATATGCACGGCGCCACCGGCGACATCATTCTGCTGGGTACCACTACGCCCCAGCTGGAAGAG  
_AF420282  : TTTCTGAAAAAGCTGTGCGACCTGTGGGAATTCCGCGGTTCCGGCGTCACCAACATGCACGGCTCCACCGGTGACATCATCTTCATCGGTACCTCCACGCCTCAGCTGGAAGAG  
_CP001735. : TACCTCCGTCAGCTGTGCGACCTTTGGGATTTCCGCGGCAGCGGTCTGACCAACATGCATGGGTCCACCGGTGATATCGTTTTCCTCGGTACCCGGACCGAACAGTTGGAAGAA  
AJ277293.1 : GTCCTCAGAAAGCTTTGCGACATCTGGGAAGAAAAGGGAAGCGGGCTTTTCAATTTCCATGGTTCCACCGGAGACATCATTCTTCTGGGAACCACGACGGATCAGCTGGAGCCG  
AF269147   : TTCCTGCGCGGCCTGTGCGACATTTGGGAACTCCGTGGCTCCGGTCTGACCAACATGCACGGTTCCACCGGCGACATCGTGCTCATCGGCACCCAGACCCCGCAGCTTGAAGAG  
_CP003221  : TTCCTGACAGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGCATGACCAACATGCACGGCTCCACCGGTGACATCGTGCTCCTGGGCACCTTCACCGAGCAGCTCGAAGAG  
AF327308   : TTCCTGACAGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGCATGACCAACATGCACGGCTCCACCGGTGACATCGTGCTCCTGGGCACCTTCACCGAGCAGCTCGAAGAG  
AB061535   : TTCCTGCGCGACCTGTGCGACATTTGGGACATGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACTGGCGACATCGTGCTTCTTGGCACCCAGACCGCCCAGCTCGAAGAA  
AF271772   : TTCCTGACAGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGCATGACCAACATGCACGGCTCCACCGGTGACATCGTGCTCCTGGGCACCTTCACCGAGCAGCTCGAAGGA  
EU716165   : TTCCTGACAGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGCATGACCAACATGCACGGCTCCACCGGTGACATCGTGCTCCTGGGCACCTTCACCGAGCAGCTCGAAGAG  
____NC_016 : TTCCTGACAGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGCATGACCAACATGCACGGCTCCACCGGTGACATCGTGCTCCTGGGCACCTTCACCGAGCAGCTCGAAGAG  
CP000112.1 : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACCGGTGACATCGTTCTGCTGGGTACCACCACTCCCCAGCTGGAAGAG  
NZ_ATHI010 : TACCTGCGCGGCCTGATCGACATCTGGGACATGCGCGGCTCCGGCCTGACCAACATGCACGGTTCCACCGGCGACATGGTGTGGCTGGGCACCTTCACCGAGCAGCTCGAAGAG  
_AB061536  : TACCTGCGCGGCATCATGGACATCTGGGACCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTGCTCGGCACCACCACCCCGCAGCTGGAAGAA  
_AY626026  : TACCTGCGCGGCATCATGGACATCTGGGACCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTGCTGGGCACCACCACCCCGCAGCTGGAAGAA  
____DQ0926 : TTCCTGCGCGACCTGTGCGATATCTGGGACATGCGCGGCTCTGGCCTGACTAACATGCACGGTTCCACCGGCGATATCGTGCTGCTCGGTACCCAGACCCCCCAGCTGGAAGAA  
AF273034   : TTCCTGCGCGACCTGTGCGACATCTGGGATCTGCGTGGTTCTGGTCTGACCAACATGCACGGCTCCACCGGCGACATCGTGCTGCTCGGTACCCAGACTGCCCAGCTGGAAGAA  
AY015495   : TTCCTGCGCGACCTGTGCGACATTTGGGATCTGCGTGGTTCTGGTCTGACCAACATGCACGGCTCCACCGGCGACATCGTGCTGCTCGGTACCCAGACTGCCCAGCTGGAAGAA  
_DQ450464  : TTCCTGCGCGACCTGTGCGACATTTGGGATCTGCGTGGTTCTGGTCTGACCAACATGCACGGCTCCACCGGCGACATCGTGCTGCTCGGTACCCAGACTGCCCAGCTGGAAGAA  
CP014229   : TTCCTGCGCGACCTGTGCGACATCTGGGATCTGCGCGGTTCCGGCCTGACCAACATGCACGGTTCCACGGGCGACATCGTGCTGCTGGGCACCCAGACCGTCCAGCTGGAAGAA  
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_CP006585  : TACCTGGAAGCCATCTGCGACGTCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGGTCCACCGGCGACATCGTGCTTCTGGGCACCCAGACCCCGCAGCTCGAAGAA  
AF482461.1 : TTCCTGCGTGATCTCTGCGACCTGTGGGACCTCCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTTCTCGGTACCCAGACCCCGCAGCTCGAAGAA  
AB061539   : TTCCTGCGCGACCTGTGCGACATTTGGGACATGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACTGGCGACATCGTGCTTCTTGGCACCCAGACCGCCCAGCTCGAAGAA  
AF418183   : TTCCTGCGCGACCTGTGCGACATTTGGGACATGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACTGGCGACATCGTGCTTCTTGGCACCCAGACCGCCCAGCTCGAAGAA  
AP010904   : TACCTGCGCGGCATCATGGACATCTGGGACCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTGCTCGGCACCACCACCCCGCAGCTGGAAGAA  
AY626033.1 : TTCCTGCGTGATCTCTGCGACCTGTGGGACCTCCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTTCTCGGTACTCAGACCCCGCAGCTCGAAGAA  
FO203427   : TTCCTGCGCTCCTTGATGGACATCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGTGACGTTGTCCTGCTTGGTACATCCACCCCGCAGCTCGAAGAA  
AF482462   : TTCCTGCGTGACCTGTGCGACATCTGGGACCTGCGCGGTTCCGGTATGACCAACATGCACGGTTCCACCGGTGACATCGTGCTCCTGGGCACCCAGACCCCGCAGCTGGAAGAA  
_CP001649  : TTCCTGAACAAGATCATCGACATTTGGGATATGCGCGGTTCCGGTCTGACCAACATGCACGGTTCTACCGGTGACATCGTCTTCCTCGGTACCACCACTCCTCAGCTCGAAGAA  
DSU58116   : TTCCTGCGTGATCTCTGCNACCTGTGGGACCTGCGCNGTTCCGGTCTGACCAACATGCACGGCTCCACCGGTGACATCGTGCTTCTCGGTACTCAGACCCCGCAGCTCGAAGAA  
HM800739_1 : TACCTGCGCGGCATCATGGACATCTGGGACCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACCGGTGACATCGTTCTGCTGGGCACCACCACCCCGCAGCTCGAAGAA  
CP014206   : CTGCTCAACGGCCTGATGGACATCTGGGAACTCCGTGGTTCCGGTCTGACCAACATGCACGGCGCCACCGGCGACATCGTGTTCCTGGGCACCACCACTCCCCAGCTCGAAGAG  
AM494494   : TTCCTGCGCGACCTGTGCGACATTTGGGACCTGCGTGGTTCCGGTCTGACCAACATGCACGGTTCCACCGGCGACATCGTGCTGCTTGGCACCCAGACCGCCCAGCTGGAAGAA  
AM494495   : TATCTGCGCCAGATCATGGATATCTGGGATCTGCGCGGTTCCGGCCTGACCAACATGCACGGTTCCACCGGCGACATCGTGCTGCTCGGCACCACCACCCCGCAGCTCGAGGAA  
AM494497   : TTCCTGCGCGACCTGTGCGACATTTGGGATCTGCGTGGTTCCGGTCTGACCAACATGCACGGTTCCACCGGTGACATCGTGCTGCTCGGTACCCAGACTGCCCAGCTGGAAGAA  
_KJ801800  : TACCTGCGCGGCATCATGGACATCTGGGACCTGCGCGGCTCGGGTCTGACCAACATGCACGGCTCCACCGGCGACATCGTCCTGCTCGGCACCACCACGGCCCAATTGGAAGAG  
KJ801801   : TTCCTGCGCGACCTGTGCGACATCTGGGATCTGCGTGGTTCCGGTCTGACCAACATGCACGGTTCCACCGGTGACATCGTGCTGCTCGGTACCCAGACTGCCCAGCTGGAAGAA  
CP002297   : TACCTGCGCCAGCTGTGCGACATCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACGGGTGACATCGTTCTCCTCGGCACGCAGACCCCCCAGCTCGAAGAA  
CP000527   : TACCTGCGCCAGCTGTGCGACATCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACGGGTGACATCGTTCTCCTCGGCACGCAGACCCCCCAGCTCGAAGAA  
AE017285   : TACCTGCGCCAGCTGTGCGACATCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACGGGTGACATCGTTCTCCTCGGCACGCAGACCCCCCAGCTCGAAGAA  
DVU16723   : TACCTGCGCCAGCTGTGCGACATCTGGGACCTGCGCGGTTCCGGTCTGACCAACATGCACGGCTCCACGGGTGACATCGTTCTCCTCGGCACGCAGACCCCCCAGCTCGAAGAA  
AB061541   : TTCCTGCGCGACCTTTGCGACATTTGGGACATGCGTGGCTCCGGCCTGACCAACATGCACGGCTCCACCGGCGACATCGTGCTTCTTGGCACCCAGACCGCTCAGCTCGAAGAA  
AB061538   : TATCTCCGCCAGATCATGGACATCTGGGATCTGCGCGGCTCGGGCCTGACCAACATGCACGGTTCCACCGGCGACATCGTGCTGCTCGGCACCACCACCCCGCAGCTCGAGGAA  
AY749039   : TACCTGCGCGGCATCATGGACATCTGGGATCTGCGCGGTTCCGGCCTGACCAACATGCACGGCTCCACGGGCGACATCGTGCTGCTCGGCACCACCACGCCGCAGCTGGAAGAA  
_AY626029  : TTCCTCCGTCAGCTCTGCGACCTGTGGGAACTCCGCGGTTCGGGCCTGACCAACATGCACGGCTCCACGGGCGACATCGTGCTCCTGGGCACGACCACCCCGCAGCTGGAAGAG  
_U78738    : TTCCTGCGCGACCTTTGCGACATTTGGGACATGCGTGGCTCCGGCCTGACCAACATGCACGGCTCCACCGGCGACATCGTGCTTCTTGGCACCCAGACCGCTCAGCTCGAAGAA  
CP002431   : TTCCTGAACAGCCTCATGGACATCTGGGAACTGCGCGGCTCCGGCCTTACCAACATGCACGGCGCCACCGGCGACATCGTGCTGCTTGGCACGTCCACCCCGCAGCTTGAGGAG  
AB061540   : TTCCTCCGTCAGCTCTGCGACCTCTGGGAGTTCCGCGGCTCCGGTCTGACCAACATGCATGGCGCCACCGGCGACATCGTGTTCATCGGCACCACCACCCCGCAGCTCGAAGAG  
CP002085   : CGTCTGCGCGAGATCATGGACATCTGGAACCGCCGTGGCTCCAGCATGCTCAACATGCACGGCTCCACCGGCGACATCATTCTGCTGGGCGCCTTCACCGAGCAGCTCGAGCCC  
FO203503   : TATCTTAGAAAATTGACCGACCTTTGGGACTTCAGGGGTTCCGGTGTTACCAATATGCATGGCGCAACCGGTGATATCATTCTTCTGGGAACAACTACTCCTCAGTTAGAAGAA  
CP003360   : TTCCTGCGCGAACTCTGTGATCTGTGGGACAGACACGGAAGCGGTTTGACGAACATGCACGGATCGACCGGTGATATCGTCTTCTTGGGAACTACCACCGATCATCTCGAGCCC  
F4         : TACCTCCGCCAGATCTGCGATCTGTGGGACCTTCGCGGCTCCGGTCTGACCAACCTG---------------------------------------------------------  
F6         : TACCTCCGCCAGATCTGCGATCTGTGGGACCTTCGCGGCTCCGGTCTGACC---------------------------------------------------------------  
E5         : TACCTCCGCCAGATCTGCGATCTGTGGGACCTTCGCGGCTCCGGTCTGACCAACCTGCACGGCNCCNCA---------------------------------------------  
C4         : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGC--------------------------------------------------------  
C11        : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGCNNGG----------------------------------------------------  
D4         : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGC--------------------------------------------------------  
D12        : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGC--------------------------------------------------------  
A7         : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGC--------------------------------------------------------  
B8         : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGC--------------------------------------------------------  
C1         : TACCTGCGCAAGCTCTGCGATATCTGGGACCTGCGCGGTTCCGGCCTGACCAACCTGCNC------------------------------------------------------  
C_B6       : TACCTGCGCNAGNTCTGCGA----------------------------------------------------------------------------------------------  
C_D5       : TACCTGCGCAAGCTNTGCGA----------------------------------------------------------------------------------------------  
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F1         : TACCTCCGCCAGATCTGCGATCTGTGGGACCTTCGCGGCTCCGGTCTGACCAACCTGCNCGG----------------------------------------------------  
             t ccT     a  T    gA  t tggga  t cg gg tccgg  tgaccaacatgca gg  ccac gg ga atc t  t  t gg ac    ac    cag t ga ga         
 
 
Figure A.2.6. Cont Alignment showing the dsr sequences of known taxa from database belonging to Deltaproteobacteria and those of 
random clones from healthy control and UC patients.
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Appendix 3: Taxonomic report 
 
Table A.3.1 Accesion number of dsrB gene sequences used in this study 
Bacteria Accession number 
Desulfovibrio gigas DSM 1382 = ATCC 19364 CP006585.1 
Desulfatibacillum alkenivorans AK-01 CP001322.1 
Desulfovibrio desulfuricans isolate SRDQC DQ450464.1 
Desulfovibrio desulfuricans dsrA gene for sulfite 
reductase and dsrB gene for sulfite reductase 
AJ249777.1 
Desulfovibrio vulgaris DP4 CP000527.1 
Desulfovibrio piger ATCC 29098 Scfld439 NZ_DS996396.1 
Desulfocapsa sulfexigens DSM 10523 CP003985.1 
Desulfovibrio piezophilus C1TLV30 FO203427.1 
Desulfovibrio vulgaris str. 'Miyazaki F' CP001197.1 
Desulfovibrio salexigens DSM 2638 CP001649.1 
Desulfovibrio vulgaris RCH1 CP002297.1 
Desulfovibrio alaskensis G20 CP000112.1 
Desulfobacter vibrioformis dissimilatory sulfite redutase AJ250472.1 
Desulfovibrio aespoeensis Aspo-2 CP002431.1 
 
Table A.3.2 Accesion number of sat gene sequences used in this study 
 
Bacteria Accession number 
Desulfobulbus japonicus DSM 18378 KE386997.1 
Desulfobulbus propionicus DSM 2032 CP002364.1 
Desulfobacter curvatus DSM 3379 KB893012.1 
Desulfobacula sp. TS genomic scaffold TS-13370 KL662031.1 
Desulfobulbus elongatus DSM 2908 JHZB01000003.1 
Desulfobulbus mediterraneus DSM 13871 AUCW01000004.1 
Desulfobulbus sp. Tol-SR contig_611 JROS01000122.1 
Desulfocurvus vexinensis DSM 17965 JAEX01000001.1 
Desulfonauticus sp. A7A AVAG01000038.1 
Desulforegula conservatrix Mb1Pa 
I997DRAFT_scaffold00017.17_C 
AUEY01000017.1 
Desulfosarcina sp. BuS5 AXAM01000009.1 
Desulfovibrio alaskensis DSM 16109 AXWQ01000004.1 
Desulfovibrio aminophilus DSM 12254 AUMA01000020.1 
Desulfovibrio magneticus str. ALAO01000129.1 
Desulfovibrio gigas strain ATCC 19364 KF113861.1 
Desulfovibrio longus DSM 6739 ATVA01000004.1 
Desulfatibacillum aliphaticivorans DSM 15576 AUCT01000002.1 
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Table A.3.3 Accesion number of aprA gene sequences used in this study 
Bacteria Accession number 
Thiobacillus denitrificans strain DSM 12475 NZ_AQWL00000000.1 
Thiohalocapsa halophila strain DSM 6210 EF618603.1 
 
Thiorhodovibrio winogradskyi strain DSM 6702 AprB 
(aprB) and AprA (aprA) genes 
EF641946.1 
Desulfococcus multivorans strain DSM 2059 NZ_CP015381.1 
Desulfobacter sp. DSM 2057 AprB (aprB) and AprA 
(aprA) genes 
EF442909.1 
Desulfobacterium autotrophicum strain DSM 3382 AF418108.1 
Desulfovibrio sulfodismutans strain DSM 3969 AprB 
(aprB) and AprA (aprA) genes, 
EF442897.1 
Desulfomicrobium baculatum DSM 4028 NC_013173.1 
Desulfovibrio piger ATCC 29098 Scfld442 genomic 
scaffold 
NZ_DS996397.1 
Desulfovibrio ferrophilus strain DSM 15579 AprB 
(aprB) and AprA (aprA) genes 
EF442884.1 
Desulfocaldus sp. Hobo AprB (aprB) and AprA (aprA) 
genes 
EF442898.1 
Desulfohalobium retbaense DSM 5692 adenosine-5'-
phosphosulfate reductase alpha subunit (apsA) gene 
AF418125.1 
Desulfovibrio alaskansis G20 CP000112.1 
 
Desulfovibrio desulfuricans subsp. desulfuricans AF226708.1 
 
Table A.3.4 Accesion number of dsrA gene sequences used in this study 
Bacteria Accession number 
Desulfovibrio gigas DSM 1382 = ATCC 19364 CP006585.1 
Desulfomonile tiedjei DSM 6799 CP003360.1 
Desulfovibrio desulfuricans dsrA gene for sulfite 
reductase and dsrB gene for sulfite reductase 
AJ249777.1 
Desulfovibrio vulgaris DP4 CP000527.1 
Desulfocapsa sulfexigens DSM 10523 CP003985.1 
Desulfovibrio piezophilus C1TLV30 FO203427.1 
Desulfovibrio vulgaris str. 'Miyazaki F' CP001197.1 
Desulfurivibrio alkaliphilus AHT2 CP001940.1 
Desulfovibrio salexigens DSM 2638                     CP001649.1 
Desulfobacter vibrioformis dissimilatory sulfite 
redutase 
AJ250472.1 
Desulfovibrio hydrothermalis str. FO203519.1 
Desulfohalobium retbaense DSM 5692 CP001734.1 
Desulfococcus oleovorans Hxd3 CP000859.1 
Desulfobacula toluolica Tol2 NC_018645.1 
Bilophila wadsworthia dissimilatory sulfite reductase 
A and dissimilatory sulfite reductase B genes 
AF269147.2 
Desulfobacter postgatei 2ac9 CM001488.1 
Desulfohalobium retbaense DSM 5692 NC_013223. 
Desulfobulbus propionicus DSM 2032 CP002364.1 
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Desulfarculus baarsii DSM 2075 CP002085.1 
Desulfotalea psychrophila LSv54 CR522870.1 
 
Table A.3.5 Accesion number of beta-gal gene sequences used in this study 
Bacteria Accession number 
Escherichia coli EBG repressor (ebgR), EBG 
enzyme alpha subunit 
M64441.1 
E.coli beta-gal gene M38327.1 
Escherichia coli strain 86-24 EU889485.1 
Enterobacter cloacae gene for beta-gal     D42077.1 
Escherichia coli strain TW14359 EU889487.1 
Escherichia coli strain ST540 CP007265.1 
Enterobacter cloacae CHS 79 aeeaF-
supercont1.1.C16 
JMUS01000016.1 
Klebsiella pneumoniae beta-gal HQ324708.1 
Klebsiella pneumoniae UCI 68 aeeav-
supercont1.3.C7 
JMZU01000007.1 
Citrobacter freundii MGH 56 aedZq-
supercont1.2.C34 
JMUJ01000034.1 
Lelliottia amnigena CHS 78 aedZL-
supercont1.2.C11 
JMZV01000011.1 
Salmonella enterica subsp. enterica serovar 
Typhi str 
CP002099.1 
Shigella sonnei Ss046 CP000038.1 
Enterobacter aerogenes MGH 61 aeeaS-
supercont1.1.C16 
JMUL01000016.1 
Enterobacter cloacae JMUU01000020.1 
Raoultella sp. UIWRF1100 beta-gal KR424228.1 
 
 
Table A.3.6 Accesion number of nan-H gene sequences used in this study 
Bacteria Accession number 
Bacteroides fragilis neuraminidase (nanH) 
gene 
M31663.1 
Bacteroides fragilis neuraminidase (nanH) 
gene 
AF031639.1 
Bacteroides fragilis strain KLE1758 LTZK01000072.1 
Bacteroides fragilis strain IQS-1 
neuraminidase (nanH) gene 
KU378646.1 
Bacteroides fragilis NCTC 9343 CR626927.1 
Bacteroides intestinalis strain KLE1704 LTDF01000084.1 
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Table A.3.7 Accesion number of leuB gene sequences used in this study 
Bacteria Accession number 
Bacteroides caecimuris strain I48 CP015401.1 
Bacteroides cellulosilyticus strain WH2 NZ_CP012801.1 
Bacteroides dorei CP007619.1 
Bacteroides fragilis strain BOB25 CP011073.1 
Bacteroides helcogenes P 36-108 NC_014933.1 
Bacteroides intestinalis DSM 17393 NZ_ABJL02000008.1 
Bacteroides mediterraneensis NZ_LT635783.1 
Bacteroides nordii CL02T12C05 NZ_JH724315.1 
Bacteroides ovatus strain ATCC 8483 NZ_CP012938.1 
Bacteroides salyersiae strain 
2789STDY5608871 
NZ_CYXS01000012.1 
Bacteroides sp. NZ_FNVX01000005.1 
Bacteroides thetaiotaomicron strain 7330 NZ_CP012937.1 
 
Table A.3.7.Cont  
 
 
 
 
Table A.3.8 Accesion number of TcdC gene sequences used in this study 
Bacteria Accession number 
C.difficile tcdA, tdcC genes and cdd1 gene Y10689.1 
C.difficile tcdC gene X92982.1 
Clostridium difficile tcdC gene for TcdC 
strain M7 
AJ428943.1 
Clostridium difficile strain ATCC 43594 
Cdd1 (cdd1) gene, partial cds; and TcdC 
(tcdC) gene 
DQ870674.1 
Clostridium difficile strain 79A292 Cdd1 
(cdd1) gene, partial cds; and TcdC (tcdC) 
gene 
DQ870676.1 
Clostridium difficile strain CH6186 tcdC 
(tcdC) gene, tcdC-mb1 
FJ409548. 
 
 
 
 
 
 
 
 
Bacteria Accession number 
Bacteroides uniformis strain 
2789STDY5834898 
NZ_CZAO01000004.1 
Bacteroides vulgatus ATCC 8482 CP000139.1 
Bacteroides xylanisolvens XB1A FP929033.1 
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Table A.3.9 Accesion number of hydA gene sequences used in this study 
 
Bcteria Accession number 
Clostridium stercorarium subsp. leptospartum DSM 
9219 
NZ_CP014673.1 
Clostridium autoethanogenum DSM 10061, CP006763.1 
Clostridium perfringens hydA gene for hydrogenase AB016820.1 
 
 Clostridium felsineum strain DSM794 FeFe-
hydrogenase gene 
 
JF720844.1 
Clostridium kluyveri DSM 555 CP000673.1 
[Clostridium] celerecrescens strain 152B JPME01000007.1 
Clostridium sp.  hydA gene GQ180214.1 
Table A.3.10 Accesion number of fadA gene sequences used in this study 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Bcteria Accession number 
Fusobacterium equinum strain CMW8396 LRPX01000104.1 
Fusobacterium sp. GG657973.1 
Fusobacterium nucleatum strain PK1594 
adhesin A (fadA) gene  
DQ012979.1 
Fusobacterium gonidiaformans ATCC 25563 ACET02000016.1 
Fusobacterium hwasookii ChDC F128 ALVD01000022.1 
Fusobacterium massiliense strain Marseille-
P2749 
NZ_LT608327.1 
Fusobacterium necrophorum strain ATCC 
25286 
FMXX01000074.1 
Fusobacterium sp. GL988028.1 
Fusobacterium nucleatum strain 3349 adhesin 
A (fadA) gene  
DQ012978.1 
Fusobacterium periodonticum strain 33693 
adhesin A (fadA) gene 
DQ012980.1 
Fusobacterium ulcerans ATCC 49185 ACDH02000047.1 
Fusobacterium varium ATCC 27725 ACIE02000038.1 
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